{
  "name" : "dacemirror.sci-hub.se_journal-article_53f2a6b2c8b54a971110db7fd9a90c8e_liu2016.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Part one: Chitosan and Hyaluronan based systems",
    "authors" : [ "Kegang Liu", "Xiaohua Jiang" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.\nAccepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.\nYou can find more information about Accepted Manuscripts in the Information for Authors.\nPlease note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.\nAccepted Manuscript\nNanoscale\nwww.rsc.org/nanoscale\nView Article Online View Journal\nThis article can be cited before page numbers have been issued, to do this please use: K. Liu, X. Jiang and P. Hunziker, Nanoscale, 2016, DOI: 10.1039/C6NR04489A."
    }, {
      "heading" : "Nanoscale",
      "text" : "REVIEW\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1\nPlease do not adjust margins\nPlease do not adjust margins\nReceived 00th January 20xx, Accepted 00th January 20xx\nDOI: 10.1039/x0xx00000x\nwww.rsc.org/\nCarbohydrate-based amphiphilic nano delivery system for cancer\ntherapy\nPart one: Chitosan and Hyaluronan based systems\nKegang Liu,* a Xiaohua Jiang b and Patrick Hunziker* a,c\nNanoparticles (NPs) are novel drug delivery system that attract more and more attention in recent years, and have been introduced for the treatment of cancer, infection, inflammation and other diseases. Among the numerous classes of materials employed for constructing NPs, organic polymers are outstanding due to the flexibility of design, synthesis, ease of modification and functionalization. In particular, NPs based amphiphilic polymers make a great contribution to the delivery of poorly-water soluble drugs. For example, natural, biocompatible and biodegradable products like polysaccharides are widely used as building blocks for the preparation of such drug delivery vehicles. This review will detail carbohydrate based amphiphilic polymeric systems for cancer therapy. Specifically, it focuses on the nature of the polymer employed for the preparation of targeted nanocarriers, the synthetic methods, as well as strategies for application and the evaluation of biological activity. Applications of the amphiphilic polymer systems include drug delivery, gene delivery, photosensitizer delivery, diagnostic imaging as well as specific ligand-assisted cellular uptake. As a result, a thorough understanding of the relationship between chemical structure and biological properties facilitates the optimal design and rational clinic application of the resulting carbohydrate based nano delivery systems for cancer therapy. In part one, chitosan and hyaluronan based systems will be elucidated according to their recent progresses."
    }, {
      "heading" : "1. Introduction",
      "text" : "Nanoparticles (NPs) as novel drug delivery vehicles attract significant attention in recent years and have been introduced for the treatment of cancer, infection, inflammation and other diseases. 1-3 They have several advantages compared to traditional therapeutics. First, rapid clearance of drugs by phagocytes can be alleviated by controlling the size of NPs. Second, the ability of encapsulating and delivering poorly water soluble drugs endows NPs a great potential for pharmaceutical application. Third, the potential of controlled drug release permits to tailor pharmacokinetics of drugs and reduce their toxic side effects. Last, improved bio-distribution and enhanced intracellular penetration increase efficacy of drugs. 1, 4, 5 The aforementioned advantages of NPs match the requirements to improve chemotherapy in cancer, are relevant to increase the drug levels achieved in tumor tissue and to\nreduce the drug exposure of normal tissues. 6 NPs tailored to optimal size can pass through the capillary vascular walls and promote passive tumour targeting due to the enhanced permeability and retention (EPR) effect of the tumour vasculature. The increased permeability of tumour neovasculature enhances the extravasation of NPs due to large gaps between vascular endothelial cells and persistent angiogenesis within some tumours. In addition, impaired tumour lymphatic drainage acts synergistically towards an accumulation of NPs in the tumour surrounding. 7, 8 On the other hand, specific receptors overexpressed on the cell membrane of tumour cells can be exploited to design complementary targeting ligands attached to the NPs. The specific ligands such as vitamins, 6, 9-11 aptamers, 12 lectins, 13, 14 carbohydrates, 15 affibodies, 16 antibodies 17 and antibody fragments, 18, 19 can exhibit the ability of mediating endocytosis, thereby increasing the specificity of drug delivery 1, 20-22 Furthermore, trigger mechanisms for releasing therapeutic cargo increases diffusion and bioavailability of drugs in cancer environment, and included altered pH, enzymatic cleavage and many more. Generally, the bio-distribution of NPs are highly dependent on size, geometrical shape and surface characteristics. 2, 3 In this regard, a broad spectrum of NPs have been designed and fabricated, such as nanomicelle, nanovesicle, nanoliposome nanodendrimer, nanogels. 5 These NPs can be classified in\nPage 1 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nterms of the constituting materials, and encompass polymeric NPs, mesoporous NPs, magnetic NPs, gold NPs etc. 23, 24 Among the numerous materials employed for constructing NPs, organic polymers demonstrate specific advantages in their flexibility of design, synthesis, modification and functionalization. In particular, NPs based amphiphilic polymers make a significant contribution to the delivery of poorly-water soluble drugs. The materials used are typically biocompatible or biodegradable, such as copolymers of polyethylene glycol, poly (lactic acid), polycaprolactone, poly (glycolic acid), polysaccharides, polypeptides etc. In particular, polysaccharides are widely used as the building blocks for the preparation of drug delivery vehicles. 3 This review will focus on carbohydrate based amphiphilic polymeric systems for cancer therapy. It will specifically focus on the nature of the polymer employed for the preparation of targeted nanocarriers, the synthetic method for the architecture as well as strategies for application and the description of biological activities. The application of the composite amphiphilic polymer system includes drug delivery, gene delivery, photo sensitizer delivery, diagnostic imaging as well as specific ligands assisted uptake."
    }, {
      "heading" : "2. General introduction of anti-cancer drugs using modified carbohydrate amphiphilic polymers based delivery systems",
      "text" : "Chemotherapy is one of the three traditional strategies (surgery, radiotherapy and chemotherapy) to treat cancer. However, traditional chemotherapeutic strategies are limited in their effectiveness due to poor solubility of some active drug candidates, non-specific distribution, high toxicity to normal healthy tissues and resistance of cancer cell. 25-30 Fortunately, the evolution of nanotechnology provides new treatment options for cancer treatment. The NPs based delivery systems overcomes the limitations by increasing the solubility of drugs and decreasing the toxicity to normal healthy tissues. 31, 32 Cancer may be multidrug resistant (MDR) in its initial presentation or may be evolve during therapy, based on increased expression of drug efflux pumps in the cell membrane and anti-apoptotic pathways. 33 New methodologies are required to overcome the stubborn issue. Recently, therapeutic oligonucleotides as genetic drugs (e.g. small interference RNA siRNA, or plasmid DNA) can knock down gene expression by either gene interruption of the transcriptional DNA or RNA interference. Such nucleic acid therapy options open the door to new treatment options for cancer. 30 However, naked oligonucleotides show poor therapeutic efficiency due to their short half-live in blood circulation caused by degradation by ribonucleases in the blood stream, 34 as well as poor cellular uptake. 35 In contrast, encapsulated siRNAs by NPs to treat MDR of cancer can achieve impressive results, 36, 37 and targeted polymeric nanosystems are an attractive carrier system in this regard. In the following text, we will discuss anti-cancer drugs using carbohydrate-based amphiphilic nano delivery systems."
    }, {
      "heading" : "2.1. Small molecules as anti-cancer drugs",
      "text" : "There are two main resources for small molecular anti-cancer drugs: natural compounds extracted from plants and synthetic compounds. According to their mechanism of action, they can be generally divided into three main categories: antimetabolites, which can block the synthesis of DNA building blocks; genotoxic agents, which directly damage the DNA in the nucleus of the cell; mitotic spindle inhibitors, which affect the synthesis or breakdown of the mitotic spindles. 25, 38 Examples of antimetabolite drugs include methotrexate (Abitrexate®), fluorouracil (Adrucil®), hydroxyurea (Hydrea®), and mercaptopurine (Purinethol®). Examples of genotoxic agents include cisplatin (Platinol®) and antibiotics: daunorubicin (Cerubidine®), doxorubicin (Adriamycin®), and etoposide (VePesid®). Examples of mitotic spindle inhibitors agents include vinblastine (Velban®), vincristine (Oncovin®) and pacitaxel (Taxol®). 25 A number of drugs have been investigated as models in combination with in carbohydratebased amphiphilic polymers system for cancer therapy (Fig. 1a). Methotrexate (MTX) formerly known as amethopterin, is an antimetabolite and antifolate drug, 39 which can be grafted to amphiphilic polymers system via an ester bond by a reaction between a carboxylic acid functional group from methotrexate and a hydroxyl group from polymers. Camptothecin (CPT) is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme topoisomerase I (topo I). 40 It is natural product isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree), a tree native to China used as a cancer treatment in Traditional Chinese Medicine. 41 The disadvantage of its low solubility in water can be overcome by encapsulating the drug in amphiphilic polymeric nanocarriers. Alternatively, it also can be grafted to amphiphilic polymers via a ester bond or a carbamate bond (-NHC(O)O-) using its OH group and then forming nanoparticles by self-assembly in aqueous solution. Doxorubicin and paclitaxel are two important representatives of hydrophilic and hydrophobic drugs, respectively. Doxorubicin is an anthracycline antibiotic and works by intercalating DNA for cancer therapy. 42 Its HCl salt has a relatively good solubility in water so that it can be directly encapsulated by hydrophilic segments of NPs. On the other hand, doxorubicin is a multifunctional compound, which can form a hydrazone bond between a ketone functional group (from doxorubicin) and a hydrazine functional group from polymers. The drug-polymer conjugate is pH sensitive so that active doxorubicin can be released in an acidic condition, e.g. in a cancer tissue. In addition, free amino group of doxorubicin can form an amide or a carbamate bond with corresponding functional groups from polymers. Then doxorubicin is grafted to the polymer through the covalent bond, which can be released by hydrolysis. Paclitaxel is a mitosis inhibitor and a natural product first isolated from the bark of the Pacific yew tree in 1967. 43 Paclitaxel has a poor solubility in water and this\nPage 2 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3\nPlease do not adjust margins\nPlease do not adjust margins\nproperty hinders its clinical application but, can be overcome by encapsulation within hydrophobic segments of a polymer.\nFig. 1 Chemical structures of representative anti-cancer drugs and photosensitizers. a) Anti-cancer drugs, b) Photosensitizers."
    }, {
      "heading" : "2.2. Photosensitizers",
      "text" : "Photodynamic therapy (PDT) using photosensitizers has a significant potential for treating cancer and other diseases. 44 Mechanistically, a photosensitizer irradiated with light of a proper wavelength can transfer energy to triplet molecular oxygen ( 3 O2) resulting in the production of singlet oxygen ( 1 O2) and other reactive oxygen species (Scheme 1). This species is highly cytotoxic so that tumour cells can be destroyed through apoptosis or necrosis. 45, 46 PDT can effectively and selectively treat diseased tissues accompanied with minimal damage to adjacent healthy tissues. 47 Photosensitizers can also emit fluorescence (near infrared with good tissue penetration) during irradiation, which enables to monitor their presence in target tumour tissues. 48 Nevertheless, poor solubility in water and less tumour target specificity of photosensitizers limit their broad utilization. 49 NPs, in particular polymeric nanocarriers, have the ability of increasing drug solubility by encapsulating water-insoluble photosensitizers within their hydrophobic segments. Furthermore, the therapeutic efficacy of such drugs can be improved by prolonging their circulation time in the blood stream and the EPR effect in certain tumour tissues. There are several photosensitizers classes, including porphyrins, chlorophylls and dyes, such as aminolevulinic acid (ALA), m-tetra hydroxy phenylchlorin (mTHPC), phthalocyanine metal complexes, and chlorin derivatives. 50 In recent research, protoporphyrin IX and chlorin e6 (Ce6) are frequently used as model drugs in carbohydrate-based amphiphilic polymers system for PDT of cancers (Fig. 1b). 48, 51, 52 Protoporphyrin IX and Ce6 are both heterocyclic and aromatic compounds. Protoporphyrin IX is a derivative of porphin consisting of four pyrrole rings. In contrast, Ce6 contains three pyrrole rings and one pyrroline ring. The four rings are coupled through four methine (=CH-) linkages to construct a huge conjugated aromatic system. They can not only be physically encapsulated into amphiphilic polymers due to their hydrophobic properties, but can also be conjugated to amphiphilic polymers through their aliphatic carboxylic function groups via amide, ester or carbamate bonds.\nScheme 1 Simplified Jablonski diagram for photo-processes involved in PDT."
    }, {
      "heading" : "2.3. Nucleic acids (siRNA, Anti sense RNA, micro RNA, plasmid DNA etc.)",
      "text" : "Using nucleic acid therapy for the treatment of cancer and other diseases (inflammation, cardiovascular or metabolic\ndisorders etc.) is of great promise. 53, 54 Nucleic acids such as micro RNA (miRNA), antisense RNA, small interfering RNA (siRNA) and plasmid DNA (pDNA) have a large potential for the clinical application in the treatment of diseases caused by gene disorders characterized by defective, missing, low or over gene expression. For example, siRNA can knock down the expression of unwanted encoded protein on the posttranscriptional level and pDNA has the ability to replace defective gene or supply the missing gene to restore normal functional protein expression. 35, 55 As mentioned, therapy based on simple injection of the naked nucleic acid is not practical due to its rapid nuclease degradation, poor cellular uptake and low transfection efficiency. 56, 57 New strategies for formulating such gene drugs in NPs need to overcome those obstacles. Currently, two main gene delivery systems using nanocarriers are pursued: viral vectors and non-viral vectors. Virus mediated gene delivery system is based on a replication-deficient viral particle carrying a gene intended for delivery. The optimized virus can inject the DNA into a host cell leading to a high efficiency of transfection; the drawbacks include a limited payload capacity, risks due to random insertion sites in the host genome and cytophathic effects as well as mutagenesis. 58-60 Therefore, a substantial emphasis is currently given to develop non-viral gene delivery. Extensive research using non-viral delivery system for gene therapy shows promising results for several approaches: low immunogenicity, versatility and ease of manufacturing. 61 There is progress in improving the low transfection efficiency of nonviral delivery systems through chemical structure optimization. Prominent examples of non-viral delivery systems include liposomes, cationic polymers and other NPs. Cationic polymers forming nanocarriers seem to afford particular advantages compared to other systems, because they can offer well defined physicochemical properties, a high extent of molecular diversity and high gene packing capacity. Cationic polymers can form polyectrolyte complexes with the negatively charged of nucleotides and thus encapsulate them. 62 Carbohydratebased polymeric systems, in particular chitosan are an important class of cationic polymers for gene delivery. After extensive modification of the delivery system by introducing targeting ligands, modification of particle surfaces, adding pH and redox stimulus etc., the nanocarriers can pass though extra- and intra- cellular barriers and deliver its payload in the target tissue so that the encapsulated gene achieves its desired effect with high efficacy. 35, 57, 63"
    }, {
      "heading" : "3. Design and fabrication of carbohydrate based amphiphilic NPs",
      "text" : "At present, lipids, natural and synthetic polymers are typically used as drug delivery vectors. 1 A plethora of nanocarriers for cancer therapy based on these materials has emerged and showed impressive results in preclinical studies during the past decade. Amphiphilic NPs, especially in carbohydrate (polysaccharide) based NPs, are designed and synthesized using different chemical and physical strategies. Amphiphilic system for drug delivery combines hydrophilic segments and\nPage 3 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nhydrophobic moieties. The hydrophilic segments are responsible for hydration and swelling, while the hydrophobic moieties tend to minimize the water contact, since their contact with water is energetically unfavourable. 64 Due to the high hydrophilicity of polysaccharides, introducing or grafting hydrophobic parts to polysaccharides is the key for constructing such amphiphilic system. Depending on properties of polysaccharides (hydrophilic) or modified polysaccharides (hydrophobic or hydrophilic), there are two general methods to build the amphiphilic system: covalent conjugation and non-covalent intermolecular interaction as shown in Fig. 2. 3\nFig. 2 Two general methods to build the amphiphilic system: covalent conjugation and non-covalent intermolecular interactions.\n3.1. Covalent method\nPolysaccharides containing hydroxyl, carboxylic acid and amino functional groups can react with a wide range of hydrophobic moieties via ester, amide, urea, hydrazone or carbamate bonds to form amphiphilic molecules. The hydrophobic moieties include small hydrophobic molecules such as bile acids, fatty acids, cholesterol; hydrophobic macromolecules such as polyester, polyanhydride; hydrophobic drugs such as paclitaxel. 3 The covalent chemical bonds between polysaccharides and hydrophobic can be labile for efficient drug release, such as pH sensitive (hydrazone bond) or enzyme cleavable (ester bond) and reductive (disulfide bond) etc. under cancer cell condition. The resulting amphiphilic polymers tend to self-assemble into NPs at aqueous environment due to hydrophobic interactions. 65"
    }, {
      "heading" : "3.2. Non-covalent method",
      "text" : "Non-covalent interaction may refers to electrostatic interactions, 66 host-guest recognition, 67-69 π-π stacking, 70, 71 hydrogen bonding, 72-74 metal-ligand, 75-77 charge transfer interaction 78, 79 etc. 80 In contrast to covalent interaction, such interactions are often relatively weak. Constructed by such non-covalent interactions, the resulting amphiphilic systems are normally defined as supramolecular amphiphiles (namely superamphiphiles). 80, 81\nThese supramolecular amphiphilies are promising as stimuli-\nresponsive nanocarriers because of their specific properties. 80 In carbohydrate based amphiphilic system for drug delivery, the most frequently used non-covalent interactions exploited to construct supramolecular amphiphilic systems are electrostatic interaction; host-guest recognition; π-π stacking, or the combination of them.\n3.2.1. Electrostatic interaction\nPolyelectrolytes (macromolecules with charges) are formed by ionic cross-linkers through electrostatic attraction between molecules with cationic and anionic groups. Some polyelectrolytic complexes can further self-assemble into different NPs. 66, 82-84 However, the resulting NPs are labile in external environment because of the less stable ionic crosslinkers as networks. 85 Generally, the formation and stability of the complexes are not only dependent on inner factors of polyelectrolytes, such as charge density, chain flexibility, molecular weight and distribution of charge, but also on outer factors, such as ionic strength, temperature, pH value and mixing procedure. Polysaccharides are an important building block to form polyelectrolytes. 86, 87 For example, positively charged polysaccharide such as chitosan, negatively charged polysaccharides such as hyaluronan, heparin, can all form complexes with oppositely charged polyelectrolytes (polysaccharides, peptides, nucleic acids). Neutral polysaccharide also can be transformed into charged polyelectrolytes through various chemical modifications. Typical chemical modifications are 1) Introduction of amino group to polysaccharides for positively charged polyelectrolytes; 2) Introduction of carboxylic group or sulphate group to polysaccharides for negatively charged polyelectrolytes. 88 Due to the advantage of polysaccharides, nucleic acids involved gene therapy using polysaccharides as vehicles get increasing attention recently. 35"
    }, {
      "heading" : "3.2.2. Host-guest recognition",
      "text" : "Host-guest chemistry is a form of molecular recognition and interaction through non-covalent bonding. Such host-guest recognition is a commonly used method to construct supramolecular amphiphilic delivery system. 65, 80 Among common host molecules like cyclodextrins (CDs), calixarenes, pillararenes, cucurbiturils, porphyrins, the CDs are the most frequently applied molecule class in pharmaceutics and drug delivery. CDs are able to form inclusion complexes with hydrophobic molecules in their hydrophobic cavity. 80 There are two general forms of these complexes: 1) Linear polymers can enter the cavities of CDs to form polypseudorotaxanes. 2) CDs cavities host hydrophobic head parts of guest molecules through hydrophobic interactions to form host-guest complexes. 88 The amphiphilicity of the whole complex could be adjusted by modification of host CDs and guest molecules. 65 The modification aims at introducing hydrophobic moieties to CDs only, to guest molecules only or to the combination of both."
    }, {
      "heading" : "3.2.3. π-π stacking",
      "text" : "π-π stacking refers to attractive, noncovalent interactions between aromatic rings. These interactions are very important in catalysis, protein-ligand interactions, and molecular recognition. 89, 90 Recently, intermolecular π-π stacking\nPage 4 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5\nPlease do not adjust margins\nPlease do not adjust margins\nattraction has been paid more and more attention and has been utilized for drug delivery. This type of drug delivery system can be constructed by aromatic (π-rich) drugs such as anti-cancer drug doxorubicin and aromatic (π-rich) groups in nanostructures such as graphene, 91 carbon nanotubes, 92, 93 fullerene, 94 carbon black nanoparticles. 95, 96 However, without proper surface modification, those π carbon nanostructures can’t disperse into water and limit their application. Polysaccharides are usually biocompatible and biodegradable and are suited to be conjugated with aromatic moieties for carrying aromatic drugs using intermolecular π-π stacking attraction. 96 On the other hand, non-aromatic drugs also can be transformed into candidates (prodrugs) for π-π stacking drug delivery by introducing aromatic moieties via cleavable chemical bonds. Besides π-π stacking, hydrophobic interaction can have a synergistic effect for drug encapsulation and selfassembly to form nanostructures as micelles or vesicles. 80"
    }, {
      "heading" : "3.3. Morphology of nanoparticles",
      "text" : "Amphiphilic NPs can possess a variety of shapes, typically determined by chemical composition and physical assembly method, and include, e.g., micelles, vesicles, nanogels and dendrimers, all of which have been produced and investigated in detail. 97-100 • NPs composed from amphiphilic polymers can be produced by flash solvent and non-solvent nanoprecipitation methods; both approaches allow size control. The surface of NPs can be modified with functional groups such as targeting molecules or stealthy-conveying macromolecules to assure long circulation time of circulation in blood stream, and thereby optimal deposition of the drug carbo at the target site. 101 • Micelles with core-shell nanostructure structure are formed by certain amphiphilic polymers through self-assembly in aqueous solution. 80 The hydrophobic blocks interact with each other and aggregate to create an inner core surrounded by an outer corona consisting of hydrophilic segments. 102, 103 Micelle size can be formed by varying the ratio and type of hydrophobic and hydrophilic moieties. Cargo molecules can be covalently conjugated to the polymers or physically encapsulated into the interior of micelles. • Vesicles can be produced by natural, modified natural or fully synthetic polymers. 80 Vesicles form through aggregation of such molecules, and typically consist of an encapsulating layer that resembles the biologic cell membrane, which contains an inner volume of solvent. Due to the distinctive structures, both hydrophilic and hydrophobic drugs can be embedded in the vesicles. 104-106 • Nanogels are polymeric particles resembling a 3D molecular mesh formed via covalent linkages or self-assembly. Nanogels exhibit a highly porous polymer network, so drugs can be loaded into the inner volume of the gel structure. 107 The swelling behaviour of nanogels can be adjusted for the\ncontrol release of a cargo drug in proper environmental conditions. 108 • Dendrimers are formed from successively controlled addition of monomers to an initiator molecule and have a uniform tree-like structure. Drugs can be retained in the branched entities via non-covalent interactions or attached to surface functional groups of dendrimers as conjugates. 109"
    }, {
      "heading" : "4. Polysaccharides (oligosaccharides) based amphiphilic delivery system for cancer therapy",
      "text" : "Polysaccharides are polymeric carbohydrate molecules constructed by numerous identical or differential monosaccharide units connected via glycosidic bonds. Polysaccharides are abundant as biopolymers in various natural resources including algae (e.g. alginate), plants (e.g. pectin, cellulose, cyclodextrins), microorganisms (e.g. dextran, pullulan) and animals (e.g. chitosan, hyaluronan, chondroitin and heparin). 110 Depending on building block chemistry and production mechanisms, these biopolymers can exibit various chemical structures (Fig. 3), such as linear to highly branched structure, variable chemical compositions (α or β glycosidic bonds, different monosaccharide units), a broad range of molecular weights and various charge states (neutral, positively charged or negatively charged). The diversity of such structures, displaying a wide range of physiochemical and biological characteristics attracts increasing attention for pharmaceutical and biomedical application. From the viewpoint of biological properties, polysaccharides often display low toxicity, good biocompatibility and biodegradability while immunogenicity depends on individual structure. Polysaccharides have also a relatively chemical stability and a hydrophilic nature, display an ease of chemical modification and processing can be low-cost depending on the complexity of the target structure. Due to the availability of various functional groups on polysaccharides like hydroxyl, amine, and carboxylic acid, a plethora of derivatives are produced by different chemical reactions such as oxidation, sulfation, esterification, amidation or other synthetic methods. 3, 5, 35 These chemical modifications in accordance with variations of their physicochemical and biological characteristics are definitely in favour of their biomedical applications. In addition, other specific properties, such as bioadhesion (chitosan, alginate), ligand targeting (hyaluronic acid HA) are advantagous in drug delivery. For example, hyaluronic acid (HA) has been used for targeting specific organs or cells and also prolonging the drug residence time. 111 In recent years, polysaccharides and their derivatives used as drug delivery system have been extensively investigated. Carbohydratebased amphiphilic delivery systems for cancer therapy are elucidated below.\nPage 5 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nFig. 3 Chemical structures of polysaccharides frequently incorporated in nanocarriers for nucleic acid delivery. Dextran consists of repeating α-1, 6-linked D-glucose units with low degree of α-1, 3-branching. Chitosan is a positively charged polysaccharide with repeating D-glucosamine and N-acetyl-Dglucosamine units that are linked via β-(1, 4) glycosidic bonds. Hyaluronan is an anionic polysaccharide composed of Dglucuronic acid and N-acetyl-D-glucosamine disaccharide building blocks, linked via alternating β-1,4 and β-1,3-glycosidic bonds. Alginate is composed of alternating blocks of β-(1, 4)-Dmannuronic acid and α-(1, 4)-L-guluronic acid. Pullulan consists of α-1, 6-linked maltotriose units. β-cyclodextrin is a heptameric cyclic oligosaccharide, consisting of α-1, 4 glycosidic bonds. Heparin is composed of α or β-(1, 4) linked uronic acid (90% α-L-iduronic acid, 10% β-D-glucuronic acid) and α-D-glucosamine residues."
    }, {
      "heading" : "4.1. Chitosan based amphiphilic delivery system for cancer therapy",
      "text" : ""
    }, {
      "heading" : "4.1.1. Introduction to chitosan",
      "text" : "Chitosan (CS) is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-Dglucosamine (Fig. 3). Normally, CS is commercially produced by deacetylation of chitin, a main structural element in the exoskeleton of crustaceans (e.g., crabs and shrimp) and cell walls of fungi. 112 CS and its derivatives have a number of applications relevant to agriculture, 113 wine-making, 114 polyurethane paint coating, 115 dietary supply 116 and biomedicine. 117 For example, some uses in agriculture and wine-making are contributed from their anti-fungal, antibacterial and anti-parasitic properties. 113, 114 Recently, their applications in biomedicine are increasingly explored. 117 CS and its derivatives have specific chemical structures, i.e. primary amino groups and β-(1-4) linked glycosidic bonds. The β-(1-4) linked glycosidic bonds and hexose units render them biodegradable and biocompatible which is essential for the application of biomedicine. 118 Primary amino functional groups endow CS and its derivatives with specific functionalities in biomedicine. CS carry positive charges through protonated amine groups, which, for example, contribute to haemostatic functionality. 119 The haemostatic agent works by an interaction between the cell membrane of erythrocytes (negative charge) and the protonated chitosan (positive charge) leading to involvement of platelets and rapid thrombus formation. Its positive charge also facilitates adherence and permeation to mucosal surfaces so that it is frequently utilized in mucosal drug delivery. 112 Furthermore, CS can interact with other negatively charged bio-molecules to form polyelectrolyte complex. For example, polyplexes formed by interaction between nucleic acids and CS are commonly investigated for gene therapy. 5 Additionally, other two important properties of CS in biomedicine are also conveyed\nby primary amino groups. First, CS typically only dissolve in acidic aqueous solution due to its primary amines with a pKa around ~ 6.5. 120 Second, although the high density of positive charges of CS can enhance cellular uptake, their cellular toxicity increase correspondingly. 117 However, a drug delivery platform based CS and its derivatives should display high solubility and low toxicity under normal physiological conditions. Fortunately, primary amine as an actively chemical group can be readily modified by different reactions in combination with other modifications on the hydroxyl groups so that CS derivatives can be tuned to optimized properties for drug delivery, such as high solubility, low toxicity, good stability, proper particle sizes and surface charges. 112 Such amphiphilic CS derivatives are a promising platform for drug delivery in cancer therapy. The following text will mainly focus on the most recent advances with this type of CS derivatives including various chemical modifications and their applications as nanocarriers."
    }, {
      "heading" : "4.1.2. Small molecules as anti-cancer drugs using chitosan based amphiphilic delivery system",
      "text" : ""
    }, {
      "heading" : "4.1.2.1. Chitosan-drug conjugates for cancer therapy",
      "text" : "Chitosan-drug conjugates for delivering small molecular introduced at 70`s last century is a promising methodology for cancer therapy. 121 Two types of covalent bonds are utilized to construct the conjugates. First, the conjugates are constructed by labile covalent bonds between chitosan or chitosan derivatives and drugs, which can be cleavable by hydrolysis or enzymatic degradation in specifically physiological conditions, such as cancer environments (acidic). Second, the conjugates also can be built by stable covalent bonds, such as amide bond. Imitating several successful cases of other polymers, 122 chitosan - anticancer drug conjugates have been investigated. 123-129 These conjugates utilize CS or its derivatives as hydrophilic segments and anticancer drugs as hydrophobic segments to form amphiphilic system that self-assemble in aqueous solution to form micelles. For instance, Kwon et al. have synthesized glycol chitosan-doxorubicin (GC-DOX) conjugate shown in Fig. 4 123-125 and evaluated its potency for drug delivery. The preparation of GC-DOX is depicted in scheme 2. First, the doxorubicin reacted with cis-aconitic anhydride in pyridine to introduce acid labile covalent amide bond (acid-labile cis-aconityl linkage), followed by reaction with glycol chitosan using carbodiimide chemistry (EDC and NHS) to afford GC-DOX conjugate. The GC-DOX conjugates formed self-assembled NPs in an aqueous condition only contain 2-5 wt. % DOX. When the loading amount of DOX was above 5.5 wt. %, the GC-DOC conjugates precipitated owing to the formation of many hydrogen bonds and specially crystal structure of DOX. Fortunately, the loading amount of DOX in the NPs could increase up to 38.9 wt.% by physical entrapment of nanoparticles where π-π interaction may take effect. In vivo\nPage 6 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7\nPlease do not adjust margins\nPlease do not adjust margins\ntest showed the DOX–GC NPs preferentially accumulated in the tumour tissue by EPR effect. Furthermore, due to the acid labile cis-aconityl linkage, the release rate of DOX from the nanoparticles was pH dependent.\nFig. 4 Chemical structures of representative anti-cancer drugCS conjugates. Amide and ester bonds were selected for these constructions.\nScheme 2 Schematic illustration of chemical synthesis of GCDOX. Acid-labile cis-aconityl linkage was selected for pH sensitive segment in GC-DOX conjugate. 123-125\nJon et al. developed a platform for oral delivery of paclitaxel (PTX) through chemical conjugation of PTX to a low molecular weight chitosan (LMWC) (Fig. 4). 126 The synthesis of LMWCPTX conjugate is shown in Scheme 3. Generally, the drug molecules were covalently linked to LMWC through succinate linkers that were known to be cleaved to release a parent PTX drug under physiological conditions with hours of half-life. 130 LMWC-PTX was synthesized in two steps. First, the cleavable linker was introduced by a reaction between PTX and succinic anhydride to provide intermediate PTX-Suc. Then coupling of the activated ester form of the succinic acid-modified PTX to the amine groups of LMWC using carbodiimide chemistry afforded the LMWC-PTX conjugate. Compared to native PTX, the LMWC-PTX conjugate contained 12 wt.% PTX and showed greatly enhanced water solubility (>1 mg/mL). At the same time, the conjugate showed comparable IC50 values to that of the parent PTX against human cancer cell lines. In mice model test of anti-cancer, the conjugate was administered orally to mice and exhibited significant inhibition of tumour growth, which was comparable to the injected form of PTX formulated in cremophor EL/ethanol (iv) (clinically available) but with much lower toxicity. In addition, LMWC-PTX was absorbed in the small intestine after oral administration and kept its intact conjugate form before reaching the bloodstream. Interestingly, the author suggested that the strong antitumor activity of LMWC-PTX after oral administration may be attributable to its greater water solubility, prolonged retention in the GI tract, and ability to bypass P-gp efflux pumps in the GI tract as well as CYP 450-dependent metabolism in intestine and liver. 126 In 2014, this type of labile ester bond was further utilized to synthesize another amphiphilic carboxymethyl chitosan-quercetin (CQ) conjugate. In this study, quercetin acted not only as a P-gp inhibitor by bypassing the P-gp drug efflux pumps, but also as a hydrophobic segment of CQ conjugate to encapsulate paclitaxel (PTX) aiming to improve its oral bioavailability by increasing its water solubility. As a result, the PTX-loaded CQ NPs significantly enhanced the oral bioavailability of PTX with high antitumor efficacy against\ntumour xenograft models as compared to commercially available Taxol® and Taxol® with verapamil. 127\nScheme 3 Schematic illustration of chemical synthesis of LMWC-PTX. Hydrolysable ester bond was built in LMWC-PTC conjugate. Adapted with permission from Ref. 126. Copyright 2008 American Chemical Society.\nLu and Zheng et al. designed and synthesized a novel amphiphilic polymeric prodrug Cis-3-(9H-purin-6-ylthio)-acrylic acid-graft carboxymethyl chitosan (PTA-g-CMCS) (Fig. 4). 128 Regarding the amphiphilic system, carboxymethyl chitosan (CMCS) behaved as hydrophilic moiety, in contrast, 3-(9Hpurin-6-ylthio)-acrylic acid residue as hydrophobic moiety. In order to increase the solubility of 6-Mercaptopurine (6-MP, used to treat blood cancers and other diseases) in physiological condition and decrease its side effects in convent treatment, PTA-g-CMCS conjugate was synthesized by a Michael addition reaction between 6-MP and propiolic acid to form an intermediate and carbodiimide chemistry between the intermediate and carboxymethyl chitosan. When drugchitosan conjugates approached the cancer sites where GSH was over expressed (the concentration of GSH is 4-fold higher than that in normal cells), another Michael addition and following elimination reactions were subtly utilized to release 6-MP. The whole synthetic route of amphiphilic prodrug PTAg-CMCS and the mechanism of releasing drug 6-MP are shown in Scheme 4. Additionally, the PTA-g-CMCS nano-system had good in vitro stability and the drug release obviously influenced by GSH concentration. MTT assay demonstrated that this system had lower cytotoxicity on mouse fibroblast cell line (L929) and higher inhibition ratio on HL-60 cells in the presence of GSH. It was believed this GSH dependent polymeric prodrug had the potential to be used as a carrier for 6-MP. 128\nScheme 4 Synthesis of polymer PTA-g-CMCS and the working mechanism of drug 6-MP release. a) Schematic illustration of chemical synthesis of PTA-g-CMCS and the reactions for 6-MP release in a redox surrounding; b) A cartoon showing drug 6- MP release in GSH condition. Adapted and reprinted from Ref. 128. Copyright 2012 with permission from Elsevier.\nBesides labile bonds, relatively stable amide bonds for preparing chitosan-anticancer drug conjugate were also introduced. 129 Recently, Sadeghi-aliabadi et al. synthesized novel amphiphilic derivatives of Methotrexate-chitosan oligosaccharide (MTX–CHO) with different molar feeding ratios of MTX. They found that both, drug loaded and unloaded MTX–CHO micelles showed significant cytotoxicity on MDA-\nPage 7 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nMB-231. However, the loaded micelle was more effective compared to the unloaded one, which showed that the utilization of non-labile bond could hamper the efficacy of MTX. 129"
    }, {
      "heading" : "4.1.2.2. Amphiphilic polymers formed by small hydrophobic molecules grafted chitosan and its derivatives for cancer therapy",
      "text" : "In recent years, small hydrophobic molecules were frequently used to modify chitosan or its derivatives to form polymeric amphiphiles that spontaneously form micelles or micelle-like aggregates. These amphiphiles as carriers for encapsulating anti-cancer drugs, especially hydrophobic drugs and their anticancer efficiencies were extensively investigated. In general, these small hydrophobic molecules can be classified as saturated linear, unsaturated linear molecules (Fig. 5), cyclic aliphatic molecules (Fig. 6) and other heterocyclic aromatic molecules (Fig. 7) etc. For the attachment of such hydrophobic part to chitosan, the primary amine group of chitosan has been utilized mainly through carbodiimide chemistry with acid and imine reduction with aldehyde etc. The degree of the substitution of the hydrophobic moiety dramatically influences the physicochemical properties of NPs (e.g., solubility, size, ability of encapsulation of drug), further affects the biodistribution of NPs in vivo as well. Generally, using the modified amphiphilic conjugates to encapsulate anticancer drugs shows impressive therapeutic efficacies in vitro and in vivo compared to relevant free drugs, especially in respect of high drug solubility, high cellular uptake, long circulation time, sustained drug release, minor cytotoxicity, and improved tumour repression. In the following text, recent published examples are described in detail. Long linear aliphatic carbon chain (C6-C20) acids and aldehydes are normally selected as starting materials for the contribution of hydrophobic moieties of amphiphilic polymers, such as stearic acid (C18), 131-136 arachidic acid (C20), 137 palmitic acid (C16), 138, 139 oleic acid (C18), 140, 141 linoleic acid (C18) 142, 143 hexanoic acid (C6) 144 and octaldehyde (C8). 145-149 Most such aliphatic acids known as fatty acids are natural products and are readily available as plant oils or animal fats. In addition, they are typically biocompatible or biodegradable. Hu et al. synthesized a series of stearic acid grafted chitosan oligosaccharides (CSO-SA) with different degree of amino substitution (SD) by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC)-mediated coupling reaction (Fig. 5). All the amphiphilic polymers can form micelles with very low critical micelle concentration (CMC) and CMC is SD dependent. They proved that the cell cytotoxicity of paclitaxel encapsulated in micelles was improved strongly because the micelles with high DS present specific spatial structure with multiple hydrophobic minor cores leading to excellent internalization into cancer cells and accumulation in cytoplasm. 131 Meanwhile, the release rate of drug from micelles was also lowered by increasing the SD of CSO-SA. For further better drug control, glutaraldehyde was introduced to the surfaces of CSO-SA micelles to form corresponding imine cross-linker with amine (Fig. 5). 132 Using\nthis cross-linker, the initial burst release of the micelles could be markedly reduced and the drug release time could be prolonged. To obtain an active-targeting carrier to cancer cells, folate-conjugated stearic acid grafted chitosan oligosaccharide (Fa-CSOSA) was also synthesized by EDC-mediated coupling reaction. The cellular uptake of Fa-CSOSA micelles was greatly enhanced against a folate receptor over-expressing cell line (Hela), compared to the result in a folate receptor deficient cell line (A549). 133 Another model drug DOX encapsulated in these micelles showed similar results as PTX under in vitro test, such as cytotoxicity, drug release and other parameters. 134-136 Further studies showed the core of CSO-SA micelles modified by the physical solubilisation of stearic acid (SA) can reduce the burst drug release and enhance the physical stability of CSO-SA micelles. 136 Compared to the method of introducing glutaraldehyde to attain above aims, the physical encapsulation of SA to the core of micelle should be much safer because of the high toxicity of glutaraldehyde. Moona et al. prepared chitosan oligosaccharide–arachidonic acid (CSOAA) conjugate and used it for the development of self-assembled NPs for doxorubicin (DOX) delivery (Fig. 5). 137 The DOX-loaded CSOAA-based NPs showed a spherical shape with a mean diameter of 130 nm and a CMC value that was relatively low. DOX-loaded CSOAA based NPs showed a sustained and pH-dependent drug release profile. Such DOXloaded CSOAA-based NPs significantly inhibited FaDu tumour growth in vivo. 137 Chen et al. synthesized oleic acid modified chitosan (OCH) amphiphilic polymers (Fig. 5). 140 The resulting OCH based NPs were in a spherical shape and diameter of 255.3 nm. The haemolysis rates of OCH NPs tested in different conditions were within permissible limits (5%). The OCH NPs showed no cytotoxicity to mouse embryo fibroblasts. Doxorubicin (DOX) was efficiently loaded into OCH NPs and could be released in a sustained way at pH 7.4. Compared to DOX solution, the inhibitory rates of DOX-OCH NP suspension to different human cancer cells (A549, Bel-7402, HeLa, and SGC-7901) were significantly improved. In 2015, this type of amphiphilic polymer, named CS-OA, was utilized to build stimuli-responsive drug delivery systems combined with singlewall carbon nanotubes (CNT) for NIR irradiation and poly(Nisopro-pylacrylamide) (PNIPAAm) selected as the thermo responsive material to enhance the tumour-targeting drug transportation and minimize the severe side effects along with the chemotherapy. As a result, DOX-loaded CS/PNIPAAm@CNT exhibited high cytotoxicity in HeLa cells owing to the enhanced DOX release under increased temperature triggered by NIR irritation. 141 Another unsaturated linear fatty acid----linoleic acid (LA) grafted carboxymethyl chitosans (CMCS) were prepared by Liu et al. 142 The critical aggregation concentrations (CAC) of LA modified CMCS in aqueous solution were very low in a range of 0.061–0.081 mg/mL. Adriamycin as model anticancer drug was encapsulated into the LA modified CMCS. Both CAC and drug loading efficiency of the resulting NPs were influenced by the SD of LA. In vitro anticancer activity of the resulting NPs loaded with Adriamycin against Hela cells was comparable to the activity of free Adriamycin. Uchegbu et al. synthesized and characterised a so-called triple action\nPage 8 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 9\nPlease do not adjust margins\nPlease do not adjust margins\nnanomedicine from a chitosan amphiphile: a quaternary ammonium palmitoyl glycol chitosan (GCPQ) (Fig.5). 138, 139 A palmitoyl function group was introduced by carbodiimide chemistry and followed by another reaction between the free amine of chitosan and methyl iodide to form quaternary ammonium. The GCPQ NP significantly enhances the oral absorption of hydrophobic drugs (e.g., griseofulvin and cyclosporin A) and, to a lesser extent, the absorption of hydrophilic drugs (e.g., ranitidine). They suggested that the mechanism of hydrophobic drug absorption facilitated by the nanomedicine is as follows: (a) increasing the dissolution rate of hydrophobic molecules, (b) adhering to and penetrating the mucus layer and thus enabling intimate contact between the drug and the gastrointestinal epithelium absorptive cells, and (c) enhancing the transcellular transport of hydrophobic compounds. 139\nApart from carbodiimide chemistry to graft hydrophobic small\nmolecules onto CS or its derivatives, the reduction of imine formed between hydrophobic aldehyde and the amine of chitosan was also utilized to construct amphiphilic nanocarriers for drug delivery. Zhang and Ping et al. synthesized a series of chitosan derivatives with long alkyl chains (n=8, 10, 12) as hydrophobic parts and sulfated groups as hydrophilic parts. 145, 146 Alkylation (reduction of imine with KBH4) and sulfonylation was conducted at the C-2 position and sulfonylation at the C-6 position of the chitosan, respectively. A series of biological tests, such as injection anaphylaxis and haemolysis as well as cytotoxicity, showed that the resulting chitosan amphiphiles possesses a promising potential as a carrier of PTX. 147 Zhou et al. also synthesized a similar series of amphiphilically modified chitosan molecules with long alkyl chains as hydrophobic moieties and glycol groups as hydrophilic moieties (N-octyl-O-glycol chitosan, OGC). 148 Haemolysis, acute toxicity and histopathological studies through i.v. administration showed that OGC was biocompatible and exhibited low toxicity as an excipient. Furthermore, PTX-loaded OGC micelles had advantages over the commercially available injectable preparation of PTX (Taxol®), in terms of low toxicity levels and increased tolerated dose. Recently, Zhang et al. found the N-octyl-O-sulfate chitosan (NOSC), and its paclitaxel (PTX)-encapsulated micelles (PTX-M) could overcome or circumvent multidrug resistance (MDR) in cancer therapy (Fig. 5). 149 The optimal cytotoxicity on the multidrug resistance HepG2 (HepG2-P) cells resulted from a combination of the inhibiting P-gp effect of NOSC and the bypassing P-gp action of the intact PTX-M. In addition, in vivo study demonstrated that most of PTX-M is delivered at the tumour site due to the synergetic effect of NOSC micelles on drug delivery and P-gp inhibition. The case of targeting controlled release core−shell nanocarriers with the potenYal to overcome (MDR) is rare. In 2015, Liu et al. prepared amphiphilic chitosan (CHC) based NPs loaded by demethoxycurcumin (DMC) as a model drug and coated with an anti-EGFR antibody layer as a ligand (Fig. 5). 144 This formulation achieved high cytotoxicity against MDR cell and the therapeutic potential was confirmed in an A549 xenograft lung tumour mouse model. These results suggest the anti-\nEGFR coated core−shell nanocarriers are highly promising for treating hypoxic MDR cancers, such as non-small cell lung cancer. 144\nFig. 5 Chemical structures of representative small hydrophobic molecules (saturated and unsaturated linear)-CS conjugates. The related hydrophobic molecules (long carbon chains) are listed on right side.\nSteroids are a class of cyclically aliphatic molecules with a chemical structure that contains a core of gonane, among which, bile acid (5β-cholanic acid, deoxycholic acid or cholic acid) and cholesterol are commonly selected as hydrophobic moieties to construct amphiphilic polymers with chitosan or its derivatives (Fig. 6). Kwon et al. synthesized a series of 5βcholanic acid or deoxycholic acid covalently modified glycol chitosans (HGCs) using carbodiimide chemistry. 150, 151 The degree of hydrophobic substitution influenced the amphiphilicity of the HGCs, by which the size, zeta potential, and morphology of related HGC NPs were greatly influenced as well. The critical aggregation concentration of HGCs was quite low and self-assembled NPs were stable enough for more than one week in the physiological condition, and animal experiments showed a prolonged blood circulation. The HGC NPs exhibited high tumour specificity for delivery of diverse anticancer drugs such as cisplatin, 152 camptothecin, 153 paclitaxel and its derivative docetaxel, 154, 155 as well as antiangiogenic peptide drug RGD. 156 The same group also evaluated the encapsulation of adriamycin using deoxycholic acid-conjugated chitosan NPs as drug containers. 157 Ma et al. not only grafted deoxycholic acid as hydrophobic moieties in 2- position of CS, but also conjugated glycidol to the same position of CS as hydrophilic moieties. 158 After the selfassembly of the resulting amphiphilic (glycidol-chitosandeoxycholic acid, G-CS-DCA) polymers, G-CS-DCA can form NPs in very low CAC from 0.043 mg/mL to 0.013 mg/mL with the increase of degree of substitution (DS) of DCA. Doxorubicin (DOX) could be easily encapsulated into G-CS-DCA NPs and keep a sustained release manner without burst release when exposed to PBS (pH 7.4) at 37 o C. High antitumor efficacy to MCF-7 cells suggested that G-CS-DCA NPs may be a promising carrier for DOX delivery in cancer therapy. 158 In 2014, another series of novel amphiphilic deoxycholic acid and phosphorylcholine grafted chitosan derivatives DCA–PCCs were prepared by the combination of Atherton–Todd reaction and carbodiimide coupling reaction. 159 Cholesterol and its derivative can also be utilized as a hydrophobic segment to build amphiphilic chitosan based NPs. Zhang et al. synthesized cholesterol-modified chitosan conjugate with succinyl linkages (CHCS). Epirubicin (EPB, a derivative of doxorubicin), as a model anticancer drug, was physically entrapped inside CHCS self-aggregated NPs by the remote loading method. EPB-\nPage 9 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "10 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nloaded CHCS self-aggregated NPs were almost spherical in shape and their size increased with the increase of EPB-loading content. The in vitro release behaviour of EPB from CHCS selfaggregated NPs showed that the release rate decreased with the pH increase of the release media. In phosphate buffered saline (PBS, pH 7.4), the EPB release was very slow and the total release amount was about 24.9% in 48 h. 160 The bile acid, cholic acid, can be used in similar fashion as other bile acids, such as 5β-cholanic acid and deoxycholic acid that are utilized to construct amphiphilic chitosan based NPs for drug delivery. Pan et al. prepared amphiphilic N-(2, 3-dihydroxypropyl)– chitosan–cholic acid (DHP–CS–CHO) micelle as a carrier for paclitaxel delivery (Fig. 6). 161 Such PTX loaded chitosan derivative micelles could inhibit MCF-7 cell growth and induce apoptosis. In 2014, Zhai et al. synthesized an amphiphilic conjugate GA-CMCA by decorating O-carboxymethyl chitosan (OCMC) with cholic acid (CA) and glycyrrhetinic acid (GA), which was conjugated to the polymer via a succinate linker. The resulting NPs were utilized for potential liver-targeted delivery (Fig. 6). 162 As a promising carrier for liver targeted drug deliver, the GA-CMCA based NP was examined by haemolysis test, in vitro cytotoxicity assay and cellular uptake study.\nFig. 6 Chemical structures of representative small hydrophobic molecules (cyclic aliphatic) -CS conjugates. The hydrophobic segments are mainly from steroids or their derivatives (deoxycholic acid, cholesterol, 5-β-cholanic acid, cholic acid and glycyrrhetinic acid).\nIn another line of reasearch, a number of aromatic molecules were selected as hydrophobic moieties to build amphiphilic chitosan derivatives for drug carries, such as NAc-histidine, 163 N-benzyl, 164 2-nitrobenzyl alcohol, 165, 166 aromatic disulphide, 167 α-tocopherol, 168 FITC 123-125 (Fig. 7). Cho et al. described N-acetyl histidine conjugated glycol chitosan (NAcHis-GC) self-assembled NPs as a promising system for intracytoplasmic delivery of drugs. N-acetyl histidine was chosen as grafted residue to chitosan, not only because Nacetyl histidine (NAcHis) is hydrophobic at neutral pH, which can be utilized for constructing amphiphilic conjugates, but also because NAcHis can be protonated to enable the drug to readily escape from the endosomes in slightly acidic environments (Fig. 7, 8). Furthermore, the cell cycle analysis demonstrated that paclitaxel loaded NAcHis-GC NPs were effective in inducing arrest of cell growth. 163 Another novel pH responsive BSCS micelle was synthesized and its anti-cervical cancer activity for oral curcumin delivery was evaluated by Sajomsang’s group (Fig.7). 164 Besides pH as a stimuli for drug release, other factors, such as light (external stimulus) 165, 166 and redox (internal stimulus) 167 are also utilized to control the drug release. Huang et al. designed the dual pH-/lightresponsive cross-linked polymeric micelles (CPM) which were prepared by the self-assembly of amphiphilic glycol chitosan-o-\nnitrobenzyl succinate conjugates (GC-NBSCs, Fig. 7) and then cross-linking with glutaraldehyde (GA). The conjugate GC-NBSC was synthesized by grafting hydrophobic light-sensitive Onitrobenzyl succinate (NBS) onto the main chain of hydrophilic glycol chitosan (GC). The micelles exhibited good biocompatibility against NIH/3T3 cells and camptothecin (CPT) was selected as a model drug. The in vitro evaluation demonstrated that the encapsulated CPT could be released rapidly at low pH with the UV light irradiation. 166 Similarly, in the same year, Gu et al. prepared another light sensitive conjugate N-succinyl-N’-4-(2-nitrobenzyloxy)-succinyl-chitosan (SNSC, Fig. 7), also containing light-sensitive triggering group 2- nitrobenzyl alcohol on the hydrophobic block. On the other hand, near-infrared light (two photon photolysis) was utilized to trigger micelles for fast controlled drug release in deep tissue. The method can overcome the drawbacks of using UV or visible light for drug release, such as skin damage and extend the depth limit when application in deep tissues is desired. 165 In 2014, Zhang et al. synthesized a novel amphiphilic thiolated carboxymethyl chitosan (TCM-Chitosan, Fig. 7), which can self-assembled into disulfide bond crosslinked NPs in deionized water. The particle size changed with pH values and GSH concentrations, exhibiting an obvious pH/redox responsibility. Methotrexate as a model drug was encapsulated in NPs and the resulting NPs against HeLa cells reached an inhibition rate of 90%. 167\nThe vitamin E derivative (+) α-tocopheryl succinate (α-TOS) exerts pro-apoptotic effects in a wide range of tumours and is well tolerated by normal tissues. 169-172 Dou et al. synthesized PTX-loaded tocopheryl succinate-conjugated chitosan oligosaccharide (CSO–TOS) NPs for synergistic chemotherapy (Fig. 7). In vitro studies showed that PTX-loaded CSO–TOS NPs had excellent cellular uptake ability by human glioma U87 cells and were more potent than free PTX in cytotoxicity. They found that a synergistic effect between TOS and PTX was achieved in the therapeutic effects of carrier materials. In addition, in vivo pharmacokinetic results indicated that the PTX-loaded CSO–TOS NPs had a longer systemic circulation time and slower plasma elimination rate than those of Taxol. The author suggested that CSO–TOS could be a potential vehicle for delivering hydrophobic chemotherapeutic drugs to tumours. 168 Fluorescein isothiocyanate (FITC) can be used as an active intermediate of fluorophores functionality to label other molecules. Kwon et al. synthesized FITC-conjugated glycol-chitosan (FIT-GC) where FITC also acted as hydrophobic moiety (Fig. 7). They used the nanoaggregate based selfassembly of FIT-GC to investigate its bio-distribution in tumour-bearing rats. 123-125\nPage 10 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 11\nPlease do not adjust margins\nPlease do not adjust margins\nFig. 7 Chemical structures of representative small hydrophobic molecules (aromatic)-CS conjugates. The small hydrophobic molecules were conjugated to CS via amide bonds.\nFig. 8 Schematic representation of endosomal escape and drug release of histidylated polymer nanoparticles. The pHdependent endosomal-membrane destabilization by histidine correlated with the protonation of its imidazole groups. The pKa of the imidazole group is around 6.5. In a slightly acidic milieu, such as in endosomes, the imidazole group is protonated, interacts with negatively charged lipid bilayers and induces the influx of water and ions into endosomes, thus causing endosome destabilization and drug release into the cytosol. Reprinted from Ref. 163. Copyright 2006 with permission from Elsevier."
    }, {
      "heading" : "4.1.2.3. Amphiphilic co-polymers formed by macromolecules grafted chitosan and its derivatives for cancer therapy",
      "text" : "Polymers as hydrophilic moieties or hydrophobic moieties grafted onto chitosan to construct amphiphilic block copolymers for anti-cancer therapy were also investigated recently. Numerous polymers were synthesized in this field. Usually, they belong to one of four types, namely polyesters, poly acrylic acid or acrylate, polystyrene derivative, poly ethylene glycol. Synthetic polyesters such as poly (β-malic acid) (PMLA) 173 and poly (ɛ-caprolactone) (PCL), 174-176 poly (lactide) (PLA), 177, 178 are all biodegradable with excellent mechanical strength, biocompatibility, and nontoxicity (Fig. 9). Yin et al. designed and synthesized chitosan derivatives carrying linoleic acid (LA) as hydrophobic moieties and poly (β-malic acid) (PMLA) as hydrophilic moieties (LA/PMLA double grafted chitosan, LMC) (Fig. 9). 173 The synthesis of LMC is shown in scheme 5-1. Under catalysis of TFA, lactic acid was selected as an initiator to initiate the ring-opening polymerization of lactone (benzyl malolactonate) and thus form PMLABz with lactic acid as its carboxyl terminal which was modified as corresponding carbonyl chloride for a conjugation onto chitosan. MeSO3H acted as a solvent as well as a catalyst in the acylation of chitosan. Linoleic chloride firstly reacted with chitosan, followed by the addition of PMLABz carbonyl chloride. Benzyl groups could be hydrolysed directly by the strong acid of MeSO3H when ice was introduced. The resulting LMC had long hydrophilic chains for the encapsulation of PTX, and long PMLA chains to reduce absorption of plasma opsonins and decrease the clearance of the reticuloendothelial system (RES). In addition, the lateral carboxyl acids of PMLA provided modification sites for conjugation of targeting molecules. Paclitaxel (PTX) was loaded into the LMC NPs with a maximum loading capacity of 9.9% and PTX-LMC NPs exhibited a sustained release and the release rate was affected by the LA content and PMLA length. The LMC NPs were demonstrated as\nsafe drug carriers for i.v. by haemolysis and acute toxicity assessment. Additionally, PTX-LMC showed significantly potent tumour inhibition efficacy, relative to that of TAXOL in S-180 bearing mice. 173 The similar synthetic methodology was used to prepared copolymer chitosan-graft-poly (ε-caprolactone) (CS-g-PCL) and the copolymer based micelles was utilized for 5- fluorouracil drug delivery. 175 In 2013, Song et al. prepared an amphiphilic poly (lactic acid)-grafted-chitosan (PLA-g-CS) copolymer and evaluated its potential for ocular delivery of amphotericin B. 178 They used a “protection-graftdeprotection” procedure to finish the synthesis of PLA-g-CS. First, the primary amino group was protected by phthaloyl group. Second, the primary hydroxyl group of chitosan reacted with PLA- isocyanate intermediate that was prepared in advance to introduce PLA to chitosan. In the end, the phthaloyl group was removed by using N2H4.H2O at high temperature. 178 Later, Halila et al. prepared redox-stimuli responsive micelles from DOX-encapsulating polycaprolactone-g-chitosan oligosaccharide (PCL-g-CO). 176 The synthetic route was depicted in scheme 5-2. Briefly, polyester PCL-Cl was synthesized by copolymerization of α-chloro-ε-caprolactone (αClεCL) generated by Baeyer-Villiger oxidation of αchlorocyclohexanone and ε-caprolactone (ε-CL) using DSDOP as initiator. Then pendent chloride units of PCL-Cl were quantitatively substituted by azide groups to produce polyester PCL-N3. Finally, the PCL-g-COs copolymers were prepared by copper (I) - catalyzed azide-alkyne cycloaddition (CuAAC) coupling PCL-N3 and COs-alkynyl which was provided by a reduction reaction between chitosan and 4-(prop-2ynyloxy) benzenamine. The resulting PCL-g-COs micelles had COs shell and a PCL core as well as a disulfide-containing bisalkyne cross-linker utilized to lock the core-micelles structure which can be degraded in response to physiological (redox) stimuli. 176\nFig. 9 Chemical structures of representative macromolecules (polyesters) grafted CS. The macromolecules were conjugated to CS via amide, ester or amine (PCL-g-CO) bonds. Polyesters act as hydrophobic segments and CS acts as hydrophilic segment in these conjugates.\nScheme 5-1 Schematic illustration of chemical synthesis of LA/PMLA-CS (LMC). Polyester PMLABz was synthesized by acid (TFA) catalysed ring-opening polymerization. Adapted with permission from Ref. 173, copyright 2009 American Chemical Society.\nScheme 5-2 Schematic illustration of chemical synthesis of PCL-g-COs. Copper (I) - catalyzed azide-alkyne cycloaddition (CuAAC) is the key step for synthesis of PCL-g-COs. Adapted from Ref. 176. Copyright 2014 with permission from Elsevier.\nPage 11 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "12 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nSome chitosan based amphiphilic copolymers consist of poly acrylic acid (acrylate) 179-182 or poly styrene derivative, 183, 184 which can be produced by free radical polymerization of related monomers. Ponchel et al. prepared thiolated chitosanpoly (isobutyl cyanoacrylate) core-shell NPs and evaluated their potential mucoadhesion behaviours and calcium binding capacities. 179-181 Poly (isobutyl cyanoacrylate) acted as a hydrophobic moiety. Liu et al. reported a new type of amphiphilic carboxymethyl-hexanoyl chitosan (CHC)–poly (acrylic acid) (PAA) hybrid macromolecule where poly (acrylic acid) (PAA) and carboxymethyl group acted as hydrophilic moieties, hexanoyl group as hydrophobic moiety (Fig. 10). 182 The CHC–PAA hybrid NPs showed excellent encapsulation efficiency greater than 90% for a hydrophobic anti-cancer substance, (S)-(+)-camptothecin. Acrylic acid substitution gave rise to high pH responsiveness in terms of size and the volumetric change of the NPs and such a pH-responsive behaviour rendered a robust control of drug release shifting between acidic and basic environments. CHC-PAA can be a potential candidate for oral drug delivery applications. 182 Kwon et al. developed glycol chitosan NPs with hydrotropic oligomers (HO-GC) as a new tumour targeting drug delivery system where hydrotropic 2-(4-(vinylbenzyloxy)-N,Ndiethylnicotinamide) (VBODENA-COOH) oligomers directly conjugated to glycol chitosan polymers were used for enhancing the aqueous solubility of paclitaxel (Fig. 9). 183, 184 The schematic illustration of the synthesis for such polymers was shown in scheme 6. VBODENA monomer containing the vinyl group was firstly synthesized from 2-hydroxy nicotinic acid. Secondly, oligo (VBODENA)-COOH was prepared from the VBODENA monomer by free radical chain transfer polymerization in the presence of 3-mercaptopropionic acid (MPA) as functional chain transfer agent and AIBN as an initiator. Finally, The HO-GC conjugate was obtained by chemical conjugation of the carboxylic group of VBODENA oligomer to the amine group of GC in the presence of EDAC and HOBt. It should be addressed that N, Ndiethylnicotinamide (DENA) is considered as the most effective hydrotropic agent, which can increase the aqueous solubility of PTX. As a result, water-insoluble paclitaxel (PTX) was readily encapsulated into HO-CNPs with a high drug loading amount up to 24.2 wt. % by simple dialysis method. The PTX encapsulated HO-CNPs (PTX-HO-CNPs) were very stable in aqueous media up to 50 days. PTX-HO-CNPs presented rapid cellular uptake and lower cytotoxicity in cell culture system, compared to Cremophor EL/ethanol formulation of PTX. Furthermore, PTX-HO-CNPs showed the higher therapeutic efficacy, compared to Abraxane®, a commercialized PTXformulation (Fig. 11). These overall results demonstrate its potential as a new nano-sized PTX carrier for cancer treatment. 184 Fig. 10 Chemical structures of representative macromolecules (poly acrylic acid and polystyrene) grafted chitosan. Hexanoyl residues act as hydrophobic segments in conjugate CHC-PAA. VBODENA-COOH oligomers act as hydrophobic segments in conjugate HO-GC. Scheme 6 Schematic illustration of chemical synthesis of HOGC. Polymer DENA-Oligomer (HO) was synthesized by free radical chain transfer polymerization in the presence of 3- mercaptopropionic acid (MPA) as functional chain transfer agent and AIBN as an initiator. Adapted from Ref. 183. Copyright 2009 with permission from Elsevier. Fig. 11 Stability of NPs PTX-HO-CNPs and the NPs related studies in vivo and ex vivo. a) Stability of PTX-HO-CNPs in PBS for 50 days. b) Excised tumour images after tumour therapy. c) Histological analysis of tumour tissue after tumour therapy with PTX-HO-CNPs (blue: DAPI for nucleus staining, red: TUNEL for the imaging of cell death). Reprinted from Ref. 184. Copyright 2013 with permission from Elsevier. Polyethylene glycol (PEG) as a hydrophilic linear chain is frequently utilized to construct nanocarrier for drug delivery because PEG chain can protect the drug-incorporating inner core from the protein adsorption and from attack of reticuloendothelial systems (RES) resulting in a prolongation of blood circulation of drug carriers. 185 PEG grafted chitosan copolymers as nanocarriers were also investigated. For example, PEG can be conjugated to chitosan by carbodiimide chemistry between a carboxylic acid group at end of PEG chain and an amine group or a primary hydroxyl group from chitosan, 186-190 as well as a reduction reaction of an imine formed by an aldehyde at end of PEG chain and the amine group from chitosan (Fig. 12). 191, 192 Opanasopit et al. synthesized N-phthaloylchitosan-grafted poly (ethylene glycol) methyl ether (PLC-g-mPEG), where phthaloyl group exhibited hydrophobic property. 186, 187 Camptothecin (CPT) and all-trans retinoic acid (ATRA) as model drugs were encapsulated into the inner core of the micelles by dialysis method, respectively. Zhang et al. synthesized a series of novel chitosan derivatives (mPEGOSC) with hydrophobic moieties of octyl and hydrophilic moieties of sulfate and polyethylene glycol monomethyl ether (mPEG) groups. 192 They evaluated the influence of the length of PEG for the inhibition to protein adsorption. Notably, paclitaxel (PTX)-loaded micelles were prepared with the highest loading rate of 42.6%. Furthermore, higher targeting efficiency of PTX-mPEGOSC2000 Mtouterus (including ovary) was estimated. In 2013, Guo et al. designed and synthesized\nanother amphiphilic copolymer CS–DCA–MPEG–FA modified with mPEG chain as a stealthy part and deoxycholic acid residue as a hydrophobic part. In addition, folic acid (FA) was\nPage 12 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 13\nPlease do not adjust margins\nPlease do not adjust margins\nconjugated to chitosan to reach a tumour cell targeting property. 191 Interestingly, Park and Jung et al. prepared alltrans retinoic acid (ATRA)-incorporated NPs of methoxy poly (ethylene glycol) (MPEG)-grafted chitosan through ioncomplex formation between ATRA and chitosan, where ATRA acted not only as a model drug, but also as a hydrophobic moiety of the NP. Compared to free ATRA, ATRA-incorporated NPs have almost similar cytotoxicity against CT-26 tumour cells and U87MG cells, but higher efficacy to inhibit invasion of tumour cells at invasion test using matrigel. 188, 189 As described previously, NPs can also be constructed through ionic interaction. Picart et al. described a method relevant to polyelectrolyte multilayer nanoshells with hydrophobic nanodomains for delivery of Paclitaxel (Fig. 12). 193 The polyelectrolyte complexes can be built between quaternized chitosan (QCHI) as polycations and decylamino hydrazide derivative of hyaluronan (HA20C10) as polyanions and hydrophobic drugs can be encapsulated within its hydrophobic domain. By using this system, the loading capacity of PTX increased dramatically.\nFig. 12 Chemical structures of representative macromolecules (glycol poly ethylene) grafted chitosan and QCHI.HA20C10 polyelectrolyte complex. PEG chains act as stealthy segments against protein adsorption and attack of reticuloendothelial systems (RES) for increasing blood circulation of drug nanocarriers."
    }, {
      "heading" : "4.1.3 Photosensitizers as anti-cancer drugs using chitosan based amphiphilic delivery system for photodynamic therapy (PDT)",
      "text" : "A large number of chemical drugs for cancer therapy including photosensitizers are hydrophobic, and two methods are utilized to introduce hydrophobic drugs into polymeric NPs: 1) physically loading into amphiphilic polymeric NPs and 2) chemical conjugation to polymeric NPs. Among these polymeric NPs, chitosan-based NPs (CNPs) were also investigated for PDT. Kim et al. prepared photosensitizer encapsulated CNPs by self-assembling amphiphilic glycol chitosan–5β-cholanic acid conjugates and a water-insoluble photosensitizer (PpIX) (HGC+PpIX) by using a dialysis method (Fig. 13). 48 Herein, photosensitizers were physically encapsulated into the NPs. Later, they developed the photosensitizer, protoporphyrin IX (PpIX), was directly conjugated to glycol chitosan (GC) NPs (PpIX-GC-NPs) as tumour-homing drug carriers (Fig. 13-i). 51 The HGC+PpIX NPs exhibited higher tumour specificity in tumour bearing mice compared to free PpIX. However, the instability of physically loaded PpIX molecules in the NPs might cause the burst drug release profile during in vivo circulation. In contrast, chemically conjugated drugs PpIX-GC although showed the same bio-distribution of nano-sized drug carriers, but no loss of conjugated drugs in the blood stream. The authors suggested a concept related to ‘on/off’ switch of fluorescence or singlet oxygen generation (Fig. 13-ii-a). According to the\nconcept, after cellular uptake of their particles, the PpIX fluorescence turned ‘on’ and restored therapeutic activity. This cellular ‘on/off’ NP system can reduce unintended cytotoxicity and increase therapeutic efficacy after cellular uptake and irradiation. Furthermore, the PpIX-GC-NPs presented prolonged blood circulation, enhanced tumour-homing ability, and improved in vivo therapeutic efficiency in tumour-bearing mice (Fig. 13-ii-b, c). Therefore they concluded that the PpIXGC-NP has great potential for synchronous PDI and PDT in cancer treatment. 51 In 2011, the same group also made another comparative study of photosensitizer (chlorin e6, ce6) physically loaded (HGC+Ce6) and conjugated glycol chitosan (GC-Ce6) NPs for cancer therapy (Fig. 14). The result is very similar to photosensitizer (PpIX), which showed that the photosensitizer conjugated glycol chitosan (GC-Ce6) NPs with excellent tumour targeting properties have potential for PDT in cancer treatment. 52 In 2013, the ‘on/off’ concept was further confirmed by a novel photosensitizer-chitosan conjugate PheoA-ss-GC (Fig. 14). Compared to non-reducible PheoA-ssGC NPs with stable amide linkages (PheoAeCNPs), PheoA-ss-GC NPs presented higher Cytotoxicity with light treatment owing to their photoactivity in response to intracellular reductive conditions. 194\nFig. 13 Chemical structures of representative CS based NPs for loading photosensitizers PpIX (physically and covalently) and the resulting NPs in PDT. i) Chemical structures of HGC +PpIX and PpIX-GC; ii) a) PDT reaction mechanism of PpIX-NPs in target tumour cell; b) PDT comparison in mice of treating with PpIX or PpIX-GC-NP; c) Tumour volume comparison of treating with saline, PpIx and PpIX-GC-NP. Reprinted from Ref. 51. Copyright 2011 with permission from Elsevier.\nFig. 14 Chemical structures of representative CS based NPs for loading photosensitizers Ce6 (physically and covalently) and PheoA (redox and stable covalent). Physical encapsulation: HGE+Ce6. Covalent conjugates: GC-Ce6, PheoA-ss-GC and PheoA-GC."
    }, {
      "heading" : "4.1.4. Nucleic acids (siRNA, antisense RNA, micro RNA, plasmid DNA) as anti-cancer drugs using chitosan based amphiphilic delivery system for cancer therapy",
      "text" : "Recently, chitosan-based nanocarriers have become one of the non-viral vectors that have gained increasing interest as a safe delivery system for gene materials, such as plasmid DNA (pDNA), oligonucleotides and siRNA. 57 The nterest in the application of chitosan as nanocarrier for gene delivery is mainly attributed to its low toxicity, low immunogenicity and excellent biocompatibility as well as a strong positive charge density. Due to its positive charge, chitosan can readily form polyelectrolyte complexes with negatively charged nucleotides by electrostatic interaction. 35 On the other hand, chitosan also can form NPs with other negative charged molecules for further encapsulation of nucleic acids. In general, there are\nPage 13 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "14 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nthree types of chitosan-based nanocarriers for nucleic acids. 35 First, therapeutic nucleic acids can be encapsulated in chitosan hydrogel NPs (nanogels) in which chitosan polymeric chains are interconnected via covalent or ionic cross-linkages. For example, the group of Maria Alonso pioneered TPP induced ionic gelation of chitosan to form nanoscopic drug delivery carriers 112 and Csaba et al. formulated pDNA and short dsDNA oligonucleotides into chitosan/TPP (tripolyphospate) crosslinked NPs prepared with chitosan of varying Mw. chitosan. 195 Second, chitosan as a polycation can directly form polyelectrolyte complexes with nucleic acids. Third, NPs, formed by negatively charged and degradable polymers in advance, can be coated with chitosan. The resulting new NPs can further encapsulate nucleic acids in high efficiency. However, the gene delivery efficiency of chitosan is significantly influenced by the relevant parameters of formulation, such as the Mw of chitosan, its degree of deacetylation, the charge ratio of chitosan to DNA/siRNA (N/P ratio), the chitosan salt form used, the DNA/siRNA concentration, pH, serum, additives, the preparation techniques of chitosan/nucleic acid particles and routes of administration. The influence of these parameters has recently been reviewed in detail by Mao et al. and Kim et al., respectively. 56, 57\nAlthough chitosan as a non-viral gene delivery vector has many advantages, the poor solubility and stability of the polyplex at physiological pH, the low cell specificity as well as the resulting low transfection efficiency significantly limit the application of this system. 57 Taking all steps influencing the final transfection efficiency into consideration, including enzymatic degradation, inefficient cellular uptake, encapsulation in endo-lysosomes, failure of NA/polymer dissociation and nuclear localization, several strategies are utilized to alleviate or solve these limitations. For example, conjugating stealth-conveying polymers to chitosan, such as PEG, 196, 197 can improve stability of the polyplex in biological fluids (serum). Conjugating a cellspecific ligand to chitosan, such as transferrin-, folate-, mannose- and galactose-conjugated chitosans, can enhance cellular uptake efficiency and specificity toward the target cells. 198-202 To get efficient release from endosomes into the cytoplasm, chitosan carriers can either be modified with certain chemical segments, such as PEI and other chemical segments for proton sponge effect. 203-206 Generally, chitosan based nanocarriers for gene delivery with high transfection efficiency can be achieved by certain modifications of the chitosan structure including non-covalent interaction and covalent conjugation. In this process, related physicochemical characteristics of nanocarriers are altered, as well. Among these modifications, amphiphilic delivery system occupies a large proportion. The following text will describe the detail according to their possible working mechanisms."
    }, {
      "heading" : "4.1.4.1. Nanocarriers formed by no covalent interactions",
      "text" : "As aforementioned, chitosan based nanocarriers can be prepared by non-covalent interactions like electrostatic\ninteraction, by which positively charged chitosan can cover the surface of NPs assembled by negatively charged polymers. Poly-(ɛ-caprolactone) (PCL) 207 and poly (D, L-lactic-co-glycolic acid) (PLGA) 208-210 particles are highly selected due to their biodegradable, biocompatible and negatively charged characters (Fig. 15). The resulting core-shell NPs endowed with a positive zeta-potential can enhance the particles' affinity with negatively charged cellular membranes and trigger subsequent endocytic uptake (in vitro). Furthermore, chitosan owns high affinity to mucosal surfaces (in vivo). These amphiphilic NPs for nucleic acids delivery are mainly formulated by an emulsion-diffusion-evaporation technique using poly-(vinyl alcohol) (PVA) as a stabilizer. Lehr et al. developed chitosan and its derivative modified PCL 207 and PLGA 208-210 NPs to deliver nucleic acids. Especially, they applied chitosan-coated PLGA particulate carriers binding the antisense oligonucleotides, 2′-O-methyl-RNA as a flexible and efficient delivery system to lung cancer cells. 208, 209 Yuan et al. also studied chitosan-PLGA NPs as a siRNA delivery system in the HEK 293 T cell. 211 Poly-(vinyl alcohol) (PVA) is not the only material as a stabilizer. Yamamoto et al. used cationic lipid (1, 2-dioleoyl-3-trimethylammonium-propane, DOTAP) to stabilize siRNA, which highly improved the encapsulation efficiency of siRNA. 212\nFig. 15 Chemical structures of representative CS based materials for gene encapsulation and delivery using noncovalent interaction. The gene delivery system includes: positively charged CS or its derivative, negatively charged polymer (e.g., PCL, PLGA), and stabilizer (e.g., PVA, DOTAP).\nBeside DOTAP as a stabilizer, such type of cationic lipids can also be applied to form liposomes covered with chitosan by electrostatic interaction for gene delivery. Liang et al. evaluated the feasibility of chitosan-coated liposomes (CSLP) as vehicles for anti-sense oligodeoxynucleotides (ASON), in which phosphatidylcholine and cholesterol were used to coconstruct the liposomes. 213"
    }, {
      "heading" : "4.1.4.2 Nanocarriers constructed by covalent conjugations",
      "text" : "Directly conjugating hydrophobic units to chitosan and its derivatives is another option of building non-viral amphiphilic system for gene delivery. Regarding the possible working mechanisms, such as favourable dissociation including proton spongy effect, thermo-responsive release is preferable among numbers of cases. Hydrophobic units in the polymeric carriers may assist the dissociation of chitosan/DNA complexes, to facilitate release of DNA when compared to the strong bind through ionic interactions between cationic units and the phosphates of DNA. Hydrophobic interaction may increase the penetration of carriers into cells or destabilize endosomal membranes and favour the DNA release into the cytoplasm in gene delivery applications. As mentioned above, a number of hydrophobic modified chitosans are investigated, such as stearic acid modified chitosan, 214, 215 linoleic acid modified\nPage 14 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 15\nPlease do not adjust margins\nPlease do not adjust margins\nchitosan, 216, 217 5-β cholanic acid modified chitosan, 218 deoxycholic acid modified chitosan, 219-221 N-alkylated chitosan, 222, 223 N-/2(3)-(dodec-2-enyl) succinoyl grafted chitosan, 224 quaternized N-(4-pyridinylmethyl) chitosan, 225 quaternized N-(4-N,N-dimethylaminobenzyl) chitosan, 226 photosensitizer-triphenylphophyrin grafted chitosan, 227 hydrophobic aromatic polymer grafted chitosan 228 (Fig. 16). The hydrophobized chitosan were prepared by simply chemical reactions, such as carbodiimide chemistry, alkylation or acylation under basic conditions using related alkyl halides (bromide) or acyl chloride, as well as reduction of imines.\nFig. 16 Representative chemical structures of hydrophobically modified chitosan and its derivatives as matrixes for gene delivery.\nThere are some impressive studies related to cancer therapy in above cases. Hu et al. modified chitosan oligosaccharide (CSO) with stearic acid (SA) as a hydrophobic group and investigated the transfection efficiency of the resulting micelle/DNA complexes in A549 cells (Fig. 16). 214 They found that the transfection of SA-CSO/DNA complexes increased with the post-transfection time over 76 h. The achievement approached that of Lipofectamine TM 2000/DNA and was much higher than that of CSO/DNA. In addition, due to the high cytotoxicity of LipofectamineTM 2000, transfection with LipofectamineTM 2000/DNA could not last long time and rapidly decreased after 24 h. In order to increase transfection efficiency, Singh et al. grafted cell-penetrating peptidepenetratin onto linoleic acid modified chitosan to provide dual functionalized chitosan (CS-Lin-Pen) as a nonviral gene carrier. The CS-Lin-Pen/pDNA polyplexes exhibited ∼34 to 40 fold higher transfection in comparison with unmodified chitosan in HEK 293, CHO, and HeLa cells. 216 In 2014, Yin et al. prepared folate (FA) modified amphiphilic linoleic acid (LA) and poly (βmalic acid) (PMLA) double grafted chitosan (LMC) (NPs), which were developed for the co-delivery of paclitaxel (PTX) and survivin shRNA-expressing plasmid (iSur-pDNA). 217 This codelivery system demonstrated a dramatically improved antitumor efficiency (in vitro and in vivo) compared to single administration with PTX or pDNA (Fig. 17). They subtly utilized the hydrophobicity of LA and the hydrophilicity of PMLA to control the entire delivery processes including PTX loading and release, resistance of protein adsorption, cellular uptake and the intracellular disassociation of pDNA. In addition, the antitumor efficacy of NPs was further strengthened through the active targeting induced by the ligand modification. The above result could give vital understandings on the design of amphiphilic NPs as co-delivery systems for tumour therapy. Photochemical internalization (PCI) is also utilized to induce release of trapped drugs and macromolecules from endosomes into the cytosol with the assistance of selected photosensitizers in combination with light. Másson et al. prepared water-soluble amphiphilic chitosan NPs conjugated\nwith the photosensitizer meso-tetraphenylporphyrin (TPP). 227 Due to the π-π stacking of the photosensitizer, these carriers can unfold in the lipophilic environment and the photosensitizer moiety can be inserted into the cell membrane. The gene delivery efficacy of the NPs mediated by photochemical internalization (PCI) was evaluated in vitro using the HCT116/LUC human colon carcinoma cell line, which was comparable to the current clinical candidate TPCS2a.\nFig. 17 Antitumor efficiencies of LMC NPs and FA-LMC NPs compared to single administration with PTX or pDNA. (A) Tumour growth curves of H-22 tumour bearing mice following treatment with PTX injection and various NPs formulations. Indicated values were mean ± SD (n ¼ 6). (B) Photographs of tumour from each treatment group excised on day 14. (C) Survival curves of H-22 tumour bearing mice treated with PTX injection and various NPs formulations. Reprinted from Ref. 217. Copyright 2014 with permission from Elsevier.\nThe above examples demonstrated the primary amine of chitosan can be utilized as the counterpart of negatively charged nucleic acids to form complexes with them. Besides this, quaternized chitosan also was explored to compress and encapsulate nucleic acid for gene delivery. Opanasopit et al. designed and synthesized two types of hydrophobic moieties modified chitosans, i.e. quaternized N-(4-pyridinylmethyl) chitosan (TM-Py-CS) and quaternized N-(4-N,Ndimethylaminobenzyl) chitosan (TM-Bz-CS) (Fig. 16). 225, 226 The synthesis route was shown in scheme 7. First, chitosan reacted with different aromatic aldehydes such as 4-N, Ndimethylamino benzaldehyde or 4-pyridinecarboxaldehyde at acidic condition to form imines intermediates that can be reduced by NaCNBH3 at pH 5 to produce related secondary amines intermediates. Second, N-methylation of above intermediates using methyl iodide and the following ion exchange by 15% sodium chloride aqueous solution afforded final compounds----quaternized N-(4-pyridinylmethyl) chitosan(TM-Py-CS) and quaternized N-(4-N,Ndimethylaminobenzyl) (TM-Bz-CS) chitosan. They investigated the transfection efficiency of above modified chitosans using the pDNA encoding green fluorescent protein (pEGFP-C2) on human hepatoma cell lines (Huh 7 cells). High transfection efficiencies were obtained in both cases, but highly dependent on the degree of quaternization (DQ), the extent of N-aromatic substitution (ES) and the weight ratio. The results indicated that the improved gene transfection was possibly due to aromatic substitutions (4-pyridinylmethyl and N, Ndimethylaminobenzyl) on CS, which promoted the interaction and condensation with DNA and increased the water solubility of CS. In general, these delivery systems show promising potential as gene carriers by efficient DNA condensation and mediated higher levels of gene transfection in Huh7 cells.\nPage 15 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "16 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nScheme 7 Schematic illustration of syntheses of quaternized N-(4-pyridinylmethyl) chitosan (TM-Py-CS) and quaternized N(4-N, N-dimethylaminobenzyl) chitosan (TM-Bz-CS). Adapted from Ref. 225, 226. Copyright 2008 with permission from Elsevier.\nChitosan were functionalized with different imidazole moieties with the aim of improving its buffering capacity, promoting the endosomal escape ability of chitosan–DNA complexes, and ultimately increasing their transfection efficiency, such as urocanic acid modified chitosan, 229 imidazole acetic acid modified chitosan 206 and histidine derivative modified chitosan 230 (Fig. 18). Urocanic acid modified chitosan (UAC) showed good DNA binding ability, high protection of DNA from nuclease attack, and low cytotoxicity. The transfection efficiency of chitosan, coupled with urocanic acid, into 293T cells was highly enhanced and strengthened with an increase of urocanic contents in the UAC. 229 Similarly, imidazole-acetic acid modified chitosan had no cytotoxic effect in 293T cells and the resulting polymers with the highest degree of substitution could enhance b-gal expression in 293T and HepG2 cells. 206 Hashida et al. designed and synthesized histidine modified chitosan. 230 The synthesis of the polymer was illustrated in scheme 8. Dipetide His-Cys-OMe was firstly synthesized starting from Cys (Acm)-OH using HBUT/HOBt as coupling reagents. Meanwhile, chitosan reacted with 2- iminothiolane to afford an intermediate that can further react with His-Cys-OMe to produce Chitosan-Cysteine-Histidine polymer conjugate via disulfide bonds. For the transfection test of gene delivery, they found histidine-modified chitosan could improve the gene transfection efficiency by increasing the buffering capacity in the pH range of endosomes and lysosomes without affecting the integrity of the complexes. They also suggested that histidine helped the uptake of pDNA by cells and increased the efficiency of escape from endosomes and lysosomes.\nFig. 18 Chemical structures of representative chitosan conjugates for proton sponge effect in gene delivery. Imidazole residue is the key structure for proton sponge effect.\nScheme 8 Schematic illustration of synthesis of ChitosanCysteine-Histidine. Dual effects for gene release can be produced by the resulting NPs (proton sponge effect from histidine residue and reduced cleavage of -SS- by GSH). Adapted with permission from Ref. 230. Copyright 2010 American Chemical Society.\nPoly (N-isopropylacrylamide) (PNIPAAm) is a typical paradigm of thermosensitive polymers and its lower critical solution temperature (LCST) is about 34 o C. When PNIPAAm grafted onto other polymers (cationic vectors) used as DNA delivery, the transfection efficiency of transgene can be adjusted by temperature change. In a word, when the temperature is below LCST, the gene transfection efficiency can be improved due to the unpacking of gene from its carrier. For example, Turk et al. reported that the PNIPAAm-PEI copolymer had lower cytotoxicity than pure PEI, which also showed higher transfection efficiency. 231, 232 In addition, PNIPAAm grafted onto chitosan or its derivatives as copolymers for gene delivery also has been investigated (Fig. 19). 233, 234 Liu et al. synthesized a carboxyl-terminated NIPAAm/vinyl lauraten (VL) copolymer by radical polymerization and the resulting copolymer was then coupled onto chitosan using carbodiimide chemistry. 233 The dissociation of the PNVLCS/DNA complexes could be tuned by varying the temperature because PNVLC showed an LCST about 26 o C. At 37 °C, the collapse of PNIPAAm in PNVLCS was favourable for the formation of compact complexes and more DNAs were shielded inside. In contrast, the PVL and PNIPAAm chains facilitated the unpacking of DNA from PNVLCS, thereby increasing the exposure of DNA at 20 o C. 233 Ma et al. also synthesized a thermoresponsive copolymer, trimethyl chitosan-g-poly (N-isopropylacrylamide) (TMC-gPNIPAAm) by coupling PNIPAAm-COOH to TMC. 234 Hereinto, PNIPAAm-COOH was prepared by radical polymerization using N-isopropylacrylamide as a monomer and 4, 4`-azo bis (4- cyanovaleric acid) as a radical initiator (Fig. 19). HEK293 cell line was chosen as a model to study cellular uptake, gene transfection and cytotoxicity of the TMC-g-PNIPAAm/DNA particles. TMC-g-PNIPAAm has stronger ability to combine with DNA at 40 o C because of the collapsed PNIPAAm chain. The grafting of PNIPAAm will not affect cellular uptake of the particles at 37 o C. Contrarily, incubation of the cultured cells at 25 o C for a while, the gene transfection efficiency was significantly improved and the optimized gene transfection efficiency achieved by TMC-g-PNIPAAm is comparable to Lipofectamine 2000. Finally, they suggest that TMC-gPNIPAAm is an effective thermoresponsive gene carrier with minimal cytotoxicity, which has great promise for practical applications.\nFig. 19 Themosenstive polymers grafted chitosans PNVLCS and TMC-g-PNIPAAm used as gene carriers. The related polymers were produced by radical polymerization. The monomers are NIPAAM and VL for synthesis of PNVLCS and NIPAAM for synthesis of TMC-g-PNIPAAm, respectively."
    }, {
      "heading" : "4.1.4.3. Nanocarriers prepared by a combination of covalent",
      "text" : "conjugation and non-covalent interaction\nPage 16 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 17\nPlease do not adjust margins\nPlease do not adjust margins\nAs mentioned above, various approaches using chitosan and its derivatives as matrixes for gene delivery have been made, including non-covalent interactions and chemical conjugations, to enhance the pharmacokinetic behaviours, cellular uptake, target specificity, and safety of siRNA therapeutics. In order to find more effective method for gene transfection, Nam et al. combined non-covalent cover with chemical conjugation, achieving impressive results. 235 They incorporated the siRNA/chitosan-g-deoxycholic acid (COSD) polyplexes into PLGA NPs (Fig. 20a) and examined the stability and gene silencing activity of siRNA using MDA-MB-435 breast cancer cells that express green fluorescent proteins. Interestingly, a simple method that effectively encapsulated hydrophilic siRNA within biodegradable solid polymer NPs using hydrophobically modified polyelectrolytes to solubilize siRNA in organic medium was proposed (Fig. 20b). As illustrated in Fig. 20b, COSD formed a spherical micelle in aqueous milieu having a hydrophobic deoxycholate core and a hydrophilic chitosan shell. On the contrary, in organic solvent, when COSD is complexed with negatively charged siRNA, deoxycholates can be exposed to the surface and form a shell layer that stabilizes the nanoscale complex in the manner of reversed micelles, which indicated that siRNA was more efficiently condensed when the complex was formed in an organic medium. The siRNA/COSD-loaded PLGA NPs exhibited homogeneous cellular uptake and a higher level of gene silencing compared to the complexes siRNA/COSD (Fig. 20c). In general, these results suggest that the encapsulation of siRNA into biodegradable polymer matrix can be an effective means of improving the structural stability of siRNA for prolonged therapeutic efficacy. 235\nFig. 20 Nanocarrier prepared by a combination of covalent conjugation and no covalent interaction. a) Chemical structure of deoxycholic acid conjugated chitosan and PLGA; b) Schematic illustration for the preparation the siRNA/COSD complex in 50% DMSO followed by the preparation of the siRNA/COSD-loaded PLGA nanoparticles and the preparation the siRNA/COSD complex in water; c) Confocal microscopic images of the cellular uptake of Cy5.5-labeled siRNA using the siRNA/COSD complex (left) and the siRNA/COSD-loaded PLGA (right) in MDA-MB-435-GFP cells post 5 h and 48 h incubation. b), c) Reprinted from Ref. 235. Copyright 2012 with permission from Elsevier.\nIn conclusion, due to the specific chemical structure of chitosan (amine active functional group), numerous chitosan based amphiphilic conjugates were developed and the resulting NPs were shown to be effective drug delivery systems for cancer therapy, especially in vitro. Targeted drug delivery and more detailed experiments in vivo need be the main target for next progress. Carefully chosen multiple combinations in respect of carriers and drugs for the\ntreatment of cancer metastasis and MDR are promising but also represent a complexity challenge. A system that optimally exploits the various specific characteristics of chitosan for optimal in vivo and clinical application needs still to be identified."
    }, {
      "heading" : "4.2. Hyaluronan based amphiphilic delivery system for cancer therapy",
      "text" : ""
    }, {
      "heading" : "4.2.1. Introduction to Hyaluronan",
      "text" : "Hyaluronic acid (HA), an anionic and nonsulfated glycosaminoglycan, is composed of alternating disaccharide units of D-glucuronic acid and D-N-acetylglucosamine which are linked via alternating β-1,4 and β-1,3 glycosidic bonds (Fig. 3). 35 Hyaluronan is widely distributed from lower organisms such as simple bacteria 236, 237 to complex eukaryotes. 238, 239 In general, HA is one of the chief components of the extracellular matrix in mammalian organisms. 240 For example, in humans, 239 HA is abundant in the vitreous body of the eye, 241 the umbilical cord, 242 synovial fluid, 243, 244 heart valves, 245 skin, 246, 247 and skeletal tissues. 246 Commercially available HA is either produced through bacterial fermentation of streptococcus species or extracted from rooster combs, umbilical cords, synovial fluids or vitreous humour. 3 HA contributes significantly to cell proliferation and migration, and participates in a number of cell surface receptor interactions. 35, 239, 248, 249 Several HA-specific cell receptors have been identified, such as cluster determinant 44 (CD44), receptors for hyaluronate-mediated motility (RHAMM, CD168), HA receptor for endocytosis (HARE) and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1). 239 Due to the ubiquitous distribution of HA throughout the body and its intrinsic properties such as hydrophilicity, biocompatibility, biodegradability and non-immunogenicity, HA exhibits excellent application prospects for application in biomedicine. On one hand, non-immunogenic, highly viscous HA solutions are commercially available as a surgical aid in ophthalmology and as visco-supplementation for synovial fluids in patients with osteoarthritis. 240 On the other hand, HA is suitable for drug delivery, especially in cancer therapy. As mentioned above, CD44 and CD168 are HA-specific cell receptors and participate in cell adhesion interactions required by tumour cells, in which CD 44 and CD168 are over-expressed. 3, 250 Therefore, HA is suitable as a targeting agent for targeting CD44 and CD168 over expressing tumours such as squamous cell carcinoma, ovarian, colon, stomach cancers etc. In addition, HA has hydroxyl and carboxylic acid functional groups that can easily be modified chemically as described in more detail below. Thus, HA is a nice platform for drug delivery and we would like to highlight the value of modified HA as amphiphilic drug delivery system for cancer therapy in the next part.\nPage 17 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "18 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins"
    }, {
      "heading" : "4.2.2. Small molecules with HA based amphiphilic delivery system for cancer therapy",
      "text" : "Scheme 9 Schematic illustration of reaction sites of hyaluronan (HA) for constructing HA based nanocarriers. Reaction sites: 1) Carboxylic acid for amide or ester bond formation; 2) Primary hydroxyl group for ester bond formation; 3) Hemiacetal for imine or subsequent amine formation; 4) N-acetyl group for primary amine formation under enzyme-lysis; 5) Vicinal diol for the formation of dialdehyde which can be used for further modifications.\nAccording to the chemical structure of HA, there are four possible sites for the chemical modification as shown in scheme 9. 250 1), the carboxylate functional group on the glucuronic acid part can react with primary amine or hydroxyl functional groups of some derivatives of drugs, small molecules or polymers to form related amides or esters. 2), the N-acetylglucosamine hydroxyl functional group can react with carboxylic acid functional groups of some derivatives of drugs, small molecules or polymers to form related esters. 3), the aldehyde end can react with primary amine functional groups of some derivatives of drugs, small molecules or polymers followed by a reduction reaction to form related secondary amines. 4), the acetyl group of the Nacetylglucosamine unit may even be enzymatically removed to form related primary amine that can conduct further related reactions. 251 5), the bond between vicinal diol of HA can be broken by sodium periodate or other periodate salt to open monosaccharide ring and leave two aldehyde groups for further modifications. Through some modifications from above five reaction sites of HA, drugs conjugated to HA become corresponding macromolecular prodrugs, which can be released in certain physiological conditions. Thus, small molecules or macromolecules grafted to HA can serve as drug carriers. The resulting HA conjugates often display amphiphilic properties and thus self-assemble to form nano drug delivery systems and their application for cancer therapy is described in more detail in the following paragraph."
    }, {
      "heading" : "4.2.2.1. Polymer-drug (HA-drug) conjugates for cancer therapy",
      "text" : "As already discussed in the chitosan-drug conjugates section, small drugs can be conjugated to HA either with relative labile or more stable covalent bonds to form prodrugs. Fig. 21 shows some recent examples. Model anti-cancer drugs such as taxol, doxorubicin, were conjugated to HA by an ester bond directly or through linkers ranging from small bifunctional molecules (Fig. 21a, b) 252-258 to a polymer modified with an enzymatically degradable peptide (GFLG) (Fig. 21c), 258 or alternatively by a pH sensitive linker (cis-aconityl) combined with a redox disulfide bond (-S-S-) (Fig. 21c). 259 Other anti-cancer drugs such\nas butyric acid and retinoic acid, can also be directly conjugated to HA by ester bonds or amide bonds (Fig. 21d). 260- 264\nFig. 21 Chemical structures of representative HA conjugates covalently grafted by small anticancer drugs. a) HA-Taxol conjugates with amide bonds; b) HA-Taxol conjugates with ester bonds; c) HA-Doxorubicin conjugates; d) HA-Butyric acid conjugate and HA-Butyric acid, Retinoic acid conjugate.\nPrestwich et al. designed and synthesized a series of HA-Taxol bioconjugates by linking the 2’-OH of Taxol via a succinate ester to adipic dihydrazide-modified HA (HA-ADH). 252 The total synthesis is depicted in scheme 10. Here, HA-ADH was prepared by carbodiimide chemistry using EDCI as a coupling reagent. As certain human cancer cell lines (e.g. some breast, colon, and ovarian cancers) overexpress HA receptors, HATaxol conjugates can show selective toxicity, while no toxicity was observed in a mouse fibroblast cell line at the same concentrations treated in parallel to the cancer cells. 252 Later, the same group synthesized a fluorescently labelled HA-Taxol (FITC-HA-Taxol) using a similar synthetic strategy and applied it to study cell-specific binding and uptake. 253 The targeted cytotoxicity of HA-Taxol bio-conjugates required receptormediated cellular uptake of the bio-conjugate with a subsequent hydrolytic release of free Taxol. In in vivo study, Klostergaard et al. demonstrated that HA-Taxol prodrugs administered loco-regionally have antitumor activity in both NMP-1 and SKOV-3ip models. 254 In 2005, Bettolo et al. developed a new class of HA-taxol conjugates. This new class of paclitaxel derivatives was synthesized by coupling HA to paclitaxel using a 4-hydroxy butanoic acid derived linker (Fig. 21b). 255 Later, Rosato et al. evaluated the hydrosoluble bioconjugate for the treatment of superficial bladder cancer. 256 Significantly improved results were obtained in comparison of conventional paclitaxel treatment in terms of hydro-solubility, in vitro activity against human bladder cancer cells, and in vivo biocompatibility. This bio-conjugate has a large potential to treat superficial urothelial malignancies. In contrast to the examples above, Lockman et al. designed and synthesized HApaclitaxel conjugates without using any linker. An ester bond was directly formed between a carboxylic acid of HA and a hydroxyl group of paclitaxel using carbodiimide chemistry. 257 The HA-paclitaxel can passively diffuse across the blood– tumour barrier and then be taken up into cancer cells (MDA– MB–231Br) via CD44 receptor-mediated endocytosis and can avoid p-glycoprotein-mediated efflux from the cancer cells. To evaluate in vivo efficacy of the nanoconjugate, a preclinical model of brain metastases of breast cancer using intracardiac injections of Luc-2 transfected MDA-B-231Br cells was used. This study suggests that the small molecular weight HApaclitaxel nanoconjugate can improve standard\nPage 18 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 19\nPlease do not adjust margins\nPlease do not adjust margins\nchemotherapeutic drug efficacy in this model as the animals administered with HA-paclitaxel nanoconjugate had significantly longer overall survival compared with the control and the paclitaxel-treated group. 257\nScheme 10 Schematic illustration of synthesis of the HA-Taxol conjugate (adipic dihydrazide-modified HA). Adapted with permission from Ref. 252. Copyright 1999 American Chemical Society.\nHA-DOX conjugate is another prodrug form for selective delivery of anticancer drug doxorubicin to HA receptor overexpressing cancer cells. Prestwich et al. applied the same synthetic strategy as the above HA-taxol conjugate to produce a HA-DOX conjugate using a non-cleavable linkage between DOX drug and HA carrier (Fig. 21 c, amide bond). 258 They also designed and synthesized N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers -DOX conjugates containing HA as a side chain (HPMA-HA-DOX), in which a lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer was used for an efficient release of drug DOX. 258 As shown in scheme 11, the conjugate HPMA-HA-DOX was synthesized using a three-step procedure. First, the polymer precursor HPMA-(GFLG)-ONp was prepared by radical precipitation copolymerization of HPMA and Nmethacryloylglycylphenylalanylleucylglycine p-nitrophenyl ester. Second, DOX was bound to the polymer precursor by aminolysis and then an activated ester HPMA-(GFLG)-DOXONp was formed. Last, the compound HPMA-HA-DOX conjugate was approached by a reaction of the activated ester HPMA-(GFLG)-DOX-ONp with HA-ADH prepared in advance by a carbodiimide coupling chemistry between HA and ADH. Unlike the HA-Taxol conjugate containing an esterase-labile bond for efficient drug release, the effectively non-cleavable linkage between drug-DOX and HA carrier prevents the drug from exerting its effect and the cytotoxicity was dramatically reduced because the polymer-drug conjugate remains sequestered in the lysosomal compartment. With an assistance of the lysosomally cleavable GFLG peptide spacer, HPMA-HA-DOX bio-conjugate had higher cytotoxicity against human breast cancer (HBL-100), ovarian cancer (SKOV-3), and colon cancer (HCT-116) cells as well as efficient internalization by cancer cells relative to the non-targeted HPMA-DOX conjugate. On the other hand, HPMA-HA-DOX showed minimal cytotoxicity toward mouse fibroblast NIH 3T3 cells. Thus, the HA-modified HPMA copolymer showed improved toxicity due to receptor-mediated uptake of the macromolecular drug. 258 Recently, another active targeting DOX delivery using HA- DOX conjugate for orthotopic ovarian cancer theranostics was developed by Wang et al. They integrated two stimuli elements (Fig. 21c, pH and GSH sensitive) to DOX-HA prodrug conjugate for drug controlled release and utilized the first and fifth reaction sites (Scheme 9) to construct the conjugate. The\ndrug carrier is capable of achieving sustained controlled release and (LHRH) peptide can enhance specific uptake of NPs by OVCAR-3 cancer cells. 259\nScheme 11 Schematic illustration of synthesis of the HPMAHA-DOX conjugate. A Lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer was used for an efficient release of drug DOX. 258\nButyric acid as one of deacetylase inhibitors (HDACi) is known to induce cell differentiation and to inhibit the growth of a variety of human tumour cells. 265-267 Unfortunately, despite its impressively biologic activity, butyrate is not an ideal therapeutic agent because its rapid metabolism cannot maintain effective plasma concentration for obtaining complete growth inhibition. To overcome the constraint, Coradini et al. developed butyrate-prodrugs using hyaluronic acid as a carrier molecule which exerts a selective uptake that allows the targeting of butyrate. 260-262 Herein, HA is known to bind to a specific transmembrane receptor, CD44, which is overexpressed on the tumour cell surface and plays a relevant role in tumour cell migration. For the synthesis of HA-But, butyric residue was introduce to HA by a reaction between 6- OH group of the N-acetylglucosamine unit in HA and butyric anhydride (Fig. 21d). They designed and conducted series of experiments to evaluate the CD44-mediated cellular targeting of HA-But in the inhibition of different carcinomas, including hepatocellular carcinoma cell lines in vitro and hepatic tumour metastases in vivo; 260 human breast-cancer cell line (MCF7); 261 a non-small cell lung carcinoma cell line (NCI-H460) in vitro and its metastatic subclone (NCI-H460M). 262 In general, the conjugate HA-But not only benefits an increased half-life of the active component, but also the potential development of a drug-delivery system specifically aiming at tumour cells, such as a promising new drug for the treatment of intrahepatic tumour lesions, 260 possible clinical application of these novel butyric prodrugs in primary and metastatic lung cancer. 262 As a histone deacetylases inhibitor, butyric acid combined with alltrans retinoic acid (ATRA) can be used for treating RA-resistant promyelocytic leukaemia. Coradini et al. explored the in vitro and in vivo effects of a novel retinoic/butyric hyaluronan ester (HBR) (Fig. 21d) on a retinoic acid (RA)-sensitive human myeloid cell line, NB4, and on its RA-resistant subclone, NB4.007/6. 263 The impressive results suggested that HBR might be useful in controlling the proliferation of RA-resistant cells and the differentiation of RA-sensitive cells. The amide bond is another alternative to couple HA and retinoic acid. In 2013, Yao et al. prepared an amphiphilic hyaluronic acid (HA)-g-alltrans retinoid acid (HRA) conjugate as a tumour-targeting nanocarriers for potentially synergistic combination chemotherapy of all-trans retinoid acid (ATRA) and paclitaxel (PTX) (Fig. 21d). 264 The HRA conjugate was synthesized by\nPage 19 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "20 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nconnecting carboxylic acid groups of HA and retinoid acid via amide bonds through a diamine linker. The HRA NPs could be endocytosed in high efficiency by cells and transported into the nucleus, which could assist the drugs aiming at the tumour due to HA receptor-mediated endocytosis and ATRA-induced nuclear translocation as well as EPR effects."
    }, {
      "heading" : "4.2.2.2. Amphiphilic polymers formed by small hydrophobic molecules grafted HA for cancer therapy",
      "text" : "As discussed in the chapter focusing on chitosan conjugates, small hydrophobic molecules including lipids (phosphatidylethanolamine lipid, 268-271 ceramide 272, 273 ), steroids (β-cholanic acid, 274-279 deoxycholic acid, 280 cholesterol 281 ), aromatic compounds (pyrenyl derivatives, 96, 282, 283 ,α-tocopherol 284 ) and simple long carbon chain, 285-287 which are biocompatible or biodegradable, can be covalently grafted onto HA to form amphiphilic macromolecules as nanocarriers. In a different study, hyaluronic acid modified mesoporous carbon NPs were designed and prepared for targeted drug delivery to CD44-overexpressing cancer cells. 288 Representative examples are illustrated in Fig. 22. There are three typical covalent bonds formed by coupling reactions between HA and small hydrophobic molecules, i.e. C-N bond (second amine), 268-271 ester 272, 273, 281, 286, 287 and amide 96, 274-280, 282-285 bonds. Poly (ethylene glycol) (PEG) chain was also introduced by an amide bond into some HA conjugates to effectively reduce liver uptake and increase the circulation time in the blood, thereby leading to selective accumulation of the NPs to the tumour site. 96, 277-279, 282 For anticancer therapy, small anticancer drugs or prodrug such as doxorubicin(DOX), camptothecin (CPT), docetaxel (DCT), 4-(N)-lauroylgemcitabine (C12GEM), were encapsulated into the nanocarriers by hydrophobic interaction or π- π stacking attraction etc.\nSzoka et al. designed and synthesized phosphatidylethanolamine lipid (POPE) derivatives containing HA oligosaccharides (HA-POPE) via an imine reduction with NaNH3CN. The imine conjugate was prepared by a reaction between the terminal aldehyde group of HA and the amine group of POPE (Fig. 22a). 268, 269 The HA-POPE conjugate based liposomes (HALs) were utilized to load Dox and target tumor cells that express CD44, such as B16F10 murine melanoma cell line. Compared to the IC50 of non-encapsulated DOX in cells expressing levels of CD44, the DOX delivered by HAL was significantly more potent. 268 Furthermore, the study also determined and modelled the kinetics of cancer cell killed by free DOX and DOX encapsulated in the targeted liposomes, respectively. 269 Another lipid-HA conjugate HA-DPPE (1,2- dipalmitoylsn-glycero-3-phosphoethanolamine) was introduced to treat pancreatic adenocarcinoma by Palmieri and Arpicco et al. 270, 271 The conjugate was synthesized in a similar method as the preparation of the conjugate HA-POPE (Fig. 22a). A lipophilic prodrug (4-(N)-lauroyl-gemcitabine,\nC12GEM) as a model drug was successfully encapsulated into the HA-DPPE participated liposomes. In vitro testing was done in MiaPaCa2 cells (CD44+) 270 and in vivo testing was conducted in a mouse xenograft tumour model of human pancreatic adenocarcinoma. 271 The results demonstrate that HAconjugated liposomes have a large potential to treat pancreatic adenocarcinoma. In 2011, Kim et al. developed Hyaluronic acid-ceramide (HA-CE) based self-assembled NPs for intravenous docetaxel (DCT) delivery (Fig. 22a). 272 It should be mentioned here that pluronic P85 (P85) was added to the NPs due to its ability to stabilize the effects of the micellar structure and overcome MDR through intracellular ATP depletion and inhibition of the ATPase activity of drug efflux proteins. The in vivo tumour targeting ability identified by NIR fluorescence imaging studies showed that the interaction between HA and CD44 receptors, together with an EPR effect, was the principal driving force for tumour targeting. Later, the same research group used nanohybrid liposomes coated with amphiphilic hyaluronic acid-ceramide (HA-CE) for targeted delivery of anticancer drug DOX and in vivo cancer imaging with reagent Magnevist, a contrast agent for magnetic resonance (MR) imaging. A series of experiments proved that the nanohybrid-liposomal system may be a useful candidate for real-time cancer diagnosis and therapy. 273\nFig. 22 Small hydrophobic molecules grafted HA as nanocarriers for drug delivery. a) Lipid-HA conjugates; b) Steroid-HA conjugates; c) Aromatics-HA conjugates; d) Long carbon chain-HA conjugates.\nPark et al. synthesized amphiphilic hyaluronic acid conjugates by chemical conjugation of hydrophobic 5-β cholanic acid to the backbone of HA using carbodiimide coupling chemistry. 274 In order to evaluate the cellular uptake and the biodistribution of resulting NPs self-assembled by the HA conjugates, the NPs were labelled by dye Cy5.5. In vitro study demonstrated that the NPs were efficiently taken up by CD44 overexpressing SCC7 cancer cells. For in vivo study, most of Cy5.5-labeled HA NPs were found in tumour and liver sites. Further study showed that HA-NPs selectively targeted to tumour tissue due to both passive accumulation via the EPR effect and active targeting by the strong receptor-binding affinity of HA to CD44 with high specificity. 275 Based on this insight, encapsulation of anti-cancer drug DOX was investigated. 276 It was found that hyaluronic acid NPs (HA-NPs), mineralized by calcium phosphate, led to robust nanocarriers for the anticancer drug doxorubicin (DOX), with a release of DOX at specific sites under mildly acidic conditions such as in the extracellular matrix of tumour tissue, in intracellular compartments (endosomes and lysosomes) of the cell. While the HA-NPs were systemically administered into tumour-bearing mice, a significant portion of HA-NPs was also found in the liver\nPage 20 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 21\nPlease do not adjust margins\nPlease do not adjust margins\nprobably due to their cellular uptake by phagocytic cells of the reticuloendothelial system and by liver sinusoidal endothelial cells expressing another HA receptor (HARE). In order to overcome the limit, the HA-NPs were chemically modified with PEG via amide bonds formation (Fig. 22b). 277 The study proved that the appropriate PEGylation of HA-NPs can provide a reduced uptake in the liver, a prolonged blood circulation, and improved tumour target ability. Later, Park et al. successfully used this PEGlated HA-NPs as nanocarriers for anticancer drugs delivery including doxorubicin (DOX) and camptothecin (CPT). 278 CPT-loaded P-HA-NPs (CPT-P-HA-NPs) showed dosedependent cytotoxicity to cancer cells (MDA-MB-231, SCC7, and HCT 116) and significantly lower cytotoxicity against normal fibroblasts (NIH-3T3) than free CPT. In addition, unlike DOX, high concentrations of CPT-P-HA-NPs demonstrated greater cytotoxicity to cancer cells than free CPT. In 2013, the same research group mineralized poly (ethylene glycol)conjugated hyaluronic acid NPs (PEG-HA-NPs) through controlled deposition of inorganic calcium and phosphate ions in the nanoparticular shell via a sequential addition method. 279 DOX as a model anticancer drug was effectively encapsulated into the mineralized NPs (Fig. 23-1). The DOX release study showed that DOX was slowly released from NPs under physiological condition (pH 7.4), whereas its release rates were much higher at mildly acidic environments (<pH 6.5). The antitumor efficacy of DOX-loaded NPs was evaluated after systemic administration into the tumour-bearing mice, compared with DOX-PEG-HANPs, from which the most effective antitumor efficacy was observed for DOX-loaded MPEG-HANPs (Fig. 23-2). Generally, these results suggest that MPEG-HANPs are promising as a drug carrier for cancer therapy.\nFig. 23 DOX-loaded mineralized NPs (DOX-M-PEG-HANPs) and its antitumor efficacy. 1) Schematic formation of DOX-M-PEGHANPs; 2) (a) Antitumor efficacies of saline, free DOX, DOXPEG-HANPs and DOX-M-HANPs. The error bars represent standard deviation (n = 5). Asterisks (*) denote statistically significant differences (*p b 0.05) calculated by one-way ANOVA test; and (b) Representative images of excised tumours. Reprinted from Ref. 279. Copyright 2013 with permission from Elsevier.\nIn modern cancer chemotherapy, targeted delivery of therapeutic agents and their stimuli-responsive release are very promising. Redox-sensitive amphiphilic delivery systems are of strong interest to trigger a burst release of encapsulated drugs in response to the intracellular redox potential. Huo et al. developed a targeted intracellular delivery system of paclitaxel (PTX) based on redox sensitive hyaluronic aciddeoxycholic acid (HA-ss-DOCA) conjugates. 280 Another noredox sensitive conjugate HA-DOCA was prepared as a comparison. Both conjugate types were synthesized by\ncarbodiimide chemistry between HA and deoxycholic acid using redox linker cystamine and no-redox linker adipic dihydrazide, respectively. The micelles formed with HA-ssDOCA exhibit excellent drug-loading capacities for PTX, a model hydrophobic anticancer drug, and also provide an effective approach for rapid transport of cargo into the cytosol, which significantly increased the antitumor efficacy of PTX against MDA-MB-231 cells, compared to the micelles formed with HA-DOCA. Besides targeting delivery, deeper tumour penetration also contributes to successful chemotherapy. Qi et al. developed tumour-homing penetrating peptide tLyP-1-functionalized tLPTS/HATS NPs which were composed of two modularized amphiphilic conjugates of tLyP-1-PEG-TOS (tLPTS) and TOS-grafted hyaluronic acid (HATS) (Fig. 22c). 284 Here, D-α-tocopheryl succinate (TOS) was conjugated to HA and penetrating peptide tLyP-1 peptide (CGNKRTR) via an amide bond, respectively. The fabricated NPs were used for tumour-targeted delivery of docetaxel (DTX).\nHaam et al. developed a π-hyaluronan (π-HA) (Fig. 22c) nanocarrier (π HNC) for CD44-targeted and pH-boosted delivery of an aromatic anticancer drug to cancer cells (Scheme 12). 96 The amphiphilic π-hyaluronan (pyrenyl hyaluronan, pHA) was synthesized using EDC chemistry, and self-assembled to form π HNC, which can load doxorubicin---an aromatic drug by π-stacking attraction. DOX-loaded pHNC (pHNC/DOX) demonstrated effectually therapeutic activity in both in vitro and in vivo models of CD44-positive human gastric cancer. Another interesting case for drug encapsulation using the π-π stacking attraction as well as hydrophobic interactions was illustrated by Char et al. NPs self-assembled by Hyaluronic acid-graphene oxide conjugates (HA-GO) (Fig. 22c) could encapsulate a photosensitizer (Ce6) in high loading amount. The HA-GO based drug delivery system were then applied as a cancer cell targeted and photoactivity switchable nanoplatform for PDT. 282 The near-infrared fluorescent dyes are utilized not only as photosensitizers for PDT in cancer therapy, but also as tumour-specific contrast agents for imaging. Normally, these near-infrared fluorescent dyes were used as a fluorescent molecule. However, few examples were reported by using the dyes as a PAT (Photoacoustic tomography) contrast agent. In addition, PAT is a powerful and non-invasive technique to visualize organs as well as diseased sites such as tumour tissues. In 2015, Miki and Ohe et al. prepared amphiphilic hyaluronic acid (HA) derivatives bearing hydrophobic indocyanine green dye derivatives and hydrophilic PEG through PyBOP condensation and coppercatalyzed click reaction (Fig. 22c). 283 By the irradiation of HA derivatives based NPs with near-infrared light, tumour sites were clearly visualized by optical imaging as well as by photoacoustic tomography.\nPage 21 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "22 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nScheme 12 Schematic illustration of the p-hyaluronan nanocarrier with doxorubicin (πHNC/DOX) for CD44-targeted and pH-boosted aromatic drug delivery. (a) Self-assembly of πHNC with a CD44 targeting hyaluronan shell and a π-rich core entrapping aromatic DOX inside via π-stacking attraction and hydrophobic interactions, and (b) The proposed in vivo delivery mechanism of pHNC/DOX to CD44 positive cancer cells; (i) Passive accumulation via the EPR effect and active targeting via CD44- mediated endocytosis, (ii) Quick release of DOX from πHNC by pH reduction in cancer, and (iii) Induced apoptosis of CD44 positive cancer cells. Reproduced from Ref. 96. Copyright 2013 with permission from the Royal Society of Chemistry.\nIn some cases, HA and folic acid are both introduced to amphiphilic delivery system to allow a dual targeting. Sun et al. developed a series of novel self-assembled hyaluronic acid derivatives (HA-C18) grafted with hydrophobic octadecyl moiety and further dual targeting folic acid-conjugated HA-C18 (FA-HA-C18) (Fig. 22d). 285 In vitro antitumor activity tests suggested PTX-loaded HA-C18 and FA-HA-C18 micelles exhibited significantly higher cytotoxic activity against MCF-7 and A549 cells. The hydrophobic segment long carbon chain in above example was conjugated to HA through amide bonds between carboxyl groups and terminal amine groups of the hydrophobic moiety. Recently, a few examples of introducing long carbon chains as hydrophobic segments to HA through ester bonds, formed by the reactions between related long carbon anhydrides and hydroxyl groups of HA, were presented to build amphiphilic HA derivatives as nanocarriers for drug delivery (Fig. 22d). 286, 287\nOne recent interesting study combined several elements to smart NPs for tumour PDT including NPs construction, targeted delivery, controlled functional material release and final therapies. 289 First, this PD-NP was constructed by Fe 3+ chelation with polydopamine NPs (PD-NPs) and photosensitizer−hyaluronic acid (PS-HA) conjugates, which were prepared by an ester formation between acetylated HA and photosensitizer pheophoride-a (Pheo-a) in advance (Scheme 13-1, 13-2b). Then, due to HA coating, the resulting NPs underwent receptor-mediated endocytosis under CD44 receptor overexpressed cancer environments, thereby producing a targeted delivery (Scheme 13-2c). Third, the resulting NPs were fluorescence/ROS switchable because the absorption wavelength of PD-NPs matched the wavelength of the fluorescence of PS-HA. When the PS-HA shielded PD-NP (PHPD-NP) was under a surrounding with the existence of hyaluronidase (HAase) that is a cancer selective enzyme, abundant in the tumor environment and plays key role for tumor proliferation and metastasis, the Fluorescence/ROS generation was off. In contrast, HA was degraded by HAase and photosensitizer was released and then produced singlet oxygen to kill cancer cells under laser irradiation (scheme 13-\n2a). Last, due to an excellent singlet oxygen generation capacity for PDT, an efficiently photothermal conversion ability for photothermal therapy (PTT) was demonstrated in the PHPD-NPs system (Scheme 13-2c). Therefore, the combination of properties afforded superior therapeutic efficacy against cancer cells.\n1)\n2)\nScheme 13 PHPD-NPs and its working mechanism in anticancer therapy. 1) Schematic illustration of iron-mediated coordination in preparation of PHPD-NPs; 2) Schematic Illustration of a tumor-Specific and photoactivity-controllable nanoparticle photomedicine. (a) Preparation process of photosensitizer−hyaluronic acid conjugates shielded polydopamine nanoparticles (PHPD-NPs) and their photoactivity on−off control; (b) chemical structure of polydopamine nanoparticles (PD-NPs) and photosensitizer−hyaluronic acid (PS-HA) conjugates; and (c) cancer-specific cellular internalization of PHPD-NPs and their photo-activity restoration by cancer specific enzyme (e.g., hyaluronidase, HAase): under laser irradiation, the ROS generated from PS and the heat from PD-NPs can effectively kill cancer cells. Adapted and reprinted with permission from Ref. 289. Copyright 2016 American Chemical Society."
    }, {
      "heading" : "4.2.2.3. Amphiphilic co-polymers formed by macromolecules grafted HA for cancer therapy",
      "text" : "NPs, fabricated through self-assembly of co-polymeric amphiphiles based on HA, have emerged as promising carriers for the delivery of anti-cancer small molecules including doxorubicin (DOX), paclitaxel (PTX). In these co-polymeric amphiphiles, HA acts as a hydrophilic segment as well as atargeting ligand of the CD44 receptor over-expressed on the surfaces of many cancer cells. Hydrophobic moieties are generally selected from some biodegradable or biocompatible polymers such as PBLG, 290, 291 PCL, 292 DENA oligomer, 293"
    }, {
      "heading" : "PLGA,",
      "text" : "294, 295 PLA, 296 and PHis 297 (Fig. 24). In some cases, poly ethylene glycol (PEG) is also introduced to the system to increase the stealth of nanocarriers (Fig. 24). 295, 296 In general, there are two steps for preparations of the targeted copolymers, i.e. polymerizations of monomers to form hydrophobic segments followed by coupling reactions with HA using carbodiimide chemistry or “click chemistry”.\nFig. 24 Representative HA-copolymer conjugates as nanocarriers for drug delivery.\nLecommandoux et al. used “click chemistry” as an easy and versatile synthetic strategy to combine hyaluronan with\nPage 22 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 23\nPlease do not adjust margins\nPlease do not adjust margins\npolyglutamate blocks. 290, 291 The synthesis of Hyaluronanblock-Poly (γ-benzyl glutamate) (PBLG-b-HYA) copolymers was illustrated in scheme 14. For the click reaction, one segment, PBLG end-functionalized by an azide group was prepared by polymerization of monomer γ-benzyl-L-glutamate (BLG) using 3-azidopropan-1-amine as an initiator. Another segment, HYA having an alkyne terminal group was obtained by an imine reduction between the hyaluronan and propargylamine using sodium cyanoborohydride as a reducing agent. Huisgen’s 1, 3- dipolar cycloaddition (click reaction) afforded the targeted PBLG-b-HYA block copolymers using CuBr as catalyst and pentamethyldiethylenetriamine (PMDETA) as ligand. The PBLG-b-HYA based nanovesicles with a controlled size, excellent colloidal stability and a high loading capacity for drug doxorubicin were evaluated in C6 glioma tumour cell lines. 290 They found that block copolymers provide significant advantages in controlling both the vesicular structure and the biofunctionality. Furthermore, they investigated the intracellular delivery of doxorubicin (DOX) loaded these polymersomes (PolyDOX) in high (MCF-7) and low (U87) CD44 expressing cancer cell models. Cytotoxicity of the drug was concentration and exposure time dependent. In addition, reactive oxygen species (ROS) level in both cells was significantly enhanced. In vivo test, PolyDOX also suppressed the growth of breast tumour on female Sprague- Dawley (SD) rats as compared to phosphate buffer saline pH 7.4 (PBS) control group. The reduced level of serum enzymes (LDH and CPK) by PolyDOX formulation indicated less cardiotoxicity of DOX after loading in polymersomes. In general, results suggest that this polymersome could be used as a self-targeting drug delivery cargo in over-expressed CD44 glycoprotein cells of breast cancer. 291 In 2015, a similar synthetic strategy was applied to prepare another amphiphilic HA derivative HA (PDA)-b-PCL by Park et al. The polycaprolactone (PCL) segment instead of PBLG was used as a hydrophobic part and the thiol reagent 2-(Pyridyldithio)-ethylamine (PDA) was introduced to HA by an amide bond to further form a bioreducible disulfide bond (-S-S-) as a cross linkage for the whole HA-NP (Fig. 24). 292 Doxorubicin (DOX), a model anticancer drug, was effectively encapsulated into the NP. The DOX-loaded bioreducible HA NPs (DOX-HA-ss-NPs) could effectively deliver the DOX into the nuclei of SCC7 cells in vitro as well as to tumours of SCC7 tumour-bearing mice in vivo. The result demonstrated an improved antitumor efficacy in tumour-bearing mice.\nScheme 14 Schematic illustration of synthesis of amphiphilic copolymer PBLG-b-HYA. Imine reduction and “click” reaction are the two key steps for the synthesis of PBLG-b-HYA.290, 291 Adapted with permission from Ref. 290. Copyright 2009 American Chemical Society.\nIn 2010, Park et al. synthesized hydrotropic HA derivatives (HydroHA) by chemical conjugation of an amine terminated hydrotropic DENA oligomer, produced by a radical polymerization of a monomer 2-(4-(Vinylbenzyloxy)-N,Ndiethylnicotinamide) (VBODENA), to the backbone of HA using carbodiimide chemistry (Fig. 24). 293 The amphiphilic HA conjugates based NPs were selectively endocytosed by the cancer cell line (SCC-7, over-expressed CD44) and could encapsulate PTX up to 20.7 wt.% by the dialysis method. The drug-loaded HydroHA NPs exhibited stronger cytotoxicity to SCC-7 than to normal fibroblast cell (CV-1). The result shows that HydroHA NPs have potential as the carrier of PTX for cancer therapy. Poly (D, L-lactide-co-glycolide) (PLGA), as a good biodegradable and hydrophobic segment, is also conjugated to HA for developing new amphiphilic drug delivery system. 294, 295 Huh et al. synthesized hyaluronic acid (HA) coated PLGA drug carriers (HCDCs) for targeted delivery of doxorubicin (DOX) as a prototype anticancer drug to treat CD44 expressed human breast cancer cell (Fig. 24). 294 The result suggested that HCDCs have therapeutic potentials of cancer as a target specific fashion by increasing the tumoricidal efficacy of targeted cancer cells, while reducing their cytotoxicity of non-targeted cells to minimize the side effect. At the same time, Agrawal et al. synthesized another novel copolymer hyaluronic acid - poly (ethylene glycol) – poly (lactide-co-glycolide) (HA-PEG-PLGA) where PEG chain was covalently connected between HA and PLGA segment (Fig. 24). 295 The NPs of DOX loaded HA-PEGPLGA were able to deliver a higher amount of DOX and significantly reduced tumour volume as compared to MPEGPLGA NPs in Ehrlich ascites tumour-bearing mice model trial. 295 Similar to the construction of the conjugate HA-PEG-PLGA, Giammona et al. synthesized one amphiphilic conjugate HA-gPLA-g-PEG, in which hydrophobic part-polylactic acid (PLA) and stealthy part-poly ethylene glycol l(PEG) were grafted to HA separately by an ester bond and an amide bond. 296 The HA-gPLA-g-PEG micelles were chosen to entrap the antitumoral drug Doxorubicin. The selective cytotoxicity of drug loaded micelles toward the CD-44 over-expressing HCT-116 cells compared to receptor deficient human derm fibroblasts has been demonstrated. Pegylated micelles showed better stability and drug loading capacity, which were able to escape from macrophage phagocytosis. As mentioned above, HA-ss-DOCA conjugate is a redoxsensitive amphiphilic molecule. Such environmental stimuliresponsive drug release concepts have recently attracted much more attention. In 2014, Chen et al. developed selfassembled pH-responsive hyaluronic acid-g-poly (L-histidine) copolymer (HA-PHis) micelles for targeted intracellular delivery of doxorubicin (Fig. 24). 297 The total synthesis of HA-PHis is schematically illustrated in scheme 15. First, poly (Nim-DNP-Lhistidine) (PHis-DNP) was prepared by ring opening polymerization of protected L-histidine Nim-carboxyanhydride using isopropylamine as an initiator. Second, HA was hydrophobically modified by chemical conjugation of PHis through amide formation using carbodiimide chemistry. Third, the imidazole protection group DNP was removed by 2-\nPage 23 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "24 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nmecaptoethanol to provide the target compound HA-PHis, where poly-L-histidine behaves as a hydrophobic segment as well as a proton sponge carrier for PH responsive drug release. In vitro studies showed that the micelles formed with HA-PHis could release DOX in a pH responsive manner and the blank micelles were nontoxic to MCF-7 cells. 297\nScheme 15 Schematic illustration of synthesis of amphiphilic conjugate HA-PHis. Adapted from Ref. 297. Copyright 2014 with permission from Elsevier."
    }, {
      "heading" : "4.2.3. Nucleic acids (siRNA, antisense RNA, micro RNA, plasmid DNA) as anti-cancer drugs using HA based amphiphilic delivery system for cancer therapy",
      "text" : "Unlike chitosan, HA carries negative charges from D-glucuronic acid unit and is therefore not suited for direct transport of nucleic acids by electrostatic interaction because the latter are also negative charged. However, strategies were designed to overcome this shortcoming due to the other virtues of HA as a vector (biodegradable, biocompatible and strongly targeted). First, HA can be used as an additive to modify an existing nucleic acid carrier and optimize the efficiency of the latter by forming a polyelectrolyte complex. Second, HA can be covalently conjugated to a positively charged unit and then satisfy the demand as a nucleic acid carrier. In recent research, HA based amphiphilic delivery systems of nucleic acids for cancer therapy mainly focus on liposome or lipid-based NPs, whose surfaces are decorated by HA. In the lipid case, lipids are conjugated to HA by a coupling reaction between an amine group of a lipid and carboxylic acid group of the HA, such as HA-DPPE, 298 HA-DOPE 299-301 (Fig. 25). Other lipids as adjuvants also take part in the formation of NPs, such as Roy-PC, DOTAP, DPPE, DOPE (Fig. 26). 298-301 However, in the liposome case, HA physically covering a liposome to carry nucleic acids by electronic static interaction is often evaluated. 302 Apart from lipids or liposomes serving as sources of positive charge and hydrophobic domain, other opportunities were explored either, such as other small hydrophobic molecule modified HA combined with PEI or its derivatives as positive segments 303 and combinations of other oligosaccharides with HA. For example, hydrophobically modified chitosan also can form NPs covered with HA by electrostatic interaction for gene delivery (Fig. 27). 304 The details of this approach are well reviewed by Dosio et al. 305\nPerr et al. prepared lipid-based NPs (HA-LNPs) composed of soybean phosphatidyl- choline (Roy-PC), 1, 2-dipalmitoyl-snglycero-3-phosphoethanolamine (DPPE), cholesterol (Chol) and HA-DPPE conjugate, which bound and internalized specifically into NCI-ADR/ Res (NAR) cells compared with non-HA coated particles. 298 The HA-LNPs loaded with siRNAs against the multidrug resistance extrusion pump, p-glycoprotein (P-gp)\ncould efficiently and specifically reduced mRNA and P-gp protein levels. HA-LNPs showed no cellular toxicity or cytokine (TNF-α, IL-10 and IL-6) induction in culture with human Peripheral Blood Mononuclear Cells (PBMCs). HA-DOPE conjugate is another amphiphilic HA-lipid conjugate where the unsaturated long carbon chain replaces the saturated long carbon chain compared with DPPE. Fattal et al. prepared series of HA-DOPE based liposomes for the targeted (CD44 receptor) delivery of nucleic acids to cancer cells. 299-301 In 2009, cationic hyaluronic acid (HA)-modified DOTAP/DOPE liposomes were designed for the targeted delivery of antitelomerase siRNA to CD44 receptor-expressing lung cancer cells-A549 cells in this group. 299 In the same year, they prepared lipoplexes containing a hyaluronic aciddioleoylphosphatidylethanolamine (HA-DOPE) conjugate and a mixture of [2 - (2, 3-didodecyloxypropyl) hydroxyethyl] ammonium bromide (DE) and DOPE to target the CD44 receptor on breast cancer cells. The existing HA-DOPE increased the level of transfection on CD44-expressing MDAMB-231 cells compared to the MCF-7 line, which expresses very low levels of CD44. Later, the same liposomes, forming the basis of a different- lipoplexes targeting the A549 lung cancer cell line were evaluated. 301 All these studies demonstrated that such novel lipoplexes could successfully be targeted to CD44-expressing cancer cells opening interesting perspectives for the treatment of different cancers.\nFig. 25 HA-lipid conjugates HA-DPPE and HA-DOPE for the delivery of nucleic acids. Lipids were attached to HA via amide bonds.\nFig. 26 Some Lipids (Roy-PC, DPPE, DOPE, DOTAP) as adjuvant for the co-construction of amphiphilic NPs for nucleic acid delivery.\nCationic liposomes without any modification have poor biocompatibility, and are therefore not suitable for efficient gene delivery in vivo. However, PEGylation is frequently performed for enhancing stability in plasma, but this process also shields the positive charge of cationic liposomes. He et al. covalently linked PEG to negatively charged HA and the PEGHA conjugate was used to coat the liposome-siRNA NPs. 302 The resulting PEG–HA–NP showed a promising result as siRNA delivery system in modifying P-glycoprotein expression in solid tumors.\nPEI and its derivatives such as positively charged polyamines,\nhave proven to be efficient reagents for compacting and encapsulating nucleic acids. Wang et al. prepared a novel target specific siRNA delivery system by using hydrophobized hyaluronic acid–spermine conjugates (HHSCs, Fig.27). 303 The\nPage 24 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 25\nPlease do not adjust margins\nPlease do not adjust margins\nsiRNA/HHSC complex was taken up preferentially through caveolae-mediated endocytosis which was facilitated by the HA-receptor mediation.\nAs discusses in the chitosan chapter above, chitosan bearing positive charge has an impressive ability to complex nucleic acids as well as other negatively charged molecules such as HA. Chen et al. described NPs made of oleoyl-carboxymethychitosan (OCMCS)/hyaluronic acid (HA) using the coacervation process as novel potential carriers for gene delivery (Fig. 27). 304 OCMCS-HA/DNA (OHD) NPs exhibited high in vitro DNA released rates and increased cellular uptake by Caco-2 cells and the present research including other data analyses showed that OHD NPs have a nice potential for the targeting and further transfer of genes to the epithelial cells.\nFig. 27 Other representative examples of amphiphilic nucleic acid delivery system. Hyaluronic acid–spermine conjugates (HHSCs) and oleoyl-carboxymethy-chitosan (OCMCS)/hyaluronic acid (HA).\nIn general, HA based amphiphilic nano drug delivery systems\nare very attractive for cancer therapy, by benefiting from their targeting property to the CD44 receptor and their degradability by tissue hyaluronidases (HAase). Both, the CD44 receptor and HAase overexpression are reported to be associated with many malignant tumors. As a result, HA decorated NPs for drug delivery can specific target a tumor and lead to sustained drug release, thereby reducing side effects from chemotherapy. However, rational design of HA based NPs for drug delivery should further take the toxicity of healthy organs into consideration, especially in the liver (main pathway of HA elimination).\nFor the purpose of clinic application of HA based NPs for anticancer therapy, researchers should not only focus on in vitro and in vivo studies. Physicochemical characterization and pharmacokinetics of NPs as well as processes of products are either important to access preclinical trial. For example, polyelectrolyte complexes are the main form for the application of HA based NPs in gene delivery due to the property of negative charge. The complexity of their preparation and the challenge of achieving reproducibility of final formulations may limit its future clinical application.\nBased on interesting examples involving HA reported in the present review, further fine-tuned hydrophobic modification and proper linker selection regarding stimulus related sustained release is desirable to facilitate translation to industry and to patients."
    }, {
      "heading" : "Acknowledgements",
      "text" : "Financial support of Claude & Giuliana Foundation and the Swiss National Science Foundation (NFP62 project) is gratefully acknowledged."
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "26 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\n20. H. Koo, M. S. Huh, I. C. Sun, S. H. Yuk, K. Choi, K. Kim\nand I. C. Kwon, Accounts of chemical research, 2011, 44, 1018-1028.\n21. L. Vannucci, E. Falvo, M. Fornara, P. Di Micco, O.\nBenada, J. Krizan, J. Svoboda, K. Hulikova-Capkova, V. Morea, A. Boffi and P. Ceci, International journal of nanomedicine, 2012, 7, 1489-1509.\n22. M. K. Yu, J. Park and S. Jon, Theranostics, 2012, 2, 3-\n44.\n23. F. Jia, X. Liu, L. Li, S. Mallapragada, B. Narasimhan and\nQ. Wang, Journal of controlled release : official journal of the Controlled Release Society, 2013, 172, 1020-1034.\n24. K. Park, S. Lee, E. Kang, K. Kim, K. Choi and I. C. Kwon,\nAdvanced Functional Materials, 2009, 19, 1553-1566.\n25. Y. A. Luqmani, Medical principles and practice :\ninternational journal of the Kuwait University, Health Science Centre, 2005, 14 Suppl 1, 35-48.\n26. L. Mu and S. S. Feng, Journal of controlled release :\nofficial journal of the Controlled Release Society, 2003, 86, 33-48.\n27. A. J. Primeau, A. Rendon, D. Hedley, L. Lilge and I. F.\nTannock, Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, 11, 8782-8788.\n28. T. W. Hambley, Coordination Chemistry Reviews,\n1997, 166, 181-223.\n29. M. A. Izquierdo, R. H. Shoemaker, M. J. Flens, G. L.\nScheffer, L. Wu, T. R. Prather and R. J. Scheper, International journal of cancer, 1996, 65, 230-237.\n30. M. Creixell and N. A. Peppas, Nano today, 2012, 7,\n367-379.\n31. M. A. Phillips, M. L. Gran and N. A. Peppas, Nano\ntoday, 2010, 5, 143-159.\n32. W. B. Liechty and N. A. Peppas, European journal of\npharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012, 80, 241-246.\n33. J. M. Adams and S. Cory, Current opinion in\nimmunology, 2007, 19, 488-496.\n34. S. H. Chen and G. Zhaori, European journal of clinical\ninvestigation, 2011, 41, 221-232.\n35. K. Raemdonck, T. F. Martens, K. Braeckmans, J.\nDemeester and S. C. De Smedt, Advanced drug delivery reviews, 2013, 65, 1123-1147.\n36. T. Kato, A. Natsume, H. Toda, H. Iwamizu, T. Sugita, R.\nHachisu, R. Watanabe, K. Yuki, K. Motomura, K. Bankiewicz and T. Wakabayashi, Gene therapy, 2010, 17, 1363-1371.\n37. K. Nakamura, A. S. Abu Lila, M. Matsunaga, Y. Doi, T.\nIshida and H. Kiwada, Molecular therapy : the journal of the American Society of Gene Therapy, 2011, 19, 2040-2047.\n38. D. B. Zamble and S. J. Lippard, Trends in biochemical\nsciences, 1995, 20, 435-439.\n39. M. Czarnecka-Operacz and A. Sadowska-Przytocka,\nPostepy dermatologii i alergologii, 2014, 31, 392-400.\n40. M. E. Wall, M. C. Wani, C. E. Cook, K. H. Palmer, A. T.\nMcPhail and G. A. Sim, Journal of the American Chemical Society, 1966, 88, 3888-3890.\n41. T. Efferth, Y. J. Fu, Y. G. Zu, G. Schwarz, V. S.\nKonkimalla and M. Wink, Current medicinal chemistry, 2007, 14, 2024-2032.\n42. R. B. Weiss, Seminars in oncology, 1992, 19, 670-686. 43. M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon and A.\nT. McPhail, Journal of the American Chemical Society, 1971, 93, 2325-2327.\n44. D. E. Dolmans, D. Fukumura and R. K. Jain, Nature\nreviews. Cancer, 2003, 3, 380-387.\n45. N. Solban, I. Rizvi and T. Hasan, Lasers in surgery and\nmedicine, 2006, 38, 522-531.\n46. J. Chen, L. Keltner, J. Christophersen, F. Zheng, M.\nKrouse, A. Singhal and S. S. Wang, Cancer journal (Sudbury, Mass.), 2002, 8, 154-163.\n47. C. Fabris, G. Valduga, G. Miotto, L. Borsetto, G. Jori, S.\nGarbisa and E. Reddi, Cancer research, 2001, 61, 7495-7500.\n48. S. J. Lee, K. Park, Y. K. Oh, S. H. Kwon, S. Her, I. S. Kim,\nK. Choi, S. J. Lee, H. Kim, S. G. Lee, K. Kim and I. C. Kwon, Biomaterials, 2009, 30, 2929-2939.\n49. V. Guillemard and H. U. Saragovi, Cancer research,\n2001, 61, 694-699.\n50. R. R. Allison, G. H. Downie, R. Cuenca, X. H. Hu, C. J.\nChilds and C. H. Sibata, Photodiagnosis and photodynamic therapy, 2004, 1, 27-42.\n51. S. J. Lee, H. Koo, D. E. Lee, S. Min, S. Lee, X. Chen, Y.\nChoi, J. F. Leary, K. Park, S. Y. Jeong, I. C. Kwon, K. Kim and K. Choi, Biomaterials, 2011, 32, 4021-4029.\n52. S. J. Lee, H. Koo, H. Jeong, M. S. Huh, Y. Choi, S. Y.\nJeong, Y. Byun, K. Choi, K. Kim and I. C. Kwon, Journal of controlled release : official journal of the Controlled Release Society, 2011, 152, 21-29.\n53. B. L. Davidson and P. B. McCray, Jr., Nature reviews.\nGenetics, 2011, 12, 329-340.\n54. K. Remaut, N. N. Sanders, B. G. De Geest, K.\nBraeckmans, J. Demeester and S. C. De Smedt, Materials Science and Engineering: R: Reports, 2007, 58, 117-161.\n55. S. D. Patil, D. G. Rhodes and D. J. Burgess, The AAPS\njournal, 2005, 7, E61-77.\n56. T.-H. Kim, H.-L. Jiang, D. Jere, I.-K. Park, M.-H. Cho, J.-\nW. Nah, Y.-J. Choi, T. Akaike and C.-S. Cho, Progress in Polymer Science, 2007, 32, 726-753.\n57. S. Mao, W. Sun and T. Kissel, Advanced drug delivery\nreviews, 2010, 62, 12-27.\n58. S. L. Ginn, I. E. Alexander, M. L. Edelstein, M. R. Abedi\nand J. Wixon, The journal of gene medicine, 2013, 15, 65-77.\n59. K. Raemdonck, R. E. Vandenbroucke, J. Demeester, N.\nN. Sanders and S. C. De Smedt, Drug discovery today, 2008, 13, 917-931.\n60. J. J. Green, R. Langer and D. G. Anderson, Accounts of\nchemical research, 2008, 41, 749-759.\n61. S. Li and L. Huang, Gene therapy, 2000, 7, 31-34. 62. J. H. Jeong, S. W. Kim and T. G. Park, Progress in\nPolymer Science, 2007, 32, 1239-1274.\n63. W. F. Lai and M. C. Lin, Journal of controlled release :\nofficial journal of the Controlled Release Society, 2009, 134, 158-168.\n64. J. C. Ed., Drug Delivery Systems: Advanced\nTechnologies Potentially Applicable in Personalised Treatment, Springer, Dordrecht ; New York, 2013.\nPage 26 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 27\nPlease do not adjust margins\nPlease do not adjust margins\n65. J. Zhang and P. X. Ma, Advanced drug delivery\nreviews, 2013, 65, 1215-1233.\n66. P. Han, S. Li, C. Wang, H. Xu, Z. Wang, X. Zhang, J.\nThomas and M. Smet, Langmuir : the ACS journal of surfaces and colloids, 2011, 27, 14108-14111.\n67. T. Bojinova, Y. Coppel, N. Lauth-de Viguerie, A. Milius,\nI. Rico-Lattes and A. Lattes, Langmuir : the ACS journal of surfaces and colloids, 2003, 19, 5233-5239.\n68. Y. Wang, N. Ma, Z. Wang and X. Zhang, Angewandte\nChemie (International ed. in English), 2007, 46, 2823- 2826.\n69. Y. J. Jeon, P. K. Bharadwaj, S. Choi, J. W. Lee and K.\nKim, Angewandte Chemie (International ed. in English), 2002, 41, 4474-4476.\n70. B. Song, Z. Wang, S. Chen, X. Zhang, Y. Fu, M. Smet\nand W. Dehaen, Angewandte Chemie (International ed. in English), 2005, 44, 4731-4735.\n71. X. Zhang, Z. Chen and F. Würthner, Journal of the\nAmerican Chemical Society, 2007, 129, 4886-4887.\n72. N. Kimizuka, T. Kawasaki and T. Kunitake, Journal of\nthe American Chemical Society, 1993, 115, 4387- 4388.\n73. N. Kimizuka, T. Kawasaki, K. Hirata and T. Kunitake,\nJournal of the American Chemical Society, 1998, 120, 4094-4104.\n74. T. M. Hermans, M. A. C. Broeren, N. Gomopoulos, A.\nF. Smeijers, B. Mezari, E. N. M. Van Leeuwen, M. R. J. Vos, P. C. M. M. Magusin, P. A. J. Hilbers, M. H. P. Van Genderen, N. A. J. M. Sommerdijk, G. Fytas and Meijer, Journal of the American Chemical Society, 2007, 129, 15631-15638.\n75. J.-F. Gohy, B. G. G. Lohmeijer and U. S. Schubert,\nMacromolecules, 2002, 35, 4560-4563.\n76. A. O. Moughton and R. K. O’Reilly, Journal of the\nAmerican Chemical Society, 2008, 130, 8714-8725.\n77. B. Song, G. Wu, Z. Wang, X. Zhang, M. Smet and W.\nDehaen, Langmuir : the ACS journal of surfaces and colloids, 2009, 25, 13306-13310.\n78. C. Wang, Y. Guo, Y. Wang, H. Xu, R. Wang and X.\nZhang, Angewandte Chemie (International ed. in English), 2009, 48, 8962-8965.\n79. K. Liu, C. Wang, Z. Li and X. Zhang, Angewandte\nChemie (International ed. in English), 2011, 50, 4952- 4956.\n80. P. Xing, T. Sun and A. Hao, RSC Advances, 2013, 3,\n24776-24793.\n81. X. Zhang and C. Wang, Chemical Society reviews,\n2011, 40, 94-101.\n82. Y. Lee, S. Fukushima, Y. Bae, S. Hiki, T. Ishii and K.\nKataoka, Journal of the American Chemical Society, 2007, 129, 5362-5363.\n83. P. Han, N. Ma, H. Ren, H. Xu, Z. Li, Z. Wang and X.\nZhang, Langmuir : the ACS journal of surfaces and colloids, 2010, 26, 14414-14418.\n84. C. Wang, Q. Chen, Z. Wang and X. Zhang, Angewandte\nChemie (International ed. in English), 2010, 49, 8612- 8615.\n85. J. H. Hamman, Marine drugs, 2010, 8, 1305-1322. 86. J. Berger, M. Reist, J. M. Mayer, O. Felt and R. Gurny,\nEuropean journal of pharmaceutics and biopharmaceutics : official journal of\nArbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2004, 57, 35-52.\n87. J. H. Park, G. Saravanakumar, K. Kim and I. C. Kwon,\nAdvanced drug delivery reviews, 2010, 62, 28-41.\n88. G. Chen and M. Jiang, Chemical Society reviews, 2011,\n40, 2254-2266.\n89. R. E. Babine and S. L. Bender, Chemical reviews, 1997,\n97, 1359-1472.\n90. F. Cozzi, R. Annunziata, M. Benaglia, K. K. Baldridge,\nG. Aguirre, J. Estrada, Y. Sritana-Anant and J. S. Siegel, Physical chemistry chemical physics : PCCP, 2008, 10, 2686-2694.\n91. L. Zhang, J. Xia, Q. Zhao, L. Liu and Z. Zhang, Small\n(Weinheim an der Bergstrasse, Germany), 2010, 6, 537-544.\n92. Z. Liu, X. Sun, N. Nakayama-Ratchford and H. Dai, ACS\nnano, 2007, 1, 50-56.\n93. X. Zhang, L. Meng, Q. Lu, Z. Fei and P. J. Dyson,\nBiomaterials, 2009, 30, 6041-6047.\n94. M. P. Evstigneev, A. S. Buchelnikov, D. P. Voronin, Y.\nV. Rubin, L. F. Belous, Y. I. Prylutskyy and U. Ritter, Chemphyschem : a European journal of chemical physics and physical chemistry, 2013, 14, 568-578.\n95. P. Chakravarty, W. Qian, M. A. El-Sayed and M. R.\nPrausnitz, Nature nanotechnology, 2010, 5, 607-611.\n96. E. Jang, E.-K. Lim, Y. Choi, E. Kim, H.-O. Kim, D.-J. Kim,\nJ.-S. Suh, Y.-M. Huh and S. Haam, Journal of Materials Chemistry B, 2013, 1, 5686-5693.\n97. J. K. Oh, R. Drumright, D. J. Siegwart and K.\nMatyjaszewski, Progress in Polymer Science, 2008, 33, 448-477.\n98. R. Subbiah, M. Veerapandian and K. S. Yun, Current\nmedicinal chemistry, 2010, 17, 4559-4577.\n99. M. Elsabahy and K. L. Wooley, Chemical Society\nreviews, 2012, 41, 2545-2561.\n100. K. Cho, X. Wang, S. Nie, Z. G. Chen and D. M. Shin,\nClinical cancer research : an official journal of the American Association for Cancer Research, 2008, 14, 1310-1316.\n101. N. Graf, D. R. Bielenberg, N. Kolishetti, C. Muus, J.\nBanyard, O. C. Farokhzad and S. J. Lippard, ACS nano, 2012, 6, 4530-4539.\n102. A. N. Lukyanov and V. P. Torchilin, Advanced drug\ndelivery reviews, 2004, 56, 1273-1289.\n103. E. A. Lysenko, A. N. Trusov, P. S. Chelushkin, T. K.\nBronich, A. V. Kabanov and A. B. Zezin, Polymer Science Series A, 2009, 51, 606-615.\n104. A. Napoli, M. J. Boerakker, N. Tirelli, R. J. Nolte, N. A.\nSommerdijk and J. A. Hubbell, Langmuir : the ACS journal of surfaces and colloids, 2004, 20, 3487-3491.\n105. A. Napoli, M. Valentini, N. Tirelli, M. Muller and J. A.\nHubbell, Nature materials, 2004, 3, 183-189.\n106. O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon,\nP. W. Kantoff, J. P. Richie and R. Langer, Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6315-6320.\n107. R. T. Chacko, J. Ventura, J. Zhuang and S.\nThayumanavan, Advanced drug delivery reviews, 2012, 64, 836-851.\n108. K. Raemdonck, J. Demeester and S. De Smedt, Soft\nMatter, 2009, 5, 707-715.\nPage 27 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "28 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\n109. D. Astruc, E. Boisselier and C. Ornelas, Chemical\nreviews, 2010, 110, 1857-1959.\n110. V. R. Sinha and R. Kumria, International journal of\npharmaceutics, 2001, 224, 19-38.\n111. J. W. Lee, J. H. Park and J. R. Robinson, Journal of\npharmaceutical sciences, 2000, 89, 850-866.\n112. K. A. Janes, P. Calvo and M. J. Alonso, Advanced drug\ndelivery reviews, 2001, 47, 83-97.\n113. J. C. Linden, R. J. Stoner and K. W. Knutson, Gardner-\nHughes, Cecilie A. Agro Food Industry Hi-Tech 2000, 32–34.\n114. L. Gomez-Rivas, B. I. Escudero-Abarca, M. G. Aguilar-\nUscanga, P. M. Hayward-Jones, P. Mendoza and M. Ramirez, Journal of industrial microbiology & biotechnology, 2004, 31, 16-22.\n115. B. Ghosh and M. W. Urban, Science (New York, N.Y.),\n2009, 323, 1458-1460.\n116. R. N. Schiller, E. Barrager, A. G. Schauss and E. J.\nNichols, J. Am. Nutraceutical Assoc. , 2001, 4, 42-49.\n117. T. Kean and M. Thanou, Advanced drug delivery\nreviews, 2010, 62, 3-11.\n118. P. Baldrick, Regulatory toxicology and pharmacology :\nRTP, 2010, 56, 290-299.\n119. M. A. Brown, M. R. Daya and J. A. Worley, The Journal\nof emergency medicine, 2009, 37, 1-7.\n120. W. E. Rudzinski and T. M. Aminabhavi, International\njournal of pharmaceutics, 2010, 399, 1-11.\n121. H. Ringsdorf, Journal of Polymer Science: Polymer\nSymposia, 1975, 51, 135-153.\n122. L. W. Seymour, K. Ulbrich, S. R. Wedge, I. C. Hume, J.\nStrohalm and R. Duncan, British journal of cancer, 1991, 63, 859-866.\n123. Y. J. Son, J. S. Jang, Y. W. Cho, H. Chung, R. W. Park, I.\nC. Kwon, I. S. Kim, J. Y. Park, S. B. Seo, C. R. Park and S. Y. Jeong, Journal of controlled release : official journal of the Controlled Release Society, 2003, 91, 135-145.\n124. J. H. Park, Y. W. Cho, Y. J. Son, K. Kim, H. Chung, S. Y.\nJeong, K. Choi, C. R. Park, R.-W. Park, I.-S. Kim and I. C. Kwon, Colloid and Polymer Science, 2006, 284, 763- 770.\n125. J. Hyung Park, S. Kwon, M. Lee, H. Chung, J. H. Kim, Y.\nS. Kim, R. W. Park, I. S. Kim, S. Bong Seo, I. C. Kwon and S. Young Jeong, Biomaterials, 2006, 27, 119-126.\n126. E. Lee, J. Lee, I. H. Lee, M. Yu, H. Kim, S. Y. Chae and S.\nJon, Journal of medicinal chemistry, 2008, 51, 6442- 6449.\n127. X. Wang, Y. Chen, F. Z. Dahmani, L. Yin, J. Zhou and J.\nYao, Biomaterials, 2014, 35, 7654-7665.\n128. X. Y. Gong, Y. H. Yin, Z. J. Huang, B. Lu, P. H. Xu, H.\nZheng, F. L. Xiong, H. X. Xu, X. Xiong and X. B. Gu, International journal of pharmaceutics, 2012, 436, 240-247.\n129. A. Fattahi, M. Asgarshamsi, F. Hasanzadeh, J.\nVarshosaz, M. Rostami, M. Mirian and H. Sadeghialiabadi, Journal of materials science. Materials in medicine, 2015, 26, 119.\n130. A. Safavy, G. I. Georg, D. Vander Velde, K. P. Raisch, K.\nSafavy, M. Carpenter, W. Wang, J. A. Bonner, M. B. Khazaeli and D. J. Buchsbaum, Bioconjugate chemistry, 2004, 15, 1264-1274.\n131. J. You, F. Q. Hu, Y. Z. Du and H. Yuan,\nBiomacromolecules, 2007, 8, 2450-2456.\n132. F. Q. Hu, G. F. Ren, H. Yuan, Y. Z. Du and S. Zeng,\nColloids and surfaces. B, Biointerfaces, 2006, 50, 97- 103.\n133. J. You, X. Li, F. de Cui, Y. Z. Du, H. Yuan and F. Q. Hu,\nNanotechnology, 2008, 19, 045102.\n134. F. Q. Hu, X. L. Wu, Y. Z. Du, J. You and H. Yuan,\nEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2008, 69, 117-125.\n135. J. You, F. Q. Hu, Y. Z. Du and H. Yuan,\nNanotechnology, 2008, 19, 255103.\n136. Y. Q. Ye, F. L. Yang, F. Q. Hu, Y. Z. Du, H. Yuan and H.\nY. Yu, International journal of pharmaceutics, 2008, 352, 294-301.\n137. U. Termsarasab, H. J. Cho, D. H. Kim, S. Chong, S. J.\nChung, C. K. Shim, H. T. Moon and D. D. Kim, International journal of pharmaceutics, 2013, 441, 373-380.\n138. I. F. Uchegbu, L. Sadiq, M. Arastoo, A. I. Gray, W.\nWang, R. D. Waigh and A. G. Schatzlein, International journal of pharmaceutics, 2001, 224, 185-199.\n139. A. Siew, H. Le, M. Thiovolet, P. Gellert, A. Schatzlein\nand I. Uchegbu, Molecular pharmaceutics, 2012, 9, 14-28.\n140. J. Zhang, X. G. Chen, Y. Y. Li and C. S. Liu,\nNanomedicine : nanotechnology, biology, and medicine, 2007, 3, 258-265.\n141. Y. Qin, J. Chen, Y. Bi, X. Xu, H. Zhou, J. Gao, Y. Hu, Y.\nZhao and Z. Chai, Acta biomaterialia, 2015, 17, 201- 209.\n142. Y. L. Tan and C. G. Liu, Colloids and surfaces. B,\nBiointerfaces, 2009, 69, 178-182.\n143. X. G. Chen, C. M. Lee and H. J. Park, Journal of\nagricultural and food chemistry, 2003, 51, 3135-3139.\n144. W. T. Huang, M. Larsson, Y. J. Wang, S. H. Chiou, H. Y.\nLin and D. M. Liu, Molecular pharmaceutics, 2015, 12, 1242-1249.\n145. C. Zhang, Q. Ping, H. Zhang and J. Shen, Carbohydrate\nPolymers, 2003, 54, 137-141.\n146. C. Zhang, P. Qineng and H. Zhang, Colloids and\nsurfaces. B, Biointerfaces, 2004, 39, 69-75.\n147. C. Zhang, G. Qu, Y. Sun, T. Yang, Z. Yao, W. Shen, Z.\nShen, Q. Ding, H. Zhou and Q. Ping, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2008, 33, 415-423.\n148. M. Huo, Y. Zhang, J. Zhou, A. Zou, D. Yu, Y. Wu, J. Li\nand H. Li, International journal of pharmaceutics, 2010, 394, 162-173.\n149. X. Jin, R. Mo, Y. Ding, W. Zheng and C. Zhang,\nMolecular pharmaceutics, 2014, 11, 145-157.\n150. K. Kim, S. Kwon, J. H. Park, H. Chung, S. Y. Jeong, I. C.\nKwon and I. S. Kim, Biomacromolecules, 2005, 6, 1154-1158.\n151. J. Y. Yhee, S. Son, S. H. Kim, K. Park, K. Choi and I. C.\nKwon, Journal of controlled release : official journal of the Controlled Release Society, 2014, 193, 202-213.\n152. J. H. Kim, Y. S. Kim, K. Park, S. Lee, H. Y. Nam, K. H.\nMin, H. G. Jo, J. H. Park, K. Choi, S. Y. Jeong, R. W. Park, I. S. Kim, K. Kim and I. C. Kwon, Journal of\nPage 28 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 29\nPlease do not adjust margins\nPlease do not adjust margins\ncontrolled release : official journal of the Controlled Release Society, 2008, 127, 41-49.\n153. K. H. Min, K. Park, Y. S. Kim, S. M. Bae, S. Lee, H. G. Jo,\nR. W. Park, I. S. Kim, S. Y. Jeong, K. Kim and I. C. Kwon, Journal of controlled release : official journal of the Controlled Release Society, 2008, 127, 208-218.\n154. J. H. Kim, Y. S. Kim, S. Kim, J. H. Park, K. Kim, K. Choi,\nH. Chung, S. Y. Jeong, R. W. Park, I. S. Kim and I. C. Kwon, Journal of controlled release : official journal of the Controlled Release Society, 2006, 111, 228-234.\n155. H. Y. Hwang, I. S. Kim, I. C. Kwon and Y. H. Kim,\nJournal of controlled release : official journal of the Controlled Release Society, 2008, 128, 23-31.\n156. J. H. Kim, Y. S. Kim, K. Park, E. Kang, S. Lee, H. Y. Nam,\nK. Kim, J. H. Park, D. Y. Chi, R. W. Park, I. S. Kim, K. Choi and I. Chan Kwon, Biomaterials, 2008, 29, 1920- 1930.\n157. Y. K. Lee, J.-H. Kim, C. I. Kwon and Y. S. Jeong, Colloid\nand Polymer Science, 2000, 278, 1216-1219.\n158. H. Zhou, W. Yu, X. Guo, X. Liu, N. Li, Y. Zhang and X.\nMa, Biomacromolecules, 2010, 11, 3480-3486.\n159. M. Wu, K. Guo, H. Dong, R. Zeng, M. Tu and J. Zhao,\nMaterials science & engineering. C, Materials for biological applications, 2014, 45, 162-169.\n160. Y.-S. Wang, L.-R. Liu, Q. Jiang and Q.-Q. Zhang,\nEuropean Polymer Journal, 2007, 43, 43-51.\n161. Z. Pan, Y. Gao, L. Heng, Y. Liu, G. Yao, Y. Wang and Y.\nLiu, Carbohydr Polym, 2013, 94, 394-399.\n162. H. Du, X. Yang, X. Pang and G. Zhai, Carbohydr Polym,\n2014, 111, 753-761.\n163. J. S. Park, T. H. Han, K. Y. Lee, S. S. Han, J. J. Hwang, D.\nH. Moon, S. Y. Kim and Y. W. Cho, Journal of controlled release : official journal of the Controlled Release Society, 2006, 115, 37-45.\n164. W. Sajomsang, P. Gonil, S. Saesoo, U. R.\nRuktanonchai, W. Srinuanchai and S. Puttipipatkhachorn, International journal of pharmaceutics, 2014, 477, 261-272.\n165. J. Cao, S. Huang, Y. Chen, S. Li, X. Li, D. Deng, Z. Qian,\nL. Tang and Y. Gu, Biomaterials, 2013, 34, 6272-6283.\n166. L. Meng, W. Huang, D. Wang, X. Huang, X. Zhu and D.\nYan, Biomacromolecules, 2013, 14, 2601-2610.\n167. C. Gao, T. Liu, Y. Dang, Z. Yu, W. Wang, J. Guo, X.\nZhang, G. He, H. Zheng, Y. Yin and X. Kong, Carbohydr Polym, 2014, 111, 964-970.\n168. Y. Tao, J. Han and H. Dou, Journal of Materials\nChemistry, 2012, 22, 8930-8937.\n169. J. M. Turley, F. W. Ruscetti, S. J. Kim, T. Fu, F. V. Gou\nand M. C. Birchenall-Roberts, Cancer research, 1997, 57, 2668-2675.\n170. M. W. Fariss, M. B. Fortuna, C. K. Everett, J. D. Smith,\nD. F. Trent and Z. Djuric, Cancer research, 1994, 54, 3346-3351.\n171. G. A. dos Santos, R. S. Abreu e Lima, C. R. Pestana, A.\nS. Lima, P. S. Scheucher, C. H. Thome, H. L. GimenesTeixeira, B. A. Santana-Lemos, A. R. Lucena-Araujo, F. P. Rodrigues, R. Nasr, S. A. Uyemura, R. P. Falcao, H. de The, P. P. Pandolfi, C. Curti and E. M. Rego, Leukemia, 2012, 26, 451-460.\n172. K. N. Prasad, B. Kumar, X. D. Yan, A. J. Hanson and W.\nC. Cole, Journal of the American College of Nutrition, 2003, 22, 108-117.\n173. Z. Zhao, M. He, L. Yin, J. Bao, L. Shi, B. Wang, C. Tang\nand C. Yin, Biomacromolecules, 2009, 10, 565-572.\n174. H. Yu, W. Wang, X. Chen, C. Deng and X. Jing,\nBiopolymers, 2006, 83, 233-242.\n175. C. Gu, V. Le, M. Lang and J. Liu, Colloids and surfaces.\nB, Biointerfaces, 2014, 116, 745-750.\n176. A. Guerry, S. Cottaz, E. Fleury, J. Bernard and S. Halila,\nCarbohydr Polym, 2014, 112, 746-752.\n177. Y. Wu, Y. Zheng, W. Yang, C. Wang, J. Hu and S. Fu,\nCarbohydrate Polymers, 2005, 59, 165-171.\n178. W. Zhou, Y. Wang, J. Jian and S. Song, International\njournal of nanomedicine, 2013, 8, 3715-3728.\n179. I. Bravo-Osuna, C. Vauthier, A. Farabollini, G. F.\nPalmieri and G. Ponchel, Biomaterials, 2007, 28, 2233-2243.\n180. I. Bravo-Osuna, T. Schmitz, A. Bernkop-Schnurch, C.\nVauthier and G. Ponchel, International journal of pharmaceutics, 2006, 316, 170-175.\n181. I. Bravo-Osuna, G. Millotti, C. Vauthier and G.\nPonchel, International journal of pharmaceutics, 2007, 338, 284-290.\n182. M.-H. Hsiao, K.-H. Lin and D.-M. Liu, Soft Matter,\n2013, 9, 2458-2466.\n183. G. Saravanakumar, K. H. Min, D. S. Min, A. Y. Kim, C.\nM. Lee, Y. W. Cho, S. C. Lee, K. Kim, S. Y. Jeong, K. Park, J. H. Park and I. C. Kwon, Journal of controlled release : official journal of the Controlled Release Society, 2009, 140, 210-217.\n184. H. Koo, K. H. Min, S. C. Lee, J. H. Park, K. Park, S. Y.\nJeong, K. Choi, I. C. Kwon and K. Kim, Journal of controlled release : official journal of the Controlled Release Society, 2013, 172, 823-831.\n185. R. Gref, Y. Minamitake, M. T. Peracchia, V.\nTrubetskoy, V. Torchilin and R. Langer, Science (New York, N.Y.), 1994, 263, 1600-1603.\n186. P. Opanasopit, T. Ngawhirunpat, T. Rojanarata, C.\nChoochottiros and S. Chirachanchai, Colloids and surfaces. B, Biointerfaces, 2007, 60, 117-124.\n187. P. Opanasopit, T. Ngawhirunpat, T. Rojanarata, C.\nChoochottiros and S. Chirachanchai, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2007, 30, 424-431.\n188. J. S. Park, Y. S. Koh, J. Y. Bang, Y. I. Jeong and J. J. Lee,\nJournal of pharmaceutical sciences, 2008, 97, 4011- 4019.\n189. Y. I. Jeong, S. H. Kim, T. Y. Jung, I. Y. Kim, S. S. Kang, Y.\nH. Jin, H. H. Ryu, H. S. Sun, S. Jin, K. K. Kim, K. Y. Ahn and S. Jung, Journal of pharmaceutical sciences, 2006, 95, 2348-2360.\n190. M. H. Hsiao, Q. Mu, Z. R. Stephen, C. Fang and M.\nZhang, ACS macro letters, 2015, 4, 403-407.\n191. Z. Shi, R. Guo, W. Li, Y. Zhang, W. Xue, Y. Tang and Y.\nZhang, Journal of materials science. Materials in medicine, 2014, 25, 723-731.\n192. G. Qu, Z. Yao, C. Zhang, X. Wu and Q. Ping, European\njournal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2009, 37, 98-105.\n193. T. Boudou, P. Kharkar, J. Jing, R. Guillot, I. Pignot-\nPaintrand, R. Auzely-Velty and C. Picart, Journal of\nPage 29 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "30 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\ncontrolled release : official journal of the Controlled Release Society, 2012, 159, 403-412.\n194. I. H. Oh, H. S. Min, L. Li, T. H. Tran, Y. K. Lee, I. C.\nKwon, K. Choi, K. Kim and K. M. Huh, Biomaterials, 2013, 34, 6454-6463.\n195. M. Malhotra, A. Kulamarva, S. Sebak, A. Paul, J.\nBhathena, M. Mirzaei and S. Prakash, Drug development and industrial pharmacy, 2009, 35, 719- 726.\n196. X. Jiang, H. Dai, K. W. Leong, S. H. Goh, H. Q. Mao and\nY. Y. Yang, The journal of gene medicine, 2006, 8, 477- 487.\n197. M. Ravina, E. Cubillo, D. Olmeda, R. Novoa-Carballal,\nE. Fernandez-Megia, R. Riguera, A. Sanchez, A. Cano and M. J. Alonso, Pharmaceutical research, 2010, 27, 2544-2555.\n198. H. Zhang, S. Mardyani, W. C. Chan and E. Kumacheva,\nBiomacromolecules, 2006, 7, 1568-1572.\n199. P. Chan, M. Kurisawa, J. E. Chung and Y. Y. Yang,\nBiomaterials, 2007, 28, 540-549.\n200. T. H. Kim, J. W. Nah, M. H. Cho, T. G. Park and C. S.\nCho, Journal of nanoscience and nanotechnology, 2006, 6, 2796-2803.\n201. S. Gao, J. Chen, X. Xu, Z. Ding, Y. H. Yang, Z. Hua and J.\nZhang, International journal of pharmaceutics, 2003, 255, 57-68.\n202. S. Mansouri, Y. Cuie, F. Winnik, Q. Shi, P. Lavigne, M.\nBenderdour, E. Beaumont and J. C. Fernandes, Biomaterials, 2006, 27, 2060-2065.\n203. T. H. Kim, S. I. Kim, T. Akaike and C. S. Cho, Journal of\ncontrolled release : official journal of the Controlled Release Society, 2005, 105, 354-366.\n204. K. Wong, G. Sun, X. Zhang, H. Dai, Y. Liu, C. He and K.\nW. Leong, Bioconjugate chemistry, 2006, 17, 152-158.\n205. B. Lu, X. D. Xu, X. Z. Zhang, S. X. Cheng and R. X. Zhuo,\nBiomacromolecules, 2008, 9, 2594-2600.\n206. C. Moreira, H. Oliveira, L. R. Pires, S. Simoes, M. A.\nBarbosa and A. P. Pego, Acta biomaterialia, 2009, 5, 2995-3006.\n207. J. Haas, M. N. Ravi Kumar, G. Borchard, U. Bakowsky\nand C. M. Lehr, AAPS PharmSciTech, 2005, 6, E22-30.\n208. N. Nafee, S. Taetz, M. Schneider, U. F. Schaefer and C.\nM. Lehr, Nanomedicine : nanotechnology, biology, and medicine, 2007, 3, 173-183.\n209. S. Taetz, N. Nafee, J. Beisner, K. Piotrowska, C. Baldes,\nT. E. Murdter, H. Huwer, M. Schneider, U. F. Schaefer, U. Klotz and C. M. Lehr, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2009, 72, 358-369.\n210. M. N. Ravi Kumar, U. Bakowsky and C. M. Lehr,\nBiomaterials, 2004, 25, 1771-1777.\n211. X. Yuan, B. A. Shah, N. K. Kotadia, J. Li, H. Gu and Z.\nWu, Pharmaceutical research, 2010, 27, 1285-1295.\n212. K. Tahara, H. Yamamoto, N. Hirashima and Y.\nKawashima, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2010, 74, 421-426.\n213. W. X. Wang, J. Q. Gao and W. Q. Liang, Drug delivery,\n2011, 18, 208-214.\n214. F. Q. Hu, M. D. Zhao, H. Yuan, J. You, Y. Z. Du and S.\nZeng, International journal of pharmaceutics, 2006, 315, 158-166.\n215. P. M. Moreno, J. C. Santos, C. P. Gomes, A. Varela-\nMoreira, A. Costa, V. Leiro, H. Mansur and A. P. Pego, Molecular pharmaceutics, 2016, DOI: 10.1021/acs.molpharmaceut.5b00538.\n216. B. Layek and J. Singh, Biomacromolecules, 2013, 14,\n4071-4081.\n217. B. Yu, C. Tang and C. Yin, Biomaterials, 2014, 35,\n6369-6378.\n218. H. S. Yoo, J. E. Lee, H. Chung, I. C. Kwon and S. Y.\nJeong, Journal of controlled release : official journal of the Controlled Release Society, 2005, 103, 235-243.\n219. K. Y. Lee, I. C. Kwon, Y. H. Kim, W. H. Jo and S. Y.\nJeong, Journal of controlled release : official journal of the Controlled Release Society, 1998, 51, 213-220.\n220. S. Y. Chae, S. Son, M. Lee, M. K. Jang and J. W. Nah,\nJournal of controlled release : official journal of the Controlled Release Society, 2005, 109, 330-344.\n221. Y. H. Kim, S. H. Gihm, C. R. Park, K. Y. Lee, T. W. Kim, I.\nC. Kwon, H. Chung and S. Y. Jeong, Bioconjugate chemistry, 2001, 12, 932-938.\n222. W. G. Liu, K. De Yao and Q. G. Liu, Journal of Applied\nPolymer Science, 2001, 82, 3391-3395.\n223. W. G. Liu, X. Zhang, S. J. Sun, G. J. Sun, K. D. Yao, D. C.\nLiang, G. Guo and J. Y. Zhang, Bioconjugate chemistry, 2003, 14, 782-789.\n224. S. Ercelen, X. Zhang, G. Duportail, C. Grandfils, J.\nDesbrieres, S. Karaeva, V. Tikhonov, Y. Mely and V. Babak, Colloids and surfaces. B, Biointerfaces, 2006, 51, 140-148.\n225. T. Rojanarata, M. Petchsangsai, P. Opanasopit, T.\nNgawhirunpat, U. Ruktanonchai, W. Sajomsang and S. Tantayanon, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2008, 70, 207-214.\n226. P. Opanasopit, W. Sajomsang, U. Ruktanonchai, V.\nMayen, T. Rojanarata and T. Ngawhirunpat, International journal of pharmaceutics, 2008, 364, 127-134.\n227. V. S. Gaware, M. Hakerud, K. Leosson, S. Jonsdottir, A.\nHogset, K. Berg and M. Masson, Journal of medicinal chemistry, 2013, 56, 807-819.\n228. R. Yoksan and M. Akashi, Carbohydrate Polymers,\n2009, 75, 95-103.\n229. T. H. Kim, J. E. Ihm, Y. J. Choi, J. W. Nah and C. S. Cho,\nJournal of controlled release : official journal of the Controlled Release Society, 2003, 93, 389-402.\n230. K. L. Chang, Y. Higuchi, S. Kawakami, F. Yamashita and\nM. Hashida, Bioconjugate chemistry, 2010, 21, 1087- 1095.\n231. H. S. Bisht, D. S. Manickam, Y. You and D. Oupicky,\nBiomacromolecules, 2006, 7, 1169-1178.\n232. M. Turk, S. Dincer, I. G. Yulug and E. Piskin, Journal of\ncontrolled release : official journal of the Controlled Release Society, 2004, 96, 325-340.\n233. S. Sun, W. Liu, N. Cheng, B. Zhang, Z. Cao, K. Yao, D.\nLiang, A. Zuo, G. Guo and J. Zhang, Bioconjugate chemistry, 2005, 16, 972-980.\nPage 30 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 31\nPlease do not adjust margins\nPlease do not adjust margins\n234. Z. Mao, L. Ma, J. Yan, M. Yan, C. Gao and J. Shen,\nBiomaterials, 2007, 28, 4488-4500.\n235. J. Y. Lee, S. H. Lee, M. H. Oh, J. S. Kim, T. G. Park and\nY. S. Nam, Journal of controlled release : official journal of the Controlled Release Society, 2012, 162, 407-413.\n236. D. A. Lowther and H. J. Rogers, Nature, 1955, 175,\n435.\n237. A. P. Maclennan, Journal of general microbiology,\n1956, 15, 485-491.\n238. P. Prehm, The Biochemical journal, 1990, 267, 185-\n189.\n239. D. Jiang, J. Liang and P. W. Noble, Physiological\nreviews, 2011, 91, 221-264.\n240. A. K. Yadav, P. Mishra and G. P. Agrawal, Journal of\ndrug targeting, 2008, 16, 91-107.\n241. K. Meyer and J. W. Palmer, Journal of Biological\nChemistry, 1934, 107, 629-634.\n242. B. Weissmann and K. Meyer, Journal of the American\nChemical Society, 1954, 76, 1753-1757.\n243. C. Ragan and K. Meyer, The Journal of Clinical\nInvestigation, 28, 56-59.\n244. D. Hamerman and H. Schuster, J Clin Invest, 1958, 37,\n57-64.\n245. S. Torii and R. Bashey, Nature, 1966, 209, 506-507. 246. S. E. Armstrong and D. R. Bell, American journal of\nphysiology. Heart and circulatory physiology, 2002, 283, H2485-2494.\n247. L. Juhlin, Journal of internal medicine, 1997, 242, 61-\n66.\n248. A. Almond, Cellular and molecular life sciences :\nCMLS, 2007, 64, 1591-1596.\n249. C. Zeng, B. P. Toole, S. D. Kinney, J. W. Kuo and I.\nStamenkovic, International journal of cancer, 1998, 77, 396-401.\n250. V. M. Platt and F. C. Szoka, Jr., Molecular\npharmaceutics, 2008, 5, 474-486.\n251. M. B. Duncan, M. Liu, C. Fox and J. Liu, Biochemical\nand biophysical research communications, 2006, 339, 1232-1237.\n252. Y. Luo and G. D. Prestwich, Bioconjugate chemistry,\n1999, 10, 755-763.\n253. Y. Luo, M. R. Ziebell and G. D. Prestwich,\nBiomacromolecules, 2000, 1, 208-218.\n254. E. Auzenne, S. C. Ghosh, M. Khodadadian, B. Rivera,\nD. Farquhar, R. E. Price, M. Ravoori, V. Kundra, R. S. Freedman and J. Klostergaard, Neoplasia, 9, 479-486.\n255. F. Leonelli, A. La Bella, A. Francescangeli, R. Joudioux,\nA.-L. Capodilupo, M. Quagliariello, L. M. Migneco, R. M. Bettolo, V. Crescenzi, G. De Luca and D. Renier, Helvetica Chimica Acta, 2005, 88, 154-159.\n256. A. Rosato, A. Banzato, G. De Luca, D. Renier, F.\nBettella, C. Pagano, G. Esposito, P. Zanovello and P. Bassi, Urologic oncology, 2006, 24, 207-215.\n257. R. K. Mittapalli, X. Liu, C. E. Adkins, M. I. Nounou, K. A.\nBohn, T. B. Terrell, H. S. Qhattal, W. J. Geldenhuys, D. Palmieri, P. S. Steeg, Q. R. Smith and P. R. Lockman, Molecular cancer therapeutics, 2013, 12, 2389-2399.\n258. Y. Luo, N. J. Bernshaw, Z. R. Lu, J. Kopecek and G. D.\nPrestwich, Pharmaceutical research, 2002, 19, 396- 402.\n259. C. J. Lin, C. H. Kuan, L. W. Wang, H. C. Wu, Y. Chen, C.\nW. Chang, R. Y. Huang and T. W. Wang, Biomaterials, 2016, 90, 12-26.\n260. D. Coradini, S. Zorzet, R. Rossin, I. Scarlata, C.\nPellizzaro, C. Turrin, M. Bello, S. Cantoni, A. Speranza, G. Sava, U. Mazzi and A. Perbellini, Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, 10, 4822- 4830.\n261. D. Coradini, C. Pellizzaro, G. Miglierini, M. G. Daidone\nand A. Perbellini, International journal of cancer, 1999, 81, 411-416.\n262. D. Coradini, C. Pellizzaro, G. Abolafio, M. Bosco, I.\nScarlata, S. Cantoni, L. Stucchi, S. Zorzet, C. Turrin, G. Sava, A. Perbellini and M. G. Daidone, Investigational new drugs, 2004, 22, 207-217.\n263. D. Coradini, C. Pellizzaro, I. Scarlata, S. Zorzet, C.\nGarrovo, G. Abolafio, A. Speranza, M. Fedeli, S. Cantoni, G. Sava, M. G. Daidone and A. Perbellini, Leukemia, 2006, 20, 785-792.\n264. J. Yao, L. Zhang, J. Zhou, H. Liu and Q. Zhang,\nMolecular pharmaceutics, 2013, 10, 1080-1091.\n265. N. F. Guilbaud, N. Gas, M. A. Dupont and A. Valette,\nJournal of cellular physiology, 1990, 145, 162-172.\n266. H. Yamamoto, J. Fujimoto, E. Okamoto, J. Furuyama,\nT. Tamaoki and T. Hashimoto-Tamaoki, International journal of cancer, 1998, 76, 897-902.\n267. O. C. Velazquez, A. Jabbar, R. P. DeMatteo and J. L.\nRombeau, Surgery, 1996, 120, 440-447; discussion 447-448.\n268. R. E. Eliaz and F. C. Szoka, Jr., Cancer research, 2001,\n61, 2592-2601.\n269. R. E. Eliaz, S. Nir, C. Marty and F. C. Szoka, Jr., Cancer\nresearch, 2004, 64, 711-718.\n270. S. Arpicco, C. Lerda, E. Dalla Pozza, C. Costanzo, N.\nTsapis, B. Stella, M. Donadelli, I. Dando, E. Fattal, L. Cattel and M. Palmieri, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2013, 85, 373-380.\n271. E. Dalla Pozza, C. Lerda, C. Costanzo, M. Donadelli, I.\nDando, E. Zoratti, M. T. Scupoli, S. Beghelli, A. Scarpa, E. Fattal, S. Arpicco and M. Palmieri, Biochimica et biophysica acta, 2013, 1828, 1396-1404.\n272. H. J. Cho, H. Y. Yoon, H. Koo, S. H. Ko, J. S. Shim, J. H.\nLee, K. Kim, I. C. Kwon and D. D. Kim, Biomaterials, 2011, 32, 7181-7190.\n273. J. H. Park, H. J. Cho, H. Y. Yoon, I. S. Yoon, S. H. Ko, J.\nS. Shim, J. H. Cho, J. H. Park, K. Kim, I. C. Kwon and D. D. Kim, Journal of controlled release : official journal of the Controlled Release Society, 2014, 174, 98-108.\n274. K. Y. Choi, K. H. Min, J. H. Na, K. Choi, K. Kim, J. H.\nPark, I. C. Kwon and S. Y. Jeong, Journal of Materials Chemistry, 2009, 19, 4102-4107.\n275. K. Y. Choi, H. Chung, K. H. Min, H. Y. Yoon, K. Kim, J. H.\nPark, I. C. Kwon and S. Y. Jeong, Biomaterials, 2010, 31, 106-114.\n276. S.-Y. Han, H. S. Han, S. C. Lee, Y. M. Kang, I.-S. Kim and\nJ. H. Park, Journal of Materials Chemistry, 2011, 21, 7996-8001.\nPage 31 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "32 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\n277. K. Y. Choi, K. H. Min, H. Y. Yoon, K. Kim, J. H. Park, I. C.\nKwon, K. Choi and S. Y. Jeong, Biomaterials, 2011, 32, 1880-1889.\n278. K. Y. Choi, H. Y. Yoon, J. H. Kim, S. M. Bae, R. W. Park,\nY. M. Kang, I. S. Kim, I. C. Kwon, K. Choi, S. Y. Jeong, K. Kim and J. H. Park, ACS nano, 2011, 5, 8591-8599.\n279. H. S. Han, J. Lee, H. R. Kim, S. Y. Chae, M. Kim, G.\nSaravanakumar, H. Y. Yoon, D. G. You, H. Ko, K. Kim, I. C. Kwon, J. C. Park and J. H. Park, Journal of controlled release : official journal of the Controlled Release Society, 2013, 168, 105-114.\n280. J. Li, M. Huo, J. Wang, J. Zhou, J. M. Mohammad, Y.\nZhang, Q. Zhu, A. Y. Waddad and Q. Zhang, Biomaterials, 2012, 33, 2310-2320.\n281. L. Deng, G. Wang, J. Ren, B. Zhang, J. Yan, W. Li and N.\nM. Khashab, RSC Advances, 2012, 2, 12909-12914.\n282. F. Li, S.-J. Park, D. Ling, W. Park, J. Y. Han, K. Na and K.\nChar, Journal of Materials Chemistry B, 2013, 1, 1678- 1686.\n283. K. Miki, T. Inoue, Y. Kobayashi, K. Nakano, H.\nMatsuoka, F. Yamauchi, T. Yano and K. Ohe, Biomacromolecules, 2015, 16, 219-227.\n284. D. S. Liang, H. T. Su, Y. J. Liu, A. T. Wang and X. R. Qi,\nBiomaterials, 2015, 71, 11-23.\n285. Y. Liu, J. Sun, W. Cao, J. Yang, H. Lian, X. Li, Y. Sun, Y.\nWang, S. Wang and Z. He, International journal of pharmaceutics, 2011, 421, 160-169.\n286. G. Huerta-Angeles, M. Bobek, E. Prikopova, D.\nSmejkalova and V. Velebny, Carbohydr Polym, 2014, 111, 883-891.\n287. L. Mayol, M. Biondi, L. Russo, B. M. Malle, K.\nSchwach-Abdellaoui and A. Borzacchiello, Carbohydr Polym, 2014, 102, 110-116.\n288. L. Wan, J. Jiao, Y. Cui, J. Guo, N. Han, D. Di, D. Chang,\nP. Wang, T. Jiang and S. Wang, Nanotechnology, 2016, 27, 135102.\n289. J. Han, W. Park, S. J. Park and K. Na, ACS applied\nmaterials & interfaces, 2016, 8, 7739-7747.\n290. K. K. Upadhyay, J. F. Le Meins, A. Misra, P. Voisin, V.\nBouchaud, E. Ibarboure, C. Schatz and S. Lecommandoux, Biomacromolecules, 2009, 10, 2802- 2808.\n291. K. K. Upadhyay, A. N. Bhatt, A. K. Mishra, B. S.\nDwarakanath, S. Jain, C. Schatz, J. F. Le Meins, A. Farooque, G. Chandraiah, A. K. Jain, A. Misra and S. Lecommandoux, Biomaterials, 2010, 31, 2882-2892.\n292. H. S. Han, T. Thambi, K. Y. Choi, S. Son, H. Ko, M. C.\nLee, D. G. Jo, Y. S. Chae, Y. M. Kang, J. Y. Lee and J. H. Park, Biomacromolecules, 2015, 16, 447-456.\n293. G. Saravanakumar, K. Y. Choi, H. Y. Yoon, K. Kim, J. H.\nPark, I. C. Kwon and K. Park, International journal of pharmaceutics, 2010, 394, 154-161.\n294. W. Hyung, H. Ko, J. Park, E. Lim, S. B. Park, Y. J. Park,\nH. G. Yoon, J. S. Suh, S. Haam and Y. M. Huh, Biotechnology and bioengineering, 2008, 99, 442-454.\n295. A. K. Yadav, P. Mishra, A. K. Mishra, P. Mishra, S. Jain\nand G. P. Agrawal, Nanomedicine : nanotechnology, biology, and medicine, 2007, 3, 246-257.\n296. G. Pitarresi, F. S. Palumbo, A. Albanese, C. Fiorica, P.\nPicone and G. Giammona, Journal of drug targeting, 2010, 18, 264-276.\n297. L. Qiu, Z. Li, M. Qiao, M. Long, M. Wang, X. Zhang, C.\nTian and D. Chen, Acta biomaterialia, 2014, 10, 2024- 2035.\n298. D. Landesman-Milo, M. Goldsmith, S. Leviatan Ben-\nArye, B. Witenberg, E. Brown, S. Leibovitch, S. Azriel, S. Tabak, V. Morad and D. Peer, Cancer letters, 2013, 334, 221-227.\n299. S. Taetz, A. Bochot, C. Surace, S. Arpicco, J. M. Renoir,\nU. F. Schaefer, V. Marsaud, S. Kerdine-Roemer, C. M. Lehr and E. Fattal, Oligonucleotides, 2009, 19, 103- 116.\n300. C. Surace, S. Arpicco, A. Dufay-Wojcicki, V. Marsaud,\nC. Bouclier, D. Clay, L. Cattel, J. M. Renoir and E. Fattal, Molecular pharmaceutics, 2009, 6, 1062-1073.\n301. A. Dufay Wojcicki, H. Hillaireau, T. L. Nascimento, S.\nArpicco, M. Taverna, S. Ribes, M. Bourge, V. Nicolas, A. Bochot, C. Vauthier, N. Tsapis and E. Fattal, Journal of controlled release : official journal of the Controlled Release Society, 2012, 162, 545-552.\n302. R. Ran, Y. Liu, H. Gao, Q. Kuang, Q. Zhang, J. Tang, K.\nHuang, X. Chen, Z. Zhang and Q. He, International journal of pharmaceutics, 2014, 477, 590-600.\n303. Y. Shen, B. Wang, Y. Lu, A. Ouahab, Q. Li and J. Tu,\nInternational journal of pharmaceutics, 2011, 414, 233-243.\n304. Y. Liu, M. Kong, X. J. Cheng, Q. Q. Wang, L. M. Jiang\nand X. G. Chen, Carbohydr Polym, 2013, 94, 309-316.\n305. F. Dosio, S. Arpicco, B. Stella and E. Fattal, Advanced\ndrug delivery reviews, 2016, 97, 204-236.\nPage 32 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "Nanoscale",
      "text" : "REVIEW\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1\nPlease do not adjust margins\nPlease do not adjust margins\nReceived 00th January 20xx, Accepted 00th January 20xx\nDOI: 10.1039/x0xx00000x\nwww.rsc.org/\nCarbohydrate-based amphiphilic nano delivery system for cancer\ntherapy\nPart two: Systems based on Cyclodextrin, Dextran and other carbohydrates\nKegang Liu,* a Xiaohua Jiang b and Patrick Hunziker* a,c\nNanoparticles (NPs) are novel drug delivery system that attract more and more attention in recent years, and have been introduced for the treatment of cancer, infection, inflammation and other diseases. Among the numerous classes of materials employed for constructing NPs, organic polymers are outstanding due to the flexibility of design, synthesis, ease of modification and functionalization. In particular, NPs based amphiphilic polymers make a great contribution to the delivery of poorly-water soluble drugs. For example, natural, biocompatible and biodegradable products like polysaccharides are widely used as building blocks for the preparation of such drug delivery vehicles. This review will detail carbohydrate based amphiphilic polymeric systems for cancer therapy. Specifically, it focuses on the nature of the polymer employed for the preparation of targeted nanocarriers, the synthetic methods, as well as strategies for application and the evaluation of biological activity. Applications of the amphiphilic polymer systems include drug delivery, gene delivery, photosensitizer delivery, diagnostic imaging as well as specific ligand-assisted cellular uptake. As a result, a thorough understanding of the relationship between chemical structure and biological properties facilitates the optimal design and rational clinic application of the resulting carbohydrate based nano delivery systems for cancer therapy. Following part one, amphiphilic nano drug delivery systems based on cyclodextrin, dextran and other cabohydrates will be discussed in this part (part two)."
    }, {
      "heading" : "4.3. Cyclodexrin based amphiphilic delivery system for cancer therapy",
      "text" : ""
    }, {
      "heading" : "4.3.1 Introduction to cyclodextrin",
      "text" : "Cyclodextrins (CDs) are naturally occurring macrocyclic oligosaccharides constructed by α-1, 4 linked D-glucopyranose units (Fig. 3), which are enzymatically produced from starch. 3,"
    }, {
      "heading" : "35, 306",
      "text" : "Cyclodextrins can comprise 5 or more α-Dglucopyranoside units, mainly 6, 7 and 8 glucose units known as α-, β- and γ-CD (Fig. 28). 306 Due to their special molecular structure, CDs form a truncated cone shape with a larger and a smaller rims (primary face and secondary face) consisting of secondary and primary hydroxyl groups, respectively (Fig. 28). This arrangement endows CDs with a typical amphiphilic\ntopology: a hydrophilic (polar) exterior and a hydrophobic (non-polar) cavity, which enables CD hosts to form inclusion complexes with hydrophobic molecules as guests. 306 CDs can be used in food, chemical industries, agriculture, environmental engineering as well as in the pharmaceutical domain. Due to the good biocompatibility of CDs including low toxicity and negligible immune response in human, 307, 308 they have been frequently utilized in pharmaceutics for the modification of drug properties, including improving the solubility of poorly water-soluble drugs, enhancing the stability against degradation by certain enzymes (endonucleases etc.) 307 and improving permeability across biological membranes. 308 Progressing from these achievements of the utilization of CDs in pharmaceutics in the past, numerous of CDs based drug delivery systems have been developed gradually in the decades, especially as amphiphilic drug delivery system for anti-cancer therapy in the form of hostguest complexes. Recent comprehensive reviews specifically on CD-mediated drug delivery are available. 3, 35, 307, 308 In the following text, CDs and chemically modified CDs based amphiphilic 80, 309 drug delivery systems for cancer therapy will be discussed systematically.\nPage 33 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nFig. 28 Chemical structures of α-, β-, γ-cyclodextrin and the truncated cone shape as a cartoon drawing. Primary face is composed of 6-OH group and secondary face is composed of 2-, 3- OH groups.\n4.3.2 Small molecules as anti-cancer drugs using cyclodextrin\nbased amphiphilic delivery system\nGenerally, there are three paths to prepare cyclodextrin based amphiphilic drug delivery systems. 80, 88 The simplest representative cases are illustrated in Fig. 29, and are 1) cyclodextrin conjugates; 2) cyclodextrin inclusion complexes; 3) pseudopolyrotaxanes. Currently, more complicated delivery systems are produced by the combination of two or even three of these strategies. Hydrophilic-hydrophobic balance, molecular shape and solvation as important criteria are taken consideration into the formation of the CD based amphiphilic assemblies.\nFig. 29 Representative examples for amphiphilic drug delivery system as nanocarriers based cyclodextrin. 1) cyclodextrin conjugate; 2) cyclodextrin inclusion complex; 3) pseudopolyrotaxane.\nFor most envisaged combinationons is desired in the assembly of an amphiphilic system, chemical modifications of the cyclodextrin are the basis or the key (Scheme 16). According to the chemical structure of cyclodextrin, hydrophilic, hydrophobic or amphiphilic substitutes from small molecules and macromolecules can be attached to its functional groups 2-OH, 3-OH in secondary face and 6-OH in primary face as reaction sites via relevant reactions. 310 Compared to the 2-OH, 3-OH in secondary face, the 6-OH in primary face is more reactive, thereby having a good potential to be modified by other functional substitutes in a few reaction steps such as - NH2, -I, -Br, -SH, -N3 etc. These important intermediates can readily undergo further modification by carbodiimide chemistry (-NH2), a SN2 reaction (-I, Br, -SH), or a “click” reaction (-N3) etc. In terms of the modification of the 2-OH, 3- OH in secondary face, the 6-OH in primary face should be protected in advance. Based on the chemical modification of CDs and the host-guest interactions, the drug amphiphilic delivery system manifests a great diversity.\nScheme 16 General synthetic way to amphiphilic cyclodextrins. 6-OH group are more reactive and can be easily replaced by other substitutes (-NH2, -I, -Br, -N3,-SH, etc.) compared to 2-, or 3-OH group.\nThe following text will introduce some cases relevant to small molecules as anti-cancer drugs using cyclodextrin based amphiphilic delivery system, self-assembled mainly via a simple hydrophobic interaction (non-inclusion complexation) or an inclusion complexation, respectively.\n4.3.2.1. Non-inclusion complexation\nIn this part of non-inclusion complexation, amphiphiles can be constructed by introducing hydrophobic segments to CDs from the sites of its hydroxyl groups in primary or secondary faces. As mentioned, hydrophobic segments can be selected from long carbon chains 311, 312 or other biocompatible hydrophobicfunction groups. 313, 314 In some cases, small anti-cancer drugs (camptothecin, 315 tubulin A 316 ) conveying hydrophobic properties can be directly conjugated onto CDs or their derivatives through physiologically labile bonds such as an ester bond, 315 or a disulfide bond. 316\nMazzaglia et al. developed NPs made of the amphiphilic\nSC16OH to entrap anticancer drug docetaxel (Doc) (Fig. 30). 311 Doc-loaded SC16OH NPs were not haemolytic toward red blood cells as compared to a commercial Doc formulation (Taxotere) which shows a dose-dependent toxicity. The NPs showed superior cell killing and cell damage after treatment of HEp-2 cells compared to equivalent doses of free Doc. The NPs based on SC16OH demonstrated a good potential in solid tumours therapy. Later, the same group designed similar NPs based on SC6OH amphiphilic CD for the delivery of a poorwater-soluble organotin (IV)-porphyrin derivative [(Bu3Sn)4TPPS] to melanoma cancer cells (Fig. 30). 312 The delivery of (Bu3Sn)4TPPS by SC6OH with respect to free (Bu3Sn)4TPPS increased the internalization efficiency and cytotoxicity to induce apoptotic cell death and changed the cellular morphology as well as prevented cell proliferation at lower concentrations. Li et al. synthesized a series of biodegradable, acid-labile materials----acetalated cyclodextrin family (Fig. 30). 313, 314, 317 These newly developed materials can hydrolyze/degrade into the corresponding precursors in a pH controlled manner. In vitro and in vivo study, the acetalated βCDs showed good biocompatibility, and may have broad applications in medicine. 313 Later, the authors described acetalated α-cyclodextrin materials as a new pH-sensitive nano-system could be utilized to incorporate the anticancer drug paclitaxel (PTX) and the resulting NPs significantly improved cytotoxic activity against various tumour cells and reversed the multidrug resistance of PTX-resistant cancer cells. In addition, in vivo antitumor studies showed that the pHsensitive nanosystems had better efficacy than PTX and pHinsensitive PLGA nano-formulations. 314 In 2015, they further proved that Ac-αCD NP could dramatically potentiate the activity of many anticancer drugs such as paclitaxel, docetaxel, cis-diamminedichloroplatinum, camptothecin, and doxorubicin. 317 The capability of Ac-αCD NP on MDR cells was attributed to a resulting combination from decreased Pgp expression, attenuated Pgp ATPase activity, and the reduced intracellular ATP level (Scheme 17). They suggested that released α-CD, produced by hydrolysis of Ac-αCD NP under acidic subcellular organelle condition, has an anti-MRD effect. These findings should be interesting for effective therapy of\nPage 34 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3\nPlease do not adjust margins\nPlease do not adjust margins\nresistant cancers by their combination with chemotherapeutic agents. 317\nFig. 30 Some examples of CDs based amphiphilic drug delivery systems without using inclusion complexation. 1) 6-OH was modified with hydrophobic long carbon chain (SC16OH, SC6OH); 2) 2-, 3-, 6-OH were hydrophobically acetalated (acetalated α and β-CDs); 3) Drug-polymer conjugate was attached to 6- position of CD by sulfide bonds (Poly (CDDCysPA-PEG)-GlyGlyGly-CPT and CDP-TubA).\nScheme 17 Schematic illustration of the sensitizing effect of Ac-αCD NP. Ac-αCD-derived Ac-αCD NP may be endocytosed by resistant cancer cells. The internalized NPs are transported via the endolysosomal compartments, into which Ac-αCD NP may be hydrolyzed to generate parent α-CD molecules. Then intracellularly delivered α-CD inhibits the Pgp expression (A), induces ATP depletion (B), and attenuates Pgp ATPase activity (C). The collective effect of these pharmacological functions contributes to enhanced drug uptake/retention and potentiated efficacy against MDR cancer cells. Reprinted from Ref. 317. Copyright 2015 with permission from Elsevier.\nDavis et al. synthesized β-cyclodextrin based linear polymers that were used for the conjugation of camptothecin (CPT). 315 The synthesis of the CPT prodrug was illustrated in scheme 18. First, 6A,6D-diiodo-6A,6D-dideoxy-β-cyclodextrin (CDDI) reacted with L-cysteine to provide an important intermediate with di-amine functional groups which could further react with Poly (ethylene glycol) dipropanoicsuccinimide (PEGDiSPA) at a basic condition to produce poly β-cyclodextrin-PEG conjugate with free carboxylic acid functional groups. Then a triglycine-modified CPT reacted with the carboxylic acid of the conjugate to produce the CPT prodrug as Poly (CDDCys-PAPEG)-GlyGlyGly-CPT. This design not only increases the solubility of CPT in water, but also helps the β-cyclodextrin-CPT conjugate to form NPs readily by self-assembly using CPT as a hydrophobic segment. The solubility of CPT in prodrug form is increased by more than three orders of magnitude and the rates of CPT release from the conjugate either in mouse or human plasma are dramatically accelerated over the rates of pure hydrolysis at pH 7.4. In 2009, Schluep et al. prepared a NP prodrug of tubulysin A and evaluated it in vitro and in vivo. 316 As well known, tubulysins are naturally occurring tetrapeptides with potent anti-proliferative activity against multiple cancer cell lines, however were highly toxic in animal models. In order to solve this problem, authors designed a linear, β-cyclodextrin based polymer covalently conjugated onto tubulysin A (TubA) through a disulfide linker (CDP-TubA) (Fig. 30). The synthesis of CDP-TubA is similar to the Poly (CDDCys-PA-PEG)-GlyGlyGlyCPT, in which the CPT modified by a triglycine linker was\nreplaced by a thiol derivative of TubA in the last coupling reaction. In vitro test, CDP-TubA showed minimal inhibition in NCI-H1299 (lung), HT-29 (colon), and A2780 (ovarian) cell lines as compared to Tub A itself. The preclinical efficacy of CDPTubA administered i.v. was evaluated in nude mice bearing s.c. implanted human HT29 colorectal and H460 non-small cell lung carcinoma tumours. A single treatment cycle of three weekly doses of CDP-TubA showed a potent antitumor effect and significantly prolonged survival compared with TubA alone. The authors suggested cyclodextrin polymerized NPs are an enabling technology for the safe and effective delivery of tubulysins for the treatment of cancer.\nScheme 18 Schematic illustration of total synthesis of the polymer Poly (CDDCys-PA-PEG)-GlyGlyGly-CPT. Adapted with permission from Ref. 315. Copyright 2003 American Chemical Society."
    }, {
      "heading" : "4.3.2.2. Inclusion complexation",
      "text" : "In the inclusion complexation part, we focus on the interactions of two components, so called “host” and “guest” molecules, which drive the related amphiphilic system to selfassemble and result in NPs for cancer therapy. The binding ability of hosts and guests is mainly attributed to hydrophobic interactions and the complementary character of size and shape between two host-guest structures. 88 A few important guest molecules for the host cyclodeyxtrin are listed in Fig 31. For example, adamantane (ADA) has been widely applied in macromolecular assembly due to its strong binding ability with an association constant around 1 × 10 5 M -1 in water. 88 In consideration of using stimuli-responsive drug release in external environment, some guest molecular residues also have been drawn more and more attentions such as benzimidazole (pH), 318 arozbenzene (light), 88 ferrocene (voltage). 319\nFig. 31 Some typical host-guest chemical structures frequently used in inclusion complex. Host: CDs; Guest molecular residues: Adamantane, Benzimidazole, Azobenzene, Ferrocene, Benzene, Polyethylene glycol etc.\nGenerally, there are two different routes to establish amphiphilic drug delivery systems via inclusion complexation. First, drugs directly involve the inclusion complexation, in which drugs can be loaded into the cavities of CDs as guest molecules as well as full or part of hydrophobic segments in related amphiphilic drug delivery systems (Fig. 32). Second, drugs are not the guest molecules involved the formation of the inclusion complexation (Fig. 33). In this category, one type\nPage 35 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nof well-known assemblied pseudopolyrotaxane (PPR), formed by a linear polymer chain threading a series of CD cavities will be discussed separately.\nFig. 32 Chemical structures of representative macromolecular amphiphiles formed via normal inclusion complex (drug involved). 1) Small molecule modified CDs + drugs; 2) Macromolecule modified CDs + drugs.\nIn the area of drugs involved in inclusion complexation, CDs can be simply modified by small molecules 320-322 or conjugated onto macromolecules hybridized with stealthy PEG chains. 323- 326 In some cases, natural polysaccharide HA-CD conjugate can be utilized as carrier for targeted drug delivery, in which HA is used as the ligand of CD44 receptor. 327 In addition, the macromolecules normally are produced by living free radical polymerization (ATRP, RAFT) 323 or controlled ring-open copolymerization 324-326 and grafted onto CDs using carbodiimide chemistry 324, 325, 327 or “click” chemistry. 323, 326\nIn the light of different targets, various small molecules were linked to cyclodextrin such as ion-chelated ligands, 320 hydrophobic moieties, 321 certain functional groups for membrane penetration. 322 Hao et al. developed a class of azaarm modified β-cyclodextrins to trap paclitaxel (PTX). The resulting novel “supramolecular amphiphiles” can further selfassemble into vesicular structures in aqueous solution (Fig. 32- 1a). 320 Interestingly, the vesicles disappeared upon the introduction of Cu 2+ into the vesicular system while PTX was released. The authors believed that the new strategy of directly employing special drugs to construct microvehicles could also carry other targeted molecules. Gourevich et al. investigated ultrasound-mediated targeted drug delivery by using 3-(2-naphthyl)-alanine modified γ-CD (ester bond in 6- position) and doxorubicin inclusion complex. 321 They examined individually the thermal and the mechanical effects of focused ultrasound for drug release and found promising influences from both of them (Fig. 32-1b). To overcome the poor solubility of anticancer molecules-curcumin analogs in water, Badea et al. used host–guest complexes derivated from physical mixtures of NC 2067 (an anolog of curcumin) and β-CD or CD gemini surfactant (β-cyclodextrin–gemini surfactant). 322 Compared with NC2067 alone in anticancer activity, the NC 2067–CD gemini surfactant complex showed a similar efficacy (Fig. 32-1c). Thermo-responsive functional materials may provide more opportunities for convenient and safe medical uses and have led to considerable attention. As mentioned before, poly (Nisopropylacrylamide) is widely used as thermally responsive material which exhibits a coil to globule transition in water around the lower critical solution temperature (LCST). 80 Stenzel et al. developed a thermo responsive drug-delivery system composed of a conjugate β-cyclodextrin-copolymer POEGMEA-b-P(NIPAAM-s-PACD) and drug albendazole (Fig. 32-\n2a). 323 Scheme 19 depicts the synthesis of copolymer POEGMEA-b-P (NIPAAM-s-PACD). Using 3-BSP as a RAFT agent to react with monomer PEGMEA assisted with AIBN, POEGMEA homopolymer was achieved. Then, intermediatestriblock copolymers were prepared by using POEGMEA40 as new macro-RAFT agent to initiate chain extension with another two monomers NIPAAm and TMSPA in same condition successively. After TMS deprotection, the copolymers were reacted with 6I-azido-6I-deoxy-β-cyclodextrin via Huisgen azide-alkyne 1, 3-dipolar cycloaddition, resulting in thermoresponsive block copolymers with pendant β-cyclodextrin groups (POEGMEA-b-P(NIPAAM-s-PACD). They found only block copolymers with small amounts of cyclodextrin were observed to have an LCST and the encapsulation of ABZ increased the LCST (Scheme 19). The ABZ-loaded polymers showed high toxicity to OVCAR-3 ovarian cancer cell lines.\nScheme 19 Schematic illustration of synthesis of the copolymer POEGMEA-b-P(NIPAAM-s-PACD) (upper) and cartoon illustration of the NP formed with this copolymer and drug ABZ at T>LCST (below). Adapted and reprinted with permission from Ref. 323. Copyright 2011 American Chemical Society.\nLater, Ma et al. prepared double hydrophilic copolymers with one polyethylene glycol (PEG) block and another βcyclodextrin (β-CD) flanking block (PEG-b-PCDs) through the post-modification of macromolecules. 324 The host–guest interaction between the β-CD unit of this host copolymer and hydrophobic drugs (C102, IBU, IND etc.) was found to be the driving force for the self-assembly of NPs (Fig. 32-2b). Relatively high drug loading was achieved by this approach. In vitro release studies suggested that the payload in nanoassemblies could be released in a sustained manner. These results exhibited the potential applications of the synthesized copolymers for the delivery of hydrophobic drugs. In 2014, Yu et al. reported another, similar chemical conjugate β - cyclodextrin-grafted poly(ethylene glycol)/poly (l-glutamic acid) diblock copolymer (mPEG-PLG(CD)) for the delivery of anticancer drug camptothecin (CPT) (Fig. 32-2c). 325 The resulting inclusion complex mPEG-PLG(CPT@CD) can sufficiently prevent CPT from hydrolyzing in physicological condition to keep its active lactone form. Poly lactic acid is another important hydrophobic sergment for constructing amphiphilic copolymer. In 2013, Li et al. synthesized cyclodextrin coulped poly (lactic acid)-b-poly (ethylene glycol) (β-CD-PLA-mPEG), a well-defined amphiphilic copolymer, by controlled ring-open copolymerization and click coupling reaction (Fig. 32-2d). 326 The β-CD-PLA-mPEG copolymer could self-assemble in aqueous solution to form micelles with a mean particle size of 159.2 nm after loaded with a hydrophobic drug (indomethacin, IND). All other properties including high drug loading efficiency and controlled release profile of IND, especially in the control of its initial burst\nPage 36 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5\nPlease do not adjust margins\nPlease do not adjust margins\nrelease, pulsing low toxicity to cells suggest micelles formed by β -CD-PLA-mPEG copolymer could be a promising controlled release system for various hydrophobic drugs.\nAs mentioned in HA section, HA is frequently used as the ligand of CD44 receptor for targeted drug delivery. Recently, Liu et al. synthesized HApCD conjugate for targeted Taxol delivery through host-guest and amphiphilic interactions (Fig. 32-2e). 327 Herein, paclitaxel was modified with porphyrin as prodrug (PorTaxol). Due to the HA shell, the resulting NPs (HATXP) were biocompatible and enzymatic biodegradable. In addition, it exhibited specific targeting internalization and similar anticancer activities with much lower side effects as compared to commercial anticancer drug Taxol.\nIn the area of amphiphilic drug delivery systems formed by inclusion complexes, CDs can be conjugated to linear (dextran, 318 PEG-b-PGMA 319 ) or dendritic (hyperbranched polyglycerols 328 ) polymers, even inorganic support (Au-NP) 329 by covalent bonds as host parts. The guest parts are selected from the residue of the guest molecules with highly binding ability - admantane, 329, 330 medium binding ability residue - benzene, 328 pH sensitive residue - benzimidazole, 318 voltage induced redox residue - ferrocene (Fc) 319 etc. (Fig. 33). After the inclusion complexation of host and guest parts, the whole system becomes amphiphilic, driving the complexes to selfassemble into NPs with anti-cancer drugs in aqueous solution.\nFig. 33 Chemical structures of representative macromolecular amphiphiles formed via normal inclusion complex (without drug involved). Guest molecular residue: 1) Benzimidazole; 2) Benzene; 3) and 4) Adamantane; 5) Ferrocene.\nChen et al. designed and synthesized intracellular pH-sensitive supramolecular block amphiphiles based on the host-guest interaction between benzimidazole (BM) modified poly(3caprolactone) (BM-PCL) and cyclodextrin (β-CD) terminated dextran (Dex-b-CD) (Fig. 33-1), which could further selfassemble into supramolecular micelles. 318 Doxorubicin (DOX) as a model anticancer drug was effectively loaded into the supramolecular micelles via hydrophobic interactions. The enhanced intracellular DOX release was observed in HepG2 cells. DOX-loaded intracellular pH-sensitive supramolecular micelles showed stronger cellular proliferation inhibition in HepG2 cells than pH insensitive micelles. These features suggested that the system provided a powerful mean for delivering and releasing cargos at the tumour sites. Pourjavadi et al. prepared a supramolecular linear-dendritic copolymer consisting of a polystyrene backbone and β-CD conjugated hyperbranched polyglycerols (β-CD-HPG) (Fig. 33-2). 328 The supramolecular linear-dendritic copolymer was formed via host-guest interactions between the β-CD of the polyglycerol conjugate as a host and phenyl rings of polystyrene as guests,\nwhich formed micelles in aqueous solutions. The micelles were suitable to encapsulate and transfer paclitaxel with a high loading capacity. In 2013, Li et al. developed a kind of amphiphilic gold NP (AuNP), in which they introduced a hydrophilic polyethylene glycol (PEG) segment and a hydrophobic poly (N-isopropylacrylamide) (PNIPAM) segment to a gold nanocrystal through the host-guest inclusion between the adamantane groups (ADA) and β-CD residues covered on the surface of gold NP (Fig. 33-3). 329 The resulting amphiphilic AuNPs self-assembled into vesicles in water above body temperature and encapsulated doxorubicin (Dox) effectively. Au vesicles disassemble into stable small AuNPs with a decrease in temperature due to the PNIPAM shifted from hydrophobic to hydrophilic, triggering the release of Dox. The authors believed that these hybrid vesicles combining polymer functionality with the intriguing properties of AuNPs could not only release free Dox and AuNP/Dox at a site of a tumour through the application of either simple ice packs or deeply penetrating cryoprobes, but also showed great potential in other therapeutic treatments such as radiofrequency ablation, due to the presence of gold. In 2014, Sansone et al. synthesized another stable core–shell nanosphere self-assembled in water from heterodimers combining a hydrophobic calix[4]arene moiety with a hydrophilic b-cyclodextrin head (CA4-βCD) (Fig. 33-4). 330 The resulting NPs showed their potential to encapsulate and provide sustained release of the anticancer drug docetaxel. Surface post-modification with glycoligands (Fig. 33-4) targeting the macrophage mannose receptor was also explored. At the same year, Yuan et al. reported a new kind of brush-like supramolecular copolymer topology based on the side chain host-guest interactions between β-CD and Fc (Fig. 33-5). 319 As depicted in scheme 20, the end-decorated homopolymer poly (ɛ-caprolactone) - ferrocene threaded onto a β-cyclodextrin-functionalized main chain polymer resulted in a class of amphiphilic noncovalent grafted copolymers, which further self-assembled into micelles. The resulting micelles exhibit reversible assembly and disassembly behaviour under an electrochemical redox trigger, which opened up a new route to smart nanocapsules for electrochemical applications, presumably also in anti-cancer drug delivery.\nScheme 20 Schematic illustration of the formation of electrochemical redox responsive micelles from brush-like supramolecular block copolymers and their controlled assembly and disassembly (controlled by electrochemical redox trigger). Reproduced from Ref. 319. Copyright 2014 with permission from the Royal Society of Chemistry.\nAs mentioned above, (pseudo) polyrotaxanes based on noncovalent interactions of α-cyclodextrin (CD) and poly (ethylene glycol) (PEG) have recently received attentions in the area of biomedicine. 65 There are two advantages of using\nPage 37 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\n(pseudo) polyrotaxanes (PPRs) as drug delivery system. 331 First, high loading content and low proportion of intermaterials in the resultant inclusion are possible, because α-cyclodextrins could be packed onto PEG chains in a well ordered and highdensity manner, and drugs could be covalently grafted to CDs through its hydroxyl groups. Second, the assembly procedure takes place in water at room temperature without using organic solvents. Based on above considerations, Ji et al. prepared stable pseudopolyrotaxane prodrug micelles with a high drug content through simple mixing of two segments (αCD-hydrazide-DOX.HCl and PEG-b-PMPC) in an aqueous medium (Fig. 34-1). 331 Here, α-CD-hydrazide-DOX-HCl was obtained through a multistep synthetic procedure for constructing a pH sensitive hydrozone bond between α-CD and Dox. PEG-b-PMPC block copolymers were synthesized by atom transfer radical polymerization (ATRP) using PEG-Br as the macroinitiator. The resulting micelles could respond to the endosomal pH, releasing DOX and inhibiting the growth of cancer cells (HepG2 cells), which implied their potential for being an efficient platform in cancer therapy. At the same year, Feng et al. synthesized another pH-sensitive nano antitumor drug delivery system by conjugating doxorubicin (DOX) to amphiphilic polyrotaxane (PR)-based block copolymers through a pH-sensitive cis-aconityl moiety (Fig. 34- 2). 332 The amphiphilic PR-based block copolymers were synthesized via in situ ATRP of poly (ethylene glycol) methyl ether methacrylate (PEGMA) initiated by PPRs self-assembled from the resulting distal 2-bromo- propionyl end-capping Pluronic F127 and various amounts of β-CDs. The resulting polymer-drug conjugates were able to self-assemble into polymeric micelles in an aqueous solution with diameters varying from 297 nm to 178 nm. The NPs had a sustained release of DOX in an acidic environment due to the pHsensitive cis-aconityl linkage and a negligible amount of release in physiological pH. Meanwhile, compared with free drug, lower cytotoxicity was observed and Dox could be efficiently transferred and released into HeLa cells. All the properties suggested that the PR-based block copolymers have the potential to be carriers for the controlled release of antitumor drugs.\nFig. 34 Chemical structures of representative macromolecular amphiphiles formed via special inclusion complex pseudopolyrotaxane (PPR) and related cartoon depictions about the NPs formed with PPRs. 1) α-CD-hydrazide-DOX.HCl + PEG-b-PMPC; 2) PR-DOX. Reproduced from Ref. 331, 332. Copyright 2013 with permission from the Royal Society of Chemistry."
    }, {
      "heading" : "4.3.3. Photosensitizers as anti-cancer drugs using cyclodextrin based amphiphilic delivery system for photodynamic therapy (PDT)",
      "text" : "As discussed, photodynamic therapy (PDT) constitutes a noninvasive method for the inactivation of cancer cells or bacteria. However, two prerequisites have to match the requirement of high efficiency of PDT, i.e. favourable photophysical properties\nof a photosensitizer (high triplet quantum yields (ϕT) and long triplet lifetimes (τT)) and good cell-penetrating properties of the photosensitizer. 333 In recent years, in terms of these criteria, some combinations of amphiphilic cyclodextrin derivatives as biovectors with porphyrins, 333-335 phthalocyanines (PCs) or their metal-complexes 336 as photosensitizers in PDT were investigated. Generally, these combinations lead to supramolecular NPs by non-covalent interactions including normal hydrophobic interaction, 333-336 electrostatic interaction, 333-335 or inclusion complexation 335, 336 (Fig. 35). Sortino et al. designed and prepared a series of supramolecular NPs formed by cationic amphiphilic cyclodextrins and anionic 5,10,15,20-tetrakis (4- sulfonatophenyl)-21H, 23H-porphyrin (TPPS) for normal PDT, 333 additional detection 334 and bimodal photodynamic action, 335 respectively. In 2006, this group prepared a carriersensitizer system consisting of cationic amphiphilic cyclodextrin, heptakis (2-o-amino-O-oligo (ethylene oxide)-6hexylthio)-β-CD (SC6CDNH2) and the anionic TPPS. SC6CDNH2 firstly self-assembled into NP in water and then TPPS were attached on the surface of the NP by an electrostatic interaction (Fig. 35-1). 333 They found that the photodynamic activity of the PPS:SC6CDNH2 NPs was strictly dependent on the molar ratio of sensitizer to carrier. From the experimental data, the molar ratio 1:10 seemed to be the best compromise which resulted in a good yield of singlet oxygen photogeneration, the highest efficiency of intracellular delivery, highest percentage of cells alive after treatment and before irradiation in the mock and a considerably high percentage of cell death after irradiation. The synthesis of the amphiphilic cationic cyclodextrin was depicted in scheme 21. 337, 338 C6-perbrominated β-cylcodextrins (heptakis (6- bromo-6-deoxy) - β - cyclodextrins) reacted with linear thiols CnH2n+1SH by nucleophilic displacement reactions to produce related thioethers. The following reaction of (6-alkylthio-6deoxy)-β-cyclodextrins with ethylene carbonate under mildly alkaline conditions provided a selective substitution at its C2 position, with a degree of substitution of 1 to 3 ethylene glycol units per glycose unit. In order to obtain the target ω-amino βCDs, first, the oligo (ethylene glycol) substituents of heptakis [6-deoxy-6-alkylthio -2-oligo-(ethylene glycol)] - β -cyclodextrin were halogenated by NBS or NIS on their terminal hydoxyl group. Second, the ω-bromo or ω-iodo-derivatives of heptakis [6-deoxy-6-alkylthio -2-oligo- (ethylene glycol)] β -cyclodextrin reacted with sodium azide to provide related azides. In the end, the azides were reduced using PPh3 in DMF, followed by\nPage 38 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7\nPlease do not adjust margins\nPlease do not adjust margins\ntreatments with an aqueous ammonia and HCl solution at PH 2 successively to provide ω-amino β- CDs as its HCl salts.\nScheme 21 Schematic illustration of synthesis of the amphiphilic cyclodextrins SC6CDNH2 and its derivatives. 337, 338\nIn order to promote cell internalization of the carrier system without affecting cell membrane morphology and detect simultaneously both drug and carrier in the cell, the same group designed a supramolecular aggregate of another novel amphiphilic CD (SC6Dns) covalently modified with dansyl groups (fluorophore) at the peripheral amino groups of SC6NH2 and its ternary complex (SC6NH2@SC6Dns/TPPS) with an anionic porphyrin TPPS (Fig. 35-2). 334 In the tested cancer cell lines (HEp-2, HeLa), the resulting NPs SC6NH2@ SC6Dns /TPPS formed by the hydrophobic and electrostatic interactions exhibited a good efficiency in cellular uptake, the simultaneous delivery and the detection of both carrier and drug inside tumour cells. In 2012, Mazzaglia and Sortino et al. developed a supramolecular nano-assembly capable of inducing remarkable levels of cancer cell death through a bimodal action based on the simultaneous photogeneration of anticancer moieties - singlet oxygen ( 1 O2) and nitric oxide (NO) (Fig. 35-3). 335 As the description of Fig. 35-3, the supramolecular nanoassembly was constructed by three noncovalent interactions: 1) a normal hydrophobic interaction of cationic amphiphilic SC6CDNH2 for forming a nanocarrier; 2) an electrostatic interaction for attaching TPPS to the surface of the carrier, 3) an inclusion complexation for trapping the NO photoreleaser AD-ph-NO2 between the cavity of β-CD and the admantyl residue of the photoreleaser. This combination demonstrated a dual photodynamic action and imaging capacities in one single nanostructure, which make this supramolecular architecture with its biocompatibility an appealing candidate for applications in biomedicine.\nFig. 35 CD based amphiphilic nano drug delivery system for PDT constructed via electronic static interaction (encapsulation of photosensitizer) and hydrophobic interaction (self-assembly). 1) Sketch of the nanoassembly formed in aqueous solution from SC6CDNH2 and TPPS; 2) Sketch of the nanoassembly formed in aqueous solution from SC6NH2, SC6Dns and TPPS; 3) Sketch of the nanoassembly formed in aqueous solution from SC6CDNH2, TPPS and AD-ph-NO2. Adapted from Ref.333-335. 1) Adapted from Ref. 333. Copyright 2006 with permission from Elsevier. 2) Adapted from Ref. 334. Copyright 2011 with permission from the Royal Society of Chemistry. 3) Adapted with permission from Ref. 335. Copyright 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.\nIn 2013, Strassert and Ravoo et al. reported another supramolecular singlet oxygen photosensitizing system from an adamantane-functionalized, hexaanionic water-soluble zinc (II) phthalocyanine (PC) and β-cyclodextrin vesicles (CDV) (Fig. 36a). 336 The designed PC was synthesized by an asymmetric statistical condensation with two admantyl anchors for further inclusion complexation with an amphiphilic β-cyclodextrin SC12CDOH produced in a similar way as molecule SC6CDOH. After the investigation of the influence of the docking of the PC to the CDVs on the PC photoluminescence as well as on the quantum yields of singlet oxygen photoproduction, they found that the host-guest interaction of the photosensitizer and the CDVs could enhance the photosensitizing ability of the PC by preventing the formation of inactive aggregates (Fig. 36b). They suggested the supramolecular assembly could be a biocompatible photoactive platform for the design of phototherapeutic agents.\nFig. 36 Zinc (II) phthalocyanine (PC) and β-cyclodextrin vesicles (CDV). a) Chemical structures of compounds SC12CDOH and AD-Pc-Zn; b) Schematic representation of cyclodextrin vesicles decorated with phthalocyanine Photosensitizer AD-Pc-Zn. b) Reproduced from Ref. 336. Copyright 2013 with permission from the Royal Society of Chemistry."
    }, {
      "heading" : "4.3.4. Nucleic acids (siRNA, antisense RNA, micro RNA, plasmid DNA) as anti-cancer drugs using cyclodextrin based amphiphilic delivery systems for cancer therapy",
      "text" : "In addition to several currently available nonviral gene vectors like cationic lipids and cationic polymers which can condense gene into multimolecular complexes (lipoplexes or polyplexes), 339 cyclodextrin containing polycations were also developed for gene delivery recently. The cyclodextrin framework endows good biocompatibility of cationic polymers through significantly alleviating the cytotoxicity both in vitro and in vivo. Furthermore, it promotes efficiency of transfection due to its unique possibilities associated with the intrinsic molecular inclusion capabilities of the CD cavity. Cyclodextrin based amphiphilic polycationic delivery systems have also drawn more attentions in recent years because they can form multifunctional nanocarriers for simultaneous drug and gene delivery. 340 Host-guest interaction and hydrophobic interaction are the two main driving forces for the formation of the nanovectors. The following text will discuss the recent results regarding two categories, i.e. host-guest interaction, versus only normal hydrophobic interaction.\nIn order to condense negatively charged nucleic acid through electrostatic interaction, cylcodextrin, unlike chitosan (positively charged), has to be modified by polymers or small molecules containing amine functional groups. In recent studies related to host-guest interaction, the cyclodextrin\nPage 39 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nbased amphiphilic nanocarriers for gene delivery are mostly produced by self-assembly between the host moleculespositively charged cyclodextrin derivatives and the guest molecules-hydrophobic (amphiphilic) polymers or drugs (Fig. 37-a). 341-343 In 2010, Ma et al. prepared a novel core-shell structured nanoassemblies assembled by a host molecule, branched polyethyleneimine conjugated β-CD (PEI-β-CD, positively charged) and a guest molecule, poly (β-benzyl Laspartate) (PBLA, a hydrophobic polymer) obtained by a ringopened polymerization. 341 As depicted in scheme 22, the benzyl group of PBLA can be entangled by the cavity of β-CD from the conjugate PEI-β-CD. The resulting NPs possess dual functions: 1) the hydrophobic core mainly composed of the hydrophobic polymer PBLA can serve as a nanocontainer to accommodate and sustain the release of hydrophobic drugs. 2) The hydrophilic shell with positive charged segment from PEI condenses pDNA through a static electronic interaction. The resulting polyplexes achieved its transfection/expression in osteoblast cells, which may be used as a new generation of multifunctional nanocarriers for simultaneous drug delivery and gene therapy.\nScheme 22 Illustration of the core-shell nanoassemblies based on PEI-CD/PBLA by a host-guest interaction. Reprinted with permission from Ref. 341. Copyright 2010 American Chemical Society.\nIn 2012, Thompson et al. developed another gene delivery vector based on host-guest interaction between small cationic molecules modified β-CD derivatives and polymers Ad-PVAPEG, which were composed of poly (vinyl alcohol) (PVA) as a main chain, poly (ethylene glycol) PEG as side chain, and adamantane (Ad) residue as a guest molecule grafted to PVA chain via an acid-sensitive benzylidene acetal linkage (Fig. 37- b). 342 The pendent polymers Ad-PVA-PEG could degrade under acidic conditions while remaining intact for more than 5 days at pH 7. These materials have 1000-fold lower cytotoxicity than 25 kDa bPEI while maintaining transfection ability according to HeLa cell culture data. All the findings suggest that degradable cationic polymer constructs may be an effective and low-toxicity vehicle for delivering nucleic acid. In 2014, Li et al. developed a multifunctional bio-reducible targeted (S-S) and synergistic co-delivery system containing paclitaxel (PTX) and p53 gene for potential cancer therapy (Fig. 37-c). 343 Here, PTX, star-shaped cationic polymer containing γcyclodextrin (γ-CD) and multiple oligoethylenimine (OEI) arms with folic acid (FA) conjugated via a disulfide linker constructed the supramolecular inclusion complex (γ-CD-OEI-SS-FA/PTX) by self-assembly. Due to the multipostive charges on the γ-CDOEI-SS-FA/PTX complex, the complex could further form polyplexes with pDNA (wide type P53) and became multifunctional co-delivery system for PTX and pDNA targeting to cancer cells that overexpress folate receptors (FRs). As a result, 1) FA-targeted function led to higher gene transfection\nefficiency in the FR-positive KB cells compared to FR negative cell lines. 2) The redox-sensitive disulfide linker in the selfassembly system further enhanced the gene transfection through the recycling of the FRs from the cytosol onto the cell membrane surface. 3) The complexed PTX and co-delivered gene-wild type P53 induced significant cell apoptosis by resulting in large cell population at sub G1 and G2/M phases. Therefore, the γ-CD-OEI-SS-FA/PTX system may be promising for the application of cancer therapy.\nFig. 37 Chemical structures of cylcodextrin based amphiphilic gene delivery system constructed by host-guest interaction. Guest molecular residue: a) Benzene; b) Adamantane; c) Benzene.\nIn the second part, polycationic amphiphilic CDs (PaCDs) are selected as gene vectors to condense nucleic acids for gene delivery. In 2009, Mellet et al. classified PaCDs into skirt- (left) and jellyfish-type (right) polycationic amphiphilic CDs (paCDs) shown in Fig. 38. 340\nFig. 38 Schematic representation of skirt- (left) and jellyfishtype (right) polycationic amphiphilic CDs (paCDs). The circles and the rectangular boxes represent positively charged groups and spacer segments, respectively. The basket-shaped scaffold represents a cyclodextrin core. Adapted with permission from Ref. 340. Copyright 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.\nAs described in Fig. 38, the two rims of cyclodextrin can be decorated with positively charged functional groups and lipophilic substitutes respectively. When the primary face is decorated with positively charged functional groups and the secondary face with lipophilic substitutes, the PaCD is defined as skirt-type PaCD. Conversely, the PaCD is in jellyfish-type. Both PaCD types can self-assemble to NPs with positively charged surfaces, and can condense nucleic acids by electrostatic interaction for gene delivery. Defaye and Mellte et al. did thoroughly examined shirt-type PaCD for gene delivery. In 2008, they prepared homogenous seven-fold symmetric polyaminothiourea and β-cyclodextrin amphiphiles HexCD-T-C2N and HexCD-T[C2N]2 (Fig. 39a).344 High transfection efficiencies of luciferase encoding reporter gene (Plasmid DNA) in BNL-CL2 cells were obtained for this homogeneous systems (HexCD-T[C2N]2) with very low toxicity profiles, which surpassed the cationic polymer PEI (25 kDa). The result may benefit from the combination of amine and thiourea groups in a C7-symmetric cluster arrangement. In order to further understand structure-activity relationship (SAR) in transfection efficiency, they designed and synthesized a small library of PaCDs (Fig. 39a).340 During this work, the structural modifications of paCDs influencing on the pDNA\nPage 40 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 9\nPlease do not adjust margins\nPlease do not adjust margins\ncomplex stability, cytotoxicity, and gene expression were seriously taken into consideration. It is worth to be stressed here that two main factors, the facial amphiphilicity and the presence of a cluster of cationic and hydrogen bonding centres for cooperative and reversible complexation of the pDNA chain are crucial to attain high transgene expression levels with a low toxicity profile.\nFig. 39 Chemical structures of Skirt-type polycationic amphiphilic cyclodextrin (paCDs). 340, 344-347\nThe synthetic strategy takes advantage of the differential reactivity of primary versus secondary hydroxyl groups on the CD rims to regioselectively decorate each rim with cationic elements and lipophilic tails, respectively (Scheme 23). 340 First, the primary face hepta-brominated β-cyclodextrin was prepared by hepta-bromination of β-cyclodextrin using Nbromosuccinimide (NBS)/triphenyl- phosphine (TPP) reagents. It reacted with N-Boc-cysteamine, followed by acylation of the secondary hydroxyl groups by using hexanoic acid anhydrides to afford intermediate tetradecahexanoate. Subsequent TFA promoted hydrolysis of the tert-butyl carbamate of the tetradecahexanoate afforded the corresponding heptacationic amphiphilic derivative. Second, the final products poly (N, N’disubstituted thiourea) derivatives from HexCD-T-C2O to HexCD-T[C2N]2 (Fig. 39) can be synthesized in the following two pathways staring from above heptacationic amphiphilic derivative. In the first pathway, the derivative can be transferred to the corresponding thio-isocyanate through a reaction between its amino groups and thiophosgene, followed by reactions with appropriately functionalized amines R 3 -NH(H) and N-deprotection in an acidic condition (TFA) to produce final product thioureas from HexCD-T-C2O to HexCDT[C2N]2. In the second pathway, the derivative could directly react with appropriately functionalized thio-isocyanates R 3 - NCS, followed by N-deprotection in same acidic condition (TFA) to provide the target compounds (Scheme 23).\nScheme 23 Schematic illustration of general synthesis of shirtstyle PaCDs. 340\nIn 2010, the same group published insights in cellular uptake and transgene expression mechanisms of pDNA-polycationic amphiphilic cyclodextrin (HexCD-T-C2N[C2N]2 NPs (CDplexes). 345 They observed that the largest fraction of gene complexes is uptaken via clathrin-dependent endocytosis (CDE), but this fraction is less relevant to transfection. The smaller fraction that is internalized via the clathrin-\nindependent endocytosis (CIE) pathway is predominantly responsible for successful transfection. Later, they also took the influence of the macrocyclic ring size on the DNA complexing and delivery properties into consideration (Fig. 39b). 346 Targeted gene delivery is an important and promising task in nanomedicine. In 2012, Rejman et al. evaluated transfection efficiencies of paCDs modified with galactose moieties for specific targeting in HepG2 cells via the asialoglycoprotein receptor (ASGPr) (Fig. 40). 348 The final result demonstrated that mRNA interfered transfection in hepatocyte would be a better solution as compared to the pDNA-mediated transfection with low efficiency and significant danger of introducing irreversible genetic modifications in the genome. In 2013, Mellet et al. developed and evaluated a new targeted gene delivery system by first preforming self-assembled nanocomplexes from a polycationic amphiphilic cyclodextrin (paCD, HexCD-T-C2N[C2N]2) and pDNA and then decorating the surface of the NPs with folic acid (FA) through supramolecular electrostatic interactions. 347 The resulting NPs efficiently promoted transfection in HeLa cells, and exhibited no associated toxicity. Meanwhile, the Fol-CDplexes were also efficient vectors for gene delivery in a mouse model (in vivo).\nFig. 40 Chemical structures of galactose-ligand modified paCDs. Adapted with permission from Ref. 348. Copyright 2012 American Chemical Society.\nIn 2013, continuing this research related to skirt-style polycationic amphiphilic CDs (paCDs), Giorgio et al. prepared monodisperse amphiphilic oligoethyleneimine (OEI-β-CD) clusters that incorporate tetraethyleneimine segments linked to the primary rim of βCD through either triazolyl or thioureidocysteaminyl connectors (Fig. 41). 349 The data of transfection efficiency for the corresponding CD:pDNA nanocomplexes (CDplexes) in BNL-CL2 murine hepatocytes demonstrated the strong beneficial effect of facial amphiphilicity and hydrogen bonds from thiourea residue.\nFig. 41 Chemical structure of another skirt-type polycationic paCD, OEI-β-CD. 349\nJellyfish-style paCDs were are also designed and applied to gene delivery (Fig. 42). 350-354 In the light of the chemical structures of Jellyfish-style paCDs in Fig. 38, 6-hydroxyl groups in the primary face of CD were replaced by alkylthio lipid chains, 2-hydroxyl groups in the secondary face of CD were selectively modified with positively charged substitutes. The synthesis of SC12NH2 and SC16NH2 were already described in the PDT paragraph above. A new approach to the synthesis of amphiphilic β-cyclodextrins (SC12TACDNH2, SC12TACDPEG) has used ‘click’ chemistry to graft positively charged residue to selectively modified 2-hydroxyl group in secondary face of CD (Scheme 24). 350 As scheme 21 illustrated, starting from the\nPage 41 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "10 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nnatural β-cyclodextrin, tert-butyldimethylsilyl group (TBS or TBDMS) were selectively introduced at the 6-positions to give heptakis (6-O-TBS)-β-cyclodextrin that reacted with propargyl bromide at basic condition to afford compound heptakis (2-Opropargyl-6-O-TBS)-β-cyclodextrin. After TBS deprotection and further bromination with a triphenylphosphine bromine complex in one step, a key bifunctional intermediate heptakis (2-O-propargyl-6-bromo-6-deoxyl)-β-cyclodextrin was provided in high yield. The key intermediate reacted with 1- azido-1-deoxy-ω-methoxy-PEG500 and tert-butyl 3- azidopropyl carbamate respectively by the copper catalyzed “click’’ reaction and then thioalkylation of both derivatives with dodecane thiol to produce SC12TACDPEG and N-Boc protected SC12TACDNH2 which was transformed to final product SC12TACDNH2 after N-deprotection in TFA solution.\nFig. 42 Chemical structures of jelly-style pcCDs SC12NH2, SC16NH2, SC12TACDNH2 and PEGlated amphiphilic β-CD SC12TACDPEG. 350-354\nScheme 24 Synthesis of jellyfish-style pcCD SC12TACDNH2 and PEGlated amphiphilic β-CD SC12TACDPEG using a “click” reaction as the key step. Adapted from Ref. 350. Copyright 2012 with permission from the Royal Society of Chemistry.\nMazzaglia et al. applied cationic amphiphilic cyclodextrins SC12NH2 and SC16NH2 to condense nucleic acids as a gene delivery system. 351 Interestingly, they found that the hydrophobic-hydrophilic balance between the two faces of cationic amphiphilic cyclodextrin gene vectors modulates the structures of complexes formed by them with DNA. SC16NH2 with longer carbon chain forms bilayer vesicles in water, which can further transform to a multilamellar complex in the presence of calf thymus DNA. In this complex, like in a sandwich, the DNA lies between the two polar layers of the cyclodextrin’s protonated amino groups in alternation with the lipidic bilayers. SC12NH2 with shorter lipid chains, in contrast, forms micelles in water, which aggregate into clusters when interacting electrostatically with DNA. These results may be relevant to the potential of such cyclodextrin-derivatives in therapeutic gene delivery such as transfection efficiency.\nIn 2012, O`Driscoll et al. synthesized amphiphilic β-\ncyclodextrins SC12TACDNH2 (polycationic) and SC12TACDPEG (neutrally PEGylated) (Fig. 42). 350 These two amphiphile classes are compatible in dual cyclodextrin formulations for delivery of siRNA (anti-luciferase siRNA as a model). A cationic cyclodextrin SC12TACDNH2 used alone with a siRNA exhibited good transfection properties in Caco2 (human colon carcinoma) cells culture. Co-formulation with a PEGylated cyclodextrin SC12TACDPEG demonstrated a lower surface charge and greater stability in a high salt environment. Unfortunately, the inclusion of the PEGylated CD also\ndramatically reduced gene transfection efficiency. When they applied the same co-formulation for neuronal siRNA delivery in 2013, the same situation was found. 352 PEGylation significantly reduced neuronal uptake and gene silencing because of the stealthy property of PEG chain. The above phenomena may require future surface modification of particles with targeting ligands for effective siRNA delivery. In the same year, they only used the cationic cyclodextrin SC12TACDNH2 based delivery system to silence TNF-α under inflammatory conditions. 353 The efficacy predicted in vitro was further confirmed in vivo trial using a murine model of acute colitis which is the first in vivo report of a CD-based siRNA delivery system with potential use for inflammatory bowel disease IBD treatment. Recently, they synthesized and characterized rabies virus glycoprotein-tagged amphiphilic cyclodextrins SC12-CD-click-PEG500-RVG for siRNA delivery in human glioblastoma cells (Fig. 42). 354 The RVGtagged CD . siRNA NPs demonstrated enhanced receptorspecific cellular uptake compared to the untargeted nanocomplexes in human glioblastoma cells. Nevertheless, the gene silencing efficiency was low and required to be improved in later study.\nIn conclusion, recent progresses related to cyclodextrin based\namphiphilic drug delivery systems have been described above. ”Normal” hydrophobic interaction and inclusion complexation (a special case of hydrophobic interaction) are the two main forces to construct such systems. In principle, the inclusion complexation endows cyclodextrin with more flexibility in drug delivery as compared with other oligosaccharides. Inclusion complexation appears to be very useful for controlled drug release. However, more efforts need to be spent in this respect for better understanding the relationship between structure and function. Independent of the method that has been applied in the delivery system, the control of the hydrophilic lipophilic balance plays a key role in the whole process, similar as mentioned in other carbohydrate sections. On the other hand, targeted drug delivery is still less explored. Therefore, novel and multi-functional assemblies that include specific, active targeting in combination with sustained drug release should be further considered. The biocompatibility, biodegradability and toxicity of resulting NPs need to be thoroughly examined for planned clinic application. In a word, the relationships among chemical decoration, self-assembly and function in drug-delivery are so integrated that a rational design and careful tesing is of particular relevance for success."
    }, {
      "heading" : "4.4. Dextran based amphiphilic delivery systems for cancer therapy",
      "text" : "Dextran is a microbial polysaccharide composed of Dglucopyranose units linked by α- (1, 6) glycosidic bonds with a low percentage of (1, 3)-linked side chains (Fig. 3). 35, 355 It is synthesized from sucrose by certain lactic-acid bacteria such as Lactobacillus, Leuconostoc and Streptococcus species. Dextran synthesis also can take place outside the cells by dextran-\nPage 42 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 11\nPlease do not adjust margins\nPlease do not adjust margins\nsucrase in the presence of sucrose. Presence of 95% linear linkages renders this dextran water-soluble, which makes it suitable for wide applications in pharmaceuticals, food, agricultural and fine chemical industries. 356 For example, dextran agents are used commonly by microsurgeons to decrease vascular thrombosis, also used as plasma volume expander to enhance peripheral blood flow or as rheological excipient in artificial tears. 357 Owing to its high water solubility, biocompatibility, biodegradability as well as ease of chemical derivatization, dextran is a suitable biomaterial to be modified for further drug delivery application. 35"
    }, {
      "heading" : "4.4.1. Small molecules as anti-cancer drugs using dextran based amphiphilic delivery system",
      "text" : "As mentioned above, dextran (hydrophilic, biocompatible and biodegradable) is a natural analog to PEG, which is an attractive hydrophilic segment for constructing amphiphilic block copolymers. 358 According to the chemical structure of dextran, the hydroxyl groups of dextran chain could be exploited for further chemical modification or ligand coupling. Scheme 25 illustrates recent results related to hydrophobic modification of dextran as vectors for drug delivery. As described in scheme 25, there are two reaction sites used for grafting hydrophobic segments onto dextran, i.e.① the anomeric position of terminal glucose residue of dextran chain 358-368 and ② 2, 3, or 4-hydroxyl groups of dextran chain. 368-388 For the reaction site ①, the terminal glucose residue of dextran chain exists equilibrium between a six membered ring--- monosaccharide form and an opened aldehyde form which can react with a small molecule or a small molecular linker owning amine group to form an imine product 367 or intermediate, respectively. The intermediate is subsequently reduced to an amine derivative by a reductant (such as NaBH4, NaBH3CN)."
    }, {
      "heading" : "358-366, 368",
      "text" : "The linker often owns dual terminal functional groups. One side of it is the amine group for grafting onto dextran. Another side of linker could be also an amine functional group for further coupling with a carboxylic acid or aldehyde functional group of a hydrophobic segment using carbodiimide chemistry or imine reduction reaction, 358-360 an alkynl or an azide functional group for further coupling with an azide or an alkynl functional group of a hydrophobic segment using copper catalyzed “click” chemistry. 362-366, 368 For the reaction site ②, there are two types of hydrophobic modifications. Frist, the glucosidic ring is not destroyed and the hydrophobic modification is performed on 2, 3, or 4-hydroxyl groups of dextran chain. 375, 377-387 Here, the hydroxyl groups of dextran chain can be directly modified by base catalyzed ring-opening reaction (epoxide) 380, 381 or Lewis acid catalyzed polymerization (anhydride). 371, 377-379 Alternatively, the hydroxyl groups of dextran chain can be directly coupled to small hydrophobic molecules, 375, 382, 383 even macromolecular segments by normal ester formation reaction 370 to produce amphiphilic dextran conjugates, or to\nsome molecular linkers to afford actived intermediates, then conjugating small hydrophobic molecules (Steroid, Curcumin, Doxorubicin, Ce6) 369, 373, 385, 386 or processing a radical polymerization to introduce PEG chains. 384 Second, the glucosidic ring can be cleaved by an oxidation of 3, 4-hydoxyl groups using periodate salt (MIO4) to afford dialdehyde intermediate, which can form imine product 374 (hydrazone) 388 or intermediate with functional amine. The imine intermediates can be reduced and subsequently followed by hydrophobic modification to produce stable secondary amine derivatives. 387\nScheme 25 General description of the preparations of amphiphilic dextran based macromolecules for drug delivery.\nThe detailed information will be introduced as follows. First, due to the aldehyde functional group of dextran from its terminal unit (reaction site ①) (Fig 43-1a) 367 or the oxidation cleavage reaction between adjacent hydroxyl groups (reaction site ② method 2) (Fig.43-2b),374 the anti-cancer drug DOX can be directly conjugated to dextran or its derivatives via imine formation between aldehyde and primary amine, thereby the product are pH sensitive in favour of drug controlled release. For example, an acid-sensitive dextran-DOX conjugate Dex-ODOX (Fig. 43-1a) was synthesized through the versatile efficient imine formation in a buffer solution of sodium acetate/acetic acid, which exhibited higher antitumor activity and lower toxicity compared with Dex-b-DOX (reduction type). 367 Recently, another interesting compound, curcumin, was also conjugated to dextran via a carbonate linker due to its anticancer activity and strong fluorescence available for bioimaging. After the modification, the shortcoming of low water solubility of curcumin was solved and the conjugate based NPs demonstrated strong fluorescence available for live-cell imaging (HeLa cells), not in normal cells. 373 As aforementioned, except small molecular drugs, other small hydrophobic molecules, such as steroid-type, were conjugated to dextran via pH or GSH (redox) sensitive linkers. Feng et al. reported a lysosome-acidity-targeting bio-responsive nanocarrier resulted from dextran (Dex) and phenylboronic acid modified cholesterol (Chol-PBA) conjugate for nucleus tropic drug delivery (Fig.43-2a). 375 Serial studies clearly confirmed a strong lysosomal-acidity dependency of nuclear drug uptake efficiency as well as chlolesterol-associated cellular uptake (dosage dependent) in this Dex/Chol-PBA based drug delivery system. In addition, the boronate-linked (pH sensitive) nanoassembly displayed nearly no cytotoxicity. 375 Another steroid related dextran conjugates (CMD-ss-LCA) based NPs were prepared by Park et al. They synthesized bioreducible carboxymethyl dextran (CMD) derivatives by the chemical modification of CMD with lithocholic acid (LCA) through a disulphide linkage (Fig. 43-2a). 369 The resulting NPs\nPage 43 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "12 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nencapsulated anticancer drug DOX in high loading efficiency and DOX was released in high speed when incubated with 10mM GSH as compared to unreducible CMD-g-LCA. In vivo study confirmed DOX-loaded bioreducible NPs exhibit higher antitumor efficacy than reduction-insensitive control NPs. 369\nIn recent studies, dextran-based amphiphilic block copolymers have been studied frequently. Dextran acts as hydrophilic segment, hydrophobic segments are always selected from biodegradable polymers such as peptides (poly (γ-benzylLglutamate) PBLG, 362, 364, 366 fluorinated peptide dendron 388 ) or polyesters (PGLA, 359, 370, 378 PLA, 363, 365, 377 P-ɛ-CL 358, 360, 371, 379 ). Fig. 43 illustrates the representative examples of dextranbased amphiphilic copolymers, of which some amphiphilic copolymers were applied to encapsulate anticancer drugs for drug delivery. Kang et al. synthesized poly (DL-lactide-coglycolide) conjugated dextran copolymer (Dex-b-PLGA) that was utilized for incorporating anticancer drug doxrubicuin. 359 As mentioned in scheme 25, two segments, amine modified dextran and NHS ester activated PLGA, were conjugated together by an amide bond formation using carbodiimide chemistry to produce copolymer Dex-b-PLGA. The in vitro anticancer effects of the polymeric micelles were studied in doxorubicin-resistant HuCC-T1 cells. They found the polymeric micelles with a very high concentration of doxorubicin showed higher cytotoxicity to doxorubicin-resistant HuCC-T1 cells than free doxorubicin. Jiang et al. applied the similar synthetic strategy to construct amphiphilic dextran-b-poly (εcaprolactone) diblock copolymers (Dex-b-PCL) for the encapsulation of anticancer drug doxorubicin. 360 Imine reduction between amino-terminated dextran and aldehyde terminated poly (ɛ-caprolactone) was the final coupling step. In vitro cytotoxicity test of DOX-Dex-b-PCL NPs against SH-SY5Y cells showed good DOX pharmacologically active and the fluorescence imaging results demonstrated that DOX-Dex-bPCL NPs could be easily uptaken by SH-SY5Y cells. In 2013, Chen et al. prepared dextran-block polylactide (Dex-b-PLA) using copper catalyzed “click “reaction as key step for building biodegradable micelles, which were utilized as vectors of anticancer drug DOX. 363 The DOX-loaded micelles exhibited a slower drug release behaviour and lower cellular proliferation inhibition against HepG2. In order to have an excellent control of the drug release from nanocontainers, the same group designed and synthesized two types of copolymers (Fig. 44), CNPBA-Dex-b-PLA 365 and PBLG-b-dextran-DPA. 366 Herein, crosslinkers 3-carboxy-5-nitrophenyl boronic acid (CNPBA) and 3, 3’-dithiodipropionic acid (DPA) were conjugated to copolymers Dex-b-PLA and PBLG-b-dextran, respectively, both of which were constructed by “click” reactions in advance. The CNPBA modified Dex-b-PLA shows excellent pH-sensitivity due to the reversible pH-dependent binding with diols to form boronate esters. Thus, copolymer CNPBA-Dex-b-PLA based shell-crosslinked micelles enable DOX loading and the drug release can be controlled by pHs. 365 The DPA modified PBLG-b-\ndextran can form disulfide shell crosslinked micelles used for stimuli-responsive (GSH) intracellular drug delivery. 366 The encapsulation efficiency and release kinetics of DOX were investigated. Boyer et al. designed and synthesized another type of pH sensitive copolymer Ac-Dextran-g-POEGMA. 384 The synthetic route is depicted in scheme 26. First, dextran has been modified by partial acetalation (hydrophobic contribution). In a subsequent synthetic step, RAFT agent 4- cyanopentanoic acid dithiobenzoate was attached to residual free hydroxyl groups. In the last step, the RAFT groups were used to control the growth of hydrophilic PEG-methacrylate chains (hydrophilic contribution) in a living free radical polymerization reaction, thereby forming amphiphilic comb like polymers Ac-Dextran-g-POEGMA. Because the acetalated dextran would hydrolyse in the cell compartments (endosome, lysosome), the resulting NPs can be used for potential doxorubicin (DOX) delivery application. This thought was further confirmed in a human neuroblastoma cell line (SY-5Y) test with an efficient accumulation of DOX and an increased toxicity.\nThese macromolecule-dextran conjugates were typically constructed through non-cleavable dextran modification (reaction site ① and reaction site ② method 1). For the reaction site ② method 2, Gu et al. utilized poly aldehydes obtained by oxidation of dextran using NaIO4 to react with fluorinated peptide dendron and produced a conjugate FPDHZN-Dex via an acid-sensitive hydrazone linkage (Fig. 43-2b). 388 As expected, in vitro drug release studies exhibited a pH dependent controlled drug release profile.\nRecently, Chang et al. combined two reaction methods at reaction site ② and dual stimuli (pH- and reduction responsive) together to build PEG coated polymeric lipid vesicles (PPLV) for enhanced tumor cellular internalization and triggered drug release (Fig.43-2c). 372, 376 As depicted in Fig 43- 2c, a long carbon chain (C18, stearyl alcohol) was conjugated to dextran via a reducible -s-s- bond (reaction site ① method 1) for a good encapsulation of hydrophobic drug. A stealth conveying PEG chain was conjugated to dextran via a pH sensitive hydrazone bond (reaction site ② method 2) for a long time blood circulation. Doxorubicin (DOX) as the antitumor drug was loaded in the cores of the PPLVs. 376 In vitro DOX release and anti-tumor efficacy were confirmed under acidic and reduction environments, respectively. For targeted drug delivery, the authors designed and synthesized similar smart pH- and reduction-dual-responsive drug delivery system based on folate–PEG-coated polymeric lipid vesicles (FPPLVs), which assisted drugs to efficiently enter tumour cells through ligand–receptor interactions. 372\nPage 44 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 13\nPlease do not adjust margins\nPlease do not adjust margins\nFig. 43 Chemical structures of representative Dextran based amphiphilic copolymers. 1) Reaction site 1 (imine products, reduction products, click reaction product); 2) Reaction site 2 (methods 1 and 2 or 1+2).\nFig. 44 Chemical structures of Dextran based amphiphilic copolymers CNPBA-Dex-b-PLA 365 and PBLG-b-dextran-DPA. 366 pH sensitive cross-linker (boronate ester) in copolymer CNPBADex-b-PLA; GSH sensitive cross linker (disulphide bond) in copolymer PBLG-b-dextran-DPA.\nScheme 26 Synthetic route of copolymer Ac-Dextran-gPOEGMA. Adapted with permission from Ref.384. Copyright 2012 American Chemical Society.\nAs mentioned above, the anticancer drug DOX can be directly conjugated to dextran for cancer therapy. Similarly, photosensitizers as anti-cancer PDT drugs can also be directly conjugated to dextran by covalent bonds to form NPs as vectors. 385, 386 Cai et al. developed the redox-responsive doxorubicin prodrug (DEX-PEI(-SS-DOX)) (Scheme 27a) micelles. 385 Based on this result, the same group developed another redox-responsive self-quenching dextran-based theranostic NPs (DEX-SS-Ce6 NPs) for tumour imaging and photodynamic therapy (Scheme 27a). 386 In both cases, the molecules Dox and Ce6 act not only as anticancer drug, but also as hydrophobic parts in the construction of amphiphilic dextan based copolymers. The synthetic route is depicted in scheme 27b. First, some hydroxyl groups in dextran were activated by 4-nitrophenyl chloroformate at basic condition to afford an intermediate DEX-PNC, which can further react with a diamine linker (or PEI) to produce another intermediate with amine functional group. In the last step, a drug or a drug conjugate owning a carboxylic acid functional group (DrugCOOH) was coupled to the above intermediate using EDC and NHS as coupling reagents to afford final amphiphilic copolymers DEX-PEI(-SS-DOX) and DEX-SS-Ce6, respectively. The (DEX-PEI (-SS-DOX)) based micelles have a high DOX loading efficiency (up to 22.5 wt% loading content), minimal drug leaking in non-reductive environments and rapid release in reductive environments. These properties enhanced the cellular accumulation of DOX and achieved endosomal escape in human breast carcinoma multidrug resistant (MCF-7/ADR) cell. 385 These results indicate that the redox-responsive DOX prodrug micelles could be a promising delivery system for overcoming multidrug resistant (MDR). The dextran-chlorin e6 conjugates (DEX-SS-Ce6) 386 based NPs exhibited cellular redoxresponsive “OFF/ON” behaviour of a fluorescence signal, an effective cellular uptake property and high phototoxicity upon near-infrared (NIR) laser irradiation. In vivo study, the DEX-SSCe6 NP in treated mice could enhance tumour targeting ability and photodynamic therapeutic efficiency as compared with free Ce6 treated mice. These results suggest that the DEXSS-\nCe6 NP is a great potential system for tumour imaging and photodynamic therapy.\nScheme 27 Two drug-DEX conjugates DEX-PEI(-SS-DOX) and DEX-SS-Ce6. a) Structures of representative dextran conjugates DEX-PEI(-SS-DOX) and DEX-SS-Ce6 as drug delivery vectors; b) Synthetic routes of copolymers DEX-PEI(-SS-DOX) and DEX-SSCe6. 385, 386"
    }, {
      "heading" : "4.4.2. Nucleic acids (siRNA) as anti-cancer drugs using dextran based amphiphilic delivery system for cancer therapy",
      "text" : "The potential application of dextran for siRNA delivery has recently been demonstrated. 35, 389-391 However, amphiphilic dextran conjugates based NPs employed to cancer therapy are rare (Fig. 45). 368, 387 Fig. 45 illustrates two representative examples. 368, 387 Both cases utilized acetalation of dextran to introduce hydrophobicity of conjugate for a pH sensitive release of nuclei acids. For introduction of positively charged segments that are needed for nucleic acid encapsulation by electronically static interaction, different methods were used. Fréchet et al. reported a novel acid-sensitive, biocompatible and biodegradable microparticulate delivery system, spermine modified acetalated-dextran (Spermine-Ac-DEX), 387 which can be used to efficiently encapsulate siRNA. The synthesis is illustrated in scheme 28. First, the oxidation of dextran with NaIO4 afforded di-aldehydes followed by the acetalation of residual hydroxyl groups under weak acidic condition. Second, spermine reacted with the aldehyde of acelated dextran to form imine intermediates, which were subsequently reduced by NaBH4 to afford final products Spermine-Ac-DEX. Due to its acid-sensitivity, spermine-Ac-DEX allowed for a selective release of siRNA after cellular internalization, with potential tunability of cargo release rate. Meanwhile, these SpermineAc-DEX based particles showed efficient gene knockdown in HeLa-luc cells, comparable to the efficiency obtained using lipofectamine, but with minimal toxicity. Thus, spermine-AcDEX represents a promising vehicle for siRNA delivery. Dai et al. used reaction site ① to introduce positively charged segments to dextran conjugate by imine reduction, click reaction and subsequent aminolysis. 368 The polysaccharideblock-polypeptide copolymer Ac-Dex-PAsp (DET) (Fig. 45) was applied for potential co-delivery of anticancer drug DOX and plasmid DNA.\nPage 45 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "14 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nScheme 28 Synthesis of amphiphilic copolymer Spermine-AcDEX for siRNA delivery. Adapted with permission from Ref. 387. Copyright 2011 American Chemical Society.\nIn conclusion, representative examples of dextran based amphiphilic drug delivery systems have been summarized here. Compared to prior sections focusing on other oligosaccharides, dextran is less explored in this domain. However, some interesting results have been achieved in recent years. Based on the development of other oligosaccharides in this domain, in combination of its own characteristics, we expect that dextran related drug delivery will make more progresses in the near future. Research is in particular needed in the in vivo context and for targeted drug delivery, followed by clinical exploration."
    }, {
      "heading" : "4.5. Other oligosaccharides based amphiphilic delivery system for cancer therapy",
      "text" : "The polysaccharides discussed above are the most frequently used in amphiphilic drug delivery system for cancer therapy. Nevertheless, other less well-known polysaccharides also make some important contributions in this regard. This section focuses on some new developments in cancer therapy achieved by pullulan, heparin, alginate, starch, cellulose, dextrin, chondrotin-based amphiphilic drug delivery system."
    }, {
      "heading" : "4.5.1. Pullulan",
      "text" : "Pullulan is a polysaccharide polymer consisting of repetitive maltotriose units connected each other via a α-1, 6-gylcosidic bond. It is produced from starch by the fungus Aureobasidium pullulans. Due to its unique chemical structure, pullulan has good biological and physicochemical features such as watersolubility and low toxicity. Therefore, pullulan and its derivatives attract increasing attention in pharmaceutical applications and chemical manipulation. 392, 393 As the other mentioned polysaccharides, pullulan can be modified to construct amphiphilic drug delivery system for cancer therapy. Pullulan, as a neutral polysaccharide with strong hydrophilicity, becomes amphiphilic through hydrophobic modifications on its hydroxyl groups mainly using ester-forming coupling reactions.\nAn excellent review related to drug delivery using pullulan and its derivatives was published by Singh et al. 394 Here, new developments in the topic of pullulan based amphiphilic drug delivery for cancer therapy are summarized. Fig. 46 illustrates some representative cases. This work can be grouped according to the chemical modification type and the application purpose. For example, in terms of hydrophobic segments, drug-pullulan conjugates (DOX 395-397 methotrexate 398, 399 ), steroid related pullulan conjugates (Cholesterol, 400-403 deoxy cholic acid, 404 ) and hydrophobic macromolecule-pullulan conjugates (PLGA 405 ) can be distinguished. Regarding stimulus condition, pH sensitive\ncombinations were reported, such as urocanic acid residue 398,"
    }, {
      "heading" : "400, 406",
      "text" : "and photoresponsive nanogels were prepared (Spiropyrane-Modified Pullulan). 407\nDoxorubicin’s primary amine functional group can be covalently conjugated onto pullulan using pH-sensitive hydrazone bonds. 395-397 Fan et al. prepared such pullulan-dox NPs and found potent cytotoxicity in the 4T1 mouse breast cancer cells. 395 Later, they found that such pullulan-DOX conjugate NPs could be utilized for hepatic targeting without an extra ligand, because pullulan on the NPs surface provided the NPs with active targeting property to hepatic cells through specific interaction with asialoglycoprotein receptors on the membrane of hepatic cells. 396 Recently, in vivo study showed that Pu-DOX NPs efficiently accumulated in the tumour site through the EPR effect, thereby inhibiting solid tumour growth and prolonging the lifetime of the experimental animals. 397 Methotrexate (MTX), a chemotherapeutic agent, was chemically conjugated to URPA, yielding MTX-URPA conjugates (Fig. 46a). The resulting MTX-URPA NPs could further encapsulate combretastatin A4 CA4 which is an antiangiogenic drug. In vitro and in vivo, CA4 and MTX showed desirable release characteristics from CA4/MTX-URPA NPs. In addition, CA4/MTX-URPA NPs led to an enhanced antitumor and anti-angiogenic effects after intravenous injection to PLC/PRF/5-bearing nude mice. 398 Zhang and Wang et al. designed a novel NP system with core−shell structure based on pullulan and poly (β-amino) ester (PBAE) for the hepatomatargeted co-delivery of gene and chemotherapy agent. 399 First, plasmid DNA expressing green fluorescent protein (pEGFP), as a model gene, was fully condensed with cationic PBAE to form the inner core of PBAE/pEGFP polycomplex. Then, the above mentioned MTX-pullulan conjugate as a prodrug was adsorbed on the surface of PBAE/pEGFP polycomplex to form MTX PL/PBAE/ pEGFP NPs which proved to lead to efficient transfection of pEGFP in HepG2 cells and exhibited significant inhibitory effect on the cell proliferation. In HepG2 tumourbearing nude mice, MTX-PL/PBAE/pEGFP NPs were mainly distributed to the tumour at 24 h post intravenous injection. The results demonstrate a significant potential for the combination of gene therapy and chemotherapy. 399\nAs mentioned earlier, steroid molecules are suited to modify polysaccharides to form amphiphilic drug delivery system because of their biocompatibility and the potential of cell membrane fusion. According to the structures of pullulan and steroid molecules, pullulan-steroid conjugates can be constructed by ester bonds or carbamate linkers. For example, cholesterol and pullulan both have hydroxyl functional groups so that succinic acid (succinic anhydride) as linker is frequently used to form di-ester (pullulan-cholesterol conjugate). Carbamate chemistry is an alternative for building pullulancholesterol conjugate. 403 Further, steroid molecules that contain carboxylic acid functional groups such as deoxy cholic\nPage 46 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 15\nPlease do not adjust margins\nPlease do not adjust margins\nacid, can directly react with pullulan to form conjugates via ester bonds. Shen et al. develop cholesterol-modified pullulan self-aggregated NPs (CHSPNs) as drug nanocarriers. 401 Epirubicin (EPI), as a model drug, was loaded into CHSPNs and the in vivo pharmacokinetics and bio-distribution were studied. Compared with the EPI solution, EPI-CHSPNs exhibited higher plasma drug concentration and longer half-life time (t1/2). Another group investigated the cellular uptake mechanism and intracellular fate of CHSP NPs in HepG2 cells. 402 Drug release triggered by the acidic endosomal/ lysosomal environment is an effective strategy for endosomal/lysosomal escape. In 2014, Zhang et al. synthesized a series of pullulan derivatives (UCPA) by conjugation of both urocanic acid (a pH-sensitive grafted moiety) and cholesterol succinate (a hydrophobically modified moiety) to pullulan. 400 Doxorubicin (DOX), as a model antitumor drug, was physically loaded into the UCPA NPs. In vitro tests confirmed that the UCPA-NPs can realize intracellular delivery of DOX after internalization and enhanced cytotoxicity of DOX against MCF7 cells. 400 In the same year, the same group found that only urocanic acid conjugated pullulan (URPA) could load Adriamycin (ADR) successfully and exhibited pH-sensitive in vitro release properties (Fig. 46d). 406 The ADR-loaded URPA (ADR/URPA) NPs had a significantly higher efficacy against drug resistant MCF-7/ADR cells than free ADR. At publication time, the authors could not elucidate the mechanism of this synergistic effect overcoming cancer drug resistance. 406\nVaccination is another strategy to treat cancer. In order to improve cancer vaccine efficacy, Shiku et al. developed a new vaccine delivery system by encapsulating a synthetic long peptide antigen within an immunologically inert nanogel of cholesteryl pullulan (CHP) (Fig. 46b). 403 Interestingly, the nanogel based vaccine was preferentially engulfed by medullary macrophages but not by other macrophages and dendritic cells after subcutaneous injection to mice. Compared to conventional vaccine formulation, the nanogel based vaccine significantly inhibited in vivo tumor growth in the prophylactic and therapeutic settings. Therefore, targeting medullary macrophages using the immunologically stealth nanoparticulate delivery system might be an effective approach to cancer vaccines. 403\nApart from the application of drug delivery by pullulan based\namphiphilic NPs, cancer diagnosis is another important application of this type of NPs. Recently, Na et al. prepared gadolinium-chelated pullulan derivative (pullulan-deoxycholic acid (DOCA)-diethylene triamine pentaacetic (DTPA)-Gd conjugate) (PDDG) NPs for improving the gadolinium (Gd) internalization efficiency in stem cells (Fig. 46b). 404 It should be mentioned that the authors utilized the photochemical internalization (PCI) method (pheoA-mediated cellular membrane damage) for effective cellular labelling with Gdbased contrast agents for cancer diagnosis. The cancer-\ntargeting and diagnostic value of the Gd-entrapped human mesenchymal stem cells (hMSCs) induced by their inherent tumour-homing properties were confirmed in a small CT26 tumour-bearing mice model. The stem cells detected an early tumour (~3 mm 3 ) within 2 h using 4.7-T MR and optical imaging. The results suggest that the PCI-mediated internalization of Gd-incorporated NPs into hMSCs is a promising protocol for efficient cell labelling and tracking. 404\nThe hydrophobic biodegradable copolymer PLGA has a\nterminal carboxylic functional group which is suitable to react with hydroxyl group of pullulan to provide PLGA-pullulan conjugate. Recently, Lee et al. manufactured FA modified PLGA-pullulan NPs (FAPuLG) for folate receptor targeted drug delivery (Fig. 46c). 405 DOX as model drug was encapsulated into the NPs and delivered to KB cells and NIH3T3-cell-bearing mice. Like FA, other ligands were also conjugated to pullulan for differential targeting purposes. For example, glycyrrhetinic acid (GA) as a liver-targeting ligand was attached to pullulan for curcumin (CUR) delivery (Fig 46d). 408 Choi et al. synthesized a ligand-pullulan conjugate (BPA), in which vitamin H (biotin) was incorporated into a hydrophobically modified pullulan acetate (PA) to improve the cancer-targeting activity and internalization of self-assembled NPs (Fig. 46d). Adriamycin (ADR) as a model drug was loaded into the BPA NPs. 409\nPhotoresponsive NPs based on this chemistry are rarely reported. Yang et al. constructed reversible light responsive nanogels from an amphiphilic spiropyrane-modified pullulan (SpP) (Fig. 46d). 407 The nanogels are photo-controllable. Under UV condition, a reversible structural transformation of the hydrophobic Sp to the hydrophilic merocyanine is reached so that the encapsulated drug can be controllably released (Fig. 46d). 407\nFig. 46 Chemical structures of representative pullulan based amphiphilic conjugates. a) Pullulan-drug conjugates; b) Pullulan-steroid conjugates; c) Pullulan-polymer conjugate; d) Other conjugates (ligand, pH sensitive and photosensitive pullulan conjugates).\nIn conclusion, hydrophobic modification endows pullulan with new life for pharmaceutic application. After certain modifications, the pullulan based amphiphilic nano drug delivery system has already been shown to be a good carrier for drug and gene release. Nevertheless, similar to dextran, more in vitro research is needed and the clinical potential needs to be explored.\n4.5.2. Starch (dextrin), Cellulose\nPage 47 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "16 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nStarch and cellulose are two less explored polysaccharides for applications in drug delivery. Starch is one of the most abundant polysaccharides in nature and is edible. It is a mixture of amylose (20 to 25% by weight) and amylopectin (75%-80% by weight). Amylose molecules consist of α-dglucopyranose units joined by α -1, 4 acetal linkages with a small amount of branching. Amylopectin molecules are much larger and highly branched consisting of α-1, 4 linear glucosidic units, and branched α-1, 6 glucosidic units. 410 Due to its limited water solubility and miscibility, the application of starch as nanocarriers in drug delivery is challenging. Nevertheless, there are two methods are utilized to solve those problems: 1) starch can be partially hydrolysed into low molecular weight fractions named dextrins that have been employed for various clinical applications, e.g. in peritoneal dialysis and postoperative adhesions. 411, 412 2) The hydrophobic modification of numerous hydroxyl groups on starch can adjust its physicochemical properties including the solubility. Following these lines, several research groups have designed and synthesized starch based amphiphilic drug delivery systems for cancer therapy.\nTypically, long carbon chain related carboxylic acids are firstly\nchosen to modify starch (dextrin) depending on the desired reaction sites. Wu et al. designed cationic amphipathic starch CSaSt (Fig. 47), which was synthesized by grafting stearic acid and glycidyl trimethyl ammonium chloride into starch. 413 The CSaSt amphiphilic conjugate based NPs can encapsulate ApoG2 (new class of anti-tumor agent) by hydrophobic interaction. For targeted DOX delivery, another type of NPs (DHA) was prepared by absorption of DOX with excess HA through electric interaction. In the end, the negatively charged DHA NPs were assembled on the surface of positively charged NPs via electrostatic interaction to form new complicated nanocarriers (MLDC NCs). The resulting dual-drug delivery system can dramatically reduce the toxicity of DOX and ApoG2, and significantly target cancer cells in vitro and in vivo. 413 Jayakannan et al. created dextrin vesicles by cleverly customizing the polysaccharide backbone with renewable resource 3-pentadecylphenol pendant molecules (Fig. 47), 414 which are capable of loading hydrophobic drugs (such as CPT) and subsequently release their 100% cargoes by esterase enzyme action under in vitro physiological conditions. Using steroid molecules to modify starch is another choice for preparing amphiphilic starch conjugate. Liu et al. developed novel amphiphilic polymers, starch–deoxycholic acid (St–DCA), in which starch (St) works as a hydrophilic segment and deoxycholic acid (DCA) acts as a hydrophobic segment (Fig. 47). 415 The self-aggregated NPs of St-DCA conjugates exhibited good pH-responsivity, which may translate to potential application in controlled drug release.\nIn some cases, the combination of a hydrophobic drug with short carbon chain modified starch can result in an amphiphilic\nnano drug delivery system. Wenz et al. prepared propyl starch (PrP-Starch) by direct propylation of 6-hydroxyl groups of starch (Fig. 47). 416 The resulting NPs by PrP-Starch can encapsulate and control the release of hydrophobic anticancer agents like docetaxel. Polymer-starch conjugate is another possibility to construct good drug delivery system. Wu et al. designed new pH-responsive NPs for controlled delivery of anticancer drug doxorubicin (Dox). 417 The NPs were constructed by polymers poly (methacrylic acid)-polysorbate 80-grafted starch (PMAA-PS80-g-St), which were synthesized by using a one-pot radical polymerization that enabled simultaneous grafting of PMAA and PS 80 onto starch, in an aqueous medium by self-assembly (Fig. 47). 417 The resulting NPs were able to efficiently load high contents of DOX with no loss of colloidal stability. In 2014, they utilized the same polymer and combined gadolinium complex and NIR dyedoxorubicin conjugate to fabricate NPs as nano-theranostic system for targeting brain metastases of breast cancer. 418 It was worthwhile to note that the PS 80 content in the nanocarriers system was optimized to facilitate brain entry. They found that treatment with Dox-loaded NPs significantly inhibited brain tumour growth as compared to free Dox at the same dose, which was confirmed by in vivo bioluminescence imaging of the brain metastases. The multifunctional NPs are promising for the treatment of brain tumour metastases. 418\nFig. 47 Chemical structures of representative starch (dextrin) based amphiphilic polymers for cancer therapy. Small molecule-starch conjugates (CsaSt, DEX-PDP, ST-DCA, PrPStrach) and polymer-starch conjugate (PMAA-PS80-g-St).\nCellulose is a linear polysaccharide composed of repeating β(1-4)-linked D-glucose units, and is insoluble in water and most organic solvents. 419 As the most abundant renewable biomass in nature, it has been widely used in membranes and pharmaceuticals due to its nontoxicity, biocompatibility, and mechanical strength. 420-422 With the increasing interest in polysaccharide based NPs for drug delivery, it is of interest to modify the structure and enhance the function of cellulose to match the requirements, for self-assembling drug carrying behaviour of amphiphilic cellulose-based polymers. Like starch, solubility is the major obstacle to wide utilization of cellulose and its derivatives in drug delivery. However, some efforts have attempted to solve this problem. First, hydrolysis of large molecular weight cellulose to smaller segments can dramatically increase its solubility in water. Second, some commercially available cellulose derivatives, such as ethyl cellulose (EC) 422-424 and carboxymethylcellulose (CMC), 425-428 are excellent starting materials for further functional modification, especially CMC exhibiting carboxylic acid functional group. Third, some room-temperature ionic liquids (ILs), being considered as desirable green solvents for a wide range of separation and as reaction media for relevant processes including catalysis, have recently been utilized to\nPage 48 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 17\nPlease do not adjust margins\nPlease do not adjust margins\nsynthesize highly substituted cellulose derivatives by directly using high molecular weight cellulose as starting materials. 429, 430 With the help of these methodologies, amphiphilic cellulose based NPs have been produced by several research groups. The following paragraph will introduce ethyl cellulose (EC), original cellulose and CMC based amphiphilic drug delivery systems. First, EC, a material that exhibits good biocompatibility, high mechanical strength, and chemical and biological stability, was utilized to conjugate aliphatic polyesters (PCL, PLLA) through the ring-opening polymerization (ROP) of lactones and lactides using tin 2- ethylhexanoate (Sn(Oct)2) as catalyst (Fig. 48a: EC-g-PCL-bPLLA). 423 Polyacrylates or their derivatives can also be grafted onto ethyl cellulose by atom transfer radical polymerization (ATRP) (Fig. 48a: EC-g-PDEAEMA, 424 EC-g-PAA 431 ), or other reactions, such as click chemistry (Fig. 48a: EC-(g-P (MEO2 MAco-OEGMA))-g-PDMAEMA 422 ). All these resulting amphiphilic copolymers can form micelles in water and have a potential for drug delivery. 422-424, 431 Second, direct modification of cellulose with hydrophobic segments including macromolecules and small molecules are feasible, especially using ionic liquids. In 2008, Liu et al. synthesized an amphiphilic copolymer cellulose-g-PLLA comprised of hydrophobic poly(l-lactide) (PLLA) segments and hydrophilic cellulose segment using ionic liquid 1-allyl-3-methylimidazolium chloride [AMIM]Cl as reaction media (Fig. 48b). 429 In 2013, Wang et al. successfully prepared another amphiphilic copolymer cellulose-graft-poly (ε-caprolactone) (cellulose-g-PCL) (Fig. 48b) via homogeneous ring-opening polymerization (ROP) of ε-CL onto softwood (cellulose) dissolved pulp substrate in ionic liquid 1-N-butyl-3methylimidazolium chloride ([Bmim]Cl). 430 Both amphiphilic copolymers cellulose-g-PLLA and cellulose-g-PCL can form micelles in aqueous media by self-assembly, thereby indicating their potential applicability in drug carrier. Recently, Ma et al. developed new biocompatible, rodlike cellulose nanocrystals (CNCs), which were made from natural cotton wool functionalized with disulfide bond-linked poly(2(dimethylamino)ethyl methacrylate) (PDMAEMA) brushes for effective biomedical applications (Fig. 48b). The resulting conjugates CNC-graft-PDMAEMA vectors (termed as CNC-SSPDs) exhibited good transfection efficiencies and low cytotoxicity due to their reducible disulfide group for cargo release. 432 In addition to macromolecules, small molecules are also utilized to decorate cellulose to produce amphiphilic polymers for drug delivery, including long carbon chains (Fig. 48b), 433 and hydrophobic anticancer drug (Fig. 48c). 425-428, 434- 437 Zhou et al. synthesized novel amphiphilic cationic cellulose (HMQC) derivatives carrying long chain alkyl groups as hydrophobic moieties and quaternary ammonium groups as hydrophilic moieties (Fig. 48b). 433 The HMQCs can selfassemble into cationic micelles in distilled water with low cytotoxicity. Prednisone acetate, a water insoluble antiinflammatory drug, was chosen as a model drug to investigate the utilization of the HMQC micelles as a delivery carrier for poorly water-soluble drugs. For the drug-cellulose conjugates, carboxymethylcellulose (CMC) as starting material was frequently used exploiting its carboxylic acid functional group. Recently, Li et al. designed a new type of cellulose based amphiphilic polymer conjugate Cellax by directly conjugating the anticancer drug docetaxel (DTX) and the stealt-conveying segment PEG onto acetylated CMC via ester bonds. 425-428, 434-437 Extensive investigations were conducted by the same group. First, the optimal conjugate formulation (Cellax) contained 37.1 ± 1.5 wt % DTX and 4.7 ± 0.8 wt % PEG, exhibited a low critical aggregation concentration of 0.6μg/mL, and formed 118−134 nm spherical NPs stable against diludon. Cellax NPs could release DTX in serum with near zero order kinetics (100% in 3 weeks) and be internalized in murine and human cancer cells. As a result, the NPs induced significantly higher cytotoxicity against a panel of tumour cell lines (2- to 40-fold lower IC50 values) compared to free DTX. 425 Second, the Cellax NP had shown enhanced pharmacokinetics, specificity of bio-distribution, anti-tumour efficacy and safety of docetaxel (DTX) in comparison with the Taxotere TM formulation in mouse tumour models. 426 Third, the Cellax NP outperforms the approved taxane nano-formulation, Abraxane (paclitaxel), in mouse tumour models with significant control of metastases, 427 such as targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma, 436 castration-resistant prostate cancer. 435 Fourth, Cellax proved also to be an effective NP against P-Glycoprotein-Mediated Multidrug Resistance 434 . In addition, the authors incorporated superparamagnetic iron oxide NPs (SPIONs) into Cellax particles to enable magnetic resonance (MR) imaging (Cellax-MR). In four tumour models, Cellax-MR uptake was linearly associated with anti-tumour efficacy and correlated with blood vessel density, which suggested that the Cellax-MR formulation has theranostic functionality for cancer therapy. 428 Finally, they found that these exciting preclinical data of Cellax were primarily driven by an albumin and SPARC (secreted protein acidic and rich in cysteine, an albumin binder) dependent internalization mechanism. 437 In 2015, another drug-cellulose conjugate PPTCMC-Ac-PEG was developed by the same group. 438 Here, drug DTX was replaced with another drug podophyllotoxin (PPT) (Fig. 48c) and they found that the smaller PPT-NPs (20 nm) displayed significantly improved efficacy against MDR tumors in mice as compared to the larger PPT-NPs, native PPT and the standard taxane chemotherapies. Apart from direct drug-CMC conjugates, non-drug small molecule-CMC conjugate (e.g., CMC-ME2MO) was synthesized to physically encapsulate anticancer drug DOX for effective treatment of non-small-cell lung cancer. 439 As CMC is hydrophilic, CMC was also used to physically coat PLGA 440 or PLGA-mPEG 441 NPs for the delivery of anticancer drugs doxorubicin 440 or cisplatin. 441\nPage 49 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "18 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nFig. 48 Chemical structures of representative cellulose based amphiphilic polymer conjugates. a) EC based copolymers; b) Directly cellulose based polymer conjugates; c) CMC based conjugates.\nIn conclusion, starch and cellulose both can be hydrophobically modified by conjugation of hydrophobic segments to their hydroxyl groups. Those conjugates can self-assembly into NPs which can be used in drug delivery for anti-cancer therapy. Some impressive results have been attained. For example, PMAA-PS80-g-St can penetrate through the blood brain barrier (BBB) and Cellax has very promising preclinical data for anticancer therapy (anti MDR and metastasis). Therefore, rational design and modification of the two oligosaccharides may provide important advances for cancer therapy. In addition, new technology for producing low molecular weight and homogenous small segments of those polysaccharides to assure their water solubility is the prerequisite to practical and economic application."
    }, {
      "heading" : "4.5.3. Heparin",
      "text" : "Heparin is a linear polysaccharide which consists of α or β-(1, 4) linked uronic acid (90% α -L-iduronic acid, 10% β -Dglucuronic acid) and α-D-glucosamine residues (Fig. 3). Structural variations at the disaccharide level are prevalent. 3, 442 Heparin is a biocompatible, biodegradable, and watersoluble natural polysaccharide and is abundant in animal tissues. The commercially available heparins in a molecular weight of ranging from 3 to 30 kDa are mainly extracted from mucosal tissues of porcine and bovine. 442 In the human body, heparin is a naturally occurring anticoagulant produced by basophils and mast cells. 443 In clinical application, heparin has been used as an anticoagulant since the 30’s of last century. 442 With further investigation, other biological activities including anti-inflammatory, anti-angiogenetic, and anti-tumour cell proliferation effects of heparin have also been demonstrated. 442, 444 Chemically modified heparins are known to effectively inhibit angiogenesis, metastasis, and tumour growth so that they have a great potential as antitumor drugs. 445, 446 Recent attention focuses on a synergic effect for cancer therapy when using heparin based drug carriers for other anticancer drugs, 447, 448 especially in amphiphilic drug delivery systems for encapsulating hydrophobic moieties.\nDue to abundant carboxyl (COO-) and sulfate (OSO3 - ) groups along the heparin chain, heparin is strongly hydrophilic so that it can be utilized as hydrophilic segments to form core-shell NPs by self-assembly in aqueous solution, when conjugated with hydrophobic moieties. As mentioned in previous part, the hydrophobic moieties are generally selected from hydrophobic drugs (e.g., taxol) including hydrophobic photosensitizers (e.g., PhA), small hydrophobic molecules (e.g., deoxycholic acid, stearylamine), or hydrophobic polymers (e.g., poly (caprolactone)) which conjugate to heparin via ester, amide or\ncarbamate chemical bonds using carboxylic acid or hydroxyl groups of heparin as corresponding reaction sites.\nDeoxycholic acid and its derivatives as small hydrophobic molecules conjugated to heparin can result in good amphiphilic drug delivery systems for cancer therapy. 449-452 In 2006, Byun et al. developed a chemically modified heparinDOCA (HD) conjugate (Fig. 49a). 449 Doxorubicin as a model anti-cancer drug was entrapped into HD based NPs with high loading efficiencies and the release of doxorubicin was controlled in a sustained manner. HD conjugates showed antiproliferative effects on tumour and endothelial cells. In animal studies, DHN 20 (one formulation of HD based NP) significantly reduced tumour growth rates and exhibited better antitumor activity than doxorubicin, which attributed to an extended circulation time in blood and a combination of the cytotoxic effect of doxorubicin and the antiproliferative effect of HD conjugate in tumour tissues. In 2008, Byun and Lee et al. described further DOC (sodium deoxycholate)-heparin NPs for in vivo tumour targeting and inhibition of angiogenesis. 450 Here, DOC and heparin were conjugated together by coupling carboxyl groups of heparin with amine groups of aminated sodium deoxycholate (Fig. 49a). The same group synthesized taurocholic acid (TCA) linked heparin-docetaxel (DTX) conjugates (HDTA) for oral delivery of anticancer drug (Fig. 49a). 451, 452 In the ternary biomolecular conjugates based NPs, docetaxel as hydrophobic segment was located inside the core and taurocholic acid on the surface of the NPs. The HDTA based NPs exhibited enhanced oral absorption, presumably through the bile acid transporters of the small intestine and passive diffusion. An anti-tumour study in MDA-MB231 and KB tumour bearing mice demonstrated significant tumour growth inhibition activity of the ternary biomolecular conjugates. 451 Later, they investigated the oral absorption mechanism using a Caco-2 cell transport system and in an animal model. 452 The conclusions from the prior study were confirmed that HDTA is mainly absorbed in the ileum and Caco-2 cell monolayer through passive diffusion and bile acid transporters. The authors suggested that the formulation has the prospect of oral anti-cancer drug delivery by exerting anti-angiogenic effects. Similarly, long carbon chain compound such as stearylamine (SA), was conjugated to Low-molecular-weight heparin (LMWH) to construct amphiphilic LMWH-SA conjugates (LHSA) (Fig. 49a). 453 The LHSA based self-assembled NPs were utilized for intravenous delivery of docetaxel (DCT).\nIn addition to the anti-cancer drug docetaxel, other anti-\ncancer drugs can be directly conjugate with heparin to form amphiphilic drug delivery systems, such as paclitaxel, 454, 455 doxorubicin 456 and all-trans-retinoid acid (ATRA) 457, 458 (Fig. 49b). In 2009, Xiang et al. synthesized a series of amphiphilic heparin-paclitaxel conjugates as prodrugs, in which succinylated-heparin carrier conjugated to paclitaxel via a single amino acid spacer. 454, 455 In aqueous solution, these\nPage 50 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 19\nPlease do not adjust margins\nPlease do not adjust margins\nprodrugs can self-assemble to form spherical shape NPs composed of a paclitaxel core and carrier shell. The prodrugs with low anticoagulant activity exhibited better in vitro cell inhibition for MCF-7 cells than free paclitaxel. In mice experiments, a prodrug Taxol-Leucine-Heparin showed a similar ovarian tumour growth inhibition as paclitaxel, a reduced toxicity and non-obvious body weight loss due to a favourable hydrolysis of the ester bond between the leucine and paclitaxel under physiological conditions. In 2013, Gu and Luo et al. prepared a dendronized heparin-doxorubicin (heparin-DOX) conjugate via an acid-labile hydrazone linkage as pH-sensitive drug delivery vehicle. 456 The heparin-DOX based NPs were shown to effectively kill cancer cells in vitro. In addition, the NPs exhibited promising biosafety and strong tumour inhibition in vivo, such as strong antitumor activity, marked antiangiogenesis effects and induced apoptosis in the 4T1 breast tumour model. The authors suggested the overall structural design of dendronized heparin-DOX conjugate based NP may provide useful design and preparation strategies for soft NPs as safe and efficient drug delivery systems. As mentioned in previous text, ATRA acts as an active metabolic of vitamin A and inhibits the proliferation of cancer cells and induces cell differentiation of malignant cells. The combination of ATRA with PTX may lead to tumour regression by downregulation of survival factors and activation of mitochondria-dependent multiple molecular mechanisms. 459 Based on this concept, Zhou et al. synthesized an amphiphilic low molecular weight heparin-all-trans-retinoid conjugate (LMWH-ATRA) with low toxicity as a nano drug carrier by selfassembly for simultaneous delivery of drugs PTX and ATRA. 457 The NPs could significantly facilitate specific uptake by cancer cells via specific peptide-mediated endocytosis pathway and induce cell-dependent nuclear translocation. Meanwhile, the co-delivery of PTX and ATRA using PTX-loaded LMWH-ATRA NPs created a synergistic effect in inhibiting tumour growth compared to individual treatment of pure PTX.\nTo achieve a targeted drug delivery system for chemotherapy, specific ligands are often conjugated to heparin via amide bonds resulting in ligand-heparin conjugates. In 2010, Yao et al. prepared a heparin-PEG-folate (H-PEG-F) containing succinylated-heparin conjugated with folate via PEG 1000/3000 spacers against folate receptor (Fig. 49c). 460 The HPEG-F showed amphiphilic properties so that it could trap a hydrophobic agent like taxol and form heparin-PEG-folatetaxol (H-PEG-F-T) NPs in aqueous solution. As expected, the resulting H-PEG-F-T NPs demonstrated far greater extent of cellular uptake for KB-3-1 cells (folate receptor overexpressing cell line) than for A549 cells (folate receptor deficiency cell line). They also found that the length of PEG chain affected the cellular uptake efficiency of NPs. In 2011, Kim et al. synthesized another ligand-mediated drug carrier, Heparinpoly (b-benzyl-L-aspartate) and folate-poly (ethylene glycol) conjugated amphiphilic copolymers (FPHP) for delivering DOX\n(Fig. 49c). 461 Here, poly (b-benzyl-L-aspartate) and folate were conjugated to heparin via amide bonds as hydrophobic moieties and the PEG as a linker between heparin and folate to increase the flexibility of folate ligand for the specific binding. Similar results were achieved as mentioned above. DOXloaded FPHP NPs exhibited more potent cytotoxicity in KB cells than on folate receptor negative A549 cells.\nIn addition to conventional hydrophobic drugs such as taxol, hydrophobic photosensitizers were also considered as cargo for ligand-mediated heparin based amphiphilic delivery systems, leading to for anti-cancer PDT strategies. In 2013, Cai et al. synthesized multifunctional heparin folic acid-IR-780 NPs (HF-IR-780 NPs) by self-assembly of the heparin-folic acid conjugate (HF) and near-infrared (NIR) fluorescence dye IR-780 through ultrasonic sound method (Fig. 49d). 462 After assembly, IR-780 proved to be a well functioning theragnostic agent due to overcoming its solubility limitation. The HF-IR-780 NPs exhibited excellent molecular targeting to folate receptor overexpressing MCF-7cells. In vivo study proved that the NPs were specifically targeted to the tumour for imaging and significantly inhibited the growth of MCF-7 xenograft tumours with irradiation of an 808 nm laser. As a result, the HF-IR-780 NPs was shown to constitute a potential theranostic agent for cancer therapy. At the same year, another hydrophobic photosensitizer, pheophorbide a (PhA) was encapsulated into heparin-folate-retinoic acid (HFR) amphiphilic bioconjugates based NPs by hydrophobic interaction in Na and Kuh’ research group (Fig. 49d). 463 The presence of folate targeting molecules could efficiently enhance cellular uptake and in vitro phototoxicity of PhA-loaded HFR NPs in folate receptor positive HeLa cells with light treatment. The same group further directly conjugated the dye PhA to heparin via an amide bond and introduced thio residue to above conjugate PhA-H for tethering Au NPs to form hybrid PhA-H/Au NPs (Fig. 49d). 464 The glutathione (GSH)-mediated switchable photoactivity of the PhA-H/AuNPs was observed by fluorescence quenching and de-quenching behaviours in the absence and presence of GSH. In contrast to free PhA, PhAH/AuNPs revealed marked phototoxicity and strong intracellular uptake in vitro cell tests and also exhibited a prolonged circulation time, enhanced tumour specificity, and improved photodynamic therapeutic efficacy in tumourbearing mice. The authors suggested PhA-H/AuNPs are an effective, smart nanomedicine platform of PDT, potentially suited for the clinical treatment of various tumours.\nPage 51 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "20 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nDeoxycholic acid and its derivative-heparin conjugates; b) Anticancer drug-heparin conjugates; c) Folate-Heparin conjugate for anti-cancer drugs (DOX or Taxol) delivery; d) Folate-Heparin and Photosensitizer-Heparin conjugate for PDT.\nIn conclusion, compared to other oligosaccharides, heparin has a more complicated chemical structure. Several heparin based amphiphilic drug delivery systems have been explored from drug-heparin conjugates to targeted drug delivery. LMWH provides more opportunities for further development in this regard. Deeper understandings for heparin based amphiphilic nano delivery systems is desirable for overcoming the current shortcomings of LMWH, such as parenteral route of administration and their relatively short circulation time. Due to the negatively charged property, heparin can form polyelectrolyte directly with positively charged moiety for special drug delivery by a combination of its anticoagulant fuction. Generally, hydrophobic modified heparin may play a vital role in respect of stability, adsorption and penetration of resulting NPs. However, the physicochemical properties of the heparin based NPs need to be well elucidated for future application."
    }, {
      "heading" : "4.5.4. Chondroitin Sulfate (CS) and Alginate",
      "text" : "Chondroitin sulfate (CS) is a physiologically specific glycosaminoglycan comprised of alternating units of β-1,3linked glucuronic acid and (β-1,4) N-acetylgalactosamine (GalNac) with sulfate groups at either the 4- or 6-position of GalNac, 465 so it has a similar chemical structure to HA, except the sulfated groups. Most chondroitin sulfate is obtained from extracts of cartilaginous cow and pig tissues (cow trachea and pig ear and nose) as well as other sources such as shark, fish, and bird cartilage. As a vital structural component in vertebrate connective tissues and cartilage, CS has many functions including swelling and hydration of collagen fibril framework, intra-cellular signalling, cell orientation, recognition and connection between extracellular matrix and cells. 466 Remarkably, CS has the ability to target tumour cells and facilitate cellular uptake via binding to hyaluronic acid receptors (e.g., CD44) that are over-expressed on cancer cells, which makes them a good candidate for specific drug delivery to solid tumors. 467, 468 The combination of these unique characteristics and its extreme hydrophilicity and biodegradability renders CS an exciting and promising material in the pharmaceutical research.\nCS based amphiphilic drug delivery systems for cancer therapy are rare. According to the chemical structure of CS, the carboxylic acid or hydroxyl group can be utilized to conjugate it to other hydrophobic moieties (polymers or small molecules) via an amide or an ester bond and the resulting amphiphilic polymer can encapsulate anticancer drugs by self-assembly to form NPs in aqueous medium. In 2008, Wang et al. developed a type of core-shell micelles based on copolymers PCL-CS,\nusing chondroitin sulfate (CS) as a hydrophilic segment and poly (ɛ-caprolactone) (PCL) as a hydrophobic segment (Fig. 50- 1a). 469 The copolymers were prepared from two segments by a radical reaction between OH-acrylated CtSs and acrylated PCLs which were provided in advance by a ring opening polymerization of ɛ-caprolactone and then acrylation. The resulting PCL-CS based NPs were later applied to load anticancer drug DOX against NCI-H358 cells. 470 In vivo study using an NCI-H358 xenograft nude mouse model showed that a treatment with the resulting drug loaded NPs suppressed growth of the lung tumour compared with those administrations with phosphate-buffered saline and free DOX. In 2014, Liu et al. prepared one type of pH-sensitive micelles formed by self-assembly of amphiphilic polymer chondroitin sulfate-histamine conjugate (CS-his) in PBS buffer (Fig. 50- 1b). 471 The conjugate was synthesized by a coupling reaction between CS and histamine. The NPs were utilized to deliver the model drug DOX and exhibited specific on-off switch drug release behaviour. The NPs had no associated cytotoxicity against HepG2 cells, while drug-loaded NPs exhibited strong cellular uptake and then possessed high cytotoxicity to the model cells. The on-off switched drug release system may offer a promising tool for cancer therapy. Recently, another DOX nano delivery system was developed by Kim et al. (Fig. 50- 1c). 472 The hydrophobic deoxycholic acid (DOCA) derivative was conjugated to the hydrophilic chondroitin sulfate (CS) backbone via amide bond. The resulting conjugate (DOCA-CS) based NPs exhibited sustained and pH-dependent release profiles of DOX. 472\nIn addition to amphiphilic conjugate directly produced by hydrophobic modification of CS, polyelectrolyte complex (PEC) is another option to form amphiphilic drug delivery system due to the negatively charged property of CS in physiological condition. Na et al. prepared a polyelectrolyte complex (PEC) between polyethylene glycolpoly ethylenimine-chlorine e6 conjugate (PEG-PEI-Ce6, positively charged from PEI) and the Black Hole Quencher-3 chondroitin sulphate conjugate (BHQ3-CS, negatively charged from CS) for PDT in cancer therapy. 473 PEC is another type of on-off system for cancer therapy. As shown in Fig. 50-2a, Ce6 was conjugated to PEI-PEG via a relatively stable amide bond. In contrast, Black Hole Quencher3 was conjugated to CS via an enzymatically labile ester bond. In this subtle design, the PEC NPs showed no photoactivity in the blood stream, while the quenched photoactivity was restored by the enzyme degradation of BHQ-3-CS after esterase treatment. After subcutaneous injection of NPs in both tumour and normal regions of HCT-116 tumour-bearing mice, the fluorescence signal in the tumours had a higher intensity compared to control region due to the enzymatictriggered dissociation of the NPS in vivo. Thus, such NPs are very promising reagents for tumour diagnosis and therapy. Intermolecular stacking interaction is another option to assemble NPs for drug delivery. The same group developed a\nPage 52 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 21\nPlease do not adjust margins\nPlease do not adjust margins\nreactive oxygen species (ROS) sensitive drug carrier, i.e. a chondroitin sulfate (CS)–anthocyanin (ATC) based nanocomplex, in which DOX was loaded in the CS–ATC nanocomplex (CS–ATC–DOX) via this intermolecular stacking interaction (π-π stacking, Fig. 50-2b). 474 Here, drug release\nand nanocomplex destruction were induced by ROS mediated ATC degradation. As shown in Fig. 50-2b, ATC can be decomposed to 2,4,6-trihydroxybenzaldehyde and protocatechuic acid at the ROS enriched tumor region (H2O2), thereby accelerating the release of DOX and achieving promising result of tumor therapy . 474\nFig. 50 Chemical structures of representative amphiphilic Chondroitin Sulfate (CS) based drug delivery system for cancer therapy.1) CS-molecule conjugates; 2) CS Nanocomplex.\nThus, CS based amphiphilic nano drug delivery systems include different conjugates (small hydrophobic molecule, macromolecule and stimulus) and poly polyelectrolyte complexes, reports that may simulate further exploration in the near future.\nAlginate is a linear anionic polysaccharide with homopolymeric blocks of (1-4)-linked β-D-mannuronate (M) and its C-5 epimer α-L-guluronate (G) residues, respectively (Fig. 3). The blocks are variable, composed of either same or alternating M and G, and the relative amount depends on the origin of the alginate. 475, 476 The sequence, composition, and molecular weight influence the physicochemical properties of alginate. 3, 477 Alginates are mainly isolated from brown seaweeds such as Laminaria hyperborea and lessonia that occur around the globe. 475\nIt has historically been most widely used in the food industry. As a shear-thinning agent, alginate is also used in textile/paper-printing industry. 475, 478 In addition, due to its attractive features including biocompatibility and non-toxicity, high water solubility, alginate is widely applied in the pharmaceutical industry such as an excipient for drugs, 479 as a dental impression material 480 and as a wound dressing. 481 Alginate as a biocompatible polymer is also used in nanomedicine for drug delivery. 3, 482\nLike chondroitin sulfate, alginate is negatively charged due to its carboxylic acid functional groups, which are always utilized to conjugate small hydrophobic molecules (e.g., drugs, steroids) or macromolecules (poly (N-isopropylacrylamide)) to produce amphiphiles via amide or ester bonds by carbodiimide chemistry. In 2012, Yuan et al. prepared glycyrrhetinic acid (GA)-modified alginate (ALG) and applied the GA-ALG conjugate to physically encapsulate DOX as NPs for targeting therapy of liver cancer (Fig. 51a). 483, 484 Here, GA is not only a ligand for the receptor on hepatocyte membranes, but also\nbehaves as a hydrophobic part to build the core of resulting NPs. These NPs exhibited good liver targeting ability. Meanwhile, the DOX cardic toxicity was reduced after administration of DOX/GA-ALG NPs and the antitumor activity of DOX against liver tumours in Kunming mice was enhanced. Histological examination further proved tumour necrosis, but the heart cells and the liver cells surrounding the tumour were not affected. Building on these results, the same group later synthesized DOX-ALG conjugate (Fig. 51a) via a pH sensitive hydrazone bond and produced GA-ALG/DOX-ALG NPs by the combination of two conjugates GA-ALG and DOX-ALG. This combination could inhibit drug leakage in the circulatory system and liver, and showed efficient hepatoma carcinoma intracellular release. An administration in ectopic tumours demonstrated that GA-ALG/DOX-ALG NPs had excellent antitumor effects with a high percentage of tumour growth inhibition (up to 78.91%). 485 For targeted drug delivery, yet another steroid (phytosterol)-alginate conjugate was combined with a FA (Folate) fragment as targeting ligand (FPA, Fig. 51a). 486 The FPA based NPs can encapsulate DOX and target to cancer cells overexpressing folate receptors and avoid cytotoxicity to normal tissues. As mentioned earlier, poly (N-isopropylacrylamide) is a thermosensitive polymer (LCST around 32°C) and is frequently conjugated to oligosaccharides as nanocarriers for specific temperature controlled drug release. Lee at al. prepared alginate-g-poly(Nisopropylacrylamide) (PNIPAAm) based NPs(Fig. 51a). 487 DOX was efficiently encapsulated in alginate-g-PNIPAAm micelles and the resulting NPs exhibited a sustained release of DOX at 37°C in vitro. DOX-loaded alginate-g-PNIPAAm micelles showed excellent anti-cancer therapeutic efficacy in vivo (in a mouse model) with minor side effects. 487\nAmphiphilic alginate conjugates were also applied to\nencapsulate photosensitizers for PDT in anticancer study. In 2014, Yuan et al. reported an amphiphilic sodium alginate derivative conjugated with cholesteryl residues (CSAD, Fig. 51b), which possesses good biocompatibility, potential interaction with cholesteryl receptors on cell surfaces. 488 The amphiphilic property drives self-assembly with integration of the photosensitizer photosan (photofrin) into NPs (PhotosanCSAD). The Photosan-CSAD NPs exhibited high fluorescence activity and reactive oxygen species (ROS) generation after incubation with human pancreatic cancer cells, resulting in strong phototoxicity. In contrast, the dark cytotoxicity was not observed. The Photosan-CSAD NPs can be promising in the PDT of pancreatic cancer. In the same year, Panyam et al. prepared another type of photosensitizer encapsulating NPs by ionic interactions among three substrates---methylene blue (MB), sodium alginate, aerosol OT (Fig. 51b). 489 Interestingly, the NP formulation of MB showed the potential of switching photochemistry of photosensitizer from type II to type I mechanism under hypoxia, which is effective to increase ROS production and cytotoxicity in tumour cells under hypoxic\nPage 53 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "22 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nconditions. This result may help improve the anticancer efficiency of PDT.\nFig. 51 Chemical structures of representative alginate based amphiphilic drug delivery system for cancer therapy. a) Alginate based amphiphilic drug delivery system for DOX delivery; b) Alginate based amphiphilic drug delivery system for cancer PDT.\nIn conclusion, alginate based amphiphilic nano drug delivery systems are less explored, especially in gene delivery. In consideration of the reaction sites and its ready availability, alginate has large potential to enrich the library of amphiphilic materials for drug delivery."
    }, {
      "heading" : "5. Summary and discussion",
      "text" : "Due to their excellent biocompatibility, biodegradability as well as their large potential for chemical modifications, polysaccharides are promising candidates for designing amphiphilic drug delivery nanocarriers in cancer therapy. In addition to the general characteristics of polysaccharides, each polysaccharide has some specific intrinsic properties, which can be exploited in the design of drug delivery systems as shown in this review. For example, HA can prolong the circulation time as a stealth alternative of PEG, potentially overcoming problems with hypersensitivity and the formation of PEG antibodies that are not unfrequently observed in patients. Chitosan is frequently applied for the assembly of polyelectrolyte complexes (PECs) with negatively charged nucleic acids due to its polycationic nature.\nPolysaccharide-based amphiphilic drug delivery system can ensure efficient encapsulation of hydrophobic anticancer drugs, can protect them from premature degradation and elimination as well as control their release kinetics, and can thus overcome drug molecule shortcomings like poor solubility, suboptimal pharmacokinetics or excess toxicity, and thus facilitate their translation to clinic trial applications as shown in the Taxol case. Such drug delivery systems are also suitable for other types of poorly water soluble anticancer agents, for example photosensitizers that are promising for near-infrared (NIR) fluorescence imaging and photo-induced cancer therapy. Among all the polysaccharides described in this review, chitosan and cyclodextrin are most frequently used for constructing amphiphilic drug delivery system. Both have low cytotoxicity, have the capability to be internalized by cells when delivered in suited form, and are simple to modify chemically. As chitosan has a primary amino group, is amenable to hydrophobic modification using different chemical reactions and possesses natural positively charges suited for gene delivery via ionic interaction with negatively charged nucleic acids. Apart from direct chemical modification,\ncycodextrin’s hydrophobic cavity can form inclusion complexes with different functional moieties for specific purposes, leading to a large spectrum of potential cyclodextrin based amphiphilic drug delivery systems and providing someunexpected advantages. Due to the strong hydrophilicity of polysaccharides, the hydrophobic properties of the resulting amphiphilic drug delivery system render them well suited to transport small hydrophobic molecules or macromolecules by covalent conjugation or by physical interaction with polysaccharides. Small molecules or macromolecules can also serve as ligands, drugs, or as sensitive elements for stimuli triggering drugs release or photodynamic activity. Derivatization of carbohydrates may alter the toxicity of the resulting amphiphilic system compared to its mother oligosaccharide and needs to be revaluated according to the regulatory criteria for nanomedical drugs. As a consequence, more in vivo data in representative animal disease models are required, focusing on pharmacokinetics (A D M E) and also giving consideration to pharmacodynamics. As many diseases are not well mirrored in animal models, new, innovative disease models are also needed, e.g. 3D organ cultures and new computational approaches. While natural polysaccharide like dextran, HA, and also heparin have certain generic effects similar to synthetic polymers like PEG when systemically applied, e.g. manifested as a major change in pharmacokinetics, there are also major substance-specific differences in their interaction with biologic systems. For specific targeting applications, pullan may facilitate hepatocyte targeting; chondroitin sulfate and HA are the ligands for CD44 (and also for CD168) overexpressed in many types of cancer cells; alginate and CS facilitate mucous-adhesive targeting (i.e., rectal and lung) depending on their way of administrations.\nMany types of polysaccharide-based amphiphilic drug delivery systems with different chemical structures, also manifested in a spectrum of nanoparticle shapes, have been employed in cancer therapy. In such materials, thorough physicochemical characterization, and profound understanding of interactions of the nanomaterial with cells and also with tissues is indispensable. Specific characteristics of polysaccharides and understanding of their natural function can be exploited to tailor nanocarrier platforms interfering in a targeted fashion with specific biological processes and are expected to contribute to mastering unresolved challenges in cancer, e.g. in limiting systemic toxicity, optimizing pharmacokinetics, in overcoming multidrug resistance, in targeting cancer stem cells, in overcoming barriers like the extracellular matrix, in approaching metastatic disease, thus contributing to enhanced efficacy and reduced toxicity to the benefit of patients. In an era of growing awareness of the importance of the immune system in cancer progression and regression, such materials may also lend themselves to contribute to local and systemic immune cell attraction and stimulation, potentially enhancing the patient’s immune defence in cancer.\nPage 54 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 23\nPlease do not adjust margins\nPlease do not adjust margins"
    }, {
      "heading" : "Acknowledgements",
      "text" : "Financial support of Claude & Giuliana Foundation and the Swiss National Science Foundation (NFP62 project) is gratefully acknowledged."
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "24 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\n341. J. Zhang, H. Sun and P. X. Ma, ACS nano, 2010, 4,\n1049-1059.\n342. A. Kulkarni, W. Deng, S. H. Hyun and D. H. Thompson,\nBioconjugate chemistry, 2012, 23, 933-940.\n343. F. Zhao, H. Yin and J. Li, Biomaterials, 2014, 35, 1050-\n1062.\n344. A. Diaz-Moscoso, P. Balbuena, M. Gomez-Garcia, C.\nOrtiz Mellet, J. M. Benito, L. Le Gourrierec, C. Di Giorgio, P. Vierling, A. Mazzaglia, N. Micali, J. Defaye and J. M. Garcia Fernandez, Chemical communications (Cambridge, England), 2008, DOI: 10.1039/b718672j, 2001-2003.\n345. B. N. Novikov, J. K. Grimsley, R. J. Kern, J. R. Wild and\nM. E. Wales, Journal of controlled release : official journal of the Controlled Release Society, 2010, 146, 318-325.\n346. C. Bienvenu, A. Martinez, J. L. Jimenez Blanco, C. Di\nGiorgio, P. Vierling, C. Ortiz Mellet, J. Defaye and J. M. Garcia Fernandez, Organic & biomolecular chemistry, 2012, 10, 5570-5581.\n347. C. Aranda, K. Urbiola, A. Mendez Ardoy, J. M. Garcia\nFernandez, C. Ortiz Mellet and C. T. de Ilarduya, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2013, 85, 390-397.\n348. N. Symens, A. Mendez-Ardoy, A. Diaz-Moscoso, E.\nSanchez-Fernandez, K. Remaut, J. Demeester, J. M. Fernandez, S. C. De Smedt and J. Rejman, Bioconjugate chemistry, 2012, 23, 1276-1289.\n349. A. Martinez, C. Bienvenu, J. L. Jimenez Blanco, P.\nVierling, C. O. Mellet, J. M. Garcia Fernandez and C. Di Giorgio, The Journal of organic chemistry, 2013, 78, 8143-8148.\n350. A. M. O'Mahony, J. Ogier, S. Desgranges, J. F. Cryan,\nR. Darcy and C. M. O'Driscoll, Organic & biomolecular chemistry, 2012, 10, 4954-4960.\n351. V. Villari, A. Mazzaglia, R. Darcy, C. M. O'Driscoll and\nN. Micali, Biomacromolecules, 2013, 14, 811-817.\n352. A. M. O'Mahony, J. Ogier, R. Darcy, J. F. Cryan and C.\nM. O'Driscoll, PloS one, 2013, 8, e66413.\n353. J. McCarthy, M. J. O'Neill, L. Bourre, D. Walsh, A.\nQuinlan, G. Hurley, J. Ogier, F. Shanahan, S. Melgar, R. Darcy and C. M. O'Driscoll, Journal of controlled release : official journal of the Controlled Release Society, 2013, 168, 28-34.\n354. M. Gooding, M. Malhotra, D. J. McCarthy, B. M.\nGodinho, J. F. Cryan, R. Darcy and C. M. O'Driscoll, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, 71, 80-92.\n355. S. R. Van Tomme and W. E. Hennink, Expert review of\nmedical devices, 2007, 4, 147-164.\n356. R. K. Purama, P. Goswami, A. T. Khan and A. Goyal,\nCarbohydrate Polymers, 2009, 76, 30-35.\n357. R. Mehvar, Journal of controlled release : official\njournal of the Controlled Release Society, 2000, 69, 1- 25.\n358. H. Sun, B. Guo, X. Li, R. Cheng, F. Meng, H. Liu and Z.\nZhong, Biomacromolecules, 2010, 11, 848-854.\n359. Y. I. Jeong, H. Kim do, C. W. Chung, J. J. Yoo, K. H.\nChoi, C. H. Kim, S. H. Ha and D. H. Kang, International journal of nanomedicine, 2011, 6, 1415-1427.\n360. B. Li, Q. Wang, X. Wang, C. Wang and X. Jiang,\nCarbohydr Polym, 2013, 93, 430-437.\n361. M. H. Alves, H. Sfeir, J. F. Tranchant, E. Gombart, G.\nSagorin, S. Caillol, L. Billon and M. Save, Biomacromolecules, 2014, 15, 242-251.\n362. C. Schatz, S. Louguet, J. F. Le Meins and S.\nLecommandoux, Angewandte Chemie (International ed. in English), 2009, 48, 2572-2575.\n363. Z. Zhao, Z. Zhang, L. Chen, Y. Cao, C. He and X. Chen,\nLangmuir : the ACS journal of surfaces and colloids, 2013, 29, 13072-13080.\n364. C. Bonduelle, J. Huang, E. Ibarboure, A. Heise and S.\nLecommandoux, Chemical communications (Cambridge, England), 2012, 48, 8353-8355.\n365. Z. Zhao, X. Yao, Z. Zhang, L. Chen, C. He and X. Chen,\nMacromolecular bioscience, 2014, 14, 1609-1618.\n366. A. Zhang, Z. Zhang, F. Shi, C. Xiao, J. Ding, X. Zhuang,\nC. He, L. Chen and X. Chen, Macromolecular bioscience, 2013, 13, 1249-1258.\n367. W. Xu, J. Ding, C. Xiao, L. Li, X. Zhuang and X. Chen,\nBiomaterials, 2015, 54, 72-86.\n368. Q. Li, W. Liu, J. Dai and C. Zhang, Macromolecular\nbioscience, 2015, 15, 756-764.\n369. T. Thambi, D. G. You, H. S. Han, V. G. Deepagan, S. M.\nJeon, Y. D. Suh, K. Y. Choi, K. Kim, I. C. Kwon, G. R. Yi, J. Y. Lee, D. S. Lee and J. H. Park, Advanced healthcare materials, 2014, 3, 1829-1838.\n370. P. Liu, J. Q. Situ, W. S. Li, C. L. Shan, J. You, H. Yuan, F.\nQ. Hu and Y. Z. Du, Nanomedicine : nanotechnology, biology, and medicine, 2015, 11, 855-866.\n371. C. Saldias, L. Velasquez, C. Quezada and A. Leiva,\nCarbohydr Polym, 2015, 117, 458-467.\n372. S. Wang, H. Wang, Z. Liu, L. Wang, X. Wang, L. Su and\nJ. Chang, Nanoscale, 2014, 6, 7635-7642.\n373. K. Nagahama, Y. Sano and T. Kumano, Bioorganic &\nmedicinal chemistry letters, 2015, 25, 2519-2522.\n374. S. M. Sagnella, H. Duong, A. MacMillan, C. Boyer, R.\nWhan, J. A. McCarroll, T. P. Davis and M. Kavallaris, Biomacromolecules, 2014, 15, 262-275.\n375. J. Y. Zhu, Q. Lei, B. Yang, H. Z. Jia, W. X. Qiu, X. Wang,\nX. Zeng, R. X. Zhuo, J. Feng and X. Z. Zhang, Biomaterials, 2015, 52, 281-290.\n376. S. Wang, S. Zhang, J. Liu, Z. Liu, L. Su, H. Wang and J.\nChang, ACS applied materials & interfaces, 2014, 6, 10706-10713.\n377. J. Raynaud, B. Choquenet, E. Marie, E. Dellacherie, C.\nNouvel, J. L. Six and A. Durand, Biomacromolecules, 2008, 9, 1014-1021.\n378. Y. Kakizawa, R. Nishio, T. Hirano, Y. Koshi, M. Nukiwa,\nM. Koiwa, J. Michizoe and N. Ida, Journal of controlled release : official journal of the Controlled Release Society, 2010, 142, 8-13.\n379. Y. Zhang, F. Wu, W. Yuan and T. Jin, Journal of\ncontrolled release : official journal of the Controlled Release Society, 2010, 147, 413-419.\n380. R. Covis, C. Ladaviere, J. Desbrieres, E. Marie and A.\nDurand, Carbohydr Polym, 2013, 95, 360-365.\n381. G. Mocanu and M. Nichifor, Carbohydrate Polymers,\n2014, 99, 235-241.\nPage 56 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 25\nPlease do not adjust margins\nPlease do not adjust margins\n382. E. M. Bachelder, T. T. Beaudette, K. E. Broaders, J.\nDashe and J. M. Frechet, Journal of the American Chemical Society, 2008, 130, 10494-10495.\n383. K. E. Broaders, J. A. Cohen, T. T. Beaudette, E. M.\nBachelder and J. M. Frechet, Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5497-5502.\n384. H. T. Duong, F. Hughes, S. Sagnella, M. Kavallaris, A.\nMacmillan, R. Whan, J. Hook, T. P. Davis and C. Boyer, Molecular pharmaceutics, 2012, 9, 3046-3061.\n385. P. Liu, B. Shi, C. Yue, G. Gao, P. Li, H. Yi, M. Li, B.\nWang, Y. Ma and L. Cai, Polymer Chemistry, 2013, 4, 5793-5799.\n386. P. Liu, C. Yue, Z. Sheng, G. Gao, M. Li, H. Yi, C. Zheng,\nB. Wang and L. Cai, Polymer Chemistry, 2014, 5, 874- 881.\n387. J. L. Cohen, S. Schubert, P. R. Wich, L. Cui, J. A. Cohen,\nJ. L. Mynar and J. M. Frechet, Bioconjugate chemistry, 2011, 22, 1056-1065.\n388. S. Ma, J. Zhou, A. R. Wali, Y. He, X. Xu, J. Z. Tang and Z.\nGu, Journal of materials science. Materials in medicine, 2015, 26, 219.\n389. K. Raemdonck, B. Naeye, K. Buyens, R. E.\nVandenbroucke, A. Høgset, J. Demeester and S. C. De Smedt, Advanced Functional Materials, 2009, 19, 1406-1415.\n390. K. Raemdonck, B. Naeye, A. Hogset, J. Demeester and\nS. C. De Smedt, Journal of controlled release : official journal of the Controlled Release Society, 2010, 145, 281-288.\n391. K. Nagane, J. Jo and Y. Tabata, Tissue engineering.\nPart A, 2010, 16, 21-31.\n392. T. D. Leathers, Applied microbiology and\nbiotechnology, 2003, 62, 468-473.\n393. R. S. Singh, G. K. Saini and J. F. Kennedy, Carbohydrate\nPolymers, 2008, 73, 515-531.\n394. R. S. Singh, N. Kaur and J. F. Kennedy, Carbohydr\nPolym, 2015, 123, 190-207.\n395. D. Lu, X. Wen, J. Liang, Z. Gu, X. Zhang and Y. Fan,\nJournal of biomedical materials research. Part B, Applied biomaterials, 2009, 89, 177-183.\n396. H. Li, S. Bian, Y. Huang, J. Liang, Y. Fan and X. Zhang,\nJournal of biomedical materials research. Part A, 2014, 102, 150-159.\n397. H. Li, Y. Cui, J. Sui, S. Bian, Y. Sun, J. Liang, Y. Fan and\nX. Zhang, ACS applied materials & interfaces, 2015, 7, 15855-15865.\n398. Y. Wang, H. Chen, Y. Liu, J. Wu, P. Zhou, Y. Wang, R.\nLi, X. Yang and N. Zhang, Biomaterials, 2013, 34, 7181-7190.\n399. Y. Liu, Y. Wang, C. Zhang, P. Zhou, Y. Liu, T. An, D. Sun,\nN. Zhang and Y. Wang, ACS applied materials & interfaces, 2014, 6, 18712-18720.\n400. Y. Wang, Y. Liu, Y. Liu, Y. Wang, J. Wu, R. Li, J. Yang\nand N. Zhang, Polymer Chemistry, 2014, 5, 423-432.\n401. S. Shen, H. Li and W. Yang, Drug delivery, 2014, 21,\n501-508.\n402. L. Jiang, X. Li, L. Liu and Q. Zhang, International\njournal of nanomedicine, 2013, 8, 1825-1834.\n403. D. Muraoka, N. Harada, T. Hayashi, Y. Tahara, F.\nMomose, S. Sawada, S. A. Mukai, K. Akiyoshi and H. Shiku, ACS nano, 2014, 8, 9209-9218.\n404. K. S. Kim, W. Park and K. Na, Biomaterials, 2015, 36,\n90-97.\n405. S. J. Lee, Y. H. Shim, J. S. Oh, Y. I. Jeong, I. K. Park and\nH. C. Lee, Nanoscale research letters, 2015, 10, 43.\n406. H. Guo, Y. Liu, Y. Wang, J. Wu, X. Yang, R. Li, Y. Wang\nand N. Zhang, Carbohydr Polym, 2014, 111, 908-917.\n407. B. Wang, K. Chen, R.-d. Yang, F. Yang and J. Liu,\nJournal of Applied Polymer Science, 2014, 131, n/an/a.\n408. R. Yuan, F. Zheng, S. Zhong, X. Tao, Y. Zhang, F. Gao,\nF. Yao, J. Chen, Y. Chen and G. Shi, Molecules (Basel, Switzerland), 2014, 19, 13305-13318.\n409. K. Na, T. Bum Lee, K. H. Park, E. K. Shin, Y. B. Lee and\nH. K. Choi, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2003, 18, 165-173.\n410. H. S. Ellis and S. G. Ring, Carbohydrate Polymers,\n1985, 5, 201-213.\n411. S. J. Davies, G. Woodrow, K. Donovan, J. Plum, P.\nWilliams, A. C. Johansson, H. P. Bosselmann, O. Heimburger, O. Simonsen, A. Davenport, A. Tranaeus and J. C. Divino Filho, Journal of the American Society of Nephrology : JASN, 2003, 14, 2338-2344.\n412. C. B. Brown, A. A. Luciano, D. Martin, E. Peers, A.\nScrimgeour and G. S. diZerega, Fertility and sterility, 2007, 88, 1413-1426.\n413. K. Li, H. Liu, W. Gao, M. Chen, Y. Zeng, J. Liu, L. Xu and\nD. Wu, Biomaterials, 2015, 39, 131-144.\n414. U. Sridhar, P. S. Pramod and M. Jayakannan, RSC\nAdvances, 2013, 3, 21237-21241.\n415. J. Yang, C. Gao, S. Lu, X. Zhang, C. Yu and M. Liu,\nCarbohydr Polym, 2014, 102, 838-845.\n416. P. Dandekar, R. Jain, T. Stauner, B. Loretz, M. Koch, G.\nWenz and C. M. Lehr, Macromolecular bioscience, 2012, 12, 184-194.\n417. A. Shalviri, H. K. Chan, G. Raval, M. J. Abdekhodaie, Q.\nLiu, H. Heerklotz and X. Y. Wu, Colloids and surfaces. B, Biointerfaces, 2013, 101, 405-413.\n418. J. Li, P. Cai, A. Shalviri, J. T. Henderson, C. He, W. D.\nFoltz, P. Prasad, P. M. Brodersen, Y. Chen, R. DaCosta, A. M. Rauth and X. Y. Wu, ACS nano, 2014, 8, 9925- 9940.\n419. D. M. Updegraff, Analytical biochemistry, 1969, 32,\n420-424.\n420. J. Liu, J. Wang, L. G. Bachas and D. Bhattacharyya,\nBiotechnology progress, 2001, 17, 866-871.\n421. M. Barsbay, O. Güven, M. H. Stenzel, T. P. Davis, C.\nBarner-Kowollik and L. Barner, Macromolecules, 2007, 40, 7140-7147.\n422. W. Yuan, J. Zhang, H. Zou, T. Shen and J. Ren,\nPolymer, 2012, 53, 956-966.\n423. W. Yuan, J. Yuan, F. Zhang and X. Xie,\nBiomacromolecules, 2007, 8, 1101-1108.\n424. D. Wang, J. Tan, H. Kang, L. Ma, X. Jin, R. Liu and Y.\nHuang, Carbohydrate Polymers, 2011, 84, 195-202.\n425. M. J. Ernsting, W. L. Tang, N. MacCallum and S. D. Li,\nBioconjugate chemistry, 2011, 22, 2474-2486.\n426. M. J. Ernsting, W. L. Tang, N. W. MacCallum and S. D.\nLi, Biomaterials, 2012, 33, 1445-1454.\n427. M. J. Ernsting, M. Murakami, E. Undzys, A. Aman, B.\nPress and S. D. Li, Journal of controlled release :\nPage 57 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "26 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nofficial journal of the Controlled Release Society, 2012, 162, 575-581.\n428. M. J. Ernsting, W. D. Foltz, E. Undzys, T. Tagami and S.\nD. Li, Biomaterials, 2012, 33, 3931-3941.\n429. H. Dong, Q. Xu, Y. Li, S. Mo, S. Cai and L. Liu, Colloids\nand surfaces. B, Biointerfaces, 2008, 66, 26-33.\n430. Y. Guo, X. Wang, Z. Shen, X. Shu and R. Sun,\nCarbohydrate Polymers, 2013, 92, 77-83.\n431. H. Kang, W. Liu, B. He, D. Shen, L. Ma and Y. Huang,\nPolymer, 2006, 47, 7927-7934.\n432. H. Hu, W. Yuan, F. S. Liu, G. Cheng, F. J. Xu and J. Ma,\nACS applied materials & interfaces, 2015, 7, 8942- 8951.\n433. Y. Song, L. Zhang, W. Gan, J. Zhou and L. Zhang,\nColloids and surfaces. B, Biointerfaces, 2011, 83, 313- 320.\n434. A. Roy, M. Murakami, M. J. Ernsting, B. Hoang, E.\nUndzys and S. D. Li, Molecular pharmaceutics, 2014, 11, 2592-2599.\n435. B. Hoang, M. J. Ernsting, M. Murakami, E. Undzys and\nS. D. Li, International journal of pharmaceutics, 2014, 471, 224-233.\n436. M. J. Ernsting, B. Hoang, I. Lohse, E. Undzys, P. Cao, T.\nDo, B. Gill, M. Pintilie, D. Hedley and S. D. Li, Journal of controlled release : official journal of the Controlled Release Society, 2015, 206, 122-130.\n437. B. Hoang, M. J. Ernsting, A. Roy, M. Murakami, E.\nUndzys and S. D. Li, Biomaterials, 2015, 59, 66-76.\n438. A. Roy, M. J. Ernsting, E. Undzys and S. D. Li,\nBiomaterials, 2015, 52, 335-346.\n439. M. Li, Z. Tang, J. Lin, Y. Zhang, S. Lv, W. Song, Y. Huang\nand X. Chen, Advanced healthcare materials, 2014, 3, 1877-1888.\n440. C. Chittasupho, K. Lirdprapamongkol, P. Kewsuwan\nand N. Sarisuta, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, 88, 529-538.\n441. L. Cheng, C. Jin, W. Lv, Q. Ding and X. Han, PloS one,\n2011, 6, e25433.\n442. R. J. Linhardt, Journal of medicinal chemistry, 2003,\n46, 2551-2564.\n443. A. C. Guyton and J. E. Hall, Textbook of Medical\nPhysiology (11), Elsevier Saunders. p. 464. ISBN 0- 7216-0240-1., 2006.\n444. B. Casu, M. Guerrini, S. Guglieri, A. Naggi, M. Perez, G.\nTorri, G. Cassinelli, D. Ribatti, P. Carminati, G. Giannini, S. Penco, C. Pisano, M. Belleri, M. Rusnati and M. Presta, Journal of medicinal chemistry, 2004, 47, 838-848.\n445. F. Lapierre, K. Holme, L. Lam, R. J. Tressler, N. Storm,\nJ. Wee, R. J. Stack, J. Castellot and D. J. Tyrrell, Glycobiology, 1996, 6, 355-366.\n446. S. Ito, H. Nakanishi, T. Hirai, T. Kato, Y. Kodera, Z.\nFeng, Y. Kasai, K. Ito, S. Akiyama, A. Nakao and M. Tatematsu, Cancer letters, 2002, 183, 195-203.\n447. X. Yang, H. Du, J. Liu and G. Zhai, Biomacromolecules,\n2015, 16, 423-436.\n448. S. S. Ibrahim, R. Osman, G. A. Awad, N. D. Mortada\nand A. S. Geneidy, Drug delivery, 2015, DOI: 10.3109/10717544.2015.1046570, 1-7.\n449. K. Park, G. Y. Lee, Y. S. Kim, M. Yu, R. W. Park, I. S.\nKim, S. Y. Kim and Y. Byun, Journal of controlled release : official journal of the Controlled Release Society, 2006, 114, 300-306.\n450. K. J. Cho, H. T. Moon, G. E. Park, O. C. Jeon, Y. Byun\nand Y. K. Lee, Bioconjugate chemistry, 2008, 19, 1346- 1351.\n451. Z. Khatun, M. Nurunnabi, G. R. Reeck, K. J. Cho and Y.\nK. Lee, Journal of controlled release : official journal of the Controlled Release Society, 2013, 170, 74-82.\n452. Z. Khatun, Nurunnabi, K. J. Cho, Y. Byun, Y. H. Bae and\nY. K. Lee, Journal of controlled release : official journal of the Controlled Release Society, 2014, 177, 64-73.\n453. D. H. Kim, U. Termsarasab, H. J. Cho, I. S. Yoon, J. Y.\nLee, H. T. Moon and D. D. Kim, International journal of nanomedicine, 2014, 9, 5711-5727.\n454. Y. Wang, D. Xin, K. Liu, M. Zhu and J. Xiang,\nBioconjugate chemistry, 2009, 20, 2214-2221.\n455. Y. Wang, D. Xin, K. Liu and J. Xiang, Pharmaceutical\nresearch, 2009, 26, 785-793.\n456. W. She, N. Li, K. Luo, C. Guo, G. Wang, Y. Geng and Z.\nGu, Biomaterials, 2013, 34, 2252-2264.\n457. L. Hou, J. Yao, J. Zhou and Q. Zhang, Biomaterials,\n2012, 33, 5431-5440.\n458. T. Zhang, H. Xiong, F. Z. Dahmani, L. Sun, Y. Li, L. Yao,\nJ. Zhou and J. Yao, Nanotechnology, 2015, 26, 145101.\n459. S. Karmakar, N. L. Banik and S. K. Ray, Cancer, 2008,\n112, 596-607.\n460. Y. Wang, Y. Wang, J. Xiang and K. Yao,\nBiomacromolecules, 2010, 11, 3531-3538.\n461. L. Li, K. M. Huh, Y.-K. Lee and S. Y. Kim, Journal of\nMaterials Chemistry, 2011, 21, 15288-15297.\n462. C. Yue, P. Liu, M. Zheng, P. Zhao, Y. Wang, Y. Ma and\nL. Cai, Biomaterials, 2013, 34, 6853-6861.\n463. T. H. Tran, B. C. Bae, Y. K. Lee, K. Na and K. M. Huh,\nCarbohydr Polym, 2013, 92, 1615-1624.\n464. L. Li, Nurunnabi, Nafiujjaman, Y. K. Lee and K. M. Huh,\nJournal of controlled release : official journal of the Controlled Release Society, 2013, 171, 241-250.\n465. R. B. Erlich, C. C. Werneck, P. A. Mourao and R.\nLinden, Experimental eye research, 2003, 77, 157-165.\n466. K. R. Kirker, Y. Luo, J. H. Nielson, J. Shelby and G. D.\nPrestwich, Biomaterials, 2002, 23, 3661-3671.\n467. C. A. Henke, U. Roongta, D. J. Mickelson, J. R. Knutson\nand J. B. McCarthy, J Clin Invest, 1996, 97, 2541-2552.\n468. F. Li and K. Na, Biomacromolecules, 2011, 12, 1724-\n1730.\n469. A. L. Chen, H. C. Ni, L. F. Wang and J. S. Chen,\nBiomacromolecules, 2008, 9, 2447-2457.\n470. Y. J. Lin, Y. S. Liu, H. H. Yeh, T. L. Cheng and L. F.\nWang, International journal of nanomedicine, 2012, 7, 4169-4183.\n471. C. Yu, C. Gao, S. Lu, C. Chen, J. Yang, X. Di and M. Liu,\nColloids and surfaces. B, Biointerfaces, 2014, 115, 331-339.\n472. J. Y. Lee, S. J. Chung, H. J. Cho and D. D. Kim,\nEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2015, 94, 532-541.\nPage 58 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nriJournal Name ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 27\nPlease do not adjust margins\nPlease do not adjust margins\n473. W. Park, S. J. Park and K. Na, Biomaterials, 2011, 32,\n8261-8270.\n474. D. Jeong, B. C. Bae, S. J. Park and K. Na, Journal of\ncontrolled release : official journal of the Controlled Release Society, 2016, 222, 78-85.\n475. A. D. Augst, H. J. Kong and D. J. Mooney,\nMacromolecular bioscience, 2006, 6, 623-633.\n476. O. Smidsrod and G. Skjak-Braek, Trends in\nbiotechnology, 1990, 8, 71-78.\n477. M. George and T. E. Abraham, Journal of controlled\nrelease : official journal of the Controlled Release Society, 2006, 114, 1-14.\n478. J. McLachlan, Plant and Soil, 89, 137-157. 479. C. V. Liew, L. W. Chan, A. L. Ching and P. W. Heng,\nInternational journal of pharmaceutics, 2006, 309, 25- 37.\n480. A. McCullagh, C. Sweet and M. Ashley, DentalUpdate,\n2005, 32, 169-175.\n481. I. R. Matthew, R. M. Browne, J. W. Frame and B. G.\nMillar, Biomaterials, 1995, 16, 275-278.\n482. H. H. Tonnesen and J. Karlsen, Drug development and\nindustrial pharmacy, 2002, 28, 621-630.\n483. C. Zhang, W. Wang, C. Wang, Q. Tian, W. Huang, Z.\nYuan and X. Chen, Science in China Series B: Chemistry, 2009, 52, 1382-1387.\n484. C. Zhang, W. Wang, T. Liu, Y. Wu, H. Guo, P. Wang, Q.\nTian, Y. Wang and Z. Yuan, Biomaterials, 2012, 33, 2187-2196.\n485. H. Guo, Q. Lai, W. Wang, Y. Wu, C. Zhang, Y. Liu and Z.\nYuan, International journal of pharmaceutics, 2013, 451, 1-11.\n486. J. Wang, M. Wang, M. Zheng, Q. Guo, Y. Wang, H.\nWang, X. Xie, F. Huang and R. Gong, Colloids and surfaces. B, Biointerfaces, 2015, 129, 63-70.\n487. D. G. Ahn, J. Lee, S. Y. Park, Y. J. Kwark and K. Y. Lee,\nACS applied materials & interfaces, 2014, 6, 22069- 22077.\n488. Z. Yu, H. Li, L. M. Zhang, Z. Zhu and L. Yang,\nInternational journal of pharmaceutics, 2014, 473, 501-509.\n489. M. Usacheva, S. K. Swaminathan, A. R. Kirtane and J.\nPanyam, Molecular pharmaceutics, 2014, 11, 3186- 3195.\nPage 59 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nPart 1 Introduction and Chitosan\nN\nN N\nN N\nH2N\nNH2\nO\nH N\nOHO\nO\nOH\nN\nN\nO\nO\nOOH\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nNH2HO .HCl\nO\nNH\nOH\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nMethotrexate Camptothecin Doxorubicin.HCl Paclitaxel\na. Anti-cancer drugs\nb. Photosensitizers\nN\nNH N\nHN\nO OH\nOH IO\nN\nNH N\nHN\nO OH\nOH O\nO\nOH\nProtoporphyrin IX Chlorine e6\nFig. 1 Chemical structures of representative anti-cancer drugs and photosensitizers. a) anti-cancer drugs, b) photosensitizers.\nL ig\nh t\n0PS\nE\n1PS*\nF lu\no re\ns c e n\nc e\n3PS*\nintersystem crossing\n3O2 ph\not op\nho re\nsc en\nce collisional energy transfer\n0PS\n1O2 *\nType I\ntype II\ne- radicals, such as OH .-\nCell\ncell apotosis\nCell\nScheme 1 Simplified Jablonski diagram for photo-processes involved in PDT.\nC o v a le n t b o n d\nN o c o v a le n t b o n d\npolysacchrides or their derivatives (hydrophilic part)\nsmall hydrophobic molecular moities or polymers owning hydrophobic properity\n+\n(no drug involved)\npolysacchride (hydrophilic part)\n+\nsmall hydrophobic drugs\nmodified polysaccharides consisting of hydrophobic parts\n+\nmoietes with opposite charges\nelectrostatic interaction\npolysaccharides or modified polysaccharides e.g.cyclodextrin\n+\nguest molecules\nmodified polysaccharides\nsupramolecules e.g. polypseudorotaxane\npolyelectrolyte complexes\nhost guest interaction e.g., hydrophobic interaction\nsmall molecular drugs or modified drugs\nπ, π interaction hydrogen bonds hydrophobic interaction\nliable bonds for readily drug release\nstable or liable chemical bonds\nGeneral NPs\nMicelles\nVesicles\nNanogels\nDendrimers\nOther complex superstructrues\nSelf-assembly\nA m p h ip h ilic d ru g d e liv e ry s y s te m\n+\nFig. 2 Two general methods to build the amphiphilic system: covalent conjugations and non-covalent intermolecular interactions.\nPage 60 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO O OHO O HO\nNH2\nHO NH\nm\nHO\nnO\nO OHO O HO\nOH NH\nHO\nn\nO\nO HO\nO\nO\nO\nHO O\nHO\nO\nOHO HO\nHO\nO\nO\nHO\nHO\nHO\nn\nm\np\nH\nO HO O HO\nOH\nO O\nOH\nHO OH\nn\nO\nOH\nO\nHO OO\nHO HO\nO HO\nHO\nHO\nOH\nn\nO\nHO\nO OO\nHO OR1 R2HN\nR1O\nn\nO\nO HO\nR1=H or SO3 -, R2=H, SO3 -, or Ac\nO\nO\nHO HO\nOH\nO\nO\nHO\nHO OH\nO\nO HO\nOH\nOH\nO\nO\nHO OH\nOH\nO O\nOH\nOH\nHO\nO\nO OH\nOH HO\nO\nO\nOH\nOH\nHO\nO\nn\nO HO\nO HO\nHO O\nHO O HO\nHO\nO OHO O HO\nOH NH\nOR2O\nO\nR1O\nO n\nChondroitin-4-sulfate: R1 = H; R2 = SO3H; Chondroitin-6-sulfate: R1 = SO3H; R2 = H.\nO O\nO HO\nHO\nn\nO HO\nOHO\nHO\nO OH\nm\nAlginate Chondroitin Sulfate\nAmylose\nDextrin in small molecular weight)\nCyclodextrin (β)\nHeparin\nPullulan\nDextran\nCellulose\nHyaluronanChitosan\nFig. 3 Chemical structures of polysaccharides frequently incorporated in nanocarriers for nucleic acid delivery. Dextran consists of repeating α-1, 6-linked D-glucose units with low degree of α-1, 3-branching. Chitosan is a positively charged polysaccharide with repeating D-glucosamine and N-acetyl-D-glucosamine units that are linked via β-(1, 4) glycosidic bonds. Hyaluronan is an anionic polysaccharide composed of D-glucuronic acid and N-acetylD-glucosamine disaccharide building blocks, linked via alternating β-1,4 and β-1,3-glycosidic bonds. Alginate is composed of alternating blocks of β-(1, 4)-D-mannuronic acid and α-(1, 4)-L-guluronic acid. Pullulan consists of α1, 6-linked maltotriose units. β-cyclodextrin is a heptameric cyclic oligosaccharide, consisting of α-1, 4 glycosidic bonds. Heparin is composed of α or β-(1, 4) linked uronic acid (90% α-L-iduronic acid, 10% β-D-glucuronic acid) and α-D-glucosamine residues.\nO\nHO NH\nO\nnO\nO O\nO\nO HO\nNH y\nOH\nO\nO\nO HO\nNH2 x\nOH\nH N\nOHO\nO\nGC-DOX Ref. 123-125\nO\nOMe\nO O\nOHHO\nOHO\nHO\nO\nO\nHO\nR=\nO\nHN\nO\nO\nOOOH\nO\nOHO\nH O\nO O\nO\nO\nLMWC-PTX Ref.126\nO\nO\nOH\nR\nO\nHO NH\nOH\nZO\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nR\nN\nN N\nN N\nN H\nO\nH2N\nH2N\nCO2H\nO\nMTX-CHO Ref. 129\nR=\nO\nHO NH\nO\nZO\nOR1\nO O\nO\nO HO\nNH y\nOR1\nO\nO\nO HO\nNH2 x\nOR1 O O O\nN\nN N\nH N\nS\nO\nPTA-g-CMCS Ref.128\nR2\nR1=H, R2=\nO\nO(H)\nO(H)\nO(H)\nO(H)\n(H)O\nR2= H, R1=\nCQ Ref. 127\n;\n;\nO\nHO NH\nOH\nnO\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nR ;\nR=\nFig. 4 Chemical structures of representative anti-cancer drug-CS conjugates. Amide and ester bonds were selected for these constructions.\nPage 61 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO O O\nO\nO HO\nNH2\nHO NH\nm\nO\nnOOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nNH2HO .HCl\nO\nO\nO\nO HO\nPyridine\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nNH HO\nOH\nO\nO\nO HO\nOH OH\nEDC, NHS\nO\nHO NH\nO\nnO\nOH\nO O\nO\nO HO\nNH2 y\nOH\nO\nO\nO HO\nNH x\nOH\nH N\nOHO\nO\nGC-DOX\nAcid-labile cis-aconityl linkageO\nOMe\nO O\nOHHO\nOHO\nHO\nO\nO\nHO\nDOC.HCl\nScheme 2 Schematic illustration of chemical synthesis of GC-DOX. Acid-labile cis-aconityl linkage was selected for pH sensitive segment in GC-DOX conjugate. 123-125\n.\nO\nNH\nOH\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nSuccinic anhydride\nPyridine\nO\nNH\nO\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nHO\nO\nO\nPTX-SucPTX\nO O OHO O HO\nNH2\nHO NH\nm\nHO\nnO\nNHS, EDC\nO\nHO NH\nOH\nnO\nO O\nOH\nO HO\nNH2 y\nO\nOH\nO HO\nNH\nx\nO\nHN\nO\nO\nOOOH\nO\nOHO\nH O\nO O\nO\nO\nO O\nhydrolyzable bond\nLMWC-PTX\nScheme 3 Schematic illustration of chemical synthesis of LMWC-PTX. Hydrolysable ester bond was built in LMWCPTC conjugate. Adapted with permission from Ref. 126. Copyright 2008 American Chemical Society.\nN\nN N\nH N\nSH\nOH\nO\nMeONa/MeOH\nN\nN N\nH N\nSO\nOH\n1. EDC, NHS;\nO\nHO NH\nO\nZO\nOH\nO O\nO\nO HO\nNH2 y\nOH\nO\nO\nO HO\nNH2 x\nOH\nO O O\n2.\n6-MP\nO\nHO NH\nO\nZO\nOH\nO O\nO\nO HO\nNH y\nOH\nO\nO\nO HO\nNH2 x\nOH\nO O O\nN\nN N\nH N\nS\nO\nGSH\nO\nHO NH\nO\nZO\nOH\nO O\nO\nO HO\nNH y\nOH\nO\nO\nO HO\nNH2 x\nOH\nO O O\nN\nN N\nH N\nS\nHO SG\nO\nHO NH\nO\nZO\nOH\nO O\nO\nO HO\nNH y\nOH\nO\nO\nO HO\nNH2 x\nOH\nO O O\nO\nSG\nN\nN N\nH N\nSH\nMichael Addition\nElimination\n6-MP\nGSH sensitive bond\nPTA-g-CMCS\na) Synthetic route of PTA-g-CMCS\nb) Mechanism of drug 6-MP release in GSH condition\nScheme 4 Synthesis of polymer PTA-g-CMCS and the working mechanism of drug 6-MP release. a) Schematic illustration of chemical synthesis of PTA-g-CMCS and the reactions for 6-MP release in a redox surrounding; b) A cartoon showing drug 6-MP release in GSH condition. Adapted and reprinted from Ref. 128. Copyright 2012 with permission from Elsevier.\nPage 62 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO NH\nOR1\nzO\nO O\nOR1\nO HO\nNH y\nO\nOR1\nO HO\nNH2 x\nR2\nR1= R 2=\nO Stearic acid\n-H or -OCH2COOH\nOctaldehyde -SO3H or -CH2CH2OH\nO Linoleic acid\nO Arachidic acid\nO Oleic acid\nRef. 131-136\n-H\n-H\nRef. 137\nRef. 137, 140, 141\nRef. 142, 143\nRef. 145-149\nCSO-SA\nCSOAA\nOCH or CS-OA\nLA-CMCS\nOGC or NOSC\n-H, or -CH2COOH\nO\n-H\nCHC\nHexanoic acid Ref. 144\nRelated hydrophobic molecules\nO Palmitic acid\nR2=R1= -CH2CH2OH\nO\nHO NH\nOR1\nz\nO O\nOR1\nO HO\nN\ny\nO\nOR1\nO HO\nNH2 x R 2\nRef. 138, 139\nGCPQ\nFig. 5 Chemical structures of representative small hydrophobic molecules (saturated and unsaturated linear)-CS conjugates. The related hydrophobic molecules (long carbon chains) are listed on right side.\nO\nHO NH\nOR1\nzO\nO O\nOR1\nO HO\nNH\ny\nO\nOR1\nO HO\nNH2 x\nR2\nR1= -H, or -CH2CH2OH R2=\nR1= -H R2=\nOH\nOHor\nDeoxycholic acid\nOH\nH H\nH\nH\nOH\nHO\nOH\nH H\nH\nH\nOH\nHO\nDeoxycholic acid\nRef.150, 157 Ref.158\nglycidol\nHGC G-CS-DCA\nOH\nH H\nH\nH\nOH\nHO\nO\nN\nO P\nO\nor\nDCA-PCC Ref. 159\nDeoxycholic acid phosphorylcholine\nR1= -H R2=\nOH\nH H\nH\nH\n5-β -cholanic acid\nR1= -CH2CH2OH R2= H\nH H\nH\nO\nCholesterol succinate\nR1= -H R2=\nRef.151-156 Ref. 160\nO\nO\nHGC CHCS\nR1= -H R2=\nOH\nOH or\nCholic acid\nOH\nH H\nH\nH\nOH\nHO\nglycidol\nOH\nDHP-CS-CHO Ref. 161\nH\nH\nH\nO\nO\nO\nO\nOH\nO\nOH\nH H\nH\nH\nOH\nHO OH\nR1= -CH2COOH R2=\nCholic acidSuc-GA\nor\nGA-CMCA Ref. 162\nFig. 6 Chemical structures of representative small hydrophobic molecules (cyclic aliphatic) -CS conjugates. The hydrophobic segments are mainly from steroids or their derivatives (deoxycholic acid, cholesterol, 5-β-cholanic acid, cholic acid and glycyrrhetinic acid).\nPage 63 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO NH\nOR1\nzO\nO O\nOR1\nO HO\nNH y\nO\nOR1\nO HO\nNH2 x\nR2\nR2= N\nN H\nO\nNHAc\nN-Acetyl-Histidine\nR1= -CH2CH2OH\nRef. 163NAcHis-GC\nR1=\nHO\nO\nO R2=\nor HO\nO\nO\nBSCS Ref. 164\nO\nO\nO NO2\nGC-NBSC\no-nitrobenzyl succinate\nO\nO\nO NO2\no-nitrobenzyl succinate OH\nO\nO\nSNSC\nR1= -CH2COOH R2= O\nor TCM-chitosan\nS S\nO\nO\nSH\nTCM-chitosan oxidation state\nR1= -CH2CH2OH R2=\nR1= H R2=\nRef. 166 Ref. 165\nRef. 167\nR2=\nR1= -H\nO\nO\nO\nO\nVitamine E succinate\nO\nO\nOH\nH N\nS\nRef. 168\nRef.123-125FIT-GC\nOHO\nCSO-TOS\nR2=\nR1= -CH2CH2OH\nor\nFig. 7 Chemical structures of representative small hydrophobic molecules (aromatic)-CS conjugates. The small hydrophobic molecules were conjugated to CS via amide bonds.\nO\nHO NH\nO\nzO\nO O\nO\nO HO\nNH y\nO\nO\nO HO\nNH2x\nN NH\nO\nNHAc\nOH OH OH\nNAcHis-GC\n.\nFig. 8 Schematic representation of endosomal escape and drug release of histidylated polymer nanoparticles. The pH-dependent endosomal-membrane destabilization by histidine correlated with the protonation of its imidazole groups. The pKa of the imidazole group is around 6.5. In a slightly acidic milieu, such as in endosomes, the imidazole group is protonated, interacts with negatively charged lipid bilayers and induces the influx of water and ions into endosomes, thus causing endosome destabilization and drug release into the cytosol. Reprinted from Ref. 163. Copyright 2006 with permission from Elsevier.\nPage 64 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nFig. 9 Chemical structures of representative macromolecules (polyesters) grafted CS. The macromolecules were conjugated to CS via amide, ester or amine (PCL-g-CO) bonds. Polyesters act as hydrophobic segments and CS acts as hydrophilic segment in these conjugates.\nOBn\nO\nOO\nHO OH\nO\nHO O O\nO\nO OBnO\nH m\nCl O O\nO\nO OBnO\nH m\nOH\n7 O\n4\nCl\n7\nO\n4\nO\nHO NH\nOH\nz\nO O\nOH\nO HO\nNH2 y\nO\nOH\nO HO\nNH2 x Ac1.\n2. Cl O O\nO\nO OBnO\nH m\nTFA, 80oC\nPMLABz\nLinoleic chloride\nO\nHO NH\nOR1\nz\nO O\nOR1\nO HO\nNH y\nO\nOR1\nO HO\nNH2 x R2\nAc\nR1= H or 7\nO\n4 or\nO O\nO\nO OHO\nH m\nLA PMLA\nR2= LA or PMLA\nLA/PMLA-CS (LMC)\nScheme 5-1 Schematic illustration of chemical synthesis of LA/PMLA-CS (LMC). Polyester PMLABz was synthesized by acid (TFA) catalysed ring-opening polymerization. Adapted with permission from Ref. 173, copyright 2009 American Chemical Society.\nO O\nO\nO\nO\nO\nN3 N\nN\nN\nOH HO NH2\nOH\nH N O O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nAc\nO\nm n\np\nPCL-g-COs\nO\nCl O\n+ O\nO\nDSDOP O O\nO O\nCl 4 4 J K\nNaN3\nO O\nO O\nN3 4 4 J K\nO\nHO NH2\nOH\nO O\nOH\nO HO\nNH\ny\nO\nOH\nO HO\nNH2\nx Ac\nOH"
    }, {
      "heading" : "H2N",
      "text" : "O\nOH HO NH2\nOH\nO O\nOH\nO HO\nNH\ny\nO\nOH\nO HO\nNH2 x\nAc\nNH\nO\n''click'' CuAAC\nPCL-Cl PCL-N3\nPCL-N3\nCOs-alkynyl\nScheme 5-2 Schematic illustration of chemical synthesis of PCL-g-COs. Copper (I) - catalyzed azide-alkyne cycloaddition (CuAAC) is the key step for synthesis of PCL-g-COs. Adapted from Ref. 176. Copyright 2014 with permission from Elsevier.\nO O\nO\nO\nO\nO\nN3 N\nN\nN\nPolyester:\nO\nHO NH\nOR1\nz\nO O\nOR1\nO HO\nNH y\nO\nOR1\nO HO\nNH2 x R 2\nAc\n-H,\n7 O\n4 O O\nO\nO OHO\nH\nm\nHydrophobic segment Hydrophilic segment\nLAPMLA\nO\nO\nO\nO\nn\n-H, O H\nO\nn\nLinoleic acid (LA)b-malic acid (PMLA)poly\nR1 R2\nRef.\n,\nPMLA, LA\n-H,\nPoly lactide(PLA)PLA PLAChitosan\nChitosan\npoly( e-caprolactone) (PCL)\n173\n174\n177\nPCL\nOH HO NH2\nOH\nH N O O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nAc\nO\nm n p\nPCL-g-CO Ref.176\nO N H\nS S\nH N\nO\nO\nO Cys-alkynyl\n-H, PCL -H PCLChitosan\nH N\nO N H O O\nO\nO\nm\nR1= -H orR2= -H\nH\n175\nPLA\nPLAChitosan 178\n+\nPage 65 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO NH\nOR1\nz\nO O\nOR1\nO HO\nNH y\nO\nOR1\nO HO\nNH2 x R 2\nAc\nR2=-CO(CH2)4CH3 or H\nCOOH\nn\nR1=-CH2COOH or -H,\nR1= -CH2CH2OH\nR2= S H\nO\nO\nN\nO\nN\nPoly acrylic acid or acrylate and polystyrene derivative\npoly arylic acid(PAA)\nRef . 182 Ref. 183,184 CHC-PAA\nHO-GC\nFig. 10 Chemical structures of representative macromolecules (poly acrylic acid and polystyrene) grafted chitosan. Hexanoyl residues act as hydrophobic segments in conjugate CHC-PAA. VBODENA-COOH oligomers act as hydrophobic segments in conjugate HO-GC.\nN OH\nOH\nO O\nNN N N\nN OH\nN\nO\nN\nN H\nN OH\nN\nO Cl\nN\nO\nN\nO\nVBODENA\nAIBN/DMF\nHS OH\nO\nOH\nS\nH\nO\nO\nN\nNO\nn O\nHO NH\nO\nz\nO O\nO\nO HO\nNH2 y\nO\nO\nO HO\nNH2 x Ac\nOH OH OH\nDENA-Oligomer (HO)\nEDC/ HOBt\nO\nHO NH\nO\nz\nO O\nO\nO HO\nNH y\nO\nO\nO HO\nNH2 x Ac\nOH OH OH\nO S\nH O\nN\nN\nO\nHO-GC\nn\nScheme 6 Schematic illustration of chemical synthesis of HO-GC. Polymer DENA-Oligomer (HO) was synthesized by free radical chain transfer polymerization in the presence of 3-mercaptopropionic acid (MPA) as functional chain transfer agent and AIBN as an initiator. Adapted from Ref. 183. Copyright 2009 with permission from Elsevier.\nFig. 11 Stability of NPs PTX-HO-CNPs and the NPs related studies in vivo and ex vivo. a) Stability of PTX-HO-CNPs in PBS for 50 days. b) Excised tumour images after tumour therapy. c) Histological analysis of tumour tissue after tumour therapy with PTX-HO-CNPs (blue: DAPI for nucleus staining, red: TUNEL for the imaging of cell death). Reprinted from Ref. 184. Copyright 2013 with permission from Elsevier.\nPage 66 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO NH\nOR1\nz\nO O\nOR1\nO HO\nNR2\ny\nO\nOR1\nO HO\nNH2 x\nO\nR1= O O\nO\nO n\nR2=\nO\nO\nR1= O O\nn ,\nor, -SO3Na\nR2= -SO3Na\nO\nHO NH\nOR2\nz\nO O\nOR2\nO R2O\nNHR1\ny\nO\nOR2\nO R2O\nNH2 x\nO\nPoly ethylene glycol (PEG)\nRef. 186, 187\nRef. 192\nPLC-g-mPEG\nmPEGOSC\nOH\nH H\nH\nH\nOH\nHO\nR1=H R2=\nor O O\nn\nCS-DCA-MPEG-FA Ref.191\n-FAor\nO\nHO NH\nOH\nz\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH3 x\nO\nO\nO\nO\nO\nO n\nO\nOR'\nO OR,\nNHR\nO\nO NH\nOH\nO\nR\nO HO\nOH\nR=COCH3, R '=H or\nHO\nN\nCl\nO\nO\nHO\nn\nR=ONa or\nO\nHNHN\nO\nNHNH\n9\nQCHI\nHA20C10 Ref. 188, 189\nRef. 193\n+\nATRA-MPEG-CS\nQCHI.HA20C10 polyelectrolyte complex\npolyelectrolyte complex\nR1=H or\nO\nR2=\nO\nor\nO O nO Ref. 190CP6C\nFig. 12 Chemical structures of representative macromolecules (glycol poly ethylene) grafted chitosan and QCHI.HA20C10 polyelectrolyte complex. PEG chains act as stealthy segments against protein adsorption and attack of reticuloendothelial systems (RES) for increasing blood circulation of drug nanocarriers.\nPage 67 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO NH\nO\nzO\nO O\nO\nO HO\nNH y\nO\nO\nO HO\nNH2 x\nOH OH OH\nO\nHO NH\nO\nzO\nO O\nO\nO HO\nNH y\nO\nO\nO HO\nNH2 x\nH\nH H\nH\nH\nOH OH OH\nO\n+\nPpIX-GCHGC+PpIX\nN\nNH N\nHN\nO OH\nOH O\nN\nH N\nN\nN H\nO\nHO\nO\ni)\na.\nb. c\nii)\nFig. 13 Chemical structures of representative CS based NPs for loading photosensitizers PpIX (physically and covalently) and the resulting NPs in PDT. i) Chemical structures of HGC +PpIX and PpIX-GC; ii) a) PDT reaction mechanism of PpIX-NPs in target tumour cell; b) PDT comparison in mice of treating with PpIX or PpIX-GC-NP; c) Tumour volume comparison of treating with saline, PpIx and PpIX-GC-NP. Reprinted from Ref. 51. Copyright 2011 with permission from Elsevier.\nPage 68 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO\nHO NH\nO\nzO\nO O\nO\nO HO\nNH y\nO\nO\nO HO\nNH2 x\nOH OH OH\nO\nHO NH\nO\nzO\nO O\nO\nO HO\nNH y\nO\nO\nO HO\nNH2 x\nH\nH H\nH\nH\nOH OH OH\nO\n+\nN\nNH N\nHN\nO OH\nOH O\nO\nOH\nN\nHNN\nNH\nO\nO\nO\nGC- Ce6HGC+Ce6 Ref. 52\nO\nHO NH\nO\nzO\nO O\nO\nO HO\nNH2 y\nO\nO\nO HO\nNH x\nOH OH OH\nO\nHO NH\nO\nzO\nO O\nO\nO HO\nNH2 y\nO\nO\nO HO\nNH x\nO\nOH OH OH\nNH\nN HN\nN\nO\nN H\nO\nO\nS\nO\nS\nNH\nN HN\nN\nO\nO\nO\nO\nPheoA-ss-GC PheoA-GCRef. 194\nFig. 14 Chemical structures of representative CS based NPs for loading photosensitizers Ce6 (physically and covalently) and PheoA (redox and stable covalent). Physical encapsulation: HGE+Ce6. Covalent conjugates: GCCe6, PheoA-ss-GC and PheoA-GC.\nOH n\npoly-(vinyl alcohol) (PVA)poly(ε-caprolactone) (PCL)\nOH\nO\nO n\nO\nO\nO\nO\nH\nHO\nx y\npoly (D, L-lactic-co-glycolic acid) (PLGA)\nO\nHO NH\nOH\nzO\nO O\nOH\nO HO\nN y\nO\nOH\nO HO\nNH2 x\nO\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nCl O\nRef. 207 Ref. 208-211\nN\nO\nO\nO\nO\n1, 2- dioleoyl-3-trimethylammonium-propane (DOTAP)\nRef. 212. .\nFig. 15 Chemical structures of representative CS based materials for gene encapsulation and delivery using nocovalent interaction. The gene delivery system includes: positively charged CS or its derivative, negatively charged polymer (e.g., PCL, PLGA), and stabilizer (e.g., PVA, DOTAP).\nPage 69 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO NH\nOR1\nzO\nO O\nOR1\nO HO\nNH y\nO\nOR1\nO HO\nNH2 x\nR2\nR2=\nOH\nH H\nH\nH\n5β -cholanic acid\nOH\nH H\nH\nH\nOH\nHO\nDeoxycholic acid 219-221\n218\nR1= -H\nO Stearic acid 214-H\n-CH2CH2OH\nStarting materials for residue R2\nO Linoleic acid\nO O O\nO OHO\nH m\n-H\nDodecyl bromide\nO\nHO2C\nAlkyl bromide\n2-(dodecen-1-yl)succinic anhydride\n-H\nH N\nO\nn\nO\nNH2 -H\nL(-)-phenylalanine\n224\n222\n223\n228\n-H\nR1=\nor\npoly beta-malic acid\nR2 =\n-H\n-H\nor\nO GGKKWKMRRNQFWIKIQR Penetratin\nO\nLinoleic acid\n216\n217\nRef.\nO\nHO NH\nOH\nz O\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nN\nx R1\nO\nOH\nO HO\nN\nn\nO\nOH\nO HO\nNH\nm Cl\nR1=\nN\nCl\nor N\nCl\nRef. 225, 226TM-Py-CS TM-Bz-CS\nN\nNH N\nHN\nN H\nN\nO\nN\nO\nN\nN\nO\nN\nO\nCl or or\nO\nHO NH\nOH\nzO\nO O\nOH\nO HO\nNH y R1\nR1=\nRef. 227TPP\nO\nHO NH2\nOH\nz-w\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nN\nx\nO\nOH\nO HO\nNH\nR w\nO\nO\nR=\nTMC-SA Ref. 215\nFig. 16 Representative chemical structures of hydrophobically modified chitosan and its derivatives as matrixes for gene delivery.\nPage 70 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nFig. 17 Antitumor efficiencies of LMC NPs and FA-LMC NPs compared to single administration with PTX or pDNA. (A) Tumour growth curves of H-22 tumour bearing mice following treatment with PTX injection and various NPs formulations. Indicated values were mean ± SD (n ¼ 6). (B) Photographs of tumour from each treatment group excised on day 14. (C) Survival curves of H-22 tumour bearing mice treated with PTX injection and various NPs formulations. Reprinted from Ref. 217. Copyright 2014 with permission from Elsevier.\nO\nHO NH\nOH\nz O\nO O\nOH\nO HO\nNH2 q\nR-CHO\naq. CH3COOH\nO\nHO NH\nOH\nz O\nO O\nOH\nO HO\nN y\nO\nOH\nO HO\nNH2 u\nR\n1. pH=5\n2. NaCNBH3\nO\nHO NH\nOH\nz O\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 u\nR\n1. NMP, 60oC 2. 15% HCl 3. NaI 4. CH3I\n15%NaCl\nO\nHO NH\nOH\nz O\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nN\nx R1\nO\nOH\nO HO\nN\nn\nO\nOH\nO HO\nNH\nm Cl\nR1=\nN\nor\nN\nR=\nN Cl\nor\nN\nCl\nquaternized N-(4-pyridinylmethyl) chitosan(TM-Py-CS)\nquaternized N-(4-N,N-dimethylaminobenzyl) chitosan(TM-Bz-CS)\nScheme 7 Schematic illustration of syntheses of quaternized N-(4-pyridinylmethyl) chitosan (TM-Py-CS) and quaternized N-(4-N, N-dimethylaminobenzyl) chitosan (TM-Bz-CS). Adapted from Ref. 225, 226. Copyright 2008 with permission from Elsevier.\nO\nHO NH\nOH\nz O\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nR1\nR1=\nNH N\nNH2\nNHO\nO\nOS S\nH2N Cl NH\nN\nO N\nN H\nO\n, ,\nRef. 229 Ref. 206 Ref. 230\nurocanic acid imidazole acetic acid histidine derivative\nFig. 18 Chemical structures of representative chitosan conjugates for proton sponge effect in gene delivery. Imidazole residue is the key structure for proton sponge effect.\nPage 71 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nH N S\nO\nNH2\nOH\nO\nSOCl2/MeOH H N S\nO\nNH2\nO\nO\nBoc-His(Boc)-OH HBUT/HOBt.H2O/DMF\nNH S\nO NH\nO O\nO\nNH N\nN\nO O O\nO\n1.95%TFA 2. Hg(CH3COO)2 50%AcOH\nSH\nNH\nO O\nO\nNH2 NH\nN\nHis-Cys-OMe\nCys(Acm)-OH\nO\nHO NH\nOH\nzO\nOO\nOH\nO HO\nNH2 m\nS\nNH2 +Cl-\n2-iminothiolane.HCl\nO\nHO NH\nOH\nzO\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2\nx\nHS NH2 +Cl-\nHis-Cys-OMe\nDMSO\nO\nHO NH\nOH\nzO\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nS NH2 +Cl-\nChitosan-Cysteine-Histidine\nS\nHN\nO O\nO\nNH2\nNH\nN\nScheme 8 Schematic illustration of synthesis of Chitosan-Cysteine-Histidine. Dual effects for gene release can be produced by the resulting NPs (proton sponge effect from histidine residue and reduced cleavage of -SS- by GSH). Adapted with permission from Ref. 230. Copyright 2010 American Chemical Society.\nO\nOH\nO HO\nNH\nm\nO\nHO NH\nOH\nzO\nO O\nOH\nO HO\nN\ny\nO\nOH\nO HO\nR1\nx Cl-\nR2\nR1= -NH2, -NHMe, -NMe2 R2=\nO\nNC\nn\nO H N\nO\nHO NH\nOH\nzO\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nR1\nR1= S\nO NH\nO\nO\nO\nm n\nRef. 233\nRef. 234\nmonomer\nN H\nO\n+ O\nO\nradical polymerization\nradical polymerization N H\nO\nmonomer\nvinyl laurate(VL)N-isopropylacrylamide (NIPAAm)\nN-isopropylacrylamide (NIPAAm)\nPNVLCS\nTMC-g-PNIPAAm\nFig. 19 Themosenstive polymers grafted chitosans PNVLCS and TMC-g-PNIPAAm used as gene carriers. The related polymers were produced by radical polymerization. The monomers are NIPAAM and VL for synthesis of PNVLCS and NIPAAM for synthesis of TMC-g-PNIPAAm, respectively.\nPage 72 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO NH\nOH\nzO\nO O\nOH\nO HO\nNH y\nO\nOH\nO HO\nNH2 x\nR1\nR1=\nOH\nH H\nH\nH\nOH\nHO Deoxycholic acid\nO\nO\nO\nO\nH\nHO\nx y\npoly (D, L-lactic-co-glycolic acid) (PLGA)\na.\nb. c.\n.\nFig. 20 Nanocarrier prepared by a combination of covalent conjugation and no covalent interaction. a) Chemical structure of deoxycholic acid conjugated chitosan and PLGA; b) Schematic illustration for the preparation the siRNA/COSD complex in 50% DMSO followed by the preparation of the siRNA/COSD-loaded PLGA nanoparticles and the preparation the siRNA/COSD complex in water; c) Confocal microscopic images of the cellular uptake of Cy5.5-labeled siRNA using the siRNA/COSD complex (left) and the siRNA/COSD-loaded PLGA (right) in MDA-MB435-GFP cells post 5 h and 48 h incubation. b), c) Reprinted from Ref. 235. Copyright 2012 with permission from Elsevier.\nPage 73 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nPage 74 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nPart 2\n4.2. Hyaluronan based amphiphilic delivery system for cancer therapy\nO OHO O HO\nOH NH\nHO\nm\nO\nO HO\nO\nH\nO OO\nO HO\nOH NH\nHO\nn\nO HO\nO\nOH\nOH\nAmide, ester\nester\nprimary amine\nrelated secondary amine\nfurther reactions\n1)\n2)\n3)\n4)\n.\n.\nPeriodate cleavage (diol cleavage) as oxidation reaction to produce dialdehyde\n5)\nScheme 9 Schematic illustration of reaction sites of hyaluronan (HA) for constructing HA based nanocarriers. Reaction sites: 1) Carboxylic acid for amide or ester bond formation; 2) Primary hydroxyl group for ester bond formation; 3) Hemiacetal for imine or subsequent amine formation; 4) N-acetyl group for primary amine formation under enzyme-lysis; 5) Vicinal diol for the formation of dialdehyde which can be used for further modifications.\nO OHO O HO\nOH NH\nHO\nm\nO\nO HO\nO\nO OO\nO HO\nOH NH\nHO\nn\nO HO\nO\nR\nO\nNH\nO\nO O\nO OH\nO\nHO O H\nO\nOO\nO O\nHN N H\nN H\nO H N\nO\nO\nO\nR=\nNH HN\nNH\nO\nH N\nO\nO\nNH\nS O\nOH\nO\nHO\nO\nNH\nO O\nO\nO\nOH\nO\nHO\nO H\nO\nO O\nO\nO\nH N HN\nHN\nO\nNH\nO\nO\nO\nor\nHA- Taxol\nFITC-HA-Taxol\nRef. 252\nRef. 253\na) HA-Taxol conjugates with amide bonds\nO OHO O HO\nOH NH\nHO\nm\nO\nO HO\nO\nO OO\nO HO\nOH NH\nHO\nn\nO HO\nO\nR\nO\nNH\nO\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nO\nO\nO\nNH\nO\nO\nO O OH\nO\nOH O\nH O\nO O\nPh\nO\nO\nRef. 255, 256 Ref. 257\nR=\nb) HA-Taxol conjugates with ester bonds\nPage 75 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nNHHO\nO OO\nO\nO NH\nHO\nm\nHN\nO HO\nO\nH H N HRHL\nNH S\nS\nO O OH O\nc) HA-Doxorubicin conjugates\nO OHO O HO\nOH NH\nHO\nm\nO\nO HO\nO\nO OO\nO HO\nOH NH\nHO\nn\nO HO\nO\nR\nNHHN\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nNHHO\nNH\nO\nO\nHN\nO O\nR=\nHA-Doxorubicin\nHN O\nHO\nHN O\nNH\nHN\nO\nO\nNH\nO\nO\nOMe\nO\nOOH\nOH\nHO\nO\nHO\nO\nO\nHN OH\nG\nF\nL\nG\nHN O\nNH\nHN\nO\nO\nNH\nO\nO\nHN\nG\nF\nL\nG\nm n\np\nHN\nHPMA\nNH NH\nO\nO\nHA-HPMA-DoxorubicinRef. 258\nor\nLHRH-HA-cys-ADOX\nLHRH peptide= (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2)\nRef. 259\nO OO\nO HO\nOH NH\nHO\nn\nO HO\nO\nOH\nd) HA-Butyric acid conjugate and HA-Butyric acid, Retinoic acid conjugate\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nO Na\nO OO\nO HO\nOH NH\nR\ny\nO HO\nO\nO Na\nR=\nO\nO\nHA-Butyric acid (HA-But) Ref. 260-262\nO\nO or O\nO\nHA-But-ATRA Ref. 263\nRetinoic acid (ATRA)\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nR\nO\nHN\nNH\nR=\nHRA, Ref. 264 Fig. 21 Chemical structures of representative HA conjugates covalently grafted by small anticancer drugs. a) HATaxol conjugates with amide bonds; b) HA-Taxol conjugates with ester bonds; c) HA-Doxorubicin conjugates; d) HA-Butyric acid conjugate and HA-Butyric acid, Retinoic acid conjugate.\nO OHO O HO\nOH NH\nHO\nm\nO\nO HO\nO\nO OO\nO HO\nOH NH\nHO\nn\nO HO\nO\nO\nNH\nOH\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nHN NH\nNH2\nO\nHN\nO\n1. O\nO\nO\n2. N OH\nO\nO\nHA\nTaxol\nADH EDCI\nOH\nO OHO O HO\nOH NH\nHO\nm\nO\nO HO\nO\nO OO\nO HO\nOH NH\nHO\nn\nO HO\nO\nHN NH\nNH2\nO\nHN\nO\nO\nNH\nO\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nHA-ADH\n+\nO\nO\nHO O HO\nOH\nNH\nHO\nm\nO\nO HO\nO\nO\nO\nO O HO\nOH\nNH\nHO\nn\nO HO\nO\nO\nNH\nO\nO O\nO OH\nO\nHO O H\nO\nOO\nO O\nH N\nN H\nNH\nO\nH N\nO O\nO\nPH=6.5\nO\nO O\nN\nO\nO\nScheme 10 Schematic illustration of synthesis of the HA-Taxol conjugate (adipic dihydrazide-modified HA). Adapted with permission from Ref. 252. Copyright 1999 American Chemical Society.\nPage 76 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nN H O\nOH HN\nO\nH N\nN H\nO\nO H N\nO\nO\nO\nNO2\nG F L G ONp\nradical irritation HN\nO\nHO\nHN O\nm\nGFLG ONp\nz\nHPMA\nO OHO O HO\nOH NH\nHO\nx\nO\nO HO\nO\nO OO\nO HO\nOH NH\nHO\ny\nO HO\nO\nHN O\nHO\nHN O\nNH\nHN\nO\nO\nNH\nO\nO\nOMe\nO\nOOH\nOH\nHO\nO\nHO\nO\nO\nHN OH\nG\nF\nL\nG\nHN O\nNH\nHN\nO\nO\nNH\nO\nO\nHN\nG\nF\nL\nG\nm n p\nN H\nH N\nNH\nO\nO\nDOX.HCl\nHN O\nHO\nHN O\nm\nGFLG DOX\nn O\nHN GFLG-ONp\np\nHA-ADH\nHPMA-HA-DOX\nScheme 11 Schematic illustration of synthesis of the HPMA-HA-DOX conjugate. A Lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer was used for an efficient release of drug DOX. 258\nHA-DPPE\nO O\nO HO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OHO\nO HO\nOH NH\nOH\nO HO\nO\nOH\nR\nR= H N\nO P\nO\nO\nOH O\n14\nO\n6 7\nO\nO\nH\nHA-POPE Ref. 268, 269 H N\nO P\nO\nOH\nO O\nO H\nO\nO\n13\n13 Ref. 270, 271\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nR\nHA-CE\nO\nO\nNH O\nHO\nOH\nO\nR=\nRef. 272, 273\na) Lipid-HA conjugates\nch-HA\nO\nH\nH H\nH\nO\nO\n3\nHA-ss-DOCA\nH\nH H\nH\nH\nOH\nOH\nHN\nO\nS\nS\nNH\nHA-DOCA\nH\nH H\nH\nH\nOH\nOH\nHN NH\nNH\nO\nHN\nO\nO\nRef. 281Ref. 280 Ref. 280\nb) Steroid-HA conjugates\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nR\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nOH\nHA-CA PEG-HA-CA\nO O\nm\nH N\nor\nNH\nHN\nO\nRef. 274-276 Ref. 277-279\nR=\nNH\nHN\nO\nPage 77 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nR1\nO OO\nO R2O\nOR NH\nHO\ny\nO HO\nO\nR2\nR1= H N N O\nO\nNN\nm\nR2= H N N\nNN\nN H\nO N N Cl-\nHA-GO\nN H\nR2=\np-HA\nOH\nOH\nOH\nO\nHO\nOH\nOH O\nOH OHO\nO\nO\nOH\nO\nNH\nHN\nO\nOH\nHO\nOH O\nH N\nO\nH N\nRef. 96\nRef. 282\nR1=H\nRef. 283\nc) Aromatics-HA conjugates\nH N\nN H\nO\nO\nO O\nHATS Ref. 284\nd) Long carbon chain-HA conjugates\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nO OO\nO HO\nOH NH\nOR2\ny\nO HO\nO\nOH\nH N 16\nNH CO2H\nO\nN H\nN\nN\nN\nN\nOH\nNH2\nO\nHA-C18 FA-HA-C18\nR1\nR1=\nR2 = H\nRef. 285\nH N 16\nR1= R 2 =\nRef. 285\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nONa\nO OO\nO RO\nOR NH\nOR\ny\nO HO\nO\nONa\nR= O\nO OO\nO RO\nOR NH\nOR\nO HO\nO\nONa\nx\nNaO\nO\nO\nR=H, or\nOSA-HA, Ref. 287Ref. 286\nFig. 22 Small hydrophobic molecules grafted HA as nanocarriers for drug delivery. a) Lipid-HA conjugates; b) Steroid-HA conjugates; c) Aromatics-HA conjugates; d) Long carbon chain-HA conjugates.\n1)\n2)\nFig. 23 DOX-loaded mineralized NPs (DOX-M-PEG-HANPs) and its antitumor efficacy. 1) Schematic formation of DOX-M-PEG-HANPs; 2) (a) Antitumor efficacies of saline, free DOX, DOX-PEG-HANPs and DOX-M-HANPs. The error bars represent standard deviation (n = 5). Asterisks (*) denote statistically significant differences (*p b 0.05) calculated by one-way ANOVA test; and (b) Representative images of excised tumours. Reprinted from Ref. 279. Copyright 2013 with permission from Elsevier.\nPage 78 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nScheme 12 Schematic illustration of the p-hyaluronan nanocarrier with doxorubicin (πHNC/DOX) for CD44targeted and pH-boosted aromatic drug delivery. (a) Self-assembly of πHNC with a CD44 targeting hyaluronan shell and a π-rich core entrapping aromatic DOX inside via π-stacking attraction and hydrophobic interactions, and (b) The proposed in vivo delivery mechanism of pHNC/DOX to CD44 positive cancer cells; (i) Passive accumulation via the EPR effect and active targeting via CD44- mediated endocytosis, (ii) Quick release of DOX from πHNC by pH reduction in cancer, and (iii) Induced apoptosis of CD44 positive cancer cells. Reproduced from Ref. 96. Copyright 2013 with permission from the Royal Society of Chemistry.\n1)\nPage 79 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\n2)\nScheme 13 PHPD-NPs and its working mechanism in anticancer therapy. 1) Schematic illustration of iron-mediated coordination in preparation of PHPD-NPs; 2) Schematic Illustration of a Tumor-Specific and PhotoactivityControllable Nanoparticle Photomedicine. (a) Preparation process of photosensitizer−hyaluronic acid conjugates shielded polydopamine nanoparticles (PHPD-NPs) and their photo-activity on−off control; (b) Chemical structure of polydopamine nanoparticles (PD-NPs) and photosensitizer−hyaluronic acid (PS-HA) conjugates; and (c) Cancerspecific cellular internalization of PHPD-NPs and their photo-activity restoration by cancer specific enzyme (e.g., hyaluronidase, HAase): under laser irradiation, the ROS generated from PS and the heat from PD-NPs can effectively kill cancer cells. Adapted and reprinted with permission from Ref. 289. Copyright 2016 American Chemical Society.\nO O\nO HO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OHO\nO HO\nOH NH\nOH\nO HO\nO\nH N\nOR1 N N N\nPBLG-b-HYA Ref. 290, 291\nN H\nN\nH\nO\nOO\nH\nm\nR2\nR1= H; R2=\nN S S\nN H\nR1=\nR2=\nO O\nO\nO n\nHA(PDA)-b-PCL Ref. 292\n;\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nR\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nOH\nR= NH S\nH\nO N N\nO\nm\nHydroHA Ref. 293\nHCDC\nO O\nH N\nN H\nO\nO\nH\nm n\nRef. 294\nO O\np\nO O\nH N\nO\nO\nH\nm n\nN H\nHA-PEG-PLGA Ref. 295 HA-PHis\nNH\nNHO\nHN N\nm\nRef. 297\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nNH\nO OO\nO HO\nOH NH\nO\ny\nO HO\nO\nOH\nO OO\nO HO\nOH NH\nOH\nZ\nO HO\nO\nOH\nO O\nm\nO\nO\nOH\nO\nO\nn\nO\nHA-g-PLA-g-PEG Ref. 296\nFig. 24 Representative HA-copolymer conjugates as nanocarriers for drug delivery.\nPage 80 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\n. Cl NH2 .HCl 1.NaN3 2.KOH\nN3 NH2\nO\nNH\nO\nO\nOBn\nO\nN3 N H\nO\nOBnO\nm\nO O O\nHO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OHO\nO HO\nOH NH\nOH\nO HO\nO\nH N\nOH N N\nN N H\nN\nH\nO\nOO\nH\nm\nO O\nO HO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OO\nO HO\nOH NH\nOH\nO HO\nO\nOH\nOH\nNH2 NaCNBH3\nO O\nO HO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OHO\nO HO\nOH NH\nOH\nO HO\nO\nH N\nOH N\nH\nH\nPMDETA/CuBr\nHA\nPBLG-b-HYA\nScheme 14 Schematic illustration of synthesis of amphiphilic copolymer PBLG-b-HYA. Imine reduction and “click” reaction are the two key steps for the synthesis of PBLG-b-HYA.290, 291 Adapted with permission from Ref. 290. Copyright 2009 American Chemical Society.\nOH\nNH2\nN\nNH\nO\nO\nO\nbenzyl chloroformate\nOH\nNH N NH\nO\n2,4-dinitrofluorobenzene\nO\nO\nHO\nN H\nN\nN\nO\nO2N NO2\nthionyl chloride O NH\nN\nN\nO\nNO2\nNO2\nO\nNim-DNP-L-histidine NCA\niso-propyl amine\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nHN\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nOH\nHA-PHis-DNP\nHN O\nN N\nm\nH N\nN H\nN N\nO\nH\nm\nO2N\nNO2\nEDC/NHS\nO2N\nNO2\n2-mecaptoethanol\nL-Histidine\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nHN\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nOH\nHA-PHis\nHN O\nNH N\nm\nHA\nScheme 15 Schematic illustration of synthesis of amphiphilic conjugate HA-PHis. Adapted from Ref. 297. Copyright 2014 with permission from Elsevier.\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nO\nO\nO P\nO\nO\nO\nO H\nO NH\nHA-DPPE\nM\nO\nO\nO P\nO\nO\nO\nO H\nO\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nOH\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nNH\nHA-DOPE\nM\n.\nFig. 25 HA-lipid conjugates HA-DPPE and HA-DOPE for the delivery of nucleic acids. Lipids were attached to HA via amide bonds.\nPage 81 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO O\nO P\nO\nO\nO N\nO H\nO\nL-a-Phophatidylcholine(Soy-PC) (Roy-PC)\nO\nO\nO P\nO\nO\nO\nO H\nO DPPE\nNH3\nO\nO\nO P\nO\nO\nO NH3O H\nO DOPE\nO\nO\nO\nO\nS O\nO\nO O\nDOTAP\nN\nFig. 26 Some Lipids (Roy-PC, DPPE, DOPE, DOTAP) as adjuvant for the co-construction of amphiphilic NPs for nucleic acid delivery.\nO OO\nO HO\nOH NH\nHO\nx\nO HO\nO\nNH\nO OO\nO HO\nOH NH\nOH\ny\nO HO\nO\nNH\nHN N H\nNH2 m\nHHSCs\nO\nHO NH\nO\nZO\nOH\nO O\nO\nO HO\nNH y\nOH\nO\nO\nO HO\nNH2\nx\nOH\nO O O\nO\nOCMCS\nHA +\n;\nRef. 303 Ref. 304\nFig. 27 Other representative examples of amphiphilic nucleic acid delivery system. Hyaluronic acid–spermine conjugates (HHSCs) and oleoyl-carboxymethy-chitosan (OCMCS)/hyaluronic acid (HA).\nPage 82 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nPart 3\n4.3. Cyclodexrin based amphiphilic delivery system for cancer therapy\nO\nOH\nHO\nHO O m\nm=6, 7, 8\nO\nOH\nHO OH\nO O\nOH\nO HO OH\nO\nOH\nO HO OH\nPrimary face\nSecondary face\nm=6 α-cyclodextrin; m=7, β-cyclodextrin; m=8,γ-cyclodextrin\n. .\n.\nFig. 28 Chemical structures of α-, β-, γ-cyclodextrin and the truncated cone shape as a cartoon drawing. Primary face is composed of 6-OH group and secondary face is composed of 2-, 3- OH groups.\nFig. 29 Representative examples for amphiphilic drug delivery system as nanocarriers based cyclodextrin. 1) cyclodextrin conjugate; 2) cyclodextrin inclusion complex; 3) pseudo-polyrotaxane.\nR1=OH, NH2, I, Br, N3, SH, SR, etc. R2, R3= H, etc.\nO\nOH\nHO\nHO O m\nm=6, 7, 8 R= Hydrophilic or hydrophobic or amphiphilic substitutes\nR4, R5= H or hydrophilic or hydrophobic or amphiphilic substitutes\nO\nR1"
    }, {
      "heading" : "R2O",
      "text" : "R3O O m\nm=6, 7, 8\nO\nR\nR4O\nR5O O m\nm=6, 7, 8\nChemical Modification\nChemical Modification\n6\n2 3\nScheme 16 General synthetic way to amphiphilic cyclodextrins. 6-OH group are more reactive and can be easily replaced by other substitutes (-NH2, -I, -Br, -N3,-SH, etc.) compared to 2-, or 3-OH group.\nLinker\nHydrophobic part\nCyclodextrin\nHydrophobic part\nCyclodextrin\nHead of guest part for a inclusion complex\n3) Pseudopolyrotaxane\n1) Cyclodextrin conjugate 2) Cyclodextrin inclusion complex\nPage 83 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO SR\nHO\nO O 7\nO\nOH\nn\nR= -C16H33, n=1-2, SC16OH; Ref. 311 -C6H13, n=2-3, SC6OH; Ref. 312\nO\nO\nO\nO O m\nO\nm=7, Acetalated β-CD m=6, Acetalated α-CD\nRef. 313, 314, 317\n1) 2)\nO\nHO HO\nOH\nO\nO\nHO\nHO OH\nO\nO HO\nOH\nS\nO\nO\nHO OH\nOH\nO O\nOH\nOH\nHO\nO\nO OH\nOH S\nO\nO\nOH\nOH\nOH\nO\nNH\nOHN\nR\nNH O O\nO NH\nR\nO n\nO\nm\nR= N\nN\nO\nO\nOO\nNH NH O\nO\nNH\nO\nPoly(CDDCys-PA-PEG)-GlyGlyGly-CPT\nN NH N N NH\nO\nO\nO\nO\nO\nO\nS\nO\nNH S S\nOH\nO\nCDP-TubA\nRef. 316Ref. 315\nor\n3)\nNon-inclusion complex:\nFig. 30 Some examples of CDs based amphiphilic drug delivery systems without using inclusion complexation. 1) 6- OH was modified with hydrophobic long carbon chain (SC16OH, SC6OH); 2) 2-, 3-, 6-OH were hydrophobically acetalated (acetalated α and β-CDs); 3) Drug-polymer conjugate was attached to 6- position of CD by sulfide bonds (Poly (CDDCys-PA-PEG)-GlyGlyGly-CPT and CDP-TubA).\nScheme 17 Schematic illustration of the sensitizing effect of Ac-αCD NP. Ac-αCD-derived Ac-αCD NP may be endocytosed by resistant cancer cells. The internalized NPs are transported via the endolysosomal compartments, into which Ac-αCD NP may be hydrolyzed to generate parent α-CD molecules. Then intracellularly delivered α-CD inhibits the Pgp expression (A), induces ATP depletion (B), and attenuates Pgp ATPase activity (C). The collective effect of these pharmacological functions contributes to enhanced drug uptake/retention and potentiated efficacy against MDR cancer cells. Reprinted from Ref. 317. Copyright 2015 with permission from Elsevier.\nPage 84 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO HO\nOH\nO\nO\nHO\nHO OH\nO\nO HO\nOH\nI\nO\nO\nHO OH\nOH\nO O\nOH\nOH\nHO\nO\nO OH\nOH I\nO\nO\nOH\nOH\nOH\nO\nO\nCDDI\nNH2 OH HS\nO\nO\nHO HO\nOH\nO\nO\nHO\nHO OH\nO\nO HO\nOH\nS\nO\nO\nHO OH\nOH\nO O\nOH\nOH\nHO\nO\nO OH\nOH S\nO\nO\nOH\nOH\nHO\nO\nNH2\nOHO\nH2N\nO OH\nO O ON\nO\nO n\nO N\nO\nO\nO\nBase\nPEG-DiSPA\nO\nHO HO\nOH\nO\nO\nHO\nHO OH\nO\nO HO\nHO\nS\nO\nO\nHO OH\nOH\nO O\nOH\nOH\nHO\nO\nO OH\nOH S\nO\nO\nOH\nOH\nOH\nO\nNH\nOHO\nNH O O\nO OH\nO n\nO\nm\n.\nN\nN\nO\nO\nOOH\nN\nN\nO\nO\nOO\nNHNH O\nO\nTFA.H2N O\n1. Boc-GlyGlyGly DIPC, DMAP 2.TFA EDC/NHS\nO\nHO HO\nOH\nO\nO\nHO\nHO OH\nO\nO HO\nOH\nS\nO\nO\nHO OH\nOH\nO O\nOH\nOH\nHO\nO\nO OH\nOH S\nO\nO\nOH\nOH\nHO\nO\nNH\nOHN\nR\nH N O\nO\nO NH\nR\nO n\nO\nm\nR= N\nN\nO\nO\nO\nO\nNH\nHN\nO\nO\nNH O\nPoly(CDDCys-PA-PEG)-GlyGlyGly-CPT\nScheme 18 Schematic illustration of total synthesis of the polymer Poly (CDDCys-PA-PEG)-GlyGlyGly-CPT. Adapted with permission from Ref. 315. Copyright 2003 American Chemical Society.\nN\nN\nFe\nAdmantane Azobenzene\nFerrocene\nO\nOH\nHO\nHO O m\nm=6, 7, 8\nBenzene\nH O O H\nPolyethylene glycol\nN\nH N\nBenzimidazole\nHost CDs Guest Molecular Residues\nFig. 31 Some typical host-guest chemical structures frequently used in inclusion complex. Host: CDs; Guest molecular residues: Adamantane, Benzimidazole, Azobenzene, Ferrocene, Benzene, Polyethylene glycol etc.\nPage 85 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO NH\nOH\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nPTXRef. 320\n1)\nO\nNH\nHO\nHO O 7\nH2N\nED-β-CD\n+\nSmall molecule modified CDs + drugs\na.\n(2-naphthyl)-alanine modified γ-CD\nO\nOH\nHO\nHO O 7\nO\nO\nHO\nHO O\nO\nH2N\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO NH2HO\n+\nDOX\nb.\nRef. 321\nO\nOH\nHO\nHO O\nO\nO(NH)\nHO\nHO O\n+\n6\nN NN ClCl-\nN\nO\nO\nO N\nCl-\nCurcumin analog NC2067CD gemini surfactant (ester or amide linker)\nO\nO\nc.\nRef. 322\nx y z\nH\nO HN O\nOO OO\nw N\nN N\nS N H\nN\nNH\nO\nO\n+\nPOEGMEA-b-P(NIPAAM-s-PACD) Albendazole(ABZ)\nOH 6\nRef. 323\n2) Macromolecule modified CDs + drugs\na.\nO O\nN H\nH N\nH\nm\nO\nHN\nO\nN H\nOH\n6\nn\nPEG-b-PCDs\nN O O\nOH\nO\nN\nO\nOH\nO\nO Cl\nC102 IBU\nIND\nor\nor\netc.\n+\nRef. 324\nb.\n+\nO O\nN H\nH N\nn\nO\nHN\nO\nN H\nOH 6\nx\nmPEG-PLG(CD) Ref. 325\nH N\nO\nOH\nO\ny H\nN\nN\nO\nO\nOOH\nCPT\nc.\nd.\nO O O O\nm n\nN\nO\nOH\nO\nO Cl\nIND\nO\nN\nN N\nOH 6\nβ-CD-PLA-mPEG\n+\nRef. 326\nHN\nN H\nOMe 6\n*\nOMe 14\nO O O\nO OH\nHO HN\nOH\nO OH\nO\nNaO\nO O O\nO OH\nHO HN\nHO\nO OH\nO\nx y\nO\nHN\nO O\nO\nO\nHO\nO\nOH\nOH\nO\nO O\nO\nO\nN\nHN\nN\nNH\nO\n+\ne.\nHApCD PorTaxol Ref. 327\nFig. 32 Chemical structures of representative macromolecular amphiphiles formed via normal inclusion complex (drug involved). 1) Small molecule modified CDs + drugs; 2) Macromolecule modified CDs + drugs.\nPage 86 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO O\nO\nw\nS S OH\nS O\n3-BSPA\nAIBN N, N-Dimethylacetamide 60oC\nx\nO OO w\nS S OH\nS O HN\nO\nNIPAAM\nO\nO\nSi\nTMSPA\nAIBN N, N-Dimethylacetamide 60oC\nx y z\nO HN O OOOO w Si\nS S OH\nS O\nTBAF\nPEGMEA\nx y z\nH\nO HN O\nOO OO\nw N\nN N\nPOEGMEA-b-P(NIPAAM-s-PACD)\nOH 6\nx y z\nH\nO HN O OO\nOO w\nN3\nOH 6\nScheme 19 Schematic illustration of synthesis of the copolymer POEGMEA-b-P(NIPAAM-s-PACD) (upper) and cartoon illustration of the NP formed with this copolymer and drug ABZ at T>LCST (below). Adapted and reprinted with permission from Ref. 323. Copyright 2011 American Chemical Society.\nOO\nHO OH\nOH\nOHO\nHO OH\nOH\nN H\nm\nN\nN N\nOH 6\nN\nN O\nO H\nO n\nDex-β-CD BM-PCL\n1)\nRef. 318\nO\nO\nOH\nO\nO\nO\nOH\nO\nOH\nHO OH\nO O\nOH\nOH\nn O\nO\nHO\nHO O 7\nβ-CD-HPG PS\nHO\n2)\nRef. 328OH OH\nAu\nS-CD\nS-CDCD-S\nS-CD\nS-CD\nS-CD\nCD-S\nCD-S\nO O O O\nn\nS N\nHN O\nO m\nADA modified PEG\nADA modified PNIPAM β-CD modified AuNPs\n3)\nRef. 329\nH\nO\nOMe\nMeO\nHO O\nO\nS\nMeO\nMeO O6\nN H N H\nH N H N\nS\nS\nOO OO\nn n n n\nn=1, 7\nO\nHO\nS\nOH HO\nHO\nO\n3\nH N H N\nS\nO\nH N\n3\nH N\nS\nCA4 -βCD\n+\nRef. 330\n4)\nC12H25 S S\nO O\nS\nOO O\nO\nO\nO m n p\nFe\nO\nO\nq\nHO\nNH OH\nHN\nPEG-b-PGMA-g-CD PCL-FcRef. 319\n5)\nFig. 33 Chemical structures of representative macromolecular amphiphiles formed via normal inclusion complex (without drug involved). Guest molecular residue: 1) Benzimidazole; 2) Benzene; 3) and 4) Adamantane; 5) Ferrocene.\nPage 87 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nScheme 20 Schematic illustration of the formation of electrochemical redox responsive micelles from brush-like supramolecular block copolymers and their controlled assembly and disassembly (controlled by electrochemical redox trigger). Reproduced from Ref. 319. Copyright 2014 with permission from the Royal Society of Chemistry.\nPage 88 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nOMe\nO\nO OH\nOH\nOH\nN\nOH\nO\nO\nNH2 . HCl\nHO\nON H\nO\nO O\nO\nO O\nO\nPO O\nO\nN\nm n\nα-CD-hydrazide-DOX.HCl PEG-b-PMPCRef. 331\n1)\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO NH HO\nH N\nO OHO O\nN H O\nO\nO\nO O O Br\nO O O\nO\nBr\nOO O\nO\nm z n p p\nk\nk\nPR-DOX\nPPEGMA-F127-PPEGMA DOX-CA-CD\n2)\nRef. 332\nFig. 34 Chemical structures of representative macromolecular amphiphiles formed via special inclusion complex pseudopolyrotaxane (PPR) and related cartoon depictions about the NPs formed with PPRs. 1) α-CD-hydrazideDOX.HCl + PEG-b-PMPC; 2) PR-DOX. Reproduced from Ref. 331, 332. Copyright 2013 with permission from the Royal Society of Chemistry.\nPage 89 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO\nBr\nHO\nHO O 7\nRSH, tBuOK, DMF O\nSR\nHO\nHO O 7\nK2CO3, ethylene carbonate, tetra-N-methylurea O\nSR\nHO\nO O 7\nO\nOH\nn\nn=0-2 R=C6H13 or C12H25 R=C6H13 or C12H25\nNBS or NIS, PPh3,DMF\nO\nSR\nHO\nO O 7\nO\nBr(I)\nn\nn=0-2\nDMF, NaN3\nO\nSR\nHO\nO O 7\nO\nN3\nn\nn=0-2\n1.Ph3P, DMF 2.10% NH3(aq) 2. 1 M HCl\nO\nSR\nHO\nO O 7\nO\nNH2.HCl\nn\nn=0-2\nSC6CDNH2, SC6NH2\nR=C6H13 or R=C12H25R=C6H13 or C12H25 R=C6H13 or C12H25\nScheme 21 Schematic illustration of synthesis of the amphiphilic cyclodextrins SC6CDNH2 and its derivatives. 337, 338\n.\nO\nSR\nHO\nO O 7\nO\nNH3\nn\nn=1-2R=C6H13\nN\nNH N\nHN\nSO3\nSO3\nO3S\nSO3\nTPPS\nSC6CDNH2(SC6NH2)\nRef. 333\n1)\nO\nSR\nHO\nO O m\nO\nNH3\nn\nn=1-2R=C6H13\nO\nSR\nHO\nO O p\nO\nNH\nn\nm+p=7\nSO O\nN SC6Dns\nTPPS\nSC6NH2\n2)\nRef. 334\nO(CH2)7NH NO2\nCF3 AD-Ph-NO2\nTPPS\nSC6CDNH2\nRef. 335\n3)\n.\nFig. 35 CD based amphiphilic nano drug delivery system for PDT constructed via electronic static interaction (encapsulation of photosensitizer) and hydrophobic interaction (self-assembly). 1) Sketch of the nanoassembly formed in aqueous solution from SC6CDNH2 and TPPS; 2) Sketch of the nanoassembly formed in aqueous solution from SC6NH2, SC6Dns and TPPS; 3) Sketch of the nanoassembly formed in aqueous solution from SC6CDNH2, TPPS and AD-ph-NO2. Adapted from Ref.333-335. 1) Adapted from Ref. 333. Copyright 2006 with permission from Elsevier. 2) Adapted from Ref. 334. Copyright 2011 with permission from the Royal Society of Chemistry. 3) Adapted with permission from Ref. 335. Copyright 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.\nPage 90 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nN N N\nN\nR2O OR2\nOR2\nOR2\nOR1R1O\nR2O\nR2O\nR1=\nCOOHHOOC R2=\nNH\nO\nN H\nO\nO\nSR\nHO\nO O 7\nO\nH\nn\nR=C12H25\nZn\nAD-Pc-Zn SC12CDOH\na)\nFig. 36 Zinc (II) phthalocyanine (PC) and β-cyclodextrin vesicles (CDV). a) Chemical structures of compounds SC12CDOH and AD-Pc-Zn; b) Schematic representation of cyclodextrin vesicles decorated with phthalocyanine Photosensitizer AD-Pc-Zn. b) Reproduced from Ref. 336. Copyright 2013 with permission from the Royal Society of Chemistry.\nScheme 22 Illustration of the core-shell nanoassemblies based on PEI-CD/PBLA by a host-guest interaction. Reprinted with permission from Ref. 341. Copyright 2010 American Chemical Society.\nPage 91 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nNH NH H\nO\nO\nO\nn\nGuest: PBLA\nN NH N N\nNH\nNH\nNH2\nN\nNH2\nNH2\nNH\nH2N\nx y z p\nHost: PEI-b-CD\n+\nRef. 341\na)\nO\nO\nHO\nOH\n7\nR\nR= NH NH2\nNH OH NH NH2\nOH O O O OH\nOO\nx y\nNH\nO\nO\nO\nm\nz\nGuest: Ad-PVA-PEGRef. 342 Host: Cationic CD derivatives\n+\nb)\nO\nO\nHO\nHO O\nO\nO\nHO\nHOO 7\nO NH\nc)\nRef. 343\nONH H2N\n14 NH\nNH S\n14\nO\nO\nS\nNH\nO\nNH\nO NH N N NH N\nO\nH2N\nO\nNH\nOH\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\ng-CD-OEI-SS-FA Guest: PTX\n+\nHost:\nO\nFig. 37 Chemical structures of cylcodextrin based amphiphilic gene delivery system constructed by host-guest interaction. Guest molecular residue: a) Benzene; b) Adamantane; c) Benzene.\nFig. 38 Schematic representation of skirt- (left) and jellyfish-type (right) polycationic amphiphilic CDs (paCDs). The circles and the rectangular boxes represent positively charged groups and spacer segments, respectively. The basket-shaped scaffold represents a cyclodextrin core. Adapted with permission from Ref. 340. Copyright 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.\nO\nS\nO\nO O\nO\nO\nH N N\nS\n7\nR1\nR1= HR2 R 2=\nOH HexCD-T-C2O NH2.HCl p P=1, 3, 5 HexCD-T-C2, 4, 6N\nNH2.HCl HexCD-T-m, pXN\nH.HCl N\nNH2.HCl HexCD-T-C2N-C2N\nN NH2.HCl\nNH2.HCl\nHexCD-T-C2N[C2N]2\nH N H N\nS\nNH2.HCl HexCD-T-C2-T-C2N\nR1, R2= NH2.HCl HexCD-T[C2N]2\na)\nO\nS\nO\nO O\nO\nO\nR\nn\nR= NH2.HCl\nN H N H\nS\nNH2.HCl\nN H N H\nS\nN\nNH2.HCl\nNH2.HCl\nN H\nS\nN\nNH2.HCl\nNH2.HCl\nn= 6, 7, 8\nb)\n.\n.\nPage 92 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nFig. 39 Chemical structures of Skirt-type polycationic amphiphilic cyclodextrin (paCDs). 340, 344-347\nO\nHO\nHO O 7\nBr\nHS NHBoc\nCs2CO3\nO\nHO\nHO O 7\nhexanoic anhydride\nDMAP\nO\nS\nO\nO O\nO\nO\nNHBoc\n7\n1. TFA/DCM 2.HCl\nO\nS\nO\nO O\nO\nO\nNH2.HCl\n7\nCSCl2 CaCO3\nO\nS\nO\nO O\nO\nO\nNCS\n7\nR3-NH(H)Et3NR 3 NCS\nO\nS\nO\nO O\nO\nO\nH N\n7\nN(H)R3\nS\nTFA/CH2Cl2\nO\nS\nO\nO O\nO\nO\nH N N\nS\n7\nR1\nR2\nEt3N\nPaCDs\nS NHBoc\nScheme 23 Schematic illustration of general synthesis of shirt-style PaCDs. 340\nO\nS\nO\nO O\nO\nO\nNHNHN\nHCl.H2N\nS\nNH2.HCl\n7-n\nO\nS\nO\nO O\nO\nO\nNH NH N NH2.HCl\nS\nNHR\nn\nNH O S O OH\nOH OH\nOH 3 NH\nS\nNH\nS R=\nNH O NH\nS\nNH\nS\nO 114\nNH O NH\nS\nNH\nS\n114\nNH O S O OH\nOH OH\nOH\n3\nNH\nS\nGal10CDs, Gal12CDs\nPEGCDs\nGalPEGCDs\nFig. 40 Chemical structures of galactose-ligand modified paCDs. Adapted with permission from Ref. 348. Copyright 2012 American Chemical Society.\nO\nLinker\nO O O\nO O S\nN H 7\nN H2\nNH3 H N\n3 Linker=\nN O\nS\nOEI-β-CD\n. .\nFig. 41 Chemical structure of another skirt-type polycationic paCD, OEI-β-CD. 349\nO\nSC12H25\nHO\nO O 7\nN N N\nNH3\nO\nSC12H25\nHO\nO O 7\nN N N O\nn\nSC12TACDPEGSC12TACDNH2\nO\nSR\nHO\nO O 7\nO\nn\nNH2.HCl\nR= -C12H25, n=1-2, SC12NH2 R= -C16H33, n= 0-1, SC16NH2\nO\nSC12H25\nHO\nO O\nN N N\nO\nSC12H25\nHO\nO O\nN N N\n9\n7-X X\nO\nNH2\nO\nHN\n9\nO\nN\nO\nO\nRVG\nRVG: CNS-targeting peptide derived\nfrom the rabies virus glycoprotein\n; ; ;\nSC12-CD-click-PEG500-RVG\nPage 93 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nFig. 42 Chemical structures of jelly-style pcCDs SC12NH2, SC16NH2, SC12TACDNH2 and PEGlated amphiphilic β-CD SC12TACDPEG. 350-354\nO\nOH\nHO\nHO O 7\nO\nOTBS\nHO\nHO O 7\nO\nOTBS\nHO\nO O 7\nO\nBr\nHO\nO O 7\ntert-butyl 3-azidopropylcarbamate O\nBr\nHO\nO O 7\nN N N\nNHBoc\nO\nSC12H25\nHO\nO O 7\nN N N\nNH3\nCuSO4 5H2O, sodium ascorbate\n1)dodecanethiol,NaH 2)TFA, CH2Cl2\nPPh3, Br2propargyl bromide, NaHTBDMSCl, pyridine\n1-azido-1-deoxy-w-methoxy-PEG500 CuSO4, 5H2O, sodium ascorbate\nO\nBr\nHO\nO O 7\nN N N O\nn\ndodecanethiol, NaH\nO\nSC12H25\nHO\nO O 7\nN N N O n\nSC12TACDPEG\nSC12TACDNH2\nβ-CD\nScheme 24 Synthesis of jellyfish-style pcCD SC12TACDNH2 and PEGlated amphiphilic β-CD SC12TACDPEG using a “click” reaction as the key step. Adapted from Ref. 350. Copyright 2012 with permission from the Royal Society of Chemistry.\nPage 94 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nPart 4\n4.4. Dextran based amphiphilic delivery system for cancer therapy\nO\nHO\nHO O p\nO\nHO\nHO\nHOHO\nHO OH\nO\nHO\nHO O p\nOH\nHO\nHO\nHOHO\nHO O\nH\n1 2 Dextran\n1\nLinkerH2N R 1 R1= NH2, N3, C CH\nReduction\nO\nHO\nHO O p\nOH\nHO\nHO\nHO HO\nHO H N Linker R1\nNaBH4 or NaBH3CN\nO\nHO\nHO O\np\nOH\nHO\nHO\nHOHO\nHO H N NHCOR2\nCopper catalyzed \"Click\" reaction\nCarbodiimide coupling or imine reduction\nor O\nHO\nHO O p\nOH\nHO\nHO\nHOHO\nHO H N NHCH2R 3\nLinker\nLinker\nO\nHO\nHO O\np\nOH\nHO\nHO\nHO HO\nHO H N Linker\nN NN\nR1 = NH2 N3 or C CHR 1=\nR4\nO\nHO\nHO O\np\nOH\nHO\nHO\nHO HO\nHO H N Linker N\nN N\nR5 or\nR2, R3, R4, R5: polymeric segment\nreaction sites\n1 2\nR2COOH or R3CHO or R 5-N3R 4C CH\nO\nHO\nHO O m\nO\nHO\nHO\nHO HO\nHO\nO n\n2\nO\nR6O\nR6O O m\nO\nR6O\nR6O\nR6O HO\nR6O\nO n\nR6, R7= H, small molecular residue or polymeric segment\n1. Small hydrophobic molecules;or some functional linkers, then small molecules conjugation, or radical polymerization Alternative: 2.Base or lewis acid catalyzed ring-opening reaction or polymerization\nMethod 1:\nH\nH\nO\n(R7)O R 7O O\nm\nO\nR7O\nR7O\nR7(H)N HO\nR7O\nO n\nH\n1.Oxidiation by MIO4, 2. further hydrophobic modification, then formation of imine with amine, reduction\nmethod2:\nImine or Amine\nAldehyde, Alcohol or Ether\nor\nNH2-R\nN R\nor\nScheme 25 General description of the preparations of amphiphilic dextran based macromolecules for drug delivery.\nO\nHO\nHO O p\nOH\nHO\nHO\nHO HO\nHO N(H)R\nR= N H\nO O\nO n\nDex-b-PCL\nO\nN H\nO\nO\nO\nO H\nm n;\nDex-b-PLGA\nS S O O\nH\nO\nn Dex-SS-PCL Ref. 358\nRef. 360 Ref. 359\nb) imine reduction products\n1) reaction site 1\n;\nR= N N N\nH N\nN\nH\nO\nO O\nH n\nDEX-b-PBLG\nN H\nH N\nN H\nH\nO\nO\nO\nN\nN\nN\nm n ;\n;\nON N N\nO H O n\nDex-b-PLA\n;\nN N N\nO\nO n\nDex-PLLA or Dex-b-PDLA\nRef. 362, 366\nRef. 365Ref. 363\nRef. 364\nc) ''Click'' reaction products\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nHO\na) imine products\nDEX-O-DOX Ref. 367\nPage 95 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO\nRO O m\nHO\nR=\nOH N\nH\nH H\nH\nHHO\nOH\nSS\nHN\nO\nCMD-SS-LCA CMD-g-LCA\nOH N\nH\nH H\nH\nHHO\nOH\nHN\nO\n;\nR= H, or O OH\nO\nO p\nO\nO\np\nO O H\nO\nO x y\n;\nDex-g-PLA DEX-PCL Dex-g-PLGA\nR= or O or\nS\nCN\nO\nS\nO\nO\ny\nx\nO\nor O\nRef. 377\nH ; H, or\nH, or\nO\nRO\nRO O m\nO\nRO\nRO\nRO\nRO\nO n\nRef. 382, 383\nRef. 379 Ref. 378\nRef. 384AC-DEX Ac-Dextran-g-POEGMA\n2) reaction site 2\n;\nH\nH H\nH\nON\nO\nH\nB\nDex/Chol-PBA\na) method 1\nR=H or\nO O\nOCH3\nOH\nO H3CO O\nDex-CCMs Ref. 373Ref. 375\npH sensitive\nPolyester\nRef. 369\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nHO\nRef. 374\nO\nR1N R1N O\nm\nO\nR1N R 2N\nHO\nHO\nO n\nR1=\nR2=\nO O\nPEG/dox dextran\nN H\nF\nF\nF\nFF\nF\nF\nO\nHN\nO\nH N\nHN\nN O\nHN\nO\nNH O\nF\nF F\nF\nF\nF F\nF\nF\nF\nFF\nF\nF\nO\nNH\nF\nF\nF F\nF\nF F\nO\nb) method 2\nO\nHO O\nm\nO\nHO\nHO\nR\nHO\nO n\nH\nR\nO\nO\np\nR\nHO\nR\nR=O, or\npH sensitive\nFPD-HZN-Dox Ref. 388\nc) method1 + method 2\nO\nRO\nRO O m\nO\nRO\nRO\nRO HO\nRO\nO n\nH\nS S\nO\nO\nO\nC18H37\nH3N\nNH3\nO O O N H\nO\nNO\nx\nR=\nor\nLDS\nO\nR1\nHO\nHO\nO\nn\nH\nO\nO\nm\nR2 HO\nR2\nR1= H, or S S\nO\nO\nO\nC18H37\nR2= O, or\nPEG-oDS\n+\nR=H or S S\nO\nO\nO\nC18H37\nNH CO2H\nO\nN H\nN\nN\nN\nN\nOH\nNH2\nO\nR=H or\nDS\nFA-DS\nO O\nN H\nO\nNO\nx\nR2= O or\nPEG-oDS\nRef. 376\nRef.372\ncombination 1\ncombination 2\nRedox:\nPPLV\nFPPLV\nFig. 43 Chemical structures of representative Dextran based amphiphilic copolymers. 1) Reaction site 1 (imine products, reduction products, click reaction product); 2) Reaction site 2 (methods 1 and 2 or 1+2).\nPage 96 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO HO\nO O OH\nHO HO\nHO HO\nHO p\nH N\nN\nNN\nO O\nH\nO\nn O\nO2N\nB(OH)2\nO\nO\nHO O\nO HO\npB\nNO2\npH sensitive cross-linker\nCNPBA-Dex-b-PLA\nTo form boronate ester with another same copolymer\nO\nHO\nO O OH\nHO\nHO\nHO HO\nHO p\nH N\nN\nNN\nN H\nN\nH\nO\nO O\nH\nn O\nS S\nR\nO\nGSH sensitive cross-linker\nR= PBLG-b-dextran\nPBLG-b-dextran-DPA\nRef. 365\nRef. 366\nFig. 44 Chemical structures of Dextran based amphiphilic copolymers CNPBA-Dex-b-PLA 365 and PBLG-b-dextranDPA. 366 pH sensitive cross-linker (boronate ester) in copolymer CNPBA-Dex-b-PLA; GSH sensitive cross linker (disulphide bond) in copolymer PBLG-b-dextran-DPA.\nO\nHO\nHO O\nm\nO\nHO\nHO\nHO HO\nHO\nO n\nOMe\nP-TsOH\nO\nO\nO O\nm\nO\nO\nHO\nO HO\nO\nO n\nO\nHO S\nO CN\nS\nDCC, DMAP\nO\nO\nO O\nm\nO\nO\nO\nO HO\nO\nO n\nO\nS OCN\nS\nO O\nO\nx\npolymerization\nO\nO\nO O\nm\nO\nO\nO\nOOH\nO\nO n\nO\nS OCN\nS\nO O\ny\nO x\nAc-Dextran-g-POEGMA Ref. 384\nScheme 26 Synthetic route of copolymer Ac-Dextran-g-POEGMA. Adapted with permission from Ref.384. Copyright 2012 American Chemical Society.\nO\nHO\nHO O\nm\nO\nHO\nO\nHO HO\nHO\nO n\nNH\nO\nNNH\nN HN O\nOH\nO\nO\nOH\nO\nHO\nHO O\nm\nO\nHO\nO\nHO HO\nHO\nO n\nNH\nHN\nO\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nHN HO\nS S\nO\nN\nH2N\nO x y\nS\nS\nNH\nDEX-PEI(-SS-DOX) DEX-SS-Ce6\nRef. 385 Ref. 3 86\na)\nO\nHO\nHO O\nm\nO\nHO\nO\nHOHO\nHO\nO n\nO\nO\nO\nHO\nHO O\nm\nO\nHO\nHO\nHO HO\nHO\nO n\nCl O\nO NO2\nDMAP\nNO2\nDEX-PNCDextran\nPEI\nO\nHO\nHO O\nm\nO\nHO\nO\nHOHO\nHO\nO nO\nDrug -COOH EDC, NHS DEX-PEI(-SS-DOX) DEX-SS-Ce6\nH2N S S NH2\nor\nR\nR= N H\nS S NH2 N H PEI or\nb)\nScheme 27 Two drug-DEX conjugates DEX-PEI(-SS-DOX) and DEX-SS-Ce6. a) Structures of representative dextran conjugates DEX-PEI(-SS-DOX) and DEX-SS-Ce6 as drug delivery vectors; b) Synthetic routes of copolymers DEX-PEI(SS-DOX) and DEX-SS-Ce6. 385, 386\nPage 97 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO O\nHO O p\nOH\nO\nO\nO O\nO HN\nN\nN N\nHN O\nNH\nH\nHN\nNH\nO\nH2N\nm\nO\nO\nO\nHO HO O\nn\nO\nO\nO\nHN\nO\nO\nO\nO\nHO O\nm\nOHO\np\nO HN\nN H\nNH2\nAc-Dex-b-PAsp(DET) Ref. 368 Spermine-modified Ac-DEX Ref. 387\nFig. 45 Chemical structures of dextran based amphiphilic copolymers (Ac-Dex-b-PAsp(DET) and Spermine-modified Ac-DEX) for gene delivery.\nO\nHO\nHO O\nn\nO\nHO\nHO\nHO\nHO\nO\nOMe\nO\nHO\nHO O m\nHO HO\np\n1. NaIO4, H2O 2.\nH+, DMSO\nO\nO HO O\nn\nO\nO\nO\nO\nO\nO\nO\nO\nHO O\nm\nOHO\np\nO\n1.Spermine 2. NaBH4 DMSO\nO\nHO HO O\nn\nO\nO\nO\nHN\nO\nO\nO\nO\nHO O\nm\nOHO\np\nO HN\nN H\nNH2\nSpermine-modified Ac-DEX\n,\nModification with amines facilitates encapsulation of nucleic acids\nScheme 28 Synthesis of amphiphilic copolymer Spermine-Ac-DEX for siRNA delivery. Adapted with permission from Ref. 387. Copyright 2011 American Chemical Society.\n4.5. Other oligosaccharides based amphiphilic delivery system for cancer therapy\n4.5.1. Pullulan\nPage 98 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO OR\nO\nHO OO\nHO HO\nOHO\nHO\nHO\nOR\nn\nO\nHO\na) Pullulan-drug conjugates\nOMe\nO\nO OH\nOH\nOH\nN\nOH\nO\nO NH2HO\nNH\nOO\nR= H, or\nH2N\nNH\nOO\nor\nPullulan-DOX Ref. 395-397\nN\nN N\nN\nNH2\nH2N\nN\nN H\nO COOH\nO\nO\nOR\nO\nRO OO\nRO RO\nORO\nRO\nRO\nOR\nn\nO\nRO\nR=H, or\nN H\nN\nO\nor\nMTX-URPA Ref. 398, 399\n;\nb) pullulan-steroid conjugates\nO\nOR\nO\nHO OO\nHO HO\nOHO\nHO\nHO\nOR\nn\nO\nHO\nR=H, or\nH\nHH\nO\nO\nO\nH\nCHSP Ref. 401, 402\n; Deoxycholic acid (DOCA)\nOH\nH H\nH\nH\nOH\nHO\nNO\nO\nO\nN\nN\nO\nO\nO\nO\nO\nO Gd\nR= H, or\nPullulan-DOCA-DTPA-Gd (PDDG)\nor\nDTPA-Gd\nRef. 404\nN H N H\nOO\nH\nHH\nO\nH\n6\nCHP\nR= H, or\nRef. 403\n.\nO\nOR1\nO\nR2O O\nO HO\nR2O\nOHO\nHO\nHO\nOR1\nn\nO\nHO\nR1, R2= H, or\nH\nHH\nO\nO\nO\nH R1 =H, or\nN H\nN\nO\nUCPA Ref. 400\nO\nOR\nO\nRO O\nO RO\nRO\nO RO\nRO\nRO\nOR\nn\nO\nRO\nR= H, or\nO\nOR\nO\nRO OO\nRO RO\nO RO\nRO\nRO\nOR\nn\nO\nRO\nO O H\nO\nO x y\nNH CO2H\nO\nN H\nN\nN\nN\nN\nOH\nN H2\nO\nPLGA\nFA\nor\nFAPuLG Ref. 405\nc) Pullulan-polymer conjugate\nH\nH\nH\nHO\nO\nO\nR=H, or\nO\nOR\nO\nHO OO\nHO HO\nO HO\nHO\nHO\nOR\nn\nO\nHO\nO\nOR1\nO\nR2O OO\nHO R2O\nOHO\nHO\nHO\nOR1\nn\nO\nHO\nR1 =H, or\nN H\nN\nO\nURPA\nO\nOAc\nO\nRO OO\nRO RO\nORO\nRO\nRO\nOAc\nn\nO\nRO\nBPA\nR= H, or\nNHHN\nS\nH H\nO\nO\nRef. 409\nd) Other Pullulan conjugates\nligand- pullulan conjuagte\npH sensitive pulluan conjugate\nRef. 406\n;\nRef. 408\nRef. 407\nPhotosensitive pullulan conjugate\nO\nOR\nO\nHO OO\nHO HO\nOHO\nHO\nHO\nOR\nn\nO\nHO\nN\nO NO2\nO\nUV vis N\nO\nO NO2\nSpiro form Merocyanine form\nR=H, or\nN\nO NO2\nO SpP\nPage 99 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nFig. 46 Chemical structures of representative pullulan based amphiphilic conjugates. a) Pullulan-drug conjugates; b) Pullulan-steroid conjugates; c) Pullulan-polymer conjugate; d) Other conjugates (ligand, pH sensitive and photosensitive pullulan conjugates).\n4.5.2. Starch (dextrin), Cellulose\nO\nHO\nHO O\nm\nO\nO\nHO\nHO O n\nHO\nO O\nO\nHO\nHO O m\nO\nO\nHO\nHO O n\nO\nDEX–PDP\nPrP-Strach\nRef. 414\nRef. 416\nO\nHO\nHO O\nm\nHO\nO\nHO\nHO O n\nO\nO OH\np\nR\nO\nO O\nO\nO\nO H\nO H\nO\nO\nH x\ny\nz\nw\nO\nO R=\nX+Y+Z+W=20\nps 80\nPMAA-PS80-g-St Ref. 417, 418\nO\nHO\nHO O m\nO\nO\nHO\nO O n\nHO\nO\nHO\nN\nCSaSt\nO\nH\nH H H\nH\nHO\nOH\nO\nHO\nHO O\nm\nO\nHO\nHO O n\nHO\nO\nST-DCA Ref. 415\nRef. 413\n; ;\n; ;\nFig. 47 Chemical structures of representative starch (dextrin) based amphiphilic polymers for cancer therapy. Small molecule-starch conjugates (CsaSt, DEX-PDP, ST-DCA, PrP-Strach) and polymer-starch conjugate (PMAA-PS80-g-St).\nEC-g-PCL-b-PLLA\nx\nO Br\nO O\nn\nN EC-g-PDEAEMA\nO\nO\nRO\nO\nO\nR=\nO\nO\nO\nO H\nn m\n;\n;\nRef. 423\nRef. 424\na) EC based copolymers\nO Br\nO HO\nn\nEC-g-PAA\nO\nN\nO\nN\nN N\nN N\nO\nO\nBr\nO O\nO\nO\nBr O\nO\nN\nO O\nO\nO\nO\nO p\n;\nx y\nor\nEC-(g-P(MEO2MA-co-OEGMA))-g-PDMAEMA Ref. 422\n8\nRef. 431\nR=H, or\nN\nOH\nCl or HMQC\nO\nRO\nOR\nRO O\nx\nR=H, or O\nO\nO\nOH n\nR=H, or O\nOH\nO\nO n\ncellulose-g-PLLA\ncellulose-g-PCL\nRef. 429\nRef. 430\nRef. 433\nb) direct cellulose based polymer conjugates\nR=H, or NH\nO Br\nO O\nn\nN\nRef. 432\nS S\nH N\nO CNC-graf t-PDMAEMA\nO\nAcO\nO\nAcO O\nAcO\nAcO\nAcO\nO O O\nAcO\nO\nAcO O\nx y z\nO\nO\nO\nn\nO\nDrug-Cellulose conjugate\n.\nO\nO\nO\nO\nO\nO\nO\nO\nO\nAcO\nO\nAcO O\nAcO\nAcO\nAcO\nO O O\nAcO\nO\nAcO\nO\nAcO\nO\nAcO\nO O\nx y z u\nO\nO\nHO\nOO\n45\nO\nHN\nO\nO\nOHOHO\nO\nOHO\nH O\nO O\nO\nO\nCellax Ref. 425-428, 434-437\nO\n;\nc) CMC based conjugates\nDrug-Celluose complexes\nO\nHO\nO\nHO O\nHO\nHO\nHO\nO O O\nHO\nO\nHO O\nx y z\nO\nO\nO\nOO\nDOX-NH3 OHO O\n+\nPPT-CMC-Ac-PEG Ref. 438\nCMC-ME2MO Ref. 439\nPage 100 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nFig. 48 Chemical structures of representative cellulose based amphiphilic polymer conjugates. a) EC based copolymers; b) Directly cellulose based polymer conjugates; c) CMC based conjugates.\n4.5.3. Heparin\nR3=H or\nO OR\n3\nHO OSO3 O3SHN\nO3SO O\nO HO\nR1=H or SO3 -, R2=H, or SO3 -, or Ac\nO\nN H\nH\nH H\nH\nH\nOH\nOH\nO O\nOR 3 HO OR1 R2HN\nR1O\nn\nO\nO HO\nO\nR3= H or\nHeparin-DOCA(HD)\nH N\nO\nONa\nH\nH H\nH\nH\nOH\nO H N\nN H\nO R3= H or\nDOC- Heparin\nO\nNH\nH\nH\nH\nH\nH\nOH\nO H N\nN H\nO\nR3= H or\nOH\nS O\nOO\nO\nNH\nOH\nO\nHO O O\nO\nOH O\nH O\nO O\nO\nO\nN H\nO H N\nor\nNa\nTCA-Hep-DTX(HDTA)\nRef. 449 Ref. 450\nRef. 451, 452\na) Deoxycholic acid and its derivative-heparin conjugates\nH N\nLHSA Ref. 453\nN H\nH N\nO\nHN O\nN H\nH N NHN\nHN\nO O\nNH2.CF3COOH\nO\nO\nO\nHN\nN H\nNH-NH2.CF3COOH\nO\nO\nNHO\nO\nN\nN N\nO\nH N\nHN\nOMe\nO\nO\nOH\nHO\nHO\nN\nHO\nO O\nH2N OH\nOMeO\nO\nOH\nHO\nOH\nO O NH2\nOH\nO OR\n3\nHO OSO3 O3SHN\nO3SO O\nO HO\nR1=H or SO3 -, R2=H, or SO3 -, or Ac\nO O\nOR 3 HO OR1 R2HN\nR1O\nn\nO\nO HO\nO\nR3= H or\nDendronized heparine-DOX Ref. 456\nHO\nR3= H or\nLMWH-ATRA Ref. 457\nN H\nO H N\nATRA\nO\nNH\nO\nO\nO O OH\nO\nOH O\nH O\nO O\nO\nO\nHN\nO\nO O\nHO R3O HO3SO HO3SHN\nHO3SO O\nO R3O\nO O OHO\nR3O OR1\nR2HN\nR1O\nn\nO\nO R3O\nO\nO\nO\nR1=H or SO3 -; R2=H, or SO3 -, or Ac; R3 =H\nO\nO\nOH R1,R 2,R3 = or\nTaxol-Leucine-Heparin\nor\nRef. 454, 455\nb) Anti-cancer drug- heparin conjugates\nPage 101 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nN H\nH N\nO\nO\nO n N H\nN\nN\nN\nO\nNH2\nHN\nH N\nOHOOC\nO\nO OR\n3\nHO OSO3 O3SHN\nO3SO O\nO HO\nR1=H or SO3 -, R2=H, or SO3 -, or Ac\nO O\nOR 3 HO OR1 R2HN\nR1O\nn\nO\nO HO\nO\nR3= OH or\nFA\nor\nHN PEG NH\nFPHP Ref. 461\nc) Folate-Heparin conjugate for anti-cancer drugs (DOX or Taxol) delivery\nO O\nHO R3O HO3SO HO3SHN\nHO3SO O\nO R3O\nO O OHO\nR3O OR1\nR2HN\nR1O\nn\nO\nO R3O\nO\nR1=H or S O3 -; R2=H, or SO3 -, or Ac; R3 =H\nO\nO\nOH R1,R 2,R3 = or\nHeparin-PEG-Folate(H-PEG-F) Ref. 460\nor\nNN\nN\nN\nO\nNH2\nN H\nN H\nO COOH\nO\nNHH N\nn\nO\nPEG H N O\nO\nd) Folate-Heparin and Photosensitizer-Heparin conjugate for PDT\nO O\nHO R3O HO3SO HO3SHN\nHO3SO O\nO R3O\nO O OHO\nR3O OR1\nR2HN\nR1O\nn\nO\nO R3O\nO\nR1=H or SO3 -; R2=H, or SO3 -, or Ac; R3 =H\nO\nO\nOH\nR1,R 2,R3 =\nor\nHeparin-folic acid(HF)\nor\nNHN\nN\nN\nO\nNH2\nN H\nN H\nO COOH\nO\nHN\nN H\nO\nO\nN\nCl NI\nIR-780\nRef. 462\nHN\nNNH\nN\nO\nO\nO\nO\nPhA-H\nHO\nN H\nN\nN\nN\nO\nNH2\nH N\nH N\nOHOOC\nO\nHN\nO OR\n3\nHO OSO3 O3SHN\nO3SO O\nO HO\nR1=H or SO3 -, R2=H, or SO3 -, or Ac\nO O\nOR 3 HO OR1 R2HN\nR1O\nn\nO\nO HO\nO\nR3= OH or\nN H\nO H N\nATRA\nFA\nHeparin-folate-retinoic acid (HFR)\nNH or\nRef. 463\nO OR\n3\nHO OSO3 O3SHN\nO3SO O\nO HO\nR1=H or SO3 -, R2=H, or SO3 -, or Ac\nO O\nOR 3 HO OR1 R2HN\nR1O\nn\nO\nO HO\nO HN\nNNH\nN\nO\nNH\nO\nO\nO\nN H\nor N H\nSHR3=\nPhA-H Ref. 464\nFig. 49 Chemical structures of representative Heparin based amphiphilic drug delivery system for cancer therapy. a) Deoxycholic acid and its derivative-heparin conjugates; b) Anti-cancer drug-heparin conjugates; c) Folate-Heparin conjugate for anti-cancer drugs (DOX or Taxol) delivery; d) Folate-Heparin and Photosensitizer-Heparin conjugate for PDT.\n4.5.4. Chondroitin Sulfate (CS) and Alginate\nPage 102 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nO OHO O RO\nO NH\nOSO3NaO\nO\nRO\nO O\nO O\nO\nO\nn\nm\nR=H or\nO\nPCL-CS Ref. 469, 470\nO OO\nO HO\nOH NH\nOH NH\nO\nHSO3O\nO n\nN\nHN\nCS-his Ref. 471\nO OO\nO HO\nOH NH\nO\nO\nO3SO\nO n\nN\nNH\nN\nHN\nHO\nO\nO\nO OH\nH N\nNN H\nmPEG-bPEI-Ce6\nN H\nN\nNH2\nHN\nN\nHN O\nO\nO m\nN\nH N\nH2N O\nO O\nm\nO\nN\nO\nN N\nN\nN\nN\nRef. 473\na) by Polyelectrolyte complex (PEC) mPEG-bPEI-Ce6+BHQ3-CS\na) Polymer(PCL)-CS Conjugate\nBHQ3-CS\nO\nNH\nH\nH H\nH\nH\nOH\nOH\nHN\nO OO\nO HO\nOH NH\nOSO3H\nO\nOH\nO\nO OHO O HO\nOH NH\nOSO3HO\nO\nOH\nO m n\nRef. 472\nb) PH-sensitive small molecule(his)-CS\nc) Small molecule(Bile-acid)-CS Conjugate\n2) CS Nanocomplex\n1) CS- molecule Conjugate\nb) by intermolecular stacking interaction CS-ATC-DOX\nO\nO\nHO\nOH\nglu\nO OO\nO HO\nOH NH\nOH OH\nO\nHSO3O\nO n\nOH\nOH\nOMe\nO\nO OH\nOH\nOH\nO\nOH\nO\nO\nNH2HO .HCl\nCS ATC DOX\nH2O2\nHO OH\nO\nOH\nOH\nOH\nO\nOH\n+ +\n+\n2,4,6-trihydroxybenzaldehyde protocatechuic acid\nDOCA-CS\nRef. 474\nFig. 50 Chemical structures of representative amphiphilic Chondroitin Sulfate (CS) based drug delivery system for cancer therapy.1) CS-molecule conjugates; 2) CS Nanocomplex.\nO O\nO HO\nR\nn\nO HO\nRO\nHO\nO OH\nm\nO H\nHO\nH\nH\nN H\nO R=\nH N\n-ONa or\nGA-ALG\nOMe\nO\nO OH\nOH\nOH\nN\nOH\nO\nO NH2HO\nNH R= -ONa or\nDOX-ALG Ref. 485Ref. 483-485\na) Alginate based amphiphilic drug delivery system for DOX delivery\nb) Alginate based amphiphilic drug delivery system for cancer PDT\nH\nHH\nO\nH\nR= -ONa or\nO O\nO HO\nR\nn\nO HO\nRO\nHO\nO OH\nm\nCSAD\nPhotosan (Photofrin)\nPhotosan-CSAD Ref. 488\nO O\nO HO\nNaO\nn\nO HO\nONaO\nHO\nO OH\nm\nS\nN\nN\nCl\nN\nMethylene blueSodium alginate\nO O\nO\nS OO O\nO- Na+\nAerosol OT\n+\nRef. 489\n+\nN H\nS\nN O\nx\nR= -ONa or\n;\nO O\nO R2O\nR1\nn\nO R2O\nR1O\nR2O\nO OR2\nm\nR1=R 2=H, or H\nHH\nO\nH\nR\nN H\nN\nN\nN\nO\nNH2\nH N\nH N\nOHOOC\nO\nFA\nFPA Ref. 486\nphytosterol\nAlginate-g-PNIPAAm Ref.487\n;\nPage 103 of 104 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A\nFig. 51 Chemical structures of representative alginate based amphiphilic drug delivery system for cancer therapy. a) Alginate based amphiphilic drug delivery system for DOX delivery; b) Alginate based amphiphilic drug delivery system for cancer PDT.\nPage 104 of 104Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n0 2\nA ug\nus t 2\n01 6.\nD ow\nnl oa\nde d\nby L\nA T\nR O\nB E\nU N\nIV E\nR SI\nT Y\no n\n02 /0\n8/ 20\n16 1\n0: 30\n:1 7.\nView Article Online DOI: 10.1039/C6NR04489A"
    } ],
    "references" : [ {
      "title" : "and R",
      "author" : [ "D. Peer", "J.M. Karp", "S. Hong", "O.C. Farokhzad", "R. Margali" ],
      "venue" : "Langer, Nature nanotechnology,",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Nature reviews",
      "author" : [ "R.A. Petros", "J.M. DeSimone" ],
      "venue" : "Drug discovery,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and D",
      "author" : [ "S. Mizrah" ],
      "venue" : "Peer, Chemical Society reviews,",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and T",
      "author" : [ "T. Jung", "W. Kamm", "A. Breitenbach", "E. Kaiserling", "J.X. Xia" ],
      "venue" : "Kissel, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "and Z",
      "author" : [ "Z. Liu", "Y. Jiao", "Y. Wang", "C. Zho" ],
      "venue" : "Zhang, Advanced drug delivery reviews,",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and R",
      "author" : [ "K. Loomis", "K. McNeele" ],
      "venue" : "V. Bellamkonda, Soft Matter,",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and H",
      "author" : [ "A.K. Iyer", "G. Khaled", "J. Fan" ],
      "venue" : "Maeda, Drug discovery today,",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and K",
      "author" : [ "H. Maeda", "J. Wu", "T. Sawa", "Y. Matsumur" ],
      "venue" : "Hori, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "and S",
      "author" : [ "A. Gabizon", "A.T. Horowitz", "D. Goren", "D. Tzemach", "F. Mandelbaum-Shavit", "M.M. Qaze" ],
      "venue" : "Zalipsky, Bioconjugate chemistry,",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "and C",
      "author" : [ "P. Pradhan", "J. Giri", "F. Rieken", "C. Koch", "O. Mykhaylyk", "M. Doblinger", "R. Banerjee", "D. Bahadu" ],
      "venue" : "Plank, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and R",
      "author" : [ "K.M. McNeeley", "E. Karathanasis", "A.V. Annapragad" ],
      "venue" : "V. Bellamkonda, Biomaterials,",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "do, H",
      "author" : [ "W. Hwan" ],
      "venue" : "Y. Ko, J. H. Lee, H. Kang, S. H. Ryu, I. C. Song, D. S. Lee and S. Kim, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and S",
      "author" : [ "S. Sakuma", "T. Yano", "Y. Masaoka", "M. Kataoka", "K. Hiwatari", "H. Tachikawa", "Y. Shoji", "R. Kimura", "H. Ma", "Z. Yang", "L. Tang", "R.M. Hoffma" ],
      "venue" : "Yamashita, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and J",
      "author" : [ "C. Bies", "C.M. Leh" ],
      "venue" : "F. Woodley, Advanced drug delivery reviews,",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "W",
      "author" : [ "K. El-Boubbou", "D.C. Zhu", "C. Vasileiou", "B. Borhan", "D. Prosperi" ],
      "venue" : "Li and X. Huang, Journal of the American Chemical Society,",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and J",
      "author" : [ "A. Puri", "G. Kramer-Marek", "R. Campbell-Massa", "A. Yavlovich", "S.C. Tele", "S.B. Lee", "J.D. Clogston", "A.K. Patri", "R. Blumentha" ],
      "venue" : "Capala, Journal of liposome research,",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "J",
      "author" : [ "P. Sapra", "E.H. Moase" ],
      "venue" : "Ma and T. M. Allen, Clinical cancer research : an official journal of the American Association for Cancer Research,",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and T",
      "author" : [ "W.W. Chen" ],
      "venue" : "M. Allen, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Journal of drug targeting, 2008, 16, 605-610",
      "author" : [ "K.M. Laginha", "E.H. Moase", "N. Yu", "A. Huang", "T.M. Allen" ],
      "venue" : " Page 25 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6.  D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  ARTICLE Journal Name 26 | J. Name.,",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and I",
      "author" : [ "H. Koo", "M.S. Huh", "I.C. Sun", "S.H. Yuk", "K. Choi", "K. Ki" ],
      "venue" : "C. Kwon, Accounts of chemical research,",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and P",
      "author" : [ "L. Vannucci", "E. Falvo", "M. Fornara", "P. Di Micco", "O. Benada", "J. Krizan", "J. Svoboda", "K. Hulikova-Capkova", "V. Morea", "A. Boff" ],
      "venue" : "Ceci, International journal of nanomedicine,",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and S",
      "author" : [ "M.K. Yu", "J. Par" ],
      "venue" : "Jon, Theranostics,",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and Q",
      "author" : [ "F. Jia", "X. Liu", "L. Li", "S. Mallapragada", "B. Narasimha" ],
      "venue" : "Wang, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and I",
      "author" : [ "K. Park", "S. Lee", "E. Kang", "K. Kim", "K. Cho" ],
      "venue" : "C. Kwon, Advanced Functional Materials,",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Medical principles and practice : international journal of the Kuwait University, Health",
      "author" : [ "Y.A. Luqmani" ],
      "venue" : "Science Centre,",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2005
    }, {
      "title" : "and I",
      "author" : [ "A.J. Primeau", "A. Rendon", "D. Hedley", "L. Lilg" ],
      "venue" : "F. Tannock, Clinical cancer research : an official journal of the American Association for Cancer Research,",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and R",
      "author" : [ "M.A. Izquierdo", "R.H. Shoemaker", "M.J. Flens", "G.L. Scheffer", "L. Wu", "T.R. Prathe" ],
      "venue" : "J. Scheper, International journal of cancer,",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "and N",
      "author" : [ "M. Creixel" ],
      "venue" : "A. Peppas, Nano today,",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and N",
      "author" : [ "M.A. Phillips", "M.L. Gra" ],
      "venue" : "A. Peppas, Nano today,",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and N",
      "author" : [ "W.B. Liecht" ],
      "venue" : "A. Peppas, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and S",
      "author" : [ "J.M. Adam" ],
      "venue" : "Cory, Current opinion in immunology,",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and G",
      "author" : [ "S.H. Che" ],
      "venue" : "Zhaori, European journal of clinical investigation,",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "K. Raemdonck", "T.F. Martens", "K. Braeckmans", "J. Demeeste" ],
      "venue" : "C. De Smedt, Advanced drug delivery reviews,",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and T",
      "author" : [ "T. Kato", "A. Natsume", "H. Toda", "H. Iwamizu", "T. Sugita", "R. Hachisu", "R. Watanabe", "K. Yuki", "K. Motomura", "K. Bankiewic" ],
      "venue" : "Wakabayashi, Gene therapy,",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and H",
      "author" : [ "K. Nakamura", "A.S. Abu Lila", "M. Matsunaga", "Y. Doi", "T. Ishid" ],
      "venue" : "Kiwada, Molecular therapy : the journal of the American Society of Gene Therapy,",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "D.B. Zambl" ],
      "venue" : "J. Lippard, Trends in biochemical sciences,",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 1995
    }, {
      "title" : "and A",
      "author" : [ "M. Czarnecka-Operac" ],
      "venue" : "Sadowska-Przytocka, Postepy dermatologii i alergologii,",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and G",
      "author" : [ "M.E. Wall", "M.C. Wani", "C.E. Cook", "K.H. Palmer", "A.T. McPhai" ],
      "venue" : "A. Sim, Journal of the American Chemical Society,",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 1966
    }, {
      "title" : "and M",
      "author" : [ "T. Efferth", "Y.J. Fu", "Y.G. Zu", "G. Schwarz", "V.S. Konkimall" ],
      "venue" : "Wink, Current medicinal chemistry,",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and A",
      "author" : [ "M.C. Wani", "H.L. Taylor", "M.E. Wall", "P. Coggo" ],
      "venue" : "T. McPhail, Journal of the American Chemical Society,",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 1971
    }, {
      "title" : "Nature reviews",
      "author" : [ "D.E. Dolmans", "D. Fukumura", "R.K. Jain" ],
      "venue" : "Cancer,",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and T",
      "author" : [ "N. Solban", "I. Rizv" ],
      "venue" : "Hasan, Lasers in surgery and medicine,",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and S",
      "author" : [ "J. Chen", "L. Keltner", "J. Christophersen", "F. Zheng", "M. Krouse", "A. Singha" ],
      "venue" : "S. Wang, Cancer journal (Sudbury, Mass.),",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "and E",
      "author" : [ "C. Fabris", "G. Valduga", "G. Miotto", "L. Borsetto", "G. Jori", "S. Garbis" ],
      "venue" : "Reddi, Cancer research,",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and I",
      "author" : [ "S.J. Lee", "K. Park", "Y.K. Oh", "S.H. Kwon", "S. Her", "I.S. Kim", "K. Choi", "S.J. Lee", "H. Kim", "S.G. Lee", "K. Ki" ],
      "venue" : "C. Kwon, Biomaterials,",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and H",
      "author" : [ "V. Guillemar" ],
      "venue" : "U. Saragovi, Cancer research,",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and C",
      "author" : [ "R.R. Allison", "G.H. Downie", "R. Cuenca", "X.H. Hu", "C.J. Child" ],
      "venue" : "H. Sibata, Photodiagnosis and photodynamic therapy,",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and K",
      "author" : [ "S.J. Lee", "H. Koo", "D.E. Lee", "S. Min", "S. Lee", "X. Chen", "Y. Choi", "J.F. Leary", "K. Park", "S.Y. Jeong", "I.C. Kwon", "K. Ki" ],
      "venue" : "Choi, Biomaterials,",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and I",
      "author" : [ "S.J. Lee", "H. Koo", "H. Jeong", "M.S. Huh", "Y. Choi", "S.Y. Jeong", "Y. Byun", "K. Choi", "K. Ki" ],
      "venue" : "C. Kwon, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and P",
      "author" : [ "B.L. Davidso" ],
      "venue" : "B. McCray, Jr., Nature reviews. Genetics,",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "K. Remaut", "N.N. Sanders", "B.G. De Geest", "K. Braeckmans", "J. Demeeste" ],
      "venue" : "C. De Smedt, Materials Science and Engineering: R: Reports,",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and D",
      "author" : [ "S.D. Patil", "D.G. Rhode" ],
      "venue" : "J. Burgess, The AAPS journal,",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "T",
      "author" : [ "T.-H. Kim", "H.-L. Jiang", "D. Jere", "I.-K. Park", "M.-H. Cho", "J.W. Nah", "Y.-J. Choi" ],
      "venue" : "Akaike and C.-S. Cho, Progress in Polymer Science,",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and T",
      "author" : [ "S. Mao", "W. Su" ],
      "venue" : "Kissel, Advanced drug delivery reviews,",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and J",
      "author" : [ "S.L. Ginn", "I.E. Alexander", "M.L. Edelstein", "M.R. Abed" ],
      "venue" : "Wixon, The journal of gene medicine,",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and S",
      "author" : [ "K. Raemdonck", "R.E. Vandenbroucke", "J. Demeester", "N.N. Sander" ],
      "venue" : "C. De Smedt, Drug discovery today,",
      "citeRegEx" : "59",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and D",
      "author" : [ "J.J. Green", "R. Lange" ],
      "venue" : "G. Anderson, Accounts of chemical research,",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and T",
      "author" : [ "J.H. Jeong", "S.W. Ki" ],
      "venue" : "G. Park, Progress in Polymer Science,",
      "citeRegEx" : "62",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and M",
      "author" : [ "W.F. La" ],
      "venue" : "C. Lin, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "63",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Drug Delivery Systems: Advanced Technologies Potentially Applicable in Personalised Treatment",
      "author" : [ "J.C. Ed" ],
      "venue" : "View Article Online DOI: 10.1039/C6NR04489A  riJournal Name ARTICLE This journal is © The Royal Society of Chemistry 20xx  J. Name.,",
      "citeRegEx" : "64",
      "shortCiteRegEx" : "64",
      "year" : 2013
    }, {
      "title" : "and P",
      "author" : [ "J. Zhan" ],
      "venue" : "X. Ma, Advanced drug delivery reviews,",
      "citeRegEx" : "65",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and M",
      "author" : [ "P. Han", "S. Li", "C. Wang", "H. Xu", "Z. Wang", "X. Zhang", "J. Thoma" ],
      "venue" : "Smet, Langmuir : the ACS journal of surfaces and colloids,",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and A",
      "author" : [ "T. Bojinova", "Y. Coppel", "N. Lauth-de Viguerie", "A. Milius", "I. Rico-Latte" ],
      "venue" : "Lattes, Langmuir : the ACS journal of surfaces and colloids,",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Angewandte Chemie (International ed",
      "author" : [ "Y. Wang", "N. Ma", "Z. Wang", "X. Zhang" ],
      "venue" : "in English),",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Angewandte Chemie (International ed",
      "author" : [ "Y.J. Jeon", "P.K. Bharadwaj", "S. Choi", "J.W. Lee", "K. Kim" ],
      "venue" : "in English),",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Angewandte Chemie (International ed",
      "author" : [ "B. Song", "Z. Wang", "S. Chen", "X. Zhang", "Y. Fu", "M. Smet", "W. Dehaen" ],
      "venue" : "in English),",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and F",
      "author" : [ "X. Zhang", "Z. Che" ],
      "venue" : "Würthner, Journal of the American Chemical Society,",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and T",
      "author" : [ "N. Kimizuka", "T. Kawasak" ],
      "venue" : "Kunitake, Journal of the American Chemical Society,",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 1993
    }, {
      "title" : "and T",
      "author" : [ "N. Kimizuka", "T. Kawasaki", "K. Hirat" ],
      "venue" : "Kunitake, Journal of the American Chemical Society,",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "G",
      "author" : [ "T.M. Hermans", "M.A.C. Broeren", "N. Gomopoulos", "A.F. Smeijers", "B. Mezari", "E.N.M. Van Leeuwen", "M.R.J. Vos", "P.C.M.M. Magusin", "P.A.J. Hilbers", "M.H.P. Van Genderen", "N.A.J.M. Sommerdijk" ],
      "venue" : "Fytas and Meijer, Journal of the American Chemical Society,",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and U",
      "author" : [ "J.-F. Gohy", "B.G.G. Lohmeije" ],
      "venue" : "S. Schubert, Macromolecules,",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "and R",
      "author" : [ "A.O. Moughto" ],
      "venue" : "K. O’Reilly, Journal of the American Chemical Society,",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and W",
      "author" : [ "B. Song", "G. Wu", "Z. Wang", "X. Zhang", "M. Sme" ],
      "venue" : "Dehaen, Langmuir : the ACS journal of surfaces and colloids,",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Angewandte Chemie (International ed",
      "author" : [ "C. Wang", "Y. Guo", "Y. Wang", "H. Xu", "R. Wang", "X. Zhang" ],
      "venue" : "in English),",
      "citeRegEx" : "78",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Angewandte Chemie (International ed",
      "author" : [ "K. Liu", "C. Wang", "Z. Li", "X. Zhang" ],
      "venue" : "in English),",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and A",
      "author" : [ "P. Xing", "T. Su" ],
      "venue" : "Hao, RSC Advances,",
      "citeRegEx" : "80",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and C",
      "author" : [ "X. Zhan" ],
      "venue" : "Wang, Chemical Society reviews,",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and K",
      "author" : [ "Y. Lee", "S. Fukushima", "Y. Bae", "S. Hiki", "T. Ishi" ],
      "venue" : "Kataoka, Journal of the American Chemical Society,",
      "citeRegEx" : "82",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and X",
      "author" : [ "P. Han", "N. Ma", "H. Ren", "H. Xu", "Z. Li", "Z. Wan" ],
      "venue" : "Zhang, Langmuir : the ACS journal of surfaces and colloids,",
      "citeRegEx" : "83",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Angewandte Chemie (International ed",
      "author" : [ "C. Wang", "Q. Chen", "Z. Wang", "X. Zhang" ],
      "venue" : "in English),",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and R",
      "author" : [ "J. Berger", "M. Reist", "J.M. Mayer", "O. Fel" ],
      "venue" : "Gurny, European journal of pharmaceutics and biopharmaceutics : official journal of  Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "86",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and I",
      "author" : [ "J.H. Park", "G. Saravanakumar", "K. Ki" ],
      "venue" : "C. Kwon, Advanced drug delivery reviews,",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and M",
      "author" : [ "G. Che" ],
      "venue" : "Jiang, Chemical Society reviews,",
      "citeRegEx" : "88",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "R.E. Babin" ],
      "venue" : "L. Bender, Chemical reviews,",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 1997
    }, {
      "title" : "and J",
      "author" : [ "F. Cozzi", "R. Annunziata", "M. Benaglia", "K.K. Baldridge", "G. Aguirre", "J. Estrada", "Y. Sritana-Anan" ],
      "venue" : "S. Siegel, Physical chemistry chemical physics : PCCP,",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and Z",
      "author" : [ "L. Zhang", "J. Xia", "Q. Zhao", "L. Li" ],
      "venue" : "Zhang, Small (Weinheim an der Bergstrasse, Germany),",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and H",
      "author" : [ "Z. Liu", "X. Sun", "N. Nakayama-Ratchfor" ],
      "venue" : "Dai, ACS nano,",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and P",
      "author" : [ "X. Zhang", "L. Meng", "Q. Lu", "Z. Fe" ],
      "venue" : "J. Dyson, Biomaterials,",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and U",
      "author" : [ "M.P. Evstigneev", "A.S. Buchelnikov", "D.P. Voronin", "Y.V. Rubin", "L.F. Belous", "Y.I. Prylutsky" ],
      "venue" : "Ritter, Chemphyschem : a European journal of chemical physics and physical chemistry,",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and M",
      "author" : [ "P. Chakravarty", "W. Qian", "M.A. El-Saye" ],
      "venue" : "R. Prausnitz, Nature nanotechnology,",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and S",
      "author" : [ "E. Jang", "E.-K. Lim", "Y. Choi", "E. Kim", "H.-O. Kim", "D.-J. Kim", "J.-S. Suh", "Y.-M. Hu" ],
      "venue" : "Haam, Journal of Materials Chemistry B,",
      "citeRegEx" : "96",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and K",
      "author" : [ "J.K. Oh", "R. Drumright", "D.J. Siegwar" ],
      "venue" : "Matyjaszewski, Progress in Polymer Science,",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and K",
      "author" : [ "R. Subbiah", "M. Veerapandia" ],
      "venue" : "S. Yun, Current medicinal chemistry,",
      "citeRegEx" : "98",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and K",
      "author" : [ "M. Elsabah" ],
      "venue" : "L. Wooley, Chemical Society reviews,",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and D",
      "author" : [ "K. Cho", "X. Wang", "S. Nie", "Z.G. Che" ],
      "venue" : "M. Shin, Clinical cancer research : an official journal of the American Association for Cancer Research,",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and S",
      "author" : [ "N. Graf", "D.R. Bielenberg", "N. Kolishetti", "C. Muus", "J. Banyard", "O.C. Farokhza" ],
      "venue" : "J. Lippard, ACS nano,",
      "citeRegEx" : "101",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and V",
      "author" : [ "A.N. Lukyano" ],
      "venue" : "P. Torchilin, Advanced drug delivery reviews,",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and A",
      "author" : [ "E.A. Lysenko", "A.N. Trusov", "P.S. Chelushkin", "T.K. Bronich", "A.V. Kabano" ],
      "venue" : "B. Zezin, Polymer Science Series A,",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and J",
      "author" : [ "A. Napoli", "M.J. Boerakker", "N. Tirelli", "R.J. Nolte", "N.A. Sommerdij" ],
      "venue" : "A. Hubbell, Langmuir : the ACS journal of surfaces and colloids,",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and J",
      "author" : [ "A. Napoli", "M. Valentini", "N. Tirelli", "M. Mulle" ],
      "venue" : "A. Hubbell, Nature materials,",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and R",
      "author" : [ "O.C. Farokhzad", "J. Cheng", "B.A. Teply", "I. Sherifi", "S. Jon", "P.W. Kantoff", "J.P. Richi" ],
      "venue" : "Langer, Proceedings of the National Academy of Sciences of the United States of America,",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and S",
      "author" : [ "R.T. Chacko", "J. Ventura", "J. Zhuan" ],
      "venue" : "Thayumanavan, Advanced drug delivery reviews,",
      "citeRegEx" : "107",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Soft Matter, 2009, 5, 707-715",
      "author" : [ "K. Raemdonck", "J. Demeester", "S. De Smedt" ],
      "venue" : " Page 27 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6.  D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  ARTICLE Journal Name 28 | J. Name.,",
      "citeRegEx" : "108",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and C",
      "author" : [ "D. Astruc", "E. Boisselie" ],
      "venue" : "Ornelas, Chemical reviews,",
      "citeRegEx" : "109",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and R",
      "author" : [ "V.R. Sinh" ],
      "venue" : "Kumria, International journal of pharmaceutics,",
      "citeRegEx" : "110",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and J",
      "author" : [ "J.W. Lee", "J.H. Par" ],
      "venue" : "R. Robinson, Journal of pharmaceutical sciences,",
      "citeRegEx" : "111",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "and M",
      "author" : [ "K.A. Janes", "P. Calv" ],
      "venue" : "J. Alonso, Advanced drug delivery reviews,",
      "citeRegEx" : "112",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "GardnerHughes, Cecilie A",
      "author" : [ "J.C. Linden", "R.J. Stoner", "K.W. Knutson" ],
      "venue" : "Agro Food Industry Hi-Tech",
      "citeRegEx" : "113",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "and M",
      "author" : [ "L. Gomez-Rivas", "B.I. Escudero-Abarca", "M.G. AguilarUscanga", "P.M. Hayward-Jones", "P. Mendoz" ],
      "venue" : "Ramirez, Journal of industrial microbiology & biotechnology,",
      "citeRegEx" : "114",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and M",
      "author" : [ "B. Ghos" ],
      "venue" : "W. Urban, Science (New York, N.Y.),",
      "citeRegEx" : "115",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Nutraceutical Assoc",
      "author" : [ "R.N. Schiller", "E. Barrager", "A.G. Schauss", "E.J. Nichols", "J. Am" ],
      "venue" : ",",
      "citeRegEx" : "116",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and M",
      "author" : [ "T. Kea" ],
      "venue" : "Thanou, Advanced drug delivery reviews,",
      "citeRegEx" : "117",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Regulatory toxicology and pharmacology",
      "author" : [ "P. Baldrick" ],
      "venue" : "RTP,",
      "citeRegEx" : "118",
      "shortCiteRegEx" : "118",
      "year" : 2010
    }, {
      "title" : "and J",
      "author" : [ "M.A. Brown", "M.R. Day" ],
      "venue" : "A. Worley, The Journal of emergency medicine,",
      "citeRegEx" : "119",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and T",
      "author" : [ "W.E. Rudzinsk" ],
      "venue" : "M. Aminabhavi, International journal of pharmaceutics,",
      "citeRegEx" : "120",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and R",
      "author" : [ "L.W. Seymour", "K. Ulbrich", "S.R. Wedge", "I.C. Hume", "J. Strohal" ],
      "venue" : "Duncan, British journal of cancer,",
      "citeRegEx" : "122",
      "shortCiteRegEx" : null,
      "year" : 1991
    }, {
      "title" : "and S",
      "author" : [ "Y.J. Son", "J.S. Jang", "Y.W. Cho", "H. Chung", "R.W. Park", "I.C. Kwon", "I.S. Kim", "J.Y. Park", "S.B. Seo", "C.R. Par" ],
      "venue" : "Y. Jeong, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "123",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and I",
      "author" : [ "J.H. Park", "Y.W. Cho", "Y.J. Son", "K. Kim", "H. Chung", "S.Y. Jeong", "K. Choi", "C.R. Park", "R.-W. Park", "I.-S. Ki" ],
      "venue" : "C. Kwon, Colloid and Polymer Science,",
      "citeRegEx" : "124",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and S",
      "author" : [ "J. Hyung Park", "S. Kwon", "M. Lee", "H. Chung", "J.H. Kim", "Y.S. Kim", "R.W. Park", "I.S. Kim", "S. Bong Seo", "I.C. Kwo" ],
      "venue" : "Young Jeong, Biomaterials,",
      "citeRegEx" : "125",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and S",
      "author" : [ "E. Lee", "J. Lee", "I.H. Lee", "M. Yu", "H. Kim", "S.Y. Cha" ],
      "venue" : "Jon, Journal of medicinal chemistry,",
      "citeRegEx" : "126",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and J",
      "author" : [ "X. Wang", "Y. Chen", "F.Z. Dahmani", "L. Yin", "J. Zho" ],
      "venue" : "Yao, Biomaterials,",
      "citeRegEx" : "127",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and X",
      "author" : [ "X.Y. Gong", "Y.H. Yin", "Z.J. Huang", "B. Lu", "P.H. Xu", "H. Zheng", "F.L. Xiong", "H.X. Xu", "X. Xion" ],
      "venue" : "B. Gu, International journal of pharmaceutics,",
      "citeRegEx" : "128",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Journal of materials science",
      "author" : [ "A. Fattahi", "M. Asgarshamsi", "F. Hasanzadeh", "J. Varshosaz", "M. Rostami", "M. Mirian", "H. Sadeghialiabadi" ],
      "venue" : "Materials in medicine,",
      "citeRegEx" : "129",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and D",
      "author" : [ "A. Safavy", "G.I. Georg", "D. Vander Velde", "K.P. Raisch", "K. Safavy", "M. Carpenter", "W. Wang", "J.A. Bonner", "M.B. Khazael" ],
      "venue" : "J. Buchsbaum, Bioconjugate chemistry,",
      "citeRegEx" : "130",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Y",
      "author" : [ "J. You", "F.Q. Hu" ],
      "venue" : "Z. Du and H. Yuan, Biomacromolecules,",
      "citeRegEx" : "131",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "F.Q. Hu", "G.F. Ren", "H. Yuan", "Y.Z. Du", "S. Zeng" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "132",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "F",
      "author" : [ "J. You", "X. Li" ],
      "venue" : "de Cui, Y. Z. Du, H. Yuan and F. Q. Hu, Nanotechnology,",
      "citeRegEx" : "133",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and H",
      "author" : [ "F.Q. Hu", "X.L. Wu", "Y.Z. Du", "J. Yo" ],
      "venue" : "Yuan, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "134",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Y",
      "author" : [ "J. You", "F.Q. Hu" ],
      "venue" : "Z. Du and H. Yuan, Nanotechnology,",
      "citeRegEx" : "135",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and H",
      "author" : [ "Y.Q. Ye", "F.L. Yang", "F.Q. Hu", "Y.Z. Du", "H. Yua" ],
      "venue" : "Y. Yu, International journal of pharmaceutics,",
      "citeRegEx" : "136",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and D",
      "author" : [ "U. Termsarasab", "H.J. Cho", "D.H. Kim", "S. Chong", "S.J. Chung", "C.K. Shim", "H.T. Moo" ],
      "venue" : "D. Kim, International journal of pharmaceutics,",
      "citeRegEx" : "137",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and A",
      "author" : [ "I.F. Uchegbu", "L. Sadiq", "M. Arastoo", "A.I. Gray", "W. Wang", "R.D. Waig" ],
      "venue" : "G. Schatzlein, International journal of pharmaceutics,",
      "citeRegEx" : "138",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and I",
      "author" : [ "A. Siew", "H. Le", "M. Thiovolet", "P. Gellert", "A. Schatzlei" ],
      "venue" : "Uchegbu, Molecular pharmaceutics,",
      "citeRegEx" : "139",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Y",
      "author" : [ "J. Zhang", "X.G. Chen" ],
      "venue" : "Y. Li and C. S. Liu, Nanomedicine : nanotechnology, biology, and medicine,",
      "citeRegEx" : "140",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and Z",
      "author" : [ "Y. Qin", "J. Chen", "Y. Bi", "X. Xu", "H. Zhou", "J. Gao", "Y. Hu", "Y. Zha" ],
      "venue" : "Chai, Acta biomaterialia,",
      "citeRegEx" : "141",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "Y.L. Tan", "C.G. Liu" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "142",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and H",
      "author" : [ "X.G. Chen", "C.M. Le" ],
      "venue" : "J. Park, Journal of agricultural and food chemistry,",
      "citeRegEx" : "143",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and D",
      "author" : [ "W.T. Huang", "M. Larsson", "Y.J. Wang", "S.H. Chiou", "H.Y. Li" ],
      "venue" : "M. Liu, Molecular pharmaceutics,",
      "citeRegEx" : "144",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and J",
      "author" : [ "C. Zhang", "Q. Ping", "H. Zhan" ],
      "venue" : "Shen, Carbohydrate Polymers,",
      "citeRegEx" : "145",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "C. Zhang", "P. Qineng", "H. Zhang" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "146",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and Q",
      "author" : [ "C. Zhang", "G. Qu", "Y. Sun", "T. Yang", "Z. Yao", "W. Shen", "Z. Shen", "Q. Ding", "H. Zho" ],
      "venue" : "Ping, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,",
      "citeRegEx" : "147",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "J",
      "author" : [ "M. Huo", "Y. Zhang", "J. Zhou", "A. Zou", "D. Yu", "Y. Wu" ],
      "venue" : "Li and H. Li, International journal of pharmaceutics,",
      "citeRegEx" : "148",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and C",
      "author" : [ "X. Jin", "R. Mo", "Y. Ding", "W. Zhen" ],
      "venue" : "Zhang, Molecular pharmaceutics,",
      "citeRegEx" : "149",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and I",
      "author" : [ "K. Kim", "S. Kwon", "J.H. Park", "H. Chung", "S.Y. Jeong", "I.C. Kwo" ],
      "venue" : "S. Kim, Biomacromolecules,",
      "citeRegEx" : "150",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and I",
      "author" : [ "J.Y. Yhee", "S. Son", "S.H. Kim", "K. Park", "K. Cho" ],
      "venue" : "C. Kwon, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "151",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Journal of  Page 28 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6",
      "author" : [ "J.H. Kim", "Y.S. Kim", "K. Park", "S. Lee", "H.Y. Nam", "K.H. Min", "H.G. Jo", "J.H. Park", "K. Choi", "S.Y. Jeong", "R.W. Park", "I.S. Kim", "K. Kim", "I.C. Kwon" ],
      "venue" : " D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  riJournal Name ARTICLE This journal is © The Royal Society of Chemistry 20xx  J. Name., 2013, 00, 1-3 | 29  Please do not adjust margins Please do not adjust margins  controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "152",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and I",
      "author" : [ "K.H. Min", "K. Park", "Y.S. Kim", "S.M. Bae", "S. Lee", "H.G. Jo", "R.W. Park", "I.S. Kim", "S.Y. Jeong", "K. Ki" ],
      "venue" : "C. Kwon, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "153",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and I",
      "author" : [ "J.H. Kim", "Y.S. Kim", "S. Kim", "J.H. Park", "K. Kim", "K. Choi", "H. Chung", "S.Y. Jeong", "R.W. Park", "I.S. Ki" ],
      "venue" : "C. Kwon, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "154",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and Y",
      "author" : [ "H.Y. Hwang", "I.S. Kim", "I.C. Kwo" ],
      "venue" : "H. Kim, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "155",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and I",
      "author" : [ "J.H. Kim", "Y.S. Kim", "K. Park", "E. Kang", "S. Lee", "H.Y. Nam", "K. Kim", "J.H. Park", "D.Y. Chi", "R.W. Park", "I.S. Kim", "K. Cho" ],
      "venue" : "Chan Kwon, Biomaterials,",
      "citeRegEx" : "156",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and Y",
      "author" : [ "Y.K. Lee", "J.-H. Kim", "C.I. Kwo" ],
      "venue" : "S. Jeong, Colloid and Polymer Science,",
      "citeRegEx" : "157",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "and X",
      "author" : [ "H. Zhou", "W. Yu", "X. Guo", "X. Liu", "N. Li", "Y. Zhan" ],
      "venue" : "Ma, Biomacromolecules,",
      "citeRegEx" : "158",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Materials science & engineering",
      "author" : [ "M. Wu", "K. Guo", "H. Dong", "R. Zeng", "M. Tu", "J. Zhao" ],
      "venue" : "C, Materials for biological applications,",
      "citeRegEx" : "159",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Q",
      "author" : [ "Y.-S. Wang", "L.-R. Liu" ],
      "venue" : "Jiang and Q.-Q. Zhang, European Polymer Journal,",
      "citeRegEx" : "160",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and Y",
      "author" : [ "Z. Pan", "Y. Gao", "L. Heng", "Y. Liu", "G. Yao", "Y. Wan" ],
      "venue" : "Liu, Carbohydr Polym,",
      "citeRegEx" : "161",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and G",
      "author" : [ "H. Du", "X. Yang", "X. Pan" ],
      "venue" : "Zhai, Carbohydr Polym,",
      "citeRegEx" : "162",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Y",
      "author" : [ "J.S. Park", "T.H. Han", "K.Y. Lee", "S.S. Han", "J.J. Hwang", "D.H. Moon", "S.Y. Ki" ],
      "venue" : "W. Cho, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "163",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and S",
      "author" : [ "W. Sajomsang", "P. Gonil", "S. Saesoo", "U.R. Ruktanonchai", "W. Srinuancha" ],
      "venue" : "Puttipipatkhachorn, International journal of pharmaceutics,",
      "citeRegEx" : "164",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Y",
      "author" : [ "J. Cao", "S. Huang", "Y. Chen", "S. Li", "X. Li", "D. Deng", "Z. Qian", "L. Tan" ],
      "venue" : "Gu, Biomaterials,",
      "citeRegEx" : "165",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and D",
      "author" : [ "L. Meng", "W. Huang", "D. Wang", "X. Huang", "X. Zh" ],
      "venue" : "Yan, Biomacromolecules,",
      "citeRegEx" : "166",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and X",
      "author" : [ "C. Gao", "T. Liu", "Y. Dang", "Z. Yu", "W. Wang", "J. Guo", "X. Zhang", "G. He", "H. Zheng", "Y. Yi" ],
      "venue" : "Kong, Carbohydr Polym,",
      "citeRegEx" : "167",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and H",
      "author" : [ "Y. Tao", "J. Ha" ],
      "venue" : "Dou, Journal of Materials Chemistry,",
      "citeRegEx" : "168",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and M",
      "author" : [ "J.M. Turley", "F.W. Ruscetti", "S.J. Kim", "T. Fu", "F.V. Go" ],
      "venue" : "C. Birchenall-Roberts, Cancer research,",
      "citeRegEx" : "169",
      "shortCiteRegEx" : null,
      "year" : 1997
    }, {
      "title" : "and Z",
      "author" : [ "M.W. Fariss", "M.B. Fortuna", "C.K. Everett", "J.D. Smith", "D.F. Tren" ],
      "venue" : "Djuric, Cancer research,",
      "citeRegEx" : "170",
      "shortCiteRegEx" : null,
      "year" : 1994
    }, {
      "title" : "and W",
      "author" : [ "K.N. Prasad", "B. Kumar", "X.D. Yan", "A.J. Hanso" ],
      "venue" : "C. Cole, Journal of the American College of Nutrition,",
      "citeRegEx" : "172",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and C",
      "author" : [ "Z. Zhao", "M. He", "L. Yin", "J. Bao", "L. Shi", "B. Wang", "C. Tan" ],
      "venue" : "Yin, Biomacromolecules,",
      "citeRegEx" : "173",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and X",
      "author" : [ "H. Yu", "W. Wang", "X. Chen", "C. Den" ],
      "venue" : "Jing, Biopolymers,",
      "citeRegEx" : "174",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "C. Gu", "V. Le", "M. Lang", "J. Liu" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "175",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and S",
      "author" : [ "A. Guerry", "S. Cottaz", "E. Fleury", "J. Bernar" ],
      "venue" : "Halila, Carbohydr Polym,",
      "citeRegEx" : "176",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "J",
      "author" : [ "Y. Wu", "Y. Zheng", "W. Yang", "C. Wang" ],
      "venue" : "Hu and S. Fu, Carbohydrate Polymers,",
      "citeRegEx" : "177",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and S",
      "author" : [ "W. Zhou", "Y. Wang", "J. Jia" ],
      "venue" : "Song, International journal of nanomedicine,",
      "citeRegEx" : "178",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and G",
      "author" : [ "I. Bravo-Osuna", "C. Vauthier", "A. Farabollini", "G.F. Palmier" ],
      "venue" : "Ponchel, Biomaterials,",
      "citeRegEx" : "179",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and G",
      "author" : [ "I. Bravo-Osuna", "T. Schmitz", "A. Bernkop-Schnurch", "C. Vauthie" ],
      "venue" : "Ponchel, International journal of pharmaceutics,",
      "citeRegEx" : "180",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and G",
      "author" : [ "I. Bravo-Osuna", "G. Millotti", "C. Vauthie" ],
      "venue" : "Ponchel, International journal of pharmaceutics,",
      "citeRegEx" : "181",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and I",
      "author" : [ "G. Saravanakumar", "K.H. Min", "D.S. Min", "A.Y. Kim", "C.M. Lee", "Y.W. Cho", "S.C. Lee", "K. Kim", "S.Y. Jeong", "K. Park", "J.H. Par" ],
      "venue" : "C. Kwon, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "183",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and K",
      "author" : [ "H. Koo", "K.H. Min", "S.C. Lee", "J.H. Park", "K. Park", "S.Y. Jeong", "K. Choi", "I.C. Kwo" ],
      "venue" : "Kim, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "184",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and R",
      "author" : [ "R. Gref", "Y. Minamitake", "M.T. Peracchia", "V. Trubetskoy", "V. Torchili" ],
      "venue" : "Langer, Science (New York, N.Y.),",
      "citeRegEx" : "185",
      "shortCiteRegEx" : null,
      "year" : 1994
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "P. Opanasopit", "T. Ngawhirunpat", "T. Rojanarata", "C. Choochottiros", "S. Chirachanchai" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "186",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and S",
      "author" : [ "P. Opanasopit", "T. Ngawhirunpat", "T. Rojanarata", "C. Choochottiro" ],
      "venue" : "Chirachanchai, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,",
      "citeRegEx" : "187",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and J",
      "author" : [ "J.S. Park", "Y.S. Koh", "J.Y. Bang", "Y.I. Jeon" ],
      "venue" : "J. Lee, Journal of pharmaceutical sciences,",
      "citeRegEx" : "188",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and S",
      "author" : [ "Y.I. Jeong", "S.H. Kim", "T.Y. Jung", "I.Y. Kim", "S.S. Kang", "Y.H. Jin", "H.H. Ryu", "H.S. Sun", "S. Jin", "K.K. Kim", "K.Y. Ah" ],
      "venue" : "Jung, Journal of pharmaceutical sciences,",
      "citeRegEx" : "189",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and M",
      "author" : [ "M.H. Hsiao", "Q. Mu", "Z.R. Stephen", "C. Fan" ],
      "venue" : "Zhang, ACS macro letters,",
      "citeRegEx" : "190",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Journal of materials science",
      "author" : [ "Z. Shi", "R. Guo", "W. Li", "Y. Zhang", "W. Xue", "Y. Tang", "Y. Zhang" ],
      "venue" : "Materials in medicine,",
      "citeRegEx" : "191",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "X",
      "author" : [ "G. Qu", "Z. Yao", "C. Zhang" ],
      "venue" : "Wu and Q. Ping, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,",
      "citeRegEx" : "192",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Journal of  Page 29 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6",
      "author" : [ "T. Boudou", "P. Kharkar", "J. Jing", "R. Guillot", "I. PignotPaintrand", "R. Auzely-Velty", "C. Picart" ],
      "venue" : " D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  ARTICLE Journal Name 30 | J. Name., 2012, 00, 1-3  This journal is © The Royal Society of Chemistry 20xx  Please do not adjust margins Please do not adjust margins  controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "193",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and K",
      "author" : [ "I.H. Oh", "H.S. Min", "L. Li", "T.H. Tran", "Y.K. Lee", "I.C. Kwon", "K. Choi", "K. Ki" ],
      "venue" : "M. Huh, Biomaterials,",
      "citeRegEx" : "194",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and S",
      "author" : [ "M. Malhotra", "A. Kulamarva", "S. Sebak", "A. Paul", "J. Bhathena", "M. Mirzae" ],
      "venue" : "Prakash, Drug development and industrial pharmacy,",
      "citeRegEx" : "195",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and Y",
      "author" : [ "X. Jiang", "H. Dai", "K.W. Leong", "S.H. Goh", "H.Q. Ma" ],
      "venue" : "Y. Yang, The journal of gene medicine,",
      "citeRegEx" : "196",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and M",
      "author" : [ "M. Ravina", "E. Cubillo", "D. Olmeda", "R. Novoa-Carballal", "E. Fernandez-Megia", "R. Riguera", "A. Sanchez", "A. Can" ],
      "venue" : "J. Alonso, Pharmaceutical research,",
      "citeRegEx" : "197",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and E",
      "author" : [ "H. Zhang", "S. Mardyani", "W.C. Cha" ],
      "venue" : "Kumacheva, Biomacromolecules,",
      "citeRegEx" : "198",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and Y",
      "author" : [ "P. Chan", "M. Kurisawa", "J.E. Chun" ],
      "venue" : "Y. Yang, Biomaterials,",
      "citeRegEx" : "199",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and C",
      "author" : [ "T.H. Kim", "J.W. Nah", "M.H. Cho", "T.G. Par" ],
      "venue" : "S. Cho, Journal of nanoscience and nanotechnology,",
      "citeRegEx" : "200",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and J",
      "author" : [ "S. Gao", "J. Chen", "X. Xu", "Z. Ding", "Y.H. Yang", "Z. Hu" ],
      "venue" : "Zhang, International journal of pharmaceutics,",
      "citeRegEx" : "201",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and J",
      "author" : [ "S. Mansouri", "Y. Cuie", "F. Winnik", "Q. Shi", "P. Lavigne", "M. Benderdour", "E. Beaumon" ],
      "venue" : "C. Fernandes, Biomaterials,",
      "citeRegEx" : "202",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and C",
      "author" : [ "T.H. Kim", "S.I. Kim", "T. Akaik" ],
      "venue" : "S. Cho, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "203",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "C",
      "author" : [ "K. Wong", "G. Sun", "X. Zhang", "H. Dai", "Y. Liu" ],
      "venue" : "He and K. W. Leong, Bioconjugate chemistry,",
      "citeRegEx" : "204",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and R",
      "author" : [ "B. Lu", "X.D. Xu", "X.Z. Zhang", "S.X. Chen" ],
      "venue" : "X. Zhuo, Biomacromolecules,",
      "citeRegEx" : "205",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and A",
      "author" : [ "C. Moreira", "H. Oliveira", "L.R. Pires", "S. Simoes", "M.A. Barbos" ],
      "venue" : "P. Pego, Acta biomaterialia,",
      "citeRegEx" : "206",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and C",
      "author" : [ "J. Haas", "M.N. Ravi Kumar", "G. Borchard", "U. Bakowsk" ],
      "venue" : "M. Lehr, AAPS PharmSciTech,",
      "citeRegEx" : "207",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and C",
      "author" : [ "N. Nafee", "S. Taetz", "M. Schneider", "U.F. Schaefe" ],
      "venue" : "M. Lehr, Nanomedicine : nanotechnology, biology, and medicine,",
      "citeRegEx" : "208",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and C",
      "author" : [ "S. Taetz", "N. Nafee", "J. Beisner", "K. Piotrowska", "C. Baldes", "T.E. Murdter", "H. Huwer", "M. Schneider", "U.F. Schaefer", "U. Klot" ],
      "venue" : "M. Lehr, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "209",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and C",
      "author" : [ "M.N. Ravi Kumar", "U. Bakowsk" ],
      "venue" : "M. Lehr, Biomaterials,",
      "citeRegEx" : "210",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "H",
      "author" : [ "X. Yuan", "B.A. Shah", "N.K. Kotadia", "J. Li" ],
      "venue" : "Gu and Z. Wu, Pharmaceutical research,",
      "citeRegEx" : "211",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and Y",
      "author" : [ "K. Tahara", "H. Yamamoto", "N. Hirashim" ],
      "venue" : "Kawashima, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "212",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and W",
      "author" : [ "W.X. Wang", "J.Q. Ga" ],
      "venue" : "Q. Liang, Drug delivery,",
      "citeRegEx" : "213",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Y",
      "author" : [ "F.Q. Hu", "M.D. Zhao", "H. Yuan", "J. You" ],
      "venue" : "Z. Du and S. Zeng, International journal of pharmaceutics,",
      "citeRegEx" : "214",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and A",
      "author" : [ "P.M. Moreno", "J.C. Santos", "C.P. Gomes", "A. VarelaMoreira", "A. Costa", "V. Leiro", "H. Mansu" ],
      "venue" : "P. Pego, Molecular pharmaceutics,",
      "citeRegEx" : "215",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and J",
      "author" : [ "B. Laye" ],
      "venue" : "Singh, Biomacromolecules,",
      "citeRegEx" : "216",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and C",
      "author" : [ "B. Yu", "C. Tan" ],
      "venue" : "Yin, Biomaterials,",
      "citeRegEx" : "217",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and S",
      "author" : [ "H.S. Yoo", "J.E. Lee", "H. Chung", "I.C. Kwo" ],
      "venue" : "Y. Jeong, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "218",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "W",
      "author" : [ "K.Y. Lee", "I.C. Kwon", "Y.H. Kim" ],
      "venue" : "H. Jo and S. Y. Jeong, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "219",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "and J",
      "author" : [ "S.Y. Chae", "S. Son", "M. Lee", "M.K. Jan" ],
      "venue" : "W. Nah, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "220",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and S",
      "author" : [ "Y.H. Kim", "S.H. Gihm", "C.R. Park", "K.Y. Lee", "T.W. Kim", "I.C. Kwon", "H. Chun" ],
      "venue" : "Y. Jeong, Bioconjugate chemistry,",
      "citeRegEx" : "221",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and Q",
      "author" : [ "W.G. Liu", "K. De Ya" ],
      "venue" : "G. Liu, Journal of Applied Polymer Science,",
      "citeRegEx" : "222",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and J",
      "author" : [ "W.G. Liu", "X. Zhang", "S.J. Sun", "G.J. Sun", "K.D. Yao", "D.C. Liang", "G. Gu" ],
      "venue" : "Y. Zhang, Bioconjugate chemistry,",
      "citeRegEx" : "223",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "S. Ercelen", "X. Zhang", "G. Duportail", "C. Grandfils", "J. Desbrieres", "S. Karaeva", "V. Tikhonov", "Y. Mely", "V. Babak" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "224",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and S",
      "author" : [ "T. Rojanarata", "M. Petchsangsai", "P. Opanasopit", "T. Ngawhirunpat", "U. Ruktanonchai", "W. Sajomsan" ],
      "venue" : "Tantayanon, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "225",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and T",
      "author" : [ "P. Opanasopit", "W. Sajomsang", "U. Ruktanonchai", "V. Mayen", "T. Rojanarat" ],
      "venue" : "Ngawhirunpat, International journal of pharmaceutics,",
      "citeRegEx" : "226",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and M",
      "author" : [ "V.S. Gaware", "M. Hakerud", "K. Leosson", "S. Jonsdottir", "A. Hogset", "K. Ber" ],
      "venue" : "Masson, Journal of medicinal chemistry,",
      "citeRegEx" : "227",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and M",
      "author" : [ "R. Yoksa" ],
      "venue" : "Akashi, Carbohydrate Polymers,",
      "citeRegEx" : "228",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and C",
      "author" : [ "T.H. Kim", "J.E. Ihm", "Y.J. Choi", "J.W. Na" ],
      "venue" : "S. Cho, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "229",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and M",
      "author" : [ "K.L. Chang", "Y. Higuchi", "S. Kawakami", "F. Yamashit" ],
      "venue" : "Hashida, Bioconjugate chemistry,",
      "citeRegEx" : "230",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and D",
      "author" : [ "H.S. Bisht", "D.S. Manickam", "Y. Yo" ],
      "venue" : "Oupicky, Biomacromolecules,",
      "citeRegEx" : "231",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and E",
      "author" : [ "M. Turk", "S. Dincer", "I.G. Yulu" ],
      "venue" : "Piskin, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "232",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Bioconjugate chemistry, 2005, 16, 972-980",
      "author" : [ "S. Sun", "W. Liu", "N. Cheng", "B. Zhang", "Z. Cao", "K. Yao", "D. Liang", "A. Zuo", "G. Guo", "J. Zhang" ],
      "venue" : " Page 30 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6.  D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  riJournal Name ARTICLE This journal is © The Royal Society of Chemistry 20xx  J. Name.,",
      "citeRegEx" : "233",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and J",
      "author" : [ "Z. Mao", "L. Ma", "J. Yan", "M. Yan", "C. Ga" ],
      "venue" : "Shen, Biomaterials,",
      "citeRegEx" : "234",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and Y",
      "author" : [ "J.Y. Lee", "S.H. Lee", "M.H. Oh", "J.S. Kim", "T.G. Par" ],
      "venue" : "S. Nam, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "235",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and H",
      "author" : [ "D.A. Lowthe" ],
      "venue" : "J. Rogers, Nature,",
      "citeRegEx" : "236",
      "shortCiteRegEx" : null,
      "year" : 1955
    }, {
      "title" : "and P",
      "author" : [ "D. Jiang", "J. Lian" ],
      "venue" : "W. Noble, Physiological reviews,",
      "citeRegEx" : "239",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and G",
      "author" : [ "A.K. Yadav", "P. Mishr" ],
      "venue" : "P. Agrawal, Journal of drug targeting,",
      "citeRegEx" : "240",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and J",
      "author" : [ "K. Meye" ],
      "venue" : "W. Palmer, Journal of Biological Chemistry,",
      "citeRegEx" : "241",
      "shortCiteRegEx" : null,
      "year" : 1934
    }, {
      "title" : "and K",
      "author" : [ "B. Weissman" ],
      "venue" : "Meyer, Journal of the American Chemical Society,",
      "citeRegEx" : "242",
      "shortCiteRegEx" : null,
      "year" : 1954
    }, {
      "title" : "and H",
      "author" : [ "D. Hamerma" ],
      "venue" : "Schuster, J Clin Invest,",
      "citeRegEx" : "244",
      "shortCiteRegEx" : null,
      "year" : 1958
    }, {
      "title" : "and R",
      "author" : [ "S. Tori" ],
      "venue" : "Bashey, Nature,",
      "citeRegEx" : "245",
      "shortCiteRegEx" : null,
      "year" : 1966
    }, {
      "title" : "American journal of physiology",
      "author" : [ "S.E. Armstrong", "D.R. Bell" ],
      "venue" : "Heart and circulatory physiology,",
      "citeRegEx" : "246",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Cellular and molecular life sciences",
      "author" : [ "A. Almond" ],
      "venue" : "CMLS,",
      "citeRegEx" : "248",
      "shortCiteRegEx" : "248",
      "year" : 2007
    }, {
      "title" : "and I",
      "author" : [ "C. Zeng", "B.P. Toole", "S.D. Kinney", "J.W. Ku" ],
      "venue" : "Stamenkovic, International journal of cancer,",
      "citeRegEx" : "249",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "and F",
      "author" : [ "V.M. Plat" ],
      "venue" : "C. Szoka, Jr., Molecular pharmaceutics,",
      "citeRegEx" : "250",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and J",
      "author" : [ "M.B. Duncan", "M. Liu", "C. Fo" ],
      "venue" : "Liu, Biochemical and biophysical research communications,",
      "citeRegEx" : "251",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and G",
      "author" : [ "Y. Lu" ],
      "venue" : "D. Prestwich, Bioconjugate chemistry,",
      "citeRegEx" : "252",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "and G",
      "author" : [ "Y. Luo", "M.R. Ziebel" ],
      "venue" : "D. Prestwich, Biomacromolecules,",
      "citeRegEx" : "253",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "and D",
      "author" : [ "F. Leonelli", "A. La Bella", "A. Francescangeli", "R. Joudioux", "A.-L. Capodilupo", "M. Quagliariello", "L.M. Migneco", "R.M. Bettolo", "V. Crescenzi", "G. De Luc" ],
      "venue" : "Renier, Helvetica Chimica Acta,",
      "citeRegEx" : "255",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and P",
      "author" : [ "A. Rosato", "A. Banzato", "G. De Luca", "D. Renier", "F. Bettella", "C. Pagano", "G. Esposito", "P. Zanovell" ],
      "venue" : "Bassi, Urologic oncology,",
      "citeRegEx" : "256",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and P",
      "author" : [ "R.K. Mittapalli", "X. Liu", "C.E. Adkins", "M.I. Nounou", "K.A. Bohn", "T.B. Terrell", "H.S. Qhattal", "W.J. Geldenhuys", "D. Palmieri", "P.S. Steeg", "Q.R. Smit" ],
      "venue" : "R. Lockman, Molecular cancer therapeutics,",
      "citeRegEx" : "257",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and G",
      "author" : [ "Y. Luo", "N.J. Bernshaw", "Z.R. Lu", "J. Kopece" ],
      "venue" : "D. Prestwich, Pharmaceutical research,",
      "citeRegEx" : "258",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "and T",
      "author" : [ "C.J. Lin", "C.H. Kuan", "L.W. Wang", "H.C. Wu", "Y. Chen", "C.W. Chang", "R.Y. Huan" ],
      "venue" : "W. Wang, Biomaterials,",
      "citeRegEx" : "259",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and A",
      "author" : [ "D. Coradini", "S. Zorzet", "R. Rossin", "I. Scarlata", "C. Pellizzaro", "C. Turrin", "M. Bello", "S. Cantoni", "A. Speranza", "G. Sava", "U. Mazz" ],
      "venue" : "Perbellini, Clinical cancer research : an official journal of the American Association for Cancer Research,",
      "citeRegEx" : "260",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and A",
      "author" : [ "D. Coradini", "C. Pellizzaro", "G. Miglierini", "M.G. Daidon" ],
      "venue" : "Perbellini, International journal of cancer,",
      "citeRegEx" : "261",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "and M",
      "author" : [ "D. Coradini", "C. Pellizzaro", "G. Abolafio", "M. Bosco", "I. Scarlata", "S. Cantoni", "L. Stucchi", "S. Zorzet", "C. Turrin", "G. Sava", "A. Perbellin" ],
      "venue" : "G. Daidone, Investigational new drugs,",
      "citeRegEx" : "262",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and A",
      "author" : [ "D. Coradini", "C. Pellizzaro", "I. Scarlata", "S. Zorzet", "C. Garrovo", "G. Abolafio", "A. Speranza", "M. Fedeli", "S. Cantoni", "G. Sava", "M.G. Daidon" ],
      "venue" : "Perbellini, Leukemia,",
      "citeRegEx" : "263",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and Q",
      "author" : [ "J. Yao", "L. Zhang", "J. Zhou", "H. Li" ],
      "venue" : "Zhang, Molecular pharmaceutics,",
      "citeRegEx" : "264",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and A",
      "author" : [ "N.F. Guilbaud", "N. Gas", "M.A. Dupon" ],
      "venue" : "Valette, Journal of cellular physiology,",
      "citeRegEx" : "265",
      "shortCiteRegEx" : null,
      "year" : 1990
    }, {
      "title" : "and T",
      "author" : [ "H. Yamamoto", "J. Fujimoto", "E. Okamoto", "J. Furuyama", "T. Tamaok" ],
      "venue" : "Hashimoto-Tamaoki, International journal of cancer,",
      "citeRegEx" : "266",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "and J",
      "author" : [ "O.C. Velazquez", "A. Jabbar", "R.P. DeMatte" ],
      "venue" : "L. Rombeau, Surgery,",
      "citeRegEx" : "267",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "and F",
      "author" : [ "R.E. Elia" ],
      "venue" : "C. Szoka, Jr., Cancer research,",
      "citeRegEx" : "268",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and F",
      "author" : [ "R.E. Eliaz", "S. Nir", "C. Mart" ],
      "venue" : "C. Szoka, Jr., Cancer research,",
      "citeRegEx" : "269",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and M",
      "author" : [ "S. Arpicco", "C. Lerda", "E. Dalla Pozza", "C. Costanzo", "N. Tsapis", "B. Stella", "M. Donadelli", "I. Dando", "E. Fattal", "L. Catte" ],
      "venue" : "Palmieri, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "270",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and M",
      "author" : [ "E. Dalla Pozza", "C. Lerda", "C. Costanzo", "M. Donadelli", "I. Dando", "E. Zoratti", "M.T. Scupoli", "S. Beghelli", "A. Scarpa", "E. Fattal", "S. Arpicc" ],
      "venue" : "Palmieri, Biochimica et biophysica acta, 2013,",
      "citeRegEx" : "271",
      "shortCiteRegEx" : null,
      "year" : 1828
    }, {
      "title" : "and D",
      "author" : [ "H.J. Cho", "H.Y. Yoon", "H. Koo", "S.H. Ko", "J.S. Shim", "J.H. Lee", "K. Kim", "I.C. Kwo" ],
      "venue" : "D. Kim, Biomaterials,",
      "citeRegEx" : "272",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and D",
      "author" : [ "J.H. Park", "H.J. Cho", "H.Y. Yoon", "I.S. Yoon", "S.H. Ko", "J.S. Shim", "J.H. Cho", "J.H. Park", "K. Kim", "I.C. Kwo" ],
      "venue" : "D. Kim, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "273",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and S",
      "author" : [ "K.Y. Choi", "K.H. Min", "J.H. Na", "K. Choi", "K. Kim", "J.H. Park", "I.C. Kwo" ],
      "venue" : "Y. Jeong, Journal of Materials Chemistry,",
      "citeRegEx" : "274",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and S",
      "author" : [ "K.Y. Choi", "H. Chung", "K.H. Min", "H.Y. Yoon", "K. Kim", "J.H. Park", "I.C. Kwo" ],
      "venue" : "Y. Jeong, Biomaterials,",
      "citeRegEx" : "275",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Journal of Materials Chemistry, 2011, 21, 7996-8001",
      "author" : [ "S.-Y. Han", "H.S. Han", "S.C. Lee", "Y.M. Kang", "I.-S. Kim", "J.H. Park" ],
      "venue" : " Page 31 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6.  D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  ARTICLE Journal Name 32 | J. Name.,",
      "citeRegEx" : "276",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and S",
      "author" : [ "K.Y. Choi", "K.H. Min", "H.Y. Yoon", "K. Kim", "J.H. Park", "I.C. Kwon", "K. Cho" ],
      "venue" : "Y. Jeong, Biomaterials,",
      "citeRegEx" : "277",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and J",
      "author" : [ "K.Y. Choi", "H.Y. Yoon", "J.H. Kim", "S.M. Bae", "R.W. Park", "Y.M. Kang", "I.S. Kim", "I.C. Kwon", "K. Choi", "S.Y. Jeong", "K. Ki" ],
      "venue" : "H. Park, ACS nano,",
      "citeRegEx" : "278",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and J",
      "author" : [ "H.S. Han", "J. Lee", "H.R. Kim", "S.Y. Chae", "M. Kim", "G. Saravanakumar", "H.Y. Yoon", "D.G. You", "H. Ko", "K. Kim", "I.C. Kwon", "J.C. Par" ],
      "venue" : "H. Park, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "279",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and Q",
      "author" : [ "J. Li", "M. Huo", "J. Wang", "J. Zhou", "J.M. Mohammad", "Y. Zhang", "Q. Zhu", "A.Y. Wadda" ],
      "venue" : "Zhang, Biomaterials,",
      "citeRegEx" : "280",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "W",
      "author" : [ "L. Deng", "G. Wang", "J. Ren", "B. Zhang", "J. Yan" ],
      "venue" : "Li and N. M. Khashab, RSC Advances,",
      "citeRegEx" : "281",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "K",
      "author" : [ "F. Li", "S.-J. Park", "D. Ling", "W. Park", "J.Y. Han" ],
      "venue" : "Na and K. Char, Journal of Materials Chemistry B,",
      "citeRegEx" : "282",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and K",
      "author" : [ "K. Miki", "T. Inoue", "Y. Kobayashi", "K. Nakano", "H. Matsuoka", "F. Yamauchi", "T. Yan" ],
      "venue" : "Ohe, Biomacromolecules,",
      "citeRegEx" : "283",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and X",
      "author" : [ "D.S. Liang", "H.T. Su", "Y.J. Liu", "A.T. Wan" ],
      "venue" : "R. Qi, Biomaterials,",
      "citeRegEx" : "284",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and Z",
      "author" : [ "Y. Liu", "J. Sun", "W. Cao", "J. Yang", "H. Lian", "X. Li", "Y. Sun", "Y. Wang", "S. Wan" ],
      "venue" : "He, International journal of pharmaceutics,",
      "citeRegEx" : "285",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and V",
      "author" : [ "G. Huerta-Angeles", "M. Bobek", "E. Prikopova", "D. Smejkalov" ],
      "venue" : "Velebny, Carbohydr Polym,",
      "citeRegEx" : "286",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and A",
      "author" : [ "L. Mayol", "M. Biondi", "L. Russo", "B.M. Malle", "K. Schwach-Abdellaou" ],
      "venue" : "Borzacchiello, Carbohydr Polym,",
      "citeRegEx" : "287",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and S",
      "author" : [ "L. Wan", "J. Jiao", "Y. Cui", "J. Guo", "N. Han", "D. Di", "D. Chang", "P. Wang", "T. Jian" ],
      "venue" : "Wang, Nanotechnology,",
      "citeRegEx" : "288",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and K",
      "author" : [ "J. Han", "W. Park", "S.J. Par" ],
      "venue" : "Na, ACS applied materials & interfaces,",
      "citeRegEx" : "289",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and S",
      "author" : [ "K.K. Upadhyay", "J.F. Le Meins", "A. Misra", "P. Voisin", "V. Bouchaud", "E. Ibarboure", "C. Schat" ],
      "venue" : "Lecommandoux, Biomacromolecules,",
      "citeRegEx" : "290",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and S",
      "author" : [ "K.K. Upadhyay", "A.N. Bhatt", "A.K. Mishra", "B.S. Dwarakanath", "S. Jain", "C. Schatz", "J.F. Le Meins", "A. Farooque", "G. Chandraiah", "A.K. Jain", "A. Misr" ],
      "venue" : "Lecommandoux, Biomaterials,",
      "citeRegEx" : "291",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and J",
      "author" : [ "H.S. Han", "T. Thambi", "K.Y. Choi", "S. Son", "H. Ko", "M.C. Lee", "D.G. Jo", "Y.S. Chae", "Y.M. Kang", "J.Y. Le" ],
      "venue" : "H. Park, Biomacromolecules,",
      "citeRegEx" : "292",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and K",
      "author" : [ "G. Saravanakumar", "K.Y. Choi", "H.Y. Yoon", "K. Kim", "J.H. Park", "I.C. Kwo" ],
      "venue" : "Park, International journal of pharmaceutics,",
      "citeRegEx" : "293",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and Y",
      "author" : [ "W. Hyung", "H. Ko", "J. Park", "E. Lim", "S.B. Park", "Y.J. Park", "H.G. Yoon", "J.S. Suh", "S. Haa" ],
      "venue" : "M. Huh, Biotechnology and bioengineering,",
      "citeRegEx" : "294",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and G",
      "author" : [ "A.K. Yadav", "P. Mishra", "A.K. Mishra", "P. Mishra", "S. Jai" ],
      "venue" : "P. Agrawal, Nanomedicine : nanotechnology, biology, and medicine,",
      "citeRegEx" : "295",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and G",
      "author" : [ "G. Pitarresi", "F.S. Palumbo", "A. Albanese", "C. Fiorica", "P. Picon" ],
      "venue" : "Giammona, Journal of drug targeting,",
      "citeRegEx" : "296",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and D",
      "author" : [ "L. Qiu", "Z. Li", "M. Qiao", "M. Long", "M. Wang", "X. Zhang", "C. Tia" ],
      "venue" : "Chen, Acta biomaterialia,",
      "citeRegEx" : "297",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and D",
      "author" : [ "D. Landesman-Milo", "M. Goldsmith", "S. Leviatan BenArye", "B. Witenberg", "E. Brown", "S. Leibovitch", "S. Azriel", "S. Tabak", "V. Mora" ],
      "venue" : "Peer, Cancer letters,",
      "citeRegEx" : "298",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and E",
      "author" : [ "S. Taetz", "A. Bochot", "C. Surace", "S. Arpicco", "J.M. Renoir", "U.F. Schaefer", "V. Marsaud", "S. Kerdine-Roemer", "C.M. Leh" ],
      "venue" : "Fattal, Oligonucleotides,",
      "citeRegEx" : "299",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and E",
      "author" : [ "C. Surace", "S. Arpicco", "A. Dufay-Wojcicki", "V. Marsaud", "C. Bouclier", "D. Clay", "L. Cattel", "J.M. Renoi" ],
      "venue" : "Fattal, Molecular pharmaceutics,",
      "citeRegEx" : "300",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and E",
      "author" : [ "A. Dufay Wojcicki", "H. Hillaireau", "T.L. Nascimento", "S. Arpicco", "M. Taverna", "S. Ribes", "M. Bourge", "V. Nicolas", "A. Bochot", "C. Vauthier", "N. Tsapi" ],
      "venue" : "Fattal, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "301",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and Q",
      "author" : [ "R. Ran", "Y. Liu", "H. Gao", "Q. Kuang", "Q. Zhang", "J. Tang", "K. Huang", "X. Chen", "Z. Zhan" ],
      "venue" : "He, International journal of pharmaceutics,",
      "citeRegEx" : "302",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Q",
      "author" : [ "Y. Shen", "B. Wang", "Y. Lu", "A. Ouahab" ],
      "venue" : "Li and J. Tu, International journal of pharmaceutics,",
      "citeRegEx" : "303",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and X",
      "author" : [ "Y. Liu", "M. Kong", "X.J. Cheng", "Q.Q. Wang", "L.M. Jian" ],
      "venue" : "G. Chen, Carbohydr Polym,",
      "citeRegEx" : "304",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and J",
      "author" : [ "C. Ortiz Mellet", "J.M. Garcia Fernande" ],
      "venue" : "M. Benito, Chemical Society reviews,",
      "citeRegEx" : "307",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Nature reviews",
      "author" : [ "M.E. Davis", "M.E. Brewster" ],
      "venue" : "Drug discovery,",
      "citeRegEx" : "308",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and C",
      "author" : [ "V. Bonnet", "C. Gervaise", "F. Djedaini-Pilard", "A. Furla" ],
      "venue" : "Sarazin, Drug discovery today,",
      "citeRegEx" : "309",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and H",
      "author" : [ "A. Jabbar" ],
      "venue" : "Sadeghian, Amphiphilic Cyclodextrins, Synthesis, Utilities and Application of Molecular Modeling in Their Design, Recent Advances in Novel Drug Carrier Systems, Ali Demir Sezer (Ed.), InTech, DOI: 10.5772/50220. Available from: http://www.intechopen.com/books/recent-advancesin-novel-drug-carrier-systems/amphiphiliccyclodextrins-synthesis-utilities-and-application-ofmolecular-modeling-in-their-design,",
      "citeRegEx" : "310",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and M",
      "author" : [ "F. Quaglia", "L. Ostacolo", "A. Mazzaglia", "V. Villari", "D. Zaccari" ],
      "venue" : "T. Sciortino, Biomaterials,",
      "citeRegEx" : "311",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and M",
      "author" : [ "A. Mazzaglia", "M.L. Bondi", "A. Scala", "F. Zito", "G. Barbieri", "F. Crea", "G. Vianelli", "P. Mineo", "T. Fiore", "C. Pellerito", "L. Pellerit" ],
      "venue" : "A. Costa, Biomacromolecules,",
      "citeRegEx" : "312",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Y",
      "author" : [ "J. Zhang", "Y. Jia", "X. Li" ],
      "venue" : "Hu and X. Li, Advanced materials (Deerfield Beach, Fla.),",
      "citeRegEx" : "313",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "S",
      "author" : [ "H. He", "S. Chen", "J. Zhou", "Y. Dou", "L. Song", "L. Che", "X. Zhou", "X. Chen", "Y. Jia", "J. Zhang" ],
      "venue" : "Li and X. Li, Biomaterials,",
      "citeRegEx" : "314",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and M",
      "author" : [ "J. Cheng", "K.T. Khin", "G.S. Jensen", "A. Li" ],
      "venue" : "E. Davis, Bioconjugate chemistry,",
      "citeRegEx" : "315",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and J",
      "author" : [ "T. Schluep", "P. Gunawan", "L. Ma", "G.S. Jensen", "J. Duringer", "S. Hinton", "W. Richte" ],
      "venue" : "Hwang, Clinical cancer research : an official journal of the American Association for Cancer Research,",
      "citeRegEx" : "316",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "X",
      "author" : [ "Q. Shi", "L. Zhang", "M. Liu", "X. Zhang", "X. Zhang", "X. Xu", "S. Chen" ],
      "venue" : "Li and J. Zhang, Biomaterials,",
      "citeRegEx" : "317",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and X",
      "author" : [ "Z. Zhang", "J. Ding", "X. Chen", "C. Xiao", "C. He", "X. Zhuang", "L. Che" ],
      "venue" : "Chen, Polymer Chemistry,",
      "citeRegEx" : "318",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and J",
      "author" : [ "A. Feng", "Q. Yan", "H. Zhang", "L. Pen" ],
      "venue" : "Yuan, Chemical communications (Cambridge, England),",
      "citeRegEx" : "319",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "The journal of physical chemistry",
      "author" : [ "T. Sun", "H. Yan", "G. Liu", "J. Hao", "J. Su", "S. Li", "P. Xing", "A. Hao" ],
      "venue" : "B,",
      "citeRegEx" : "320",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and A",
      "author" : [ "D. Gourevich", "O. Dogadkin", "A. Volovick", "L. Wang", "J. Gnaim", "S. Cochra" ],
      "venue" : "Melzer, Journal of  controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "321",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and I",
      "author" : [ "M. Poorghorban", "U. Das", "O. Alaidi", "J.M. Chitanda", "D. Michel", "J. Dimmock", "R. Verrall", "P. Grochulsk" ],
      "venue" : "Badea, International journal of nanomedicine,",
      "citeRegEx" : "322",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and M",
      "author" : [ "F. Yhaya", "J. Lim", "Y. Kim", "M. Liang", "A.M. Gregor" ],
      "venue" : "H. Stenzel, Macromolecules,",
      "citeRegEx" : "323",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and P",
      "author" : [ "J. Zhang", "K. Ellswort" ],
      "venue" : "X. Ma, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "324",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "F. Du", "H. Meng", "K. Xu", "Y. Xu", "P. Luo", "Y. Luo", "W. Lu", "J. Huang", "S. Liu", "J. Yu" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "325",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "F",
      "author" : [ "Q. He", "W. Wu", "K. Xiu", "Q. Zhang" ],
      "venue" : "Xu and J. Li, International journal of pharmaceutics,",
      "citeRegEx" : "326",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and Y",
      "author" : [ "Y. Yang", "Y.M. Zhang", "Y. Chen", "J.T. Che" ],
      "venue" : "Liu, Scientific reports,",
      "citeRegEx" : "327",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and M",
      "author" : [ "A. Pourjavadi", "M. Adel" ],
      "venue" : "Yazdi, New Journal of Chemistry,",
      "citeRegEx" : "328",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and B",
      "author" : [ "W. Ha", "Y. Kang", "S.L. Peng", "L.S. Ding", "S. Zhan" ],
      "venue" : "J. Li, Nanotechnology,",
      "citeRegEx" : "329",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and J",
      "author" : [ "L. Gallego-Yerga", "M. Lomazzi", "F. Sansone", "C. Ortiz Mellet", "A. Casnat" ],
      "venue" : "M. Garcia Fernandez, Chemical communications (Cambridge, England),",
      "citeRegEx" : "330",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and J",
      "author" : [ "Y. Wang", "H. Wang", "Y. Chen", "X. Liu", "Q. Ji" ],
      "venue" : "Ji, Chemical communications (Cambridge, England),",
      "citeRegEx" : "331",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and M",
      "author" : [ "S. Sortino", "A. Mazzaglia", "L. Monsu Scolaro", "F. Marino Merlo", "V. Valver" ],
      "venue" : "T. Sciortino, Biomaterials,",
      "citeRegEx" : "333",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and M",
      "author" : [ "A. Mazzaglia", "A. Valerio", "N. Micali", "V. Villari", "F. Quaglia", "M.A. Castriciano", "L.M. Scolaro", "M. Giuffre", "G. Siracusan" ],
      "venue" : "T. Sciortino, Chemical communications (Cambridge, England),",
      "citeRegEx" : "334",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "N. Kandoth", "E. Vittorino", "M.T. Sciortino", "T. Parisi", "I. Colao", "A. Mazzagli" ],
      "venue" : "Sortino, Chemistry (Weinheim an der Bergstrasse, Germany),",
      "citeRegEx" : "335",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and B",
      "author" : [ "J. Voskuhl", "U. Kauscher", "M. Gruener", "H. Frisch", "B. Wibbeling", "C.A. Strasser" ],
      "venue" : "J. Ravoo, Soft Matter,",
      "citeRegEx" : "336",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Bart J",
      "author" : [ "A. Mazzaglia", "R. Donohue" ],
      "venue" : "Ravoo and R. Darcy, European Journal of Organic Chemistry, 2001,",
      "citeRegEx" : "337",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and R",
      "author" : [ "R. Donohue", "A. Mazzaglia", "B.J. Ravo" ],
      "venue" : "Darcy, Chemical communications (Cambridge, England),",
      "citeRegEx" : "338",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "and E",
      "author" : [ "M.A. Mintze" ],
      "venue" : "E. Simanek, Chemical reviews,",
      "citeRegEx" : "339",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Chemistry (Weinheim an der Bergstrasse, Germany), 2009, 15, 12871-12888",
      "author" : [ "A. Diaz-Moscoso", "L. Le Gourrierec", "M. Gomez-Garcia", "J.M. Benito", "P. Balbuena", "F. Ortega-Caballero", "N. Guilloteau", "C. Di Giorgio", "P. Vierling", "J. Defaye", "C. Ortiz Mellet", "J.M. Garcia Fernandez" ],
      "venue" : " Page 55 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6.  D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  ARTICLE Journal Name 24 | J. Name.,",
      "citeRegEx" : "340",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and P",
      "author" : [ "J. Zhang", "H. Su" ],
      "venue" : "X. Ma, ACS nano,",
      "citeRegEx" : "341",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and D",
      "author" : [ "A. Kulkarni", "W. Deng", "S.H. Hyu" ],
      "venue" : "H. Thompson, Bioconjugate chemistry,",
      "citeRegEx" : "342",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and J",
      "author" : [ "F. Zhao", "H. Yi" ],
      "venue" : "Li, Biomaterials,",
      "citeRegEx" : "343",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and J",
      "author" : [ "A. Diaz-Moscoso", "P. Balbuena", "M. Gomez-Garcia", "C. Ortiz Mellet", "J.M. Benito", "L. Le Gourrierec", "C. Di Giorgio", "P. Vierling", "A. Mazzaglia", "N. Micali", "J. Defay" ],
      "venue" : "M. Garcia Fernandez, Chemical communications (Cambridge, England),",
      "citeRegEx" : "344",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and M",
      "author" : [ "B.N. Novikov", "J.K. Grimsley", "R.J. Kern", "J.R. Wil" ],
      "venue" : "E. Wales, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "345",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and J",
      "author" : [ "C. Bienvenu", "A. Martinez", "J.L. Jimenez Blanco", "C. Di Giorgio", "P. Vierling", "C. Ortiz Mellet", "J. Defay" ],
      "venue" : "M. Garcia Fernandez, Organic & biomolecular chemistry,",
      "citeRegEx" : "346",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and C",
      "author" : [ "C. Aranda", "K. Urbiola", "A. Mendez Ardoy", "J.M. Garcia Fernandez", "C. Ortiz Melle" ],
      "venue" : "T. de Ilarduya, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "347",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and J",
      "author" : [ "N. Symens", "A. Mendez-Ardoy", "A. Diaz-Moscoso", "E. Sanchez-Fernandez", "K. Remaut", "J. Demeester", "J.M. Fernandez", "S.C. De Smed" ],
      "venue" : "Rejman, Bioconjugate chemistry,",
      "citeRegEx" : "348",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and C",
      "author" : [ "A. Martinez", "C. Bienvenu", "J.L. Jimenez Blanco", "P. Vierling", "C.O. Mellet", "J.M. Garcia Fernande" ],
      "venue" : "Di Giorgio, The Journal of organic chemistry,",
      "citeRegEx" : "349",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and C",
      "author" : [ "A.M. O'Mahony", "J. Ogier", "S. Desgranges", "J.F. Cryan", "R. Darc" ],
      "venue" : "M. O'Driscoll, Organic & biomolecular chemistry,",
      "citeRegEx" : "350",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and N",
      "author" : [ "V. Villari", "A. Mazzaglia", "R. Darcy", "C.M. O'Driscol" ],
      "venue" : "Micali, Biomacromolecules,",
      "citeRegEx" : "351",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and C",
      "author" : [ "A.M. O'Mahony", "J. Ogier", "R. Darcy", "J.F. Crya" ],
      "venue" : "M. O'Driscoll, PloS one,",
      "citeRegEx" : "352",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and C",
      "author" : [ "J. McCarthy", "M.J. O'Neill", "L. Bourre", "D. Walsh", "A. Quinlan", "G. Hurley", "J. Ogier", "F. Shanahan", "S. Melgar", "R. Darc" ],
      "venue" : "M. O'Driscoll, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "353",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and C",
      "author" : [ "M. Gooding", "M. Malhotra", "D.J. McCarthy", "B.M. Godinho", "J.F. Cryan", "R. Darc" ],
      "venue" : "M. O'Driscoll, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,",
      "citeRegEx" : "354",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and W",
      "author" : [ "S.R. Van Tomm" ],
      "venue" : "E. Hennink, Expert review of medical devices,",
      "citeRegEx" : "355",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and A",
      "author" : [ "R.K. Purama", "P. Goswami", "A.T. Kha" ],
      "venue" : "Goyal, Carbohydrate Polymers,",
      "citeRegEx" : "356",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and Z",
      "author" : [ "H. Sun", "B. Guo", "X. Li", "R. Cheng", "F. Meng", "H. Li" ],
      "venue" : "Zhong, Biomacromolecules,",
      "citeRegEx" : "358",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "do, C",
      "author" : [ "Y.I. Jeong", "H. Ki" ],
      "venue" : "W. Chung, J. J. Yoo, K. H. Choi, C. H. Kim, S. H. Ha and D. H. Kang, International journal of nanomedicine,",
      "citeRegEx" : "359",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and X",
      "author" : [ "B. Li", "Q. Wang", "X. Wang", "C. Wan" ],
      "venue" : "Jiang, Carbohydr Polym,",
      "citeRegEx" : "360",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and M",
      "author" : [ "M.H. Alves", "H. Sfeir", "J.F. Tranchant", "E. Gombart", "G. Sagorin", "S. Caillol", "L. Billo" ],
      "venue" : "Save, Biomacromolecules,",
      "citeRegEx" : "361",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Angewandte Chemie (International ed",
      "author" : [ "C. Schatz", "S. Louguet", "J.F. Le Meins", "S. Lecommandoux" ],
      "venue" : "in English),",
      "citeRegEx" : "362",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "C",
      "author" : [ "Z. Zhao", "Z. Zhang", "L. Chen", "Y. Cao" ],
      "venue" : "He and X. Chen, Langmuir : the ACS journal of surfaces and colloids,",
      "citeRegEx" : "363",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and S",
      "author" : [ "C. Bonduelle", "J. Huang", "E. Ibarboure", "A. Heis" ],
      "venue" : "Lecommandoux, Chemical communications (Cambridge, England),",
      "citeRegEx" : "364",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "C",
      "author" : [ "Z. Zhao", "X. Yao", "Z. Zhang", "L. Chen" ],
      "venue" : "He and X. Chen, Macromolecular bioscience,",
      "citeRegEx" : "365",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and X",
      "author" : [ "A. Zhang", "Z. Zhang", "F. Shi", "C. Xiao", "J. Ding", "X. Zhuang", "C. He", "L. Che" ],
      "venue" : "Chen, Macromolecular bioscience,",
      "citeRegEx" : "366",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and X",
      "author" : [ "W. Xu", "J. Ding", "C. Xiao", "L. Li", "X. Zhuan" ],
      "venue" : "Chen, Biomaterials,",
      "citeRegEx" : "367",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and C",
      "author" : [ "Q. Li", "W. Liu", "J. Da" ],
      "venue" : "Zhang, Macromolecular bioscience,",
      "citeRegEx" : "368",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and J",
      "author" : [ "T. Thambi", "D.G. You", "H.S. Han", "V.G. Deepagan", "S.M. Jeon", "Y.D. Suh", "K.Y. Choi", "K. Kim", "I.C. Kwon", "G.R. Yi", "J.Y. Lee", "D.S. Le" ],
      "venue" : "H. Park, Advanced healthcare materials,",
      "citeRegEx" : "369",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "F",
      "author" : [ "P. Liu", "J.Q. Situ", "W.S. Li", "C.L. Shan", "J. You", "H. Yuan" ],
      "venue" : "Q. Hu and Y. Z. Du, Nanomedicine : nanotechnology, biology, and medicine,",
      "citeRegEx" : "370",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and A",
      "author" : [ "C. Saldias", "L. Velasquez", "C. Quezad" ],
      "venue" : "Leiva, Carbohydr Polym,",
      "citeRegEx" : "371",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "L",
      "author" : [ "S. Wang", "H. Wang", "Z. Liu", "L. Wang", "X. Wang" ],
      "venue" : "Su and J. Chang, Nanoscale,",
      "citeRegEx" : "372",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and T",
      "author" : [ "K. Nagahama", "Y. San" ],
      "venue" : "Kumano, Bioorganic & medicinal chemistry letters,",
      "citeRegEx" : "373",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and M",
      "author" : [ "S.M. Sagnella", "H. Duong", "A. MacMillan", "C. Boyer", "R. Whan", "J.A. McCarroll", "T.P. Davi" ],
      "venue" : "Kavallaris, Biomacromolecules,",
      "citeRegEx" : "374",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and X",
      "author" : [ "J.Y. Zhu", "Q. Lei", "B. Yang", "H.Z. Jia", "W.X. Qiu", "X. Wang", "X. Zeng", "R.X. Zhuo", "J. Fen" ],
      "venue" : "Z. Zhang, Biomaterials,",
      "citeRegEx" : "375",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and J",
      "author" : [ "S. Wang", "S. Zhang", "J. Liu", "Z. Liu", "L. Su", "H. Wan" ],
      "venue" : "Chang, ACS applied materials & interfaces,",
      "citeRegEx" : "376",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and A",
      "author" : [ "J. Raynaud", "B. Choquenet", "E. Marie", "E. Dellacherie", "C. Nouvel", "J.L. Si" ],
      "venue" : "Durand, Biomacromolecules,",
      "citeRegEx" : "377",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and N",
      "author" : [ "Y. Kakizawa", "R. Nishio", "T. Hirano", "Y. Koshi", "M. Nukiwa", "M. Koiwa", "J. Michizo" ],
      "venue" : "Ida, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "378",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and T",
      "author" : [ "Y. Zhang", "F. Wu", "W. Yua" ],
      "venue" : "Jin, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "379",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and A",
      "author" : [ "R. Covis", "C. Ladaviere", "J. Desbrieres", "E. Mari" ],
      "venue" : "Durand, Carbohydr Polym,",
      "citeRegEx" : "380",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Carbohydrate Polymers, 2014, 99, 235-241",
      "author" : [ "G. Mocanu", "M. Nichifor" ],
      "venue" : " Page 56 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6.  D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  riJournal Name ARTICLE This journal is © The Royal Society of Chemistry 20xx  J. Name.,",
      "citeRegEx" : "381",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and J",
      "author" : [ "E.M. Bachelder", "T.T. Beaudette", "K.E. Broaders", "J. Dash" ],
      "venue" : "M. Frechet, Journal of the American Chemical Society,",
      "citeRegEx" : "382",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and J",
      "author" : [ "K.E. Broaders", "J.A. Cohen", "T.T. Beaudette", "E.M. Bachelde" ],
      "venue" : "M. Frechet, Proceedings of the National Academy of Sciences of the United States of America,",
      "citeRegEx" : "383",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and C",
      "author" : [ "H.T. Duong", "F. Hughes", "S. Sagnella", "M. Kavallaris", "A. Macmillan", "R. Whan", "J. Hook", "T.P. Davi" ],
      "venue" : "Boyer, Molecular pharmaceutics,",
      "citeRegEx" : "384",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Y",
      "author" : [ "P. Liu", "B. Shi", "C. Yue", "G. Gao", "P. Li", "H. Yi", "M. Li", "B. Wang" ],
      "venue" : "Ma and L. Cai, Polymer Chemistry,",
      "citeRegEx" : "385",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and L",
      "author" : [ "P. Liu", "C. Yue", "Z. Sheng", "G. Gao", "M. Li", "H. Yi", "C. Zheng", "B. Wan" ],
      "venue" : "Cai, Polymer Chemistry,",
      "citeRegEx" : "386",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and J",
      "author" : [ "J.L. Cohen", "S. Schubert", "P.R. Wich", "L. Cui", "J.A. Cohen", "J.L. Myna" ],
      "venue" : "M. Frechet, Bioconjugate chemistry,",
      "citeRegEx" : "387",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Journal of materials science",
      "author" : [ "S. Ma", "J. Zhou", "A.R. Wali", "Y. He", "X. Xu", "J.Z. Tang", "Z. Gu" ],
      "venue" : "Materials in medicine,",
      "citeRegEx" : "388",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and S",
      "author" : [ "K. Raemdonck", "B. Naeye", "K. Buyens", "R.E. Vandenbroucke", "A. Høgset", "J. Demeeste" ],
      "venue" : "C. De Smedt, Advanced Functional Materials,",
      "citeRegEx" : "389",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and S",
      "author" : [ "K. Raemdonck", "B. Naeye", "A. Hogset", "J. Demeeste" ],
      "venue" : "C. De Smedt, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "390",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Tissue engineering",
      "author" : [ "K. Nagane", "J. Jo", "Y. Tabata" ],
      "venue" : "Part A,",
      "citeRegEx" : "391",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and J",
      "author" : [ "R.S. Singh", "G.K. Sain" ],
      "venue" : "F. Kennedy, Carbohydrate Polymers,",
      "citeRegEx" : "393",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and J",
      "author" : [ "R.S. Singh", "N. Kau" ],
      "venue" : "F. Kennedy, Carbohydr Polym,",
      "citeRegEx" : "394",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Journal of biomedical materials research",
      "author" : [ "D. Lu", "X. Wen", "J. Liang", "Z. Gu", "X. Zhang", "Y. Fan" ],
      "venue" : "Part B, Applied biomaterials,",
      "citeRegEx" : "395",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Journal of biomedical materials research",
      "author" : [ "H. Li", "S. Bian", "Y. Huang", "J. Liang", "Y. Fan", "X. Zhang" ],
      "venue" : "Part A,",
      "citeRegEx" : "396",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and X",
      "author" : [ "H. Li", "Y. Cui", "J. Sui", "S. Bian", "Y. Sun", "J. Liang", "Y. Fa" ],
      "venue" : "Zhang, ACS applied materials & interfaces,",
      "citeRegEx" : "397",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and N",
      "author" : [ "Y. Wang", "H. Chen", "Y. Liu", "J. Wu", "P. Zhou", "Y. Wang", "R. Li", "X. Yan" ],
      "venue" : "Zhang, Biomaterials,",
      "citeRegEx" : "398",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and Y",
      "author" : [ "Y. Liu", "Y. Wang", "C. Zhang", "P. Zhou", "Y. Liu", "T. An", "D. Sun", "N. Zhan" ],
      "venue" : "Wang, ACS applied materials & interfaces,",
      "citeRegEx" : "399",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and N",
      "author" : [ "Y. Wang", "Y. Liu", "Y. Liu", "Y. Wang", "J. Wu", "R. Li", "J. Yan" ],
      "venue" : "Zhang, Polymer Chemistry,",
      "citeRegEx" : "400",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "H",
      "author" : [ "S. Shen" ],
      "venue" : "Li and W. Yang, Drug delivery,",
      "citeRegEx" : "401",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Q",
      "author" : [ "L. Jiang", "X. Li", "L. Li" ],
      "venue" : "Zhang, International journal of nanomedicine,",
      "citeRegEx" : "402",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and H",
      "author" : [ "D. Muraoka", "N. Harada", "T. Hayashi", "Y. Tahara", "F. Momose", "S. Sawada", "S.A. Mukai", "K. Akiyosh" ],
      "venue" : "Shiku, ACS nano,",
      "citeRegEx" : "403",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and K",
      "author" : [ "K.S. Kim", "W. Par" ],
      "venue" : "Na, Biomaterials,",
      "citeRegEx" : "404",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and H",
      "author" : [ "S.J. Lee", "Y.H. Shim", "J.S. Oh", "Y.I. Jeong", "I.K. Par" ],
      "venue" : "C. Lee, Nanoscale research letters,",
      "citeRegEx" : "405",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and N",
      "author" : [ "H. Guo", "Y. Liu", "Y. Wang", "J. Wu", "X. Yang", "R. Li", "Y. Wan" ],
      "venue" : "Zhang, Carbohydr Polym,",
      "citeRegEx" : "406",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "K",
      "author" : [ "B. Wang" ],
      "venue" : "Chen, R.-d. Yang, F. Yang and J. Liu, Journal of Applied Polymer Science,",
      "citeRegEx" : "407",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and G",
      "author" : [ "R. Yuan", "F. Zheng", "S. Zhong", "X. Tao", "Y. Zhang", "F. Gao", "F. Yao", "J. Chen", "Y. Che" ],
      "venue" : "Shi, Molecules (Basel, Switzerland),",
      "citeRegEx" : "408",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and H",
      "author" : [ "K. Na", "T. Bum Lee", "K.H. Park", "E.K. Shin", "Y.B. Le" ],
      "venue" : "K. Choi, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,",
      "citeRegEx" : "409",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and S",
      "author" : [ "H.S. Elli" ],
      "venue" : "G. Ring, Carbohydrate Polymers,",
      "citeRegEx" : "410",
      "shortCiteRegEx" : null,
      "year" : 1985
    }, {
      "title" : "and J",
      "author" : [ "S.J. Davies", "G. Woodrow", "K. Donovan", "J. Plum", "P. Williams", "A.C. Johansson", "H.P. Bosselmann", "O. Heimburger", "O. Simonsen", "A. Davenport", "A. Tranaeu" ],
      "venue" : "C. Divino Filho, Journal of the American Society of Nephrology : JASN,",
      "citeRegEx" : "411",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and G",
      "author" : [ "C.B. Brown", "A.A. Luciano", "D. Martin", "E. Peers", "A. Scrimgeou" ],
      "venue" : "S. diZerega, Fertility and sterility,",
      "citeRegEx" : "412",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "L",
      "author" : [ "K. Li", "H. Liu", "W. Gao", "M. Chen", "Y. Zeng", "J. Liu" ],
      "venue" : "Xu and D. Wu, Biomaterials,",
      "citeRegEx" : "413",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and M",
      "author" : [ "U. Sridhar", "P.S. Pramo" ],
      "venue" : "Jayakannan, RSC Advances,",
      "citeRegEx" : "414",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "C",
      "author" : [ "J. Yang", "C. Gao", "S. Lu", "X. Zhang" ],
      "venue" : "Yu and M. Liu, Carbohydr Polym,",
      "citeRegEx" : "415",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and C",
      "author" : [ "P. Dandekar", "R. Jain", "T. Stauner", "B. Loretz", "M. Koch", "G. Wen" ],
      "venue" : "M. Lehr, Macromolecular bioscience,",
      "citeRegEx" : "416",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "A. Shalviri", "H.K. Chan", "G. Raval", "M.J. Abdekhodaie", "Q. Liu", "H. Heerklotz", "X.Y. Wu" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "417",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and X",
      "author" : [ "J. Li", "P. Cai", "A. Shalviri", "J.T. Henderson", "C. He", "W.D. Foltz", "P. Prasad", "P.M. Brodersen", "Y. Chen", "R. DaCosta", "A.M. Raut" ],
      "venue" : "Y. Wu, ACS nano,",
      "citeRegEx" : "418",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and D",
      "author" : [ "J. Liu", "J. Wang", "L.G. Bacha" ],
      "venue" : "Bhattacharyya, Biotechnology progress,",
      "citeRegEx" : "420",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "and L",
      "author" : [ "M. Barsbay", "O. Güven", "M.H. Stenzel", "T.P. Davis", "C. Barner-Kowolli" ],
      "venue" : "Barner, Macromolecules,",
      "citeRegEx" : "421",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and J",
      "author" : [ "W. Yuan", "J. Zhang", "H. Zou", "T. She" ],
      "venue" : "Ren, Polymer,",
      "citeRegEx" : "422",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and X",
      "author" : [ "W. Yuan", "J. Yuan", "F. Zhan" ],
      "venue" : "Xie, Biomacromolecules,",
      "citeRegEx" : "423",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "and Y",
      "author" : [ "D. Wang", "J. Tan", "H. Kang", "L. Ma", "X. Jin", "R. Li" ],
      "venue" : "Huang, Carbohydrate Polymers,",
      "citeRegEx" : "424",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "M.J. Ernsting", "W.L. Tang", "N. MacCallu" ],
      "venue" : "D. Li, Bioconjugate chemistry,",
      "citeRegEx" : "425",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "M.J. Ernsting", "W.L. Tang", "N.W. MacCallu" ],
      "venue" : "D. Li, Biomaterials,",
      "citeRegEx" : "426",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Journal of controlled release :  Page 57 of 104  Nanoscale N  an  os  ca  le  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  2  A  ug  us  t  2  01 6",
      "author" : [ "M.J. Ernsting", "M. Murakami", "E. Undzys", "A. Aman", "B. Press", "S.D. Li" ],
      "venue" : " D  ow  nl  oa  de  d  by  L  A  T  R  O  B  E  U  N  IV  E  R  SI  T  Y  o  n  02  /0  8/  20  16  1  0:  30  :1 7. View Article Online DOI: 10.1039/C6NR04489A  ARTICLE Journal Name 26 | J. Name., 2012, 00, 1-3  This journal is © The Royal Society of Chemistry 20xx  Please do not adjust margins Please do not adjust margins official journal of the Controlled Release Society,",
      "citeRegEx" : "427",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and S",
      "author" : [ "M.J. Ernsting", "W.D. Foltz", "E. Undzys", "T. Tagam" ],
      "venue" : "D. Li, Biomaterials,",
      "citeRegEx" : "428",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "H. Dong", "Q. Xu", "Y. Li", "S. Mo", "S. Cai", "L. Liu" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "429",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and R",
      "author" : [ "Y. Guo", "X. Wang", "Z. Shen", "X. Sh" ],
      "venue" : "Sun, Carbohydrate Polymers,",
      "citeRegEx" : "430",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "L",
      "author" : [ "H. Kang", "W. Liu", "B. He", "D. Shen" ],
      "venue" : "Ma and Y. Huang, Polymer,",
      "citeRegEx" : "431",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "F",
      "author" : [ "H. Hu", "W. Yuan", "F.S. Liu", "G. Cheng" ],
      "venue" : "J. Xu and J. Ma, ACS applied materials & interfaces,",
      "citeRegEx" : "432",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "Y. Song", "L. Zhang", "W. Gan", "J. Zhou", "L. Zhang" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "433",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and S",
      "author" : [ "A. Roy", "M. Murakami", "M.J. Ernsting", "B. Hoang", "E. Undzy" ],
      "venue" : "D. Li, Molecular pharmaceutics,",
      "citeRegEx" : "434",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and S",
      "author" : [ "B. Hoang", "M.J. Ernsting", "M. Murakami", "E. Undzy" ],
      "venue" : "D. Li, International journal of pharmaceutics,",
      "citeRegEx" : "435",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and S",
      "author" : [ "M.J. Ernsting", "B. Hoang", "I. Lohse", "E. Undzys", "P. Cao", "T. Do", "B. Gill", "M. Pintilie", "D. Hedle" ],
      "venue" : "D. Li, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "436",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and S",
      "author" : [ "B. Hoang", "M.J. Ernsting", "A. Roy", "M. Murakami", "E. Undzy" ],
      "venue" : "D. Li, Biomaterials,",
      "citeRegEx" : "437",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and S",
      "author" : [ "A. Roy", "M.J. Ernsting", "E. Undzy" ],
      "venue" : "D. Li, Biomaterials,",
      "citeRegEx" : "438",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and X",
      "author" : [ "M. Li", "Z. Tang", "J. Lin", "Y. Zhang", "S. Lv", "W. Song", "Y. Huan" ],
      "venue" : "Chen, Advanced healthcare materials,",
      "citeRegEx" : "439",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and N",
      "author" : [ "C. Chittasupho", "K. Lirdprapamongkol", "P. Kewsuwa" ],
      "venue" : "Sarisuta, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V,",
      "citeRegEx" : "440",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and X",
      "author" : [ "L. Cheng", "C. Jin", "W. Lv", "Q. Din" ],
      "venue" : "Han, PloS one,",
      "citeRegEx" : "441",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Textbook of Medical Physiology (11), Elsevier Saunders",
      "author" : [ "A.C. Guyton", "J.E. Hall" ],
      "venue" : "p. 464. ISBN 07216-0240-1.,",
      "citeRegEx" : "443",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and M",
      "author" : [ "B. Casu", "M. Guerrini", "S. Guglieri", "A. Naggi", "M. Perez", "G. Torri", "G. Cassinelli", "D. Ribatti", "P. Carminati", "G. Giannini", "S. Penco", "C. Pisano", "M. Belleri", "M. Rusnat" ],
      "venue" : "Presta, Journal of medicinal chemistry,",
      "citeRegEx" : "444",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "and D",
      "author" : [ "F. Lapierre", "K. Holme", "L. Lam", "R.J. Tressler", "N. Storm", "J. Wee", "R.J. Stack", "J. Castello" ],
      "venue" : "J. Tyrrell, Glycobiology,",
      "citeRegEx" : "445",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "and M",
      "author" : [ "S. Ito", "H. Nakanishi", "T. Hirai", "T. Kato", "Y. Kodera", "Z. Feng", "Y. Kasai", "K. Ito", "S. Akiyama", "A. Naka" ],
      "venue" : "Tatematsu, Cancer letters,",
      "citeRegEx" : "446",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "and G",
      "author" : [ "X. Yang", "H. Du", "J. Li" ],
      "venue" : "Zhai, Biomacromolecules,",
      "citeRegEx" : "447",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and A",
      "author" : [ "S.S. Ibrahim", "R. Osman", "G.A. Awad", "N.D. Mortad" ],
      "venue" : "S. Geneidy, Drug delivery,",
      "citeRegEx" : "448",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and Y",
      "author" : [ "K. Park", "G.Y. Lee", "Y.S. Kim", "M. Yu", "R.W. Park", "I.S. Kim", "S.Y. Ki" ],
      "venue" : "Byun, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "449",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and Y",
      "author" : [ "K.J. Cho", "H.T. Moon", "G.E. Park", "O.C. Jeon", "Y. Byu" ],
      "venue" : "K. Lee, Bioconjugate chemistry,",
      "citeRegEx" : "450",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and Y",
      "author" : [ "Z. Khatun", "M. Nurunnabi", "G.R. Reeck", "K.J. Ch" ],
      "venue" : "K. Lee, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "451",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nurunnabi, K",
      "author" : [ "Z. Khatun" ],
      "venue" : "J. Cho, Y. Byun, Y. H. Bae and Y. K. Lee, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "452",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and D",
      "author" : [ "D.H. Kim", "U. Termsarasab", "H.J. Cho", "I.S. Yoon", "J.Y. Lee", "H.T. Moo" ],
      "venue" : "D. Kim, International journal of nanomedicine,",
      "citeRegEx" : "453",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and J",
      "author" : [ "Y. Wang", "D. Xin", "K. Liu", "M. Zh" ],
      "venue" : "Xiang, Bioconjugate chemistry,",
      "citeRegEx" : "454",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and J",
      "author" : [ "Y. Wang", "D. Xin", "K. Li" ],
      "venue" : "Xiang, Pharmaceutical research,",
      "citeRegEx" : "455",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and Z",
      "author" : [ "W. She", "N. Li", "K. Luo", "C. Guo", "G. Wang", "Y. Gen" ],
      "venue" : "Gu, Biomaterials,",
      "citeRegEx" : "456",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and Q",
      "author" : [ "L. Hou", "J. Yao", "J. Zho" ],
      "venue" : "Zhang, Biomaterials,",
      "citeRegEx" : "457",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and J",
      "author" : [ "T. Zhang", "H. Xiong", "F.Z. Dahmani", "L. Sun", "Y. Li", "L. Yao", "J. Zho" ],
      "venue" : "Yao, Nanotechnology,",
      "citeRegEx" : "458",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and S",
      "author" : [ "S. Karmakar", "N.L. Bani" ],
      "venue" : "K. Ray, Cancer,",
      "citeRegEx" : "459",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and K",
      "author" : [ "Y. Wang", "Y. Wang", "J. Xian" ],
      "venue" : "Yao, Biomacromolecules,",
      "citeRegEx" : "460",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and S",
      "author" : [ "L. Li", "K.M. Huh", "Y.-K. Le" ],
      "venue" : "Y. Kim, Journal of Materials Chemistry,",
      "citeRegEx" : "461",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Y",
      "author" : [ "C. Yue", "P. Liu", "M. Zheng", "P. Zhao", "Y. Wang" ],
      "venue" : "Ma and L. Cai, Biomaterials,",
      "citeRegEx" : "462",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "K",
      "author" : [ "T.H. Tran", "B.C. Bae", "Y.K. Lee" ],
      "venue" : "Na and K. M. Huh, Carbohydr Polym,",
      "citeRegEx" : "463",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nurunnabi, Nafiujjaman, Y",
      "author" : [ "L. Li" ],
      "venue" : "K. Lee and K. M. Huh, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "464",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and R",
      "author" : [ "R.B. Erlich", "C.C. Werneck", "P.A. Moura" ],
      "venue" : "Linden, Experimental eye research,",
      "citeRegEx" : "465",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "and G",
      "author" : [ "K.R. Kirker", "Y. Luo", "J.H. Nielson", "J. Shelb" ],
      "venue" : "D. Prestwich, Biomaterials,",
      "citeRegEx" : "466",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "and J",
      "author" : [ "C.A. Henke", "U. Roongta", "D.J. Mickelson", "J.R. Knutso" ],
      "venue" : "B. McCarthy, J Clin Invest,",
      "citeRegEx" : "467",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "and J",
      "author" : [ "A.L. Chen", "H.C. Ni", "L.F. Wan" ],
      "venue" : "S. Chen, Biomacromolecules,",
      "citeRegEx" : "469",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "and L",
      "author" : [ "Y.J. Lin", "Y.S. Liu", "H.H. Yeh", "T.L. Chen" ],
      "venue" : "F. Wang, International journal of nanomedicine,",
      "citeRegEx" : "470",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "C. Yu", "C. Gao", "S. Lu", "C. Chen", "J. Yang", "X. Di", "M. Liu" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "471",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and K",
      "author" : [ "W. Park", "S.J. Par" ],
      "venue" : "Na, Biomaterials,",
      "citeRegEx" : "473",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and K",
      "author" : [ "D. Jeong", "B.C. Bae", "S.J. Par" ],
      "venue" : "Na, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "474",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and D",
      "author" : [ "A.D. Augst", "H.J. Kon" ],
      "venue" : "J. Mooney, Macromolecular bioscience,",
      "citeRegEx" : "475",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and G",
      "author" : [ "O. Smidsro" ],
      "venue" : "Skjak-Braek, Trends in biotechnology,",
      "citeRegEx" : "476",
      "shortCiteRegEx" : null,
      "year" : 1990
    }, {
      "title" : "and T",
      "author" : [ "M. Georg" ],
      "venue" : "E. Abraham, Journal of controlled release : official journal of the Controlled Release Society,",
      "citeRegEx" : "477",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "and P",
      "author" : [ "C.V. Liew", "L.W. Chan", "A.L. Chin" ],
      "venue" : "W. Heng, International journal of pharmaceutics, 2006, 309,",
      "citeRegEx" : "479",
      "shortCiteRegEx" : null,
      "year" : 2537
    }, {
      "title" : "and M",
      "author" : [ "A. McCullagh", "C. Swee" ],
      "venue" : "Ashley, DentalUpdate,",
      "citeRegEx" : "480",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "and B",
      "author" : [ "I.R. Matthew", "R.M. Browne", "J.W. Fram" ],
      "venue" : "G. Millar, Biomaterials,",
      "citeRegEx" : "481",
      "shortCiteRegEx" : null,
      "year" : 1995
    }, {
      "title" : "and J",
      "author" : [ "H.H. Tonnese" ],
      "venue" : "Karlsen, Drug development and industrial pharmacy,",
      "citeRegEx" : "482",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "and X",
      "author" : [ "C. Zhang", "W. Wang", "C. Wang", "Q. Tian", "W. Huang", "Z. Yua" ],
      "venue" : "Chen, Science in China Series B: Chemistry,",
      "citeRegEx" : "483",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and Z",
      "author" : [ "C. Zhang", "W. Wang", "T. Liu", "Y. Wu", "H. Guo", "P. Wang", "Q. Tian", "Y. Wan" ],
      "venue" : "Yuan, Biomaterials,",
      "citeRegEx" : "484",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and Z",
      "author" : [ "H. Guo", "Q. Lai", "W. Wang", "Y. Wu", "C. Zhang", "Y. Li" ],
      "venue" : "Yuan, International journal of pharmaceutics,",
      "citeRegEx" : "485",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Colloids and surfaces",
      "author" : [ "J. Wang", "M. Wang", "M. Zheng", "Q. Guo", "Y. Wang", "H. Wang", "X. Xie", "F. Huang", "R. Gong" ],
      "venue" : "B, Biointerfaces,",
      "citeRegEx" : "486",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and K",
      "author" : [ "D.G. Ahn", "J. Lee", "S.Y. Park", "Y.J. Kwar" ],
      "venue" : "Y. Lee, ACS applied materials & interfaces,",
      "citeRegEx" : "487",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and L",
      "author" : [ "Z. Yu", "H. Li", "L.M. Zhang", "Z. Zh" ],
      "venue" : "Yang, International journal of pharmaceutics,",
      "citeRegEx" : "488",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and J",
      "author" : [ "M. Usacheva", "S.K. Swaminathan", "A.R. Kirtan" ],
      "venue" : "Panyam, Molecular pharmaceutics,",
      "citeRegEx" : "489",
      "shortCiteRegEx" : null,
      "year" : 2014
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Chitosan is a positively charged polysaccharide with repeating D-glucosamine and N-acetyl-Dglucosamine units that are linked via β-(1, 4) glycosidic bonds.",
      "startOffset" : 131,
      "endOffset" : 137
    }, {
      "referenceID" : 3,
      "context" : "Chitosan is a positively charged polysaccharide with repeating D-glucosamine and N-acetyl-Dglucosamine units that are linked via β-(1, 4) glycosidic bonds.",
      "startOffset" : 131,
      "endOffset" : 137
    }, {
      "referenceID" : 0,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-Dmannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 48,
      "endOffset" : 54
    }, {
      "referenceID" : 3,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-Dmannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 48,
      "endOffset" : 54
    }, {
      "referenceID" : 0,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-Dmannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 78,
      "endOffset" : 84
    }, {
      "referenceID" : 3,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-Dmannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 78,
      "endOffset" : 84
    }, {
      "referenceID" : 0,
      "context" : "Heparin is composed of α or β-(1, 4) linked uronic acid (90% α-L-iduronic acid, 10% β-D-glucuronic acid) and α-D-glucosamine residues.",
      "startOffset" : 30,
      "endOffset" : 36
    }, {
      "referenceID" : 3,
      "context" : "Heparin is composed of α or β-(1, 4) linked uronic acid (90% α-L-iduronic acid, 10% β-D-glucuronic acid) and α-D-glucosamine residues.",
      "startOffset" : 30,
      "endOffset" : 36
    }, {
      "referenceID" : 0,
      "context" : "Chitosan (CS) is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-Dglucosamine (Fig.",
      "startOffset" : 76,
      "endOffset" : 81
    }, {
      "referenceID" : 1,
      "context" : "Chitosan (CS) is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-Dglucosamine (Fig.",
      "startOffset" : 76,
      "endOffset" : 81
    }, {
      "referenceID" : 2,
      "context" : "Chitosan (CS) is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-Dglucosamine (Fig.",
      "startOffset" : 76,
      "endOffset" : 81
    }, {
      "referenceID" : 3,
      "context" : "Chitosan (CS) is a linear polysaccharide composed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-Dglucosamine (Fig.",
      "startOffset" : 76,
      "endOffset" : 81
    }, {
      "referenceID" : 0,
      "context" : "primary amino groups and β-(1-4) linked glycosidic bonds.",
      "startOffset" : 27,
      "endOffset" : 32
    }, {
      "referenceID" : 1,
      "context" : "primary amino groups and β-(1-4) linked glycosidic bonds.",
      "startOffset" : 27,
      "endOffset" : 32
    }, {
      "referenceID" : 2,
      "context" : "primary amino groups and β-(1-4) linked glycosidic bonds.",
      "startOffset" : 27,
      "endOffset" : 32
    }, {
      "referenceID" : 3,
      "context" : "primary amino groups and β-(1-4) linked glycosidic bonds.",
      "startOffset" : 27,
      "endOffset" : 32
    }, {
      "referenceID" : 0,
      "context" : "The β-(1-4) linked glycosidic bonds and hexose units render them biodegradable and biocompatible which is essential for the application of biomedicine.",
      "startOffset" : 6,
      "endOffset" : 11
    }, {
      "referenceID" : 1,
      "context" : "The β-(1-4) linked glycosidic bonds and hexose units render them biodegradable and biocompatible which is essential for the application of biomedicine.",
      "startOffset" : 6,
      "endOffset" : 11
    }, {
      "referenceID" : 2,
      "context" : "The β-(1-4) linked glycosidic bonds and hexose units render them biodegradable and biocompatible which is essential for the application of biomedicine.",
      "startOffset" : 6,
      "endOffset" : 11
    }, {
      "referenceID" : 3,
      "context" : "The β-(1-4) linked glycosidic bonds and hexose units render them biodegradable and biocompatible which is essential for the application of biomedicine.",
      "startOffset" : 6,
      "endOffset" : 11
    }, {
      "referenceID" : 2,
      "context" : "deoxycholic acid modified chitosan, 219-221 N-alkylated chitosan, 222, 223 N-/2(3)-(dodec-2-enyl) succinoyl grafted chitosan, 224 quaternized N-(4-pyridinylmethyl) chitosan, 225 quaternized N-(4-N,N-dimethylaminobenzyl) chitosan, 226",
      "startOffset" : 79,
      "endOffset" : 82
    }, {
      "referenceID" : 0,
      "context" : "Dextran based amphiphilic delivery systems for cancer therapy Dextran is a microbial polysaccharide composed of Dglucopyranose units linked by α- (1, 6) glycosidic bonds with a low percentage of (1, 3)-linked side chains (Fig.",
      "startOffset" : 146,
      "endOffset" : 152
    }, {
      "referenceID" : 5,
      "context" : "Dextran based amphiphilic delivery systems for cancer therapy Dextran is a microbial polysaccharide composed of Dglucopyranose units linked by α- (1, 6) glycosidic bonds with a low percentage of (1, 3)-linked side chains (Fig.",
      "startOffset" : 146,
      "endOffset" : 152
    }, {
      "referenceID" : 0,
      "context" : "Dextran based amphiphilic delivery systems for cancer therapy Dextran is a microbial polysaccharide composed of Dglucopyranose units linked by α- (1, 6) glycosidic bonds with a low percentage of (1, 3)-linked side chains (Fig.",
      "startOffset" : 195,
      "endOffset" : 201
    }, {
      "referenceID" : 2,
      "context" : "Dextran based amphiphilic delivery systems for cancer therapy Dextran is a microbial polysaccharide composed of Dglucopyranose units linked by α- (1, 6) glycosidic bonds with a low percentage of (1, 3)-linked side chains (Fig.",
      "startOffset" : 195,
      "endOffset" : 201
    }, {
      "referenceID" : 0,
      "context" : "Cellulose is a linear polysaccharide composed of repeating β(1-4)-linked D-glucose units, and is insoluble in water and most organic solvents.",
      "startOffset" : 60,
      "endOffset" : 65
    }, {
      "referenceID" : 1,
      "context" : "Cellulose is a linear polysaccharide composed of repeating β(1-4)-linked D-glucose units, and is insoluble in water and most organic solvents.",
      "startOffset" : 60,
      "endOffset" : 65
    }, {
      "referenceID" : 2,
      "context" : "Cellulose is a linear polysaccharide composed of repeating β(1-4)-linked D-glucose units, and is insoluble in water and most organic solvents.",
      "startOffset" : 60,
      "endOffset" : 65
    }, {
      "referenceID" : 3,
      "context" : "Cellulose is a linear polysaccharide composed of repeating β(1-4)-linked D-glucose units, and is insoluble in water and most organic solvents.",
      "startOffset" : 60,
      "endOffset" : 65
    }, {
      "referenceID" : 0,
      "context" : "Heparin Heparin is a linear polysaccharide which consists of α or β-(1, 4) linked uronic acid (90% α -L-iduronic acid, 10% β -Dglucuronic acid) and α-D-glucosamine residues (Fig.",
      "startOffset" : 68,
      "endOffset" : 74
    }, {
      "referenceID" : 3,
      "context" : "Heparin Heparin is a linear polysaccharide which consists of α or β-(1, 4) linked uronic acid (90% α -L-iduronic acid, 10% β -Dglucuronic acid) and α-D-glucosamine residues (Fig.",
      "startOffset" : 68,
      "endOffset" : 74
    }, {
      "referenceID" : 0,
      "context" : "Alginate is a linear anionic polysaccharide with homopolymeric blocks of (1-4)-linked β-D-mannuronate (M) and its C-5 epimer α-L-guluronate (G) residues, respectively (Fig.",
      "startOffset" : 73,
      "endOffset" : 78
    }, {
      "referenceID" : 1,
      "context" : "Alginate is a linear anionic polysaccharide with homopolymeric blocks of (1-4)-linked β-D-mannuronate (M) and its C-5 epimer α-L-guluronate (G) residues, respectively (Fig.",
      "startOffset" : 73,
      "endOffset" : 78
    }, {
      "referenceID" : 2,
      "context" : "Alginate is a linear anionic polysaccharide with homopolymeric blocks of (1-4)-linked β-D-mannuronate (M) and its C-5 epimer α-L-guluronate (G) residues, respectively (Fig.",
      "startOffset" : 73,
      "endOffset" : 78
    }, {
      "referenceID" : 3,
      "context" : "Alginate is a linear anionic polysaccharide with homopolymeric blocks of (1-4)-linked β-D-mannuronate (M) and its C-5 epimer α-L-guluronate (G) residues, respectively (Fig.",
      "startOffset" : 73,
      "endOffset" : 78
    }, {
      "referenceID" : 10,
      "context" : "Hall, Textbook of Medical Physiology (11), Elsevier Saunders.",
      "startOffset" : 37,
      "endOffset" : 41
    }, {
      "referenceID" : 0,
      "context" : "Chitosan is a positively charged polysaccharide with repeating D-glucosamine and N-acetyl-D-glucosamine units that are linked via β-(1, 4) glycosidic bonds.",
      "startOffset" : 132,
      "endOffset" : 138
    }, {
      "referenceID" : 3,
      "context" : "Chitosan is a positively charged polysaccharide with repeating D-glucosamine and N-acetyl-D-glucosamine units that are linked via β-(1, 4) glycosidic bonds.",
      "startOffset" : 132,
      "endOffset" : 138
    }, {
      "referenceID" : 0,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-D-mannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 48,
      "endOffset" : 54
    }, {
      "referenceID" : 3,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-D-mannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 48,
      "endOffset" : 54
    }, {
      "referenceID" : 0,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-D-mannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 79,
      "endOffset" : 85
    }, {
      "referenceID" : 3,
      "context" : "Alginate is composed of alternating blocks of β-(1, 4)-D-mannuronic acid and α-(1, 4)-L-guluronic acid.",
      "startOffset" : 79,
      "endOffset" : 85
    }, {
      "referenceID" : 0,
      "context" : "Heparin is composed of α or β-(1, 4) linked uronic acid (90% α-L-iduronic acid, 10% β-D-glucuronic acid) and α-D-glucosamine residues.",
      "startOffset" : 30,
      "endOffset" : 36
    }, {
      "referenceID" : 3,
      "context" : "Heparin is composed of α or β-(1, 4) linked uronic acid (90% α-L-iduronic acid, 10% β-D-glucuronic acid) and α-D-glucosamine residues.",
      "startOffset" : 30,
      "endOffset" : 36
    } ],
    "year" : 2016,
    "abstractText" : "Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. Accepted Manuscript Nanoscale",
    "creator" : "Aspose Ltd."
  }
}